var images_info;if (!images_info) images_info =[]; images_info["108"]={"108003":{"type":"graphic_table","displayName":"Functional dyspepsia","title":"Rome IV Criteria for Functional Dyspepsia​","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rome IV&nbsp;Criteria for Functional Dyspepsia​</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">B1. Functional dyspepsia*</td> </tr> <tr> <td class=\"subtitle2_single\">Diagnostic criteria<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"> <ol> <li>One or more of the following: </li> </ol> </td> </tr> <tr> <td class=\"indent3\">a. Bothersome postprandial fullness</td> </tr> <tr> <td class=\"indent3\">b. Bothersome early satiation</td> </tr> <tr> <td class=\"indent3\">c. Bothersome epigastric pain</td> </tr> <tr> <td class=\"indent3\">d. Bothersome epigastric burning</td> </tr> <tr> <td class=\"indent1\"><strong>AND</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol start=\"2\"> <li>No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">B1a. Postprandial distress syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Diagnostic criteria<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Must include one or both of the following at least three days per week:</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Bothersome postprandial fullness (ie, severe enough to impact on usual activities) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Bothersome early satiation (ie, severe enough to prevent finishing a regular-size meal) </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including at upper endoscopy)</td> </tr> <tr> <td class=\"subtitle2_single\">Supportive remarks</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Postprandial epigastric pain or burning, epigastric bloating, excessive belching, and nausea can also be present </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Vomiting warrants consideration of another disorder </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Heartburn is not a dyspeptic symptom but may often coexist </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Symptoms that are relieved by evacuation of feces or gas should generally not be considered as part of dyspepsia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other individual digestive symptoms or groups of symptoms, eg, from gastroesophageal reflux disease and the irritable bowel syndrome may coexist with PDS</td> </tr> <tr> <td class=\"subtitle1_single\">B1b. Epigastric pain syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Diagnostic criteria<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Must include at least one of the following symptoms at least one day a week:</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Bothersome epigastric pain (ie, severe enough to impact on usual activities) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"><strong>AND/OR</strong></td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Bothersome epigastric burning (ie, severe enough to impact on usual activities) </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including at upper endoscopy)</td> </tr> <tr> <td class=\"subtitle2_single\">Supportive remarks</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Pain may be induced by ingestion of a meal, relieved by ingestion of a meal, or may occur while fasting </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Postprandial epigastric bloating, belching, and nausea can also be present </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Persistent vomiting likely suggests another disorder </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"4\"> <li>Heartburn is not a dyspeptic symptom but may often coexist </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"5\"> <li>The pain does not fulfill biliary pain criteria </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"6\"> <li>Symptoms that are relieved by evacuation of feces or gas generally should not be considered as part of dyspepsia </li> </ol> </td> </tr> <tr> <td class=\"indent1\">Other digestive symptoms (such as from gastroesophageal reflux disease and the irritable bowel syndrome) may coexist with EPS</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PDS: postprandial distress syndrome; EPS: epigastric pain syndrome.<br />* Must fulfill criteria for PDS and/or EPS.<br />¶ Criteria fulfilled for the last three months with symptom onset at least six months before diagnosis.</div><div class=\"graphic_reference\">Original table modified for this publication. Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorder. Gastroenterology 2016; 150:1380. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108003 Version 1.0</div></div></div>"},"108016":{"type":"graphic_table","displayName":"Inherited thrombophilia prevalence and VTE risk","title":"Prevalence of inherited thrombophilia and associated VTE risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of inherited thrombophilia and associated VTE risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Thrombophilia</td> <td class=\"subtitle1\" colspan=\"2\">Prevalence (%)</td> <td class=\"subtitle1\" rowspan=\"2\">Relative risk of a first episode of VTE compared with controls</td> </tr> <tr> <td class=\"subtitle2\">General population</td> <td class=\"subtitle2\">Individuals with VTE</td> </tr> <tr> <td>AT deficiency</td> <td>0.02 to 0.2%</td> <td>1 to 7%</td> <td>16-fold increased</td> </tr> <tr> <td>Protein C deficiency</td> <td>0.2 to 0.5%</td> <td>2 to 5%</td> <td>7-fold increased</td> </tr> <tr> <td>Protein S deficiency</td> <td>Unknown</td> <td>1%</td> <td>5-fold increased</td> </tr> <tr> <td>Factor V Leiden*</td> <td>4 to 5%</td> <td>12&nbsp;to 18%</td> <td>4- to 5-fold increased</td> </tr> <tr> <td>Prothrombin G20210A*</td> <td>2%</td> <td>5 to 8%</td> <td>3- to 4-fold increased</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These prevalences and risk estimates were aggregated from multiple studies. Refer to UpToDate content on specific inherited thrombophilias for further information on risk factors, indications for testing, and management. For FVL and prothrombin G20210A, values refer to heterozygotes. If the individual is homozygous for the defect, the risk of VTE is expected to be considerably higher. VTE risk also depends on other factors such as age and comorbidities.</div><div class=\"graphic_footnotes\">*Applies to Caucasian populations; prevalence is much lower in other groups.<br />VTE: venous thromboembolism; AT: antithrombin; FVL: factor V Leiden.</div><div id=\"graphicVersion\">Graphic 108016 Version 4.0</div></div></div>"},"108020":{"type":"graphic_figure","displayName":"Immunologic changes with allergen immunotherapy","title":"Immunologic changes with allergen immunotherapy","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Immunologic changes with allergen immunotherapy</div><div class=\"cntnt\"><img style=\"width:591px; height:510px;\" src=\"images/ALLRG/108020_Immunologic_changes_with_allergen_immunotherapy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During allergen immunotherapy, several consistent immunologic changes are observed. Allergen-specific Treg cells are generated, which&nbsp;express multiple suppressor factors, such as IL-10, TGF-beta, IL-10R, TGF-beta-R, CTLA4, PD1, HR2, FOXP3, and RUNX. Breg cells, producing IL-10 and IgG4 and expressing CD25 and CD71 on their surface, are also generated. Both Treg and Breg cells suppress allergen-specific effector Th2 cells. In addition, mast cell and basophil activity decreases and Th2 and ILC2 responses&nbsp;are suppressed. Over time, allergen-specific IgG4 in the serum increases and allergen-specific IgE decreases.</div><div class=\"graphic_footnotes\">HR2: histamine 2 receptor; IL-10: interleukin-10; IgG4: immunoglobulin G4; TGF-beta: transforming growth factor beta; IgE: immunoglobulin E; Th2: T helper type 2; ILC2: type 2 innate lymphoid cells; IL-10R:&nbsp;interleukin-10 receptor; TGF-beta-R: transforming growth factor-beta receptor; CTLA4: cytotoxic T lymphocyte-associated protein 4; PD1: programmed cell&nbsp;death&nbsp;protein 1; FOXP3: forkhead box protein 3; RUNX: runt-related transcription factor.</div><div id=\"graphicVersion\">Graphic 108020 Version 2.0</div></div></div>"},"108023":{"type":"graphic_movie","displayName":"Color Doppler nuchal cord","title":"Color Doppler nuchal cord at 13 weeks of gestation","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Color Doppler nuchal cord at 13 weeks of gestation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/108023_ColorDopplernchlcordvid.mp4\" style=\"width:688px;height:496px\"></div><img style=\"width:658px; height:446px;\" src=\"images/OBGYN/108023_ColorDopplernchlcordimg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 108023 Version 1.0</div></div></div>"},"108024":{"type":"graphic_movie","displayName":"Color Doppler nuchal cord 2","title":"Color Doppler nuchal cord at 13 weeks of gestation","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Color Doppler nuchal cord at 13 weeks of gestation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/108024_ColorDopplernchlcrd2vid.mp4\" style=\"width:688px;height:480px\"></div><img style=\"width:658px; height:446px;\" src=\"images/OBGYN/108024_ColorDopplernchlcrd2img.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 108024 Version 2.0</div></div></div>"},"108025":{"type":"graphic_form","displayName":"Sleep diary infant and child","title":"Infant and child sleep diary","html":"<div class=\"graphic\"><div style=\"width: 918px\" class=\"figure\"><div class=\"ttl\">Infant and child sleep diary</div><div class=\"cntnt\"><img style=\"width:898px; height:588px;\" src=\"images/SLEEP/108025_Sleep_diary_infant_child.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Daniel Glaze, MD, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 108025 Version 1.0</div></div></div>"},"108026":{"type":"graphic_picture","displayName":"Idiopathic guttate hypomelanosis back","title":"Idiopathic guttate hypomelanosis","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Idiopathic guttate hypomelanosis</div><div class=\"cntnt\"><img style=\"width:473px; height:756px;\" src=\"images/DERM/108026_Idiopathic_guttate_hypomela.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, white macules are present on the back.</div><div id=\"graphicVersion\">Graphic 108026 Version 1.0</div></div></div>"},"108028":{"type":"graphic_picture","displayName":"Progressive macular hypomelanosis abdomen","title":"Progressive macular hypomelanosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Progressive macular hypomelanosis</div><div class=\"cntnt\"><img style=\"width:756px; height:563px;\" src=\"images/DERM/108028_Prog_macular_hypomelanosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ill-defined hypopigmented macules are symmetrically distributed around the midline.</div><div class=\"graphic_reference\">Courtesy of Sang Ho Oh, MD.</div><div id=\"graphicVersion\">Graphic 108028 Version 1.0</div></div></div>"},"108029":{"type":"graphic_figure","displayName":"Molecular pharmacology of SERDs tamoxifen resistance","title":"Molecular pharmacology of SERDs in the setting of tamoxifen resistance","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Molecular pharmacology of SERDs in the setting of tamoxifen resistance</div><div class=\"cntnt\"><img style=\"width:742px; height:590px;\" src=\"images/ONC/108029_Mlclr_phrmclgy_SERDs_tmxfn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Molecular pharmacology of SERDs in the setting of tamoxifen resistance. Upon binding tamoxifen, ER&#945; undergoes a specific conformational change that enables the presentation of protein-protein interaction surfaces for which in tamoxifen-sensitive cells there are no compatible coregulators. Thus, tamoxifen binding commits ER down a \"nonproductive\" pathway, an activity that manifests as antagonism. It is proposed that chronic administration of tamoxifen, however, results in the selection of a subpopulation of cells that express a compatible coactivator (CoA). In this manner the pharmacology of tamoxifen \"switches\" from that of an antagonist to an agonist. SERDs, like GDC-0810,&nbsp;have activity in the setting of tamoxifen resistance because they (a) function as high affinity competitive antagonists, (b) induce a conformational change that is incompatible with coregulator interactions, and (c) target the receptor for proteasomal degradation.</div><div class=\"graphic_reference\">Reprinted with permission from McDonnell DP, Wardell SE, Norris JD. Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer. J Med Chem 2015; 58:4883. Copyright &#169; 2015 American Chemical Society.</div><div id=\"graphicVersion\">Graphic 108029 Version 1.0</div></div></div>"},"108030":{"type":"graphic_picture","displayName":"Progressive macular hypomelanosis back 2","title":"Progressive macular hypomelanosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Progressive macular hypomelanosis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/108030_Prog_macular_hypomelanosis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ill-defined hypomelanotic macules are symmetrically distributed on the back around the midline.</div><div class=\"graphic_reference\">Courtesy of Sang Ho Oh, MD.</div><div id=\"graphicVersion\">Graphic 108030 Version 1.0</div></div></div>"},"108036":{"type":"graphic_table","displayName":"Oral regimens severe malaria nonpregnant adults children","title":"Oral regimens for completion of treatment for severe malaria (following at least 24 hours of parenteral therapy) in nonpregnant adults and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral regimens for completion of treatment for severe malaria (following at least 24 hours of parenteral therapy) in nonpregnant adults and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">I. Artemisinin combination therapy</td> </tr> <tr> <td class=\"subtitle2\">Drug</td> <td class=\"subtitle2\">Formulations available</td> <td class=\"subtitle2\">Body weight (kg)</td> <td class=\"subtitle2\">Dose*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Artemether-lumefantrine<sup>&#182;</sup><sup>&#916;</sup></td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Available as tablets containing</p> <p>20 + 120 mg or</p> <p>40 + 240 mg</p> of artemether and lumefantrine, respectively; an orally disintegrating flavored tablet is available in some areas</td> <td>&nbsp;</td> <td>Dose administered orally twice daily for three days:</td> </tr> <tr> <td>5 to 15</td> <td>20 + 120 mg</td> </tr> <tr> <td>15 to &#60;25</td> <td>40 + 240 mg</td> </tr> <tr> <td>25 to &#60;35</td> <td>60 + 360 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35</td> <td>80 + 480 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Artesunate-amodiaquine</td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Available as tablets containing</p> <p>25 + 67.5 mg,</p> <p>50 + 135 mg, or</p> <p>100 + 270 mg</p> of artesunate and amodiaquine, respectively</td> <td>&nbsp;</td> <td>Dose administered orally once daily for three days:</td> </tr> <tr> <td>4.5 to 9</td> <td>25 + 67.5 mg</td> </tr> <tr> <td>9 to &#60;18</td> <td>50 + 135 mg</td> </tr> <tr> <td>18 to &#60;36</td> <td>100 + 270 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;36</td> <td>200 + 540 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">Dihydroartemisinin-piperaquine<sup>&#9674;</sup></td> <td class=\"divider_bottom\" rowspan=\"9\"> <p>Available as tablets containing</p> <p>20 + 160 mg or</p> <p>40 + 320 mg</p> of dihydroartemisinin and piperaquine, respectively</td> <td>&nbsp;</td> <td>Dose administered orally once daily for three days:</td> </tr> <tr> <td>5 to 8</td> <td>20 +160 mg</td> </tr> <tr> <td>8 to &#60;11</td> <td>30 + 240 mg</td> </tr> <tr> <td>11 to &#60;17</td> <td>40 + 320 mg</td> </tr> <tr> <td>17 to &#60;25</td> <td>60 + 480 mg</td> </tr> <tr> <td>25 to &#60;36</td> <td>80 + 640 mg</td> </tr> <tr> <td>36 to &#60;60</td> <td>120 + 960 mg</td> </tr> <tr> <td>60 to &#60;80</td> <td>160 + 1280 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;80</td> <td>200 + 1600 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Artesunate-mefloquine<sup>&#167;</sup></td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Available as tablets containing</p> <p>25 + 55 mg or</p> <p>100 + 220 mg</p> of artesunate and mefloquine hydrochloride, respectively</td> <td>&nbsp;</td> <td>Dose administered orally once daily for three days:</td> </tr> <tr> <td>5 to 9</td> <td>25 + 55 mg</td> </tr> <tr> <td>9 to &#60;18</td> <td>50 + 110 mg</td> </tr> <tr> <td>18 to &#60;30</td> <td>100 + 220 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;30</td> <td>200 + 440 mg</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">II. Alternative regimens (if ACT is not available)<sup>&#165;</sup></td> </tr> <tr> <td class=\"subtitle2\">Drug regimen<sup>&#135;</sup></td> <td class=\"subtitle2\" colspan=\"2\">Adults</td> <td class=\"subtitle2\">Children</td> </tr> <tr> <td class=\"indent2\" rowspan=\"6\"><strong>A. Artesunate</strong></td> <td rowspan=\"6\" colspan=\"2\">200 mg orally once daily for three days</td> <td>Available as 50 mg tablets</td> </tr> <tr> <td>Dose administered orally once daily for three days:</td> </tr> <tr> <td>4.5 to &#60;9 kg: 25 mg</td> </tr> <tr> <td>9 to &#60;18 kg: 50 mg</td> </tr> <tr> <td>18 to &#60;36 kg: 100 mg</td> </tr> <tr> <td>&#8805;36 kg: 200 mg</td> </tr> <tr> <td class=\"indent4\" colspan=\"4\"><strong>plus one of the following:</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Doxycycline</strong><sup>&#134;</sup></td> <td colspan=\"2\">100 mg orally twice daily for seven days</td> <td>Children &#8805;8 years: 2.2 mg/kg (maximum 100 mg) orally every 12 hours for seven days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Clindamycin</strong></td> <td colspan=\"2\">20 mg base/kg/day (up to 1.8 grams) orally divided three times daily for seven days</td> <td>6.7 mg base/kg orally (maximum 600 mg) orally every 8 hours for seven days</td> </tr> <tr> <td class=\"indent2\"><strong>B. Quinine sulfate</strong><sup>&#9674;</sup></td> <td colspan=\"2\">542 mg base ( = 650 mg salt)** orally three times daily for three or seven days<sup>&#182;&#182;</sup></td> <td>8.3 mg base/kg ( = 10 mg salt/kg) orally three times daily for three or seven days<sup>&#182;&#182;</sup></td> </tr> <tr> <td class=\"indent4\" colspan=\"4\"><strong>plus one of the following:</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Doxycycline</strong><sup>&#134;</sup></td> <td colspan=\"2\">Dosing as above</td> <td>Dosing as above</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Clindamycin</strong></td> <td colspan=\"2\">Dosing as above</td> <td>Dosing as above</td> </tr> <tr> <td class=\"indent2 divider_bottom\" rowspan=\"6\"><strong>C. Atovaquone-proguanil</strong><sup>&#916;&#916;</sup><br /> Adult tab = 250 mg atovaquone/100 mg proguanil<br /> Pediatric tab = 62.5 mg atovaquone/25 mg proguanil</td> <td class=\"divider_bottom\" rowspan=\"6\" colspan=\"2\">4 adult tabs orally once daily for three days</td> <td>5 to 8 kg: 2 pediatric tabs orally once daily for three days</td> </tr> <tr> <td>9 to 10 kg: 3 pediatric tabs orally once daily for three days</td> </tr> <tr> <td>11 to 20 kg: 1 adult tab orally once daily for three days</td> </tr> <tr> <td>21 to 30 kg: 2 adult tabs orally once daily for three days</td> </tr> <tr> <td>31 to 40 kg: 3 adult tabs orally once daily for three days</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;40 kg: 4 adult tabs orally once daily for three days</td> </tr> <tr> <td class=\"indent2\"><strong>D. Mefloquine</strong><sup>&#9674;&#9674;</sup></td> <td colspan=\"2\">684 mg base ( = 750 mg salt) orally as initial dose, followed by 456 mg base ( = 500 mg salt) orally given 6 to 12 hours after initial dose. Total dose = 1250 mg salt.</td> <td>13.7 mg base/kg ( = 15 mg salt/kg maximum 750 mg) orally as initial dose, followed by 9.1 mg base/kg ( = 10 mg salt/kg) orally given 6 to 12 hours after initial dose. Total dose = 25 mg salt/kg.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">An oral regimen should be administered for completion of treatment for severe malaria, following administration of parenteral therapy (for at least 24 hours and until oral medication can be tolerated). (Refer to the UpToDate table summarizing parenteral regimens for treatment for severe malaria.)<br />The dosing regimens listed in this table are generally consistent with the World Health Organization 2015 guidelines (3rd edition) for the treatment of malaria and the United States Centers for Disease Control and Prevention guidelines for the treatment of uncomplicated malaria in the United States (as revised July 2013) and may differ from dosing recommended in approved product information. Product availability varies by locality.</div><div class=\"graphic_footnotes\">ACT: artemisinin combination therapy.<br />* In general, the course of ACT is administered for three days. In areas of artemisinin resistance, a six-day course of treatment is warranted.<br />&para; Take after a full meal or whole milk. If patient vomits within 30 minutes of taking a dose, then they should repeat the dose. Ideally, the first two doses should be taken 8 hours apart.<br />&Delta; Artemether-lumefantrine is the only ACT available in the United States.<br /><span class=\"lozenge\">&loz;</span> Piperaquine prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine. Dihydroartemisinin-piperaquine should not be used in patients with congenital QT prolongation or who are on medications that prolong the QT interval. Dihydroartemisinin-piperaquine may be taken with food but should not be taken with a high-fat meal.<br />&sect; Regimens containing mefloquine should be avoided in patients who presented with altered consciousness, since there is an increased incidence of neuropsychiatric toxic effects associated with mefloquine in the setting of cerebral malaria. In addition, treatment with mefloquine is not recommended in persons who have acquired infections from Southeast Asia due to drug resistance. Mefloquine hydrochloride (55 mg) is equivalent to mefloquine base (50 mg); mefloquine hydrochloride (220 mg) is equivalent to mefloquine base (200 mg).<br />&yen; The alternative regimens summarized in the table are for completion of treatment for severe malaria acquired in areas with chloroquine-resistant malaria. For completion of therapy for severe malaria acquired in areas with chloroquine-sensitive malaria (Haiti, the Dominican Republic, most regions of the Mid East, and Central America west of the Panama Canal), chloroquine may be administered. Dosing of chloroquine for adults consists of 600 mg base ( = 1000 mg salt) orally immediately, followed by 300 mg base ( = 500 mg salt) orally at 6, 24, and 48 hours; total dose: 1500 mg base ( = 2500 mg salt). Dosing of chloroquine for children consists of 10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours; total dose: 25 mg base/kg. Maximum total dose: 1500 mg base ( = 2500 mg salt).<br />&Dagger; Regimens summarized include those generally available in areas where malaria is endemic. Atovaquone-proguanil is an acceptable alternative in regions where available. Adult dosing consists of 4 adult tabs (250 mg atovaquone/100 mg proguanil) orally once daily for three days. Pediatric dosing is as follows: 5 to 8 kg: 2 pediatric tabs (62.5 mg atovaquone/25 mg proguanil) orally once daily for three days; 9 to 10 kg: 3 pediatric tabs orally once daily for three days; 11 to 20 kg: 1 adult tab orally once daily for three days; 21 to 30 kg: 2 adult tabs orally once daily for three days; 31 to 40 kg: 3 adult tabs orally once daily for three days; &gt;40 kg: 4 adult tabs orally once daily for three days.<br />&dagger; Doxycycline is preferred over other tetracyclines because it does not accumulate in renal failure and has a longer half-life. Tetracycline may be used as an alternative (adult dosing: 250 mg orally four times daily for seven days; pediatric dosing: 6.25 mg/kg orally every 6 hours for seven days). Clindamycin is preferred to tetracyclines in pregnancy and children &lt;8 years of age in whom teeth are still developing.<br />** United States&ndash;manufactured quinine sulfate capsule is only available in a 324 mg (salt) strength; therefore, two capsules should be sufficient for adult dosing. Pediatric dosing may be difficult due to unavailability of noncapsule forms of quinine in the United States.<br />&para;&para; For infections acquired in Southeast Asia, oral treatment consists of quinine (seven days) plus doxycycline or clindamycin (seven days). For infections acquired outside Southeast Asia, oral treatment consists of quinine (three days) plus doxycycline, tetracycline, or clindamycin (seven days).<br />&Delta;&Delta; Atovaquone-proguanil has been associated with treatment failure and should be used only if the preceding regimens are not available. The drug should be taken with food or whole milk. If the patient vomits within 30 minutes of taking a dose, then dose should be repeated. It is also acceptable to take one-half of the dose twice daily.<br /><span class=\"double_lozenge\">&loz;&loz;</span> Treatment with mefloquine is not recommended in individuals who have acquired infections from Southeast Asia due to drug resistance. Mefloquine is associated with adverse psychiatric and neurologic events and should be used only if the preceding agents are not available. Mefloquine is not recommended for children &lt;15 kg.</div><div class=\"graphic_reference\">Adapted from: World Health Organization. Guidelines for the treatment of malaria, 3rd ed, WHO, Geneva 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/ (Accessed on March 22, 2016).<br />United States Centers for Disease Control guidelines for treatment of malaria: http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf (Accessed March 22, 2016).</div><div id=\"graphicVersion\">Graphic 108036 Version 1.0</div></div></div>"},"108037":{"type":"graphic_table","displayName":"Contraindications to aerobic exercise during pregnancy","title":"Contraindications to aerobic exercise during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to aerobic exercise during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Absolute contraindications to aerobic exercise during pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hemodynamically significant heart disease </li> <li>Restrictive lung disease </li> <li>Incompetent cervix or cerclage </li> <li>Multiple gestation at risk of premature labor </li> <li>Persistent second- or third-trimester bleeding </li> <li>Placenta previa after 26 weeks of gestation </li> <li>Premature labor during the current pregnancy </li> <li>Ruptured membranes </li> <li>Preeclampsia or pregnancy-induced hypertension </li> <li>Severe anemia </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindications to aerobic exercise during pregnancy</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Anemia </li> <li>Unevaluated maternal cardiac arrhythmia </li> <li>Chronic bronchitis </li> <li>Poorly controlled type 1 diabetes </li> <li>Extreme morbid obesity </li> <li>Extreme underweight (BMI less than 12) </li> <li>History of extremely sedentary lifestyle </li> <li>Intrauterine growth restriction in current pregnancy </li> <li>Poorly controlled hypertension </li> <li>Orthopedic limitations </li> <li>Poorly controlled seizure disorder </li> <li>Poorly controlled hyperthyroidism </li> <li>Heavy smoker </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">From: American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 650: Physical Activity and Exercise During Pregnancy and the Postpartum Period. Obstet Gynecol 2015; 126:e135. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2015&amp;issue=12000&amp;article=00058&amp;type=abstract\" target=\"_blank\">10.1097/AOG.0000000000001214</a>. Copyright &copy; 2015 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108037 Version 1.0</div></div></div>"},"108038":{"type":"graphic_picture","displayName":"Nevus anemicus face","title":"Nevus anemicus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nevus anemicus</div><div class=\"cntnt\"><img style=\"width:427px; height:648px;\" src=\"images/DERM/108038_Nevus_anemicus_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus anemicus presenting as a pale, irregularly shaped patch on the face.</div><div class=\"graphic_reference\">Courtesy of Sang Ho Oh, MD.</div><div id=\"graphicVersion\">Graphic 108038 Version 1.0</div></div></div>"},"108041":{"type":"graphic_table","displayName":"Safe and unsafe recreational exercises in pregnancy","title":"Safe and unsafe recreational exercises in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Safe and unsafe recreational exercises in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Examples of safe and unsafe physical activities during pregnancy*</td> </tr> <tr> <td class=\"subtitle2_single\">The following activities are safe to initiate or continue*:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Walking </li> <li>Swimming </li> <li>Stationary cycling </li> <li>Low-impact aerobics </li> <li>Yoga, modified<sup>&#182;</sup> </li> <li>Pilates, modified </li> <li>Running or jogging<sup>&#916;</sup> </li> <li>Racquet sports<sup>&#916;</sup><sup>&#9674;</sup> </li> <li>Strength training<sup>&#916;</sup></li> <li><sup></sup>Pelvic floor muscle training (Kegel)</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">The following activities should be avoided:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Contact sports (eg, ice hockey, boxing, soccer, and basketball) </li> <li>Activities with a high risk of falling or otherwise hitting the&nbsp;abdomen against a hard surface&nbsp;(eg, downhill snow skiing, water skiing, surfing, off-road cycling, gymnastics, and horseback riding) </li> <li>Scuba diving </li> <li>Sky diving </li> <li>\"Hot yoga\" or \"hot pilates\" </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In women with uncomplicated pregnancies in consultation with an obstetric care provider.<br />¶ Yoga positions that result in decreased venous return and hypotension should be avoided as much as possible.<br />Δ In consultation with an obstetric care provider, running or jogging, racquet sports, and strength training may be safe for pregnant women who participated in these activities regularly before pregnancy. Moderate intensity is optimal&nbsp;(eg, ≤80% age predicted maximum heart rate, rate of perceived exertion 13 or 14 on the Borg scale, or ability to converse while exercising). High intensity strenuous exercise should be avoided&nbsp;(&gt;90% age predicted maximum heart rate). <br /><FONT class=lozenge>◊</FONT> Racquet sports wherein a pregnant woman's changing balance may affect rapid movements and increase the risk of falling should be avoided as much as possible.</div><div class=\"graphic_reference\">Adapted from: American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 650: Physical Activity and Exercise During Pregnancy and the Postpartum Period. Obstet Gynecol 2015; 126:e135. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2015&amp;issue=12000&amp;article=00058&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000001214</A>. Copyright © 2015 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108041 Version 2.0</div></div></div>"},"108043":{"type":"graphic_picture","displayName":"Bier spots","title":"Bier spots","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Bier spots</div><div class=\"cntnt\"><img style=\"width:762px; height:651px;\" src=\"images/DERM/108043_Bier_spot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple white spots (Bier spots) representing a benign vascular mottling are visible on the legs of this patient. The spots become inapparent on diascopy or when the legs are elevated.</div><div class=\"graphic_reference\">Courtesy of Sang Ho Oh, MD.</div><div id=\"graphicVersion\">Graphic 108043 Version 1.0</div></div></div>"},"108044":{"type":"graphic_table","displayName":"PEARLS for open communication","title":"PEARLS for open communication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PEARLS for open communication</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>P:</strong> The clinician should acknowledge that this is a PARTNERSHIP and they are in it together.</td> </tr> <tr> <td><strong>E:</strong> The clinician should express understanding and EMPATHY.</td> </tr> <tr> <td><strong>A:</strong> The clinician should address any unmet expectation with an APOLOGY.</td> </tr> <tr> <td><strong>R:</strong> The clinician should acknowledge any patient suffering or dissatisfaction with RESPECT/REFLECTION.</td> </tr> <tr> <td><strong>L:</strong> The clinician should LEGITIMIZE the patient's concerns and feelings.</td> </tr> <tr> <td><strong>S:</strong> The clinician should SUPPORT the patient and emphasize that they will continue to work with the patient.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Acronym to help clinicians demonstrate empathy and facilitate open communication when taking a history.</div><div id=\"graphicVersion\">Graphic 108044 Version 1.0</div></div></div>"},"108045":{"type":"graphic_picture","displayName":"Subglottic hemangioma laryngoscopy","title":"Subglottic hemangioma in a young child","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Subglottic hemangioma in a young child</div><div class=\"cntnt\"><img style=\"width:726px; height:289px;\" src=\"images/PEDS/108045_Subglottichemngmlryngscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Subglottic hemangioma (arrow) seen from above the vocal cords. There is near complete obstruction of the subglottic airway.<br />(Panel B) Normal pediatric larynx.</div><div class=\"graphic_footnotes\">AC: arytenoid cartilage; AF: aryepiglottic fold; E: epiglottis; VC: vocal cord.</div><div class=\"graphic_reference\">(Panel A) Courtesy of Anna Messner, MD.<br />(Panel B) Reproduced with permission from: Nagdev A. Airway, breathing, circulation: Normal airway. In: Greenberg's Text-Atlas of Emergency Medicine, Greenberg MI, Hendrickson RG, Silverberg M, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 108045 Version 2.0</div></div></div>"},"108047":{"type":"graphic_algorithm","displayName":"Evaluation macrocytosis/macrocytic anemia","title":"Evaluation of unexplained macrocytosis (high MCV) or macrocytic anemia","html":"<div class=\"graphic\"><div style=\"width: 944px\" class=\"figure\"><div class=\"ttl\">Evaluation of unexplained macrocytosis (high MCV)&nbsp;or macrocytic anemia</div><div class=\"cntnt\"><img style=\"width:924px; height:890px;\" src=\"images/HEME/108047_Evaluation_high_MCV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common causes of macrocytosis and macrocytic anemia include alcohol; liver disease; pernicious anemia, bariatric surgery or strict veganism without vitamin B12 supplementation. Refer to UpToDate content on hemolytic anemia, megaloblastic anemia, and other disorders for more information.</div><div class=\"graphic_footnotes\">MCV: mean corpuscular volume; CBC: complete blood count; WBC: white blood cell; PLT: platelet; PMN: polymorphonuclear neutrophil; LDH: lactate dehydrogenase; HIV: human immunodeficiency virus; MMA: methylmalonic acid.</div><div id=\"graphicVersion\">Graphic 108047 Version 1.0</div></div></div>"},"108050":{"type":"graphic_figure","displayName":"Surgical anatomy of the pancreas","title":"Surgical anatomy of the pancreas","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Surgical anatomy of the pancreas</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/108050_Surgical_anatomy_of_the_pancreas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pancreas is divided into five parts including the head, uncinate process, neck, body, and tail. The head of the pancreas lies to the right of the superior mesenteric artery. The uncinate process is a variable posterolateral extension of the head that passes behind the retropancreatic vessels and anterior to the inferior vena cava and aorta. The neck is defined as the portion of the gland overlying the superior mesenteric vessels. The body and tail lie to the left of the mesenteric vessels. There is no meaningful anatomic division between the body and tail, except that the tail is near the hilum of the spleen.</div><div class=\"graphic_reference\">Modified from: Hruban RH, Pitman MB, Klimstra DS. AFIP Atlas of Tumor Pathology, Fourth Series, Fascicle Tumors of the Pancreas, American Registry of Pathology, Washington, DC in collaboration with the Armed Forces Institute of Pathology, Washington, DC, 2007.</div><div id=\"graphicVersion\">Graphic 108050 Version 1.0</div></div></div>"},"108060":{"type":"graphic_movie","displayName":"Posterior shoulder dislocation reduction demonstration","title":"Posterior shoulder dislocation reduction demonstration","html":"<div class=\"graphic normal\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Posterior shoulder dislocation reduction demonstration</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/108060_Postshldrdslctnrdctnvid.mp4\" style=\"width:624px;height:368px\"></div><img style=\"width:567px; height:346px;\" src=\"images/SM/108060_Postshldrdslctnrdctnimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To reduce a posterior shoulder dislocation, traction is applied to the arm above the elbow, and the shoulder is further adducted and internally rotated as shown in the video.</div><div class=\"graphic_reference\">Reproduced with permission from Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 108060 Version 1.0</div></div></div>"},"108061":{"type":"graphic_figure","displayName":"INRG staging based on pre-treatment imaging and pathology","title":"INRG staging based on pre-treatment imaging and pathology","html":"<div class=\"graphic\"><div style=\"width: 1066px\" class=\"figure\"><div class=\"ttl\">INRG staging based on pre-treatment imaging and pathology</div><div class=\"cntnt\"><img style=\"width:1046px; height:752px;\" src=\"images/ONC/108061_INRG_stg_pretrt_img_pthlgy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">INRG: International Neuroblastoma Risk Group; GN: ganglioneuroma; GNB: ganglioneuroblastoma; Amp: amplified.</div><div class=\"graphic_reference\">From: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Montclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009; 27:298.</LI>&#xD;&#xA;<LI>Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009; 27:289.</LI></OL>Reprinted with permission. Copyright © 2009 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108061 Version 1.0</div></div></div>"},"108065":{"type":"graphic_algorithm","displayName":"Management of anterior abdominal stab wound","title":"Management of anterior abdominal stab wound","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Management of anterior abdominal stab wound</div><div class=\"cntnt\"><img style=\"width:532px; height:628px;\" src=\"images/EM/108065_Mngmnt_anter_abd_stab_wound.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">eFAST: extended FAST ultrasound examination; LWE: local wound exploration; MDCT: multi-detector computed tomography; WBC: white blood cell.<br />* The appropriate length of observation varies according to clinical circumstances. Such characteristics as advanced age, important comorbidities, and medications that increase the risk of bleeding warrant longer observation.<br />&para; Appropriate discharge criteria are described in the topic discussing abdominal stab wounds.</div><div id=\"graphicVersion\">Graphic 108065 Version 2.0</div></div></div>"},"108078":{"type":"graphic_picture","displayName":"High-powered photomicrograph of adenocarcinoma of the lung","title":"High-powered photomicrograph of adenocarcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">High-powered photomicrograph of adenocarcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:720px; height:542px;\" src=\"images/ONC/108078_Adenocarcinoma_lung_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-powered photomicrograph demonstrating the typical acinar pattern of glandular differentiation observed in adenocarcinoma.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108078 Version 1.0</div></div></div>"},"108080":{"type":"graphic_picture","displayName":"Adenocarcinoma of the lung","title":"Adenocarcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:720px; height:542px;\" src=\"images/ONC/108080_Adencrcnma_lung_staining_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a hematoxylin and eosin-stained section of solid adenocarcinoma of the lung, confirmed by positive mucicarmine staining (not shown).</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108080 Version 2.0</div></div></div>"},"108081":{"type":"graphic_picture","displayName":"Atypical adenomatous hyperplasia","title":"Atypical adenomatous hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Atypical adenomatous hyperplasia</div><div class=\"cntnt\"><img style=\"width:764px; height:290px;\" src=\"images/ONC/108081_Atypical_adnmts_hyprplsa_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This 3-mm nodular lesion consists of atypical pneumocytes proliferating along preexisting alveolar walls. There is no invasive component.<br />(B) The slightly atypical pneumocytes are cuboidal and show gaps between the cells. Nuclei are hyperchromatic, and a few show nuclear enlargement and multinucleation.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108081 Version 1.0</div></div></div>"},"108083":{"type":"graphic_picture","displayName":"Nonmucinous adenocarcinoma in situ","title":"Nonmucinous adenocarcinoma in situ","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Nonmucinous adenocarcinoma in situ</div><div class=\"cntnt\"><img style=\"width:763px; height:291px;\" src=\"images/ONC/108083_Nonmcns_adncrcnm_in_situ_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This circumscribed nonmucinous tumor grows purely with a lepidic pattern. No foci of invasion or scarring are seen.<br />(B) The tumor shows atypical pneumocytes proliferating along the slightly thickened, but preserved, alveolar walls.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108083 Version 1.0</div></div></div>"},"108087":{"type":"graphic_picture","displayName":"Mucinous adenocarcinoma in situ","title":"Mucinous adenocarcinoma in situ","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Mucinous adenocarcinoma in situ</div><div class=\"cntnt\"><img style=\"width:720px; height:542px;\" src=\"images/ONC/108087_Mucinos_adncrcnm_in_situ_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This tumor is growing in a purely lepidic fashion and is comprised of tall columnar cells with abundant intracytoplasmic mucin.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108087 Version 1.0</div></div></div>"},"108089":{"type":"graphic_picture","displayName":"Nonmucinous minimally invasive adenocarcinoma","title":"Nonmucinous minimally invasive adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Nonmucinous minimally invasive adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:764px; height:291px;\" src=\"images/ONC/108089_Nonmuc_min_invs_adncrcnm_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This small subpleural tumor shows a predominantly lepidic growth pattern, but there is a left-of-center area of invasion measuring less than 5 mm (oval).<br />(B) The area of invasion shows acinar (oval) and solid (S) patterns.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108089 Version 1.0</div></div></div>"},"108091":{"type":"graphic_picture","displayName":"Invasive mucinous carcinoma","title":"Invasive mucinous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Invasive mucinous carcinoma</div><div class=\"cntnt\"><img style=\"width:720px; height:528px;\" src=\"images/ONC/108091_Invas_mucinous_carcinoma_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a very tightly packed proliferation of mucinous epithelium, focally associated with a desmoplastic stromal response (circle).</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108091 Version 1.0</div></div></div>"},"108092":{"type":"graphic_picture","displayName":"Papillary adenocarcinoma","title":"Papillary adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Papillary adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:764px; height:298px;\" src=\"images/ONC/108092_Papillary_adenocarcinoma_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Papillary adenocarcinoma with fibrovascular cores bears some resemblance to adenocarcinoma in situ (AIS), but the process is too complex for AIS.<br />(B) Micropapillary adenocarcinoma has no fibrovascular cores, and cells often appear to float in alveolar spaces without obvious attachment to the alveolar wall.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108092 Version 1.0</div></div></div>"},"108093":{"type":"graphic_picture","displayName":"Adenocarcinoma variants","title":"Adenocarcinoma variants","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma variants</div><div class=\"cntnt\"><img style=\"width:762px; height:512px;\" src=\"images/ONC/108093_Adenocarcinoma_variants_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This colloid adenocarcinoma contains a cystic component surrounded by a fibrous wall that is filled with pools of mucin (M); such a pattern was previously called mucinous cystadenocarcinoma. The surface of the fibrous wall is lined by well-differentiated cuboidal or columnar mucinous epithelium (arrows).<br />(B) Colloid adenocarcinoma consists of abundant pools of mucin (M) growing within and distending airspaces. Focally well-differentiated malignant mucinous glandular epithelium (arrows) grows along the surface of fibrous septa and within the pools of mucin.<br />(C) Tumor cells (T) can sometimes be seen floating in the pale mucin.<br />​(D) Fetal adenocarcinoma consists of malignant glandular cells growing in tubules and papillary structures. These tumor cells have prominent clear cytoplasm, and squamoid morules are present.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108093 Version 1.0</div></div></div>"},"108094":{"type":"graphic_picture","displayName":"Large cell undifferentiated carcinoma of the lung","title":"Large cell undifferentiated carcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Large cell undifferentiated carcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/ONC/108094_Lrg_cell_undif_crcnm_lng_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-magnification photomicrograph showing large cell undifferentiated carcinoma of the lung. The tumor cells have vesicular nuclei, prominent nucleoli, and abundant eosinophilic cytoplasm. The cells are arranged in sheets without distinct architectural features. Tumor cells did not express TTF-1 (adenocarcinoma marker) or p40 (squamous marker) by immunohistochemistry. This indicated the null phenotype of large cell carcinoma.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108094 Version 1.0</div></div></div>"},"108095":{"type":"graphic_picture","displayName":"Giant cell carcinoma of the lung","title":"Giant cell carcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Giant cell carcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:720px; height:542px;\" src=\"images/ONC/108095_Giant_cell_carcinoma_lng_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of giant cell carcinoma.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108095 Version 1.0</div></div></div>"},"108096":{"type":"graphic_picture","displayName":"Typical carcinoid tumor","title":"Typical carcinoid tumor","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Typical carcinoid tumor</div><div class=\"cntnt\"><img style=\"width:764px; height:272px;\" src=\"images/ONC/108096_Typical_carcinoid_tumor_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Carcinoid tumor of the lung: Photomicrograph showing a carcinoid tumor of the lung with a characteristic neuroendocrine growth pattern.<br />(B) Typical carcinoid tumor: Photomicrograph of a typical pulmonary carcinoid tumor with oncocytic features and abundant oxyphilic tumor cell cytoplasm.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108096 Version 1.0</div></div></div>"},"108097":{"type":"graphic_picture","displayName":"Atypical pulmonary carcinoid tumor","title":"Atypical pulmonary carcinoid tumor","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Atypical pulmonary carcinoid tumor</div><div class=\"cntnt\"><img style=\"width:720px; height:542px;\" src=\"images/ONC/108097_Atyp_pulm_carcin_tumor_HT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical carcinoid tumor with central necrosis (N) associated with karyorrhectic debris.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 108097 Version 1.0</div></div></div>"},"108112":{"type":"graphic_table","displayName":"Risk of congenital anomalies in offspring of women with diabetes","title":"Rate of congenital anomalies among offspring of 1677 women with pre-existing diabetes mellitus in the north of England ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rate&nbsp;of congenital anomalies&nbsp;among offspring of 1677 women with pre-existing diabetes mellitus&nbsp;in the&nbsp;north of England&nbsp;</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Group (subtype)*</td> <td class=\"subtitle1\" colspan=\"2\">Pregnancies with diabetes</td> <td class=\"subtitle1\" colspan=\"2\">Pregnancies without diabetes</td> <td class=\"subtitle1\" rowspan=\"2\">Relative risk (95% CI)</td> </tr> <tr> <td class=\"subtitle2\">n</td> <td class=\"subtitle2\">Rate (95% CI)</td> <td class=\"subtitle2\">n</td> <td class=\"subtitle2\">Rate (95% CI)</td> </tr> <tr> <td>Nervous system</td> <td class=\"centered\">16</td> <td class=\"centered\">9.5 (5.4, 15.4)</td> <td class=\"centered\">769</td> <td class=\"centered\">1.9 (1.8, 2.1)</td> <td class=\"centered\">5.0 (3.0, 8.1)</td> </tr> <tr> <td class=\"indent1\">Neural tube defects</td> <td class=\"centered\">10</td> <td class=\"centered\">6.0 (2.9, 10.9)</td> <td class=\"centered\">443</td> <td class=\"centered\">1.1 (1.0, 1.2)</td> <td class=\"centered\">5.4 (2.9, 10.1)</td> </tr> <tr> <td class=\"indent1\">Hydrocephalus</td> <td class=\"centered\">&nbsp;2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">115&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Microcephaly</td> <td class=\"centered\">&nbsp;1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">55&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Holoprosencephaly</td> <td class=\"centered\">&nbsp;1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">31</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Eye</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">98</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Cardiovascular system</td> <td class=\"centered\">44</td> <td class=\"centered\">26.2 (19.1, 35.1)</td> <td class=\"centered\">2919</td> <td class=\"centered\">7.3 (7.0, 7.6)</td> <td class=\"centered\">3.6 (2.7, 4.8)</td> </tr> <tr> <td class=\"indent1\">Transposition of great vessels</td> <td class=\"centered\">3</td> <td class=\"centered\">1.8 (0.4, 5.2)</td> <td class=\"centered\">130</td> <td class=\"centered\">0.3 (0.3, 0.4)</td> <td class=\"centered\">5.5 (1.8, 17.2)</td> </tr> <tr> <td class=\"indent1\">Single ventricle</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">13</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ventricular septal defect</td> <td class=\"centered\">21</td> <td class=\"centered\">12.5 (7.8, 19.1)</td> <td class=\"centered\">1285</td> <td class=\"centered\">3.2 (3.0, 3.4)</td> <td class=\"centered\">3.9 (2.6, 6.0)</td> </tr> <tr> <td class=\"indent1\">Atrial septal defect</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">217</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Atrioventricular septal defect</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">69</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tetralogy of Fallot</td> <td class=\"centered\">4</td> <td class=\"centered\">2.4 (0.7, 6.0)</td> <td class=\"centered\">95</td> <td class=\"centered\">0.24 (0.2, 0.3)</td> <td class=\"centered\">10.0 (3.7, 27.2)</td> </tr> <tr> <td class=\"indent1\">Pulmonary valve stenosis</td> <td class=\"centered\">3</td> <td class=\"centered\">1.8 (0.4, 5.2)</td> <td class=\"centered\">244</td> <td class=\"centered\">0.6 (0.5, 0.7)</td> <td class=\"centered\">2.9 (0.9, 9.1)</td> </tr> <tr> <td class=\"indent1\">Hypoplastic left heart</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">78</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Coarctation of aorta</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">101</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Total anomalous pulmonary venous return</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">35</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Orofacial clefts</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">437</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Digestive system</td> <td class=\"centered\">10</td> <td class=\"centered\">6.0 (2.9, 10.9)</td> <td class=\"centered\">421</td> <td class=\"centered\">1.05 (0.95, 1.15)</td> <td class=\"centered\">5.7 (3.0, 10.6)</td> </tr> <tr> <td class=\"indent1\">Oesophageal atresia</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">43</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Duodenal atresia or stenosis</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">36</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hirschprung's disease</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">51</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Atresia of bile ducts</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">15</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diaphragmatic hernia</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">91</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Urinary</td> <td class=\"centered\">12</td> <td class=\"centered\">7.2 (3.7, 12.5)</td> <td class=\"centered\">974</td> <td class=\"centered\">2.4 (2.3, 2.6)</td> <td class=\"centered\">2.9 (1.7, 5.2)</td> </tr> <tr> <td class=\"indent1\">Cystic kidney disease</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">200</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Congenital hydronephrosis</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">20</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bladder exstrophy</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">14</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Genital</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">76</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Limb</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">234</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Musculoskeletal</td> <td class=\"centered\">3</td> <td class=\"centered\">1.8 (0.4, 5.2)</td> <td class=\"centered\">55</td> <td class=\"centered\">0.14 (0.1, 0.2)</td> <td class=\"centered\">13.0 (4.1, 41.5)</td> </tr> <tr> <td>Syndrome (monogenic or unknown)</td> <td class=\"centered\">11</td> <td class=\"centered\">6.6 (3.2, 11.7)</td> <td class=\"centered\">439</td> <td class=\"centered\">1.1 (1.0, 1.2)</td> <td class=\"centered\">6.0 (3.1, 10.9)</td> </tr> <tr> <td class=\"indent1\">Laterality syndrome (right/left atrial isomerism, situs inversus)</td> <td class=\"centered\">6</td> <td class=\"centered\">3.6 (1.3, 7.8)</td> <td class=\"centered\">25</td> <td class=\"centered\">0.06 (0.04, 0.09)</td> <td class=\"centered\">57.2 (23.5, 139.2)</td> </tr> <tr> <td class=\"indent1\">Angelman syndrome</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">6</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Blepharophimosis-ptosis syndrome</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">3</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Laurence-Moon syndrome</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Prader-Willi syndrome</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">10</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Incontinentia pigmenti</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">6</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Associations</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">34</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Sequence</td> <td class=\"centered\">7</td> <td class=\"centered\">4.2 (1.6, 8.6)</td> <td class=\"centered\">139</td> <td class=\"centered\">0.35 (0.3, 0.4)</td> <td class=\"centered\">12.0 (5.6, 25.6)</td> </tr> <tr class=\"divider_bottom\"> <td>Caudal dysplasia sequence</td> <td class=\"centered\">5</td> <td class=\"centered\">3.0 (0.9, 6.9)</td> <td class=\"centered\">7</td> <td class=\"centered\">0.02 (0.01, 0.03)</td> <td class=\"centered\">170.2 (54.1, 535.6)</td> </tr> <tr class=\"divider_bottom\"> <td>Sirenomelia</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">6</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Partial urorectal septum malformation sequence</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">21</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Multiple anomalies</td> <td class=\"centered\">9</td> <td class=\"centered\">5.4 (2.5, 10.2)</td> <td class=\"centered\">440</td> <td class=\"centered\">1.1 (1.0, 1.2)</td> <td class=\"centered\">4.9 (2.5, 9.4)</td> </tr> <tr class=\"divider_bottom\"> <td>Total nonchromosomal</td> <td class=\"centered\">120</td> <td class=\"centered\">71.6 (59.6, 84.9)</td> <td class=\"centered\">7613</td> <td class=\"centered\">19.1 (18.6, 19.5)</td> <td class=\"centered\">3.8 (3.2, 4.5)</td> </tr> <tr class=\"divider_bottom\"> <td>Chromosomal anomalies</td> <td class=\"centered\">9</td> <td class=\"centered\">5.4 (2.5, 10.2)</td> <td class=\"centered\">1747</td> <td class=\"centered\">4.4 (4.2, 4.6)</td> <td class=\"centered\">1.2 (0.6, 2.4)</td> </tr> <tr class=\"divider_top highlight_gray_text\"> <td><strong>Grand total</strong></td> <td class=\"centered\"><strong>129</strong></td> <td class=\"centered\"><strong>76.9 (64.6, 90.8)</strong></td> <td class=\"centered\"><strong>9359</strong></td> <td class=\"centered\"><strong>23.4 (23.0, 23.9)</strong></td> <td class=\"centered\"><strong>3.3 (2.8, 3.9)</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Rates (95% CI) of major groups and selected subtypes of congenital anomalies* in pregnancies of women with and without pre-existing diabetes per 1000 singleton pregnancies and relative risk (95% CI).</div><div class=\"graphic_footnotes\">* European Surveillance of Congenital Anomalies (EUROCAT) coding.</div><div class=\"graphic_reference\">Reproduced from: Bell R, Glinianaia SV, Tennant PW, et al. Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. Diabetologia 2012; 55:936. Copyright &copy; Springer-Verlag 2012; with permission of Springer.</div><div id=\"graphicVersion\">Graphic 108112 Version 3.0</div></div></div>"},"108113":{"type":"graphic_table","displayName":"Fluid management children in resource-limited settings","title":"WHO 2016 guidelines: Fluid management in children with signs of impaired circulation in resource-limited settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO 2016 guidelines: Fluid management in children with signs of impaired circulation in resource-limited settings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Children who are not in shock but have signs of circulatory impairment</td> </tr> <tr> <td> <ol> <li>Children with only one or two signs of impaired circulation (eg, cold extremities or capillary refill &#62;3 seconds or a weak and fast pulse) but who do not have the full clinical features of shock (ie, all three signs present together) should not receive any rapid infusion of fluids but should still receive maintenance fluids appropriate for their age and weight. </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>In the absence of shock, rapid IV infusion of fluids may be particularly harmful to children who have severe febrile illness, severe pneumonia, severe malaria, meningitis, severe acute malnutrition, severe anemia, congestive heart failure with pulmonary edema, congenital heart disease, renal failure or diabetic ketoacidosis. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li>Children with any sign of impaired circulation &nbsp;(ie, cold extremities or prolonged capillary refill or weak, fast pulse) should be prioritized for full assessment and treatment and reassessed within 1 hour. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Children who are in shock</td> </tr> <tr> <td> <ol> <li>Children who are in shock (ie, who have all the following signs: cold extremities with capillary refill &#62;3 seconds and a weak and fast pulse) should receive IV fluids. <ul class=\"decimal_heading\"> <li>They should be given 10 to 20 mL/kg body weight (BW) of isotonic crystalloid fluids over 30 to 60 minutes. </li> <li>They should be fully assessed, an underlying diagnosis made, receive other relevant treatment and their condition monitored. </li> <li>The child should be reassessed at the completion of infusion and during subsequent hours to check for any deterioration: <ul> <li>If the child is still in shock, consider giving a further infusion of 10 mL/kg&nbsp;BW over 30 minutes. </li> <li>If shock has resolved, provide fluids to maintain normal hydration status only (maintenance fluids). </li> </ul> </li> <li>If, at any time, there are signs of fluid overload, cardiac failure or neurological deterioration, the infusion of fluids should be stopped, and no further IV infusion of fluids should be given until the signs resolve. </li> </ul> </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Children in shock and with severe anaemia (erythrocyte volume fraction [hematocrit] &#60;15 or hemoglobin &#60;5 g/dL as defined by WHO) should receive a blood transfusion as early as possible and receive other IV fluids only to maintain normal hydration. </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li>Children with severe acute malnutrition* who are in shock should receive 10 to 15 mL/kg&nbsp;BW of IV fluids over the first hour. Children who improve after the initial infusion should receive only oral or nasogastric maintenance fluids. Any child who does not improve after 1 hour should be given a blood transfusion (10 mL/kg&nbsp;BW slowly over at least 3 hours). </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous. WHO: World Health Organization.<br />* In infants and children aged 6 to 59 months, severe acute malnutrition is defined as weight-for-height Z-score&nbsp;&lt;–3 using WHO growth standards, or mid-upper arm circumference (MUAC)&nbsp;&lt; 11.5 cm;&nbsp;or clinical signs of bilateral oedema of nutritional origin.</div><div class=\"graphic_reference\">Adapted from: Updated guideline: paediatric emergency triage, assessment and treatment. Geneva: World Health Organization, 2016. Available <A spellcheck=true href=\"http://www.who.int/maternal_child_adolescent/documents/paediatric-emergency-triage-update/en/\" target=_blank>here</A> (Accessed on May 13, 2016).</div><div id=\"graphicVersion\">Graphic 108113 Version 3.0</div></div></div>"},"108114":{"type":"graphic_movie","displayName":"Subaortic membrane 3D echo","title":"Three-dimensional echocardiography (3D echo) of a subaortic membrane","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Three-dimensional echocardiography (3D echo) of a subaortic membrane</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/108114_Subaortcmembrn3Dechovid.mp4\" style=\"width:640px;height:480px\"></div><img style=\"width:573px; height:402px;\" src=\"images/PEDS/108114_Subaortcmembrn3Dechoimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis image demonstrating a discrete protruding septal muscular ridge and associated membrane arising anteriorly from the ventricular septum a few millimeters below the aortic annulus.</div><div id=\"graphicVersion\">Graphic 108114 Version 1.0</div></div></div>"},"108115":{"type":"graphic_movie","displayName":"BAV with R-N fusion","title":"Bicommissural aortic valve with fusion of the right-noncoronary commissure","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Bicommissural aortic valve with fusion of the right-noncoronary commissure</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/108115_BAVwithRNfusionvid.mp4\" style=\"width:640px;height:496px\"></div><img style=\"width:576px; height:426px;\" src=\"images/PEDS/108115_BAVwithRNfusionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiographic en-face view of a bicommissural aortic valve with fusion of the right-noncoronary commissure; by convention the valve is demonstrated as if viewed from below.</div><div id=\"graphicVersion\">Graphic 108115 Version 1.0</div></div></div>"},"108135":{"type":"graphic_figure","displayName":"Flow-volume loop with knee pattern","title":"Expiratory flow-volume curve showing \"knee\" pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Expiratory flow-volume curve showing \"knee\" pattern</div><div class=\"cntnt\"><img style=\"width:406px; height:417px;\" src=\"images/PULM/108135_Flow-volume_loop_with_knee_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Expiratory flow-volume curve showing a \"knee\" pattern, which is considered to be a normal variant most commonly seen in young adults.</div><div class=\"graphic_footnotes\">TLC: total lung capacity; RV: residual volume.</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Shin HH, Sears MR, Hancox RJ. Prevalence and correlates of a 'knee' pattern on the maximal expiratory flow-volume loop in young adults. Respirology 2014; 19:1052.</LI>&#xD;&#xA;<LI>Johnston R. What’s a normal Flow-volume Loop? PFT Blog. Available at: <A spellcheck=true href=\"http://www.pftforum.com/blog/whats-a-normal-flow-volume-loop\" target=_blank>http://www.pftforum.com/blog/whats-a-normal-flow-volume-loop</A> (Accessed on July 7, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 108135 Version 1.0</div></div></div>"},"108136":{"type":"graphic_table","displayName":"Brief resolved unexplained event (BRUE)","title":"Brief resolved unexplained event (BRUE) in infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Brief resolved unexplained event (BRUE) in infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definition:</td> </tr> <tr class=\"divider_bottom\"> <td>A sudden, brief, and now resolved* episode in an infant that includes <strong>one or more </strong>of the following features: <ul class=\"decimal_heading\"> <li>Cyanosis or pallor </li> <li>Absent, decreased, or irregular breathing </li> <li>Marked change in tone (hyper- or hypotonia) </li> <li>Altered level of responsiveness </li> </ul> The term should be applied only when there is no explanation for the episode after a focused history and physical examination.</td> </tr> <tr> <td class=\"subtitle1_single\">Low risk characteristics:</td> </tr> <tr> <td>Infants who have experienced BRUE are at low&nbsp;risk for having a recurrence or serious underlying disorder if they have <strong>all </strong>of the following: <ul class=\"decimal_heading\"> <li>Age &#62;60 days </li> <li>Gestational age &#8805;32 weeks and postconceptional age &#8805;45 weeks </li> <li>Occurrence of only one BRUE (no prior BRUE, and BRUE did not occur in clusters) </li> <li>Duration of BRUE &#60;1 minute </li> <li>No cardiopulmonary resuscitation (CPR) by a trained medical provider was required </li> <li>No concerning historical features<sup>&#182;</sup> </li> <li>No concerning physical examination findings<sup>&#916;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">* The term \"brief\" indicates that the estimated duration of the event was less than one minute; \"resolved\" indicates that the infant is asymptomatic on presentation after the event.</SPAN><br />¶ Concerning historical features include social risk factors for child abuse, respiratory illness or exposure, recent injury, other symptoms in days preceding the event (fever, fussiness, diarrhea or decreased intake), administration or access to medications, history of episodic vomiting or lethargy,&nbsp;developmental delay or congenital anomalies,&nbsp;family history of BRUE or sudden unexplained death in a sibling.&nbsp;<br />Δ Concerning physical examination findings include any&nbsp;signs of&nbsp;injury, including bleeding or bruising (especially on the scalp&nbsp;trunk, face or ears), or bulging anterior fontanel; altered sensorium; fever or toxic appearance; respiratory distress; and&nbsp;abdominal distension or vomiting. </div><div class=\"graphic_reference\">Data from: Tieder JS, Bonkowsky JL, Etzel RA, et al. Brief resolved unexplained events (formerly apparent life-threatening events) and evaluation of lower-risk infants: Executive summary. Pediatrics 2016; 137:e2 0160591.</div><div id=\"graphicVersion\">Graphic 108136 Version 2.0</div></div></div>"},"108137":{"type":"graphic_picture","displayName":"Atopic keratoconjunctivitis","title":"Atopic keratoconjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Atopic keratoconjunctivitis</div><div class=\"cntnt\"><img style=\"width:576px; height:425px;\" src=\"images/ALLRG/108137_Atopic_keratoconjunctivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmentation and erythema of lid skin, also termed \"panda eyes,\" is typically seen in mild-to-moderate disease.</div><div class=\"graphic_reference\">From: La Rosa M, Lionetti E, Reibaldi M, et al. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr 2013; 39:18. Copyright &copy; 2013 La Rosa et al. Reproduced under the Creative Commons Attribution License (<a href=\"http://creativecommons.org/licenses/by/2.0/\" target=\"_blank\">CC BY 2.0</a>).</div><div id=\"graphicVersion\">Graphic 108137 Version 1.0</div></div></div>"},"108138":{"type":"graphic_table","displayName":"Genetic disorders associated with renal hypodysplasia","title":"Genetic disorders associated with renal hypodysplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic disorders associated with renal hypodysplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Inheritance pattern</td> <td class=\"subtitle1\">Gene and chromosomal location</td> <td class=\"subtitle1\">OMIM number</td> <td class=\"subtitle1\">Renal and urological anomalies</td> <td class=\"subtitle1\">Extrarenal anomalies</td> </tr> <tr class=\"divider_bottom\"> <td>Branchio-oto-renal (BOR) syndrome</td> <td>Autosomal dominant</td> <td><em>EYA1</em> on 8q13.3<br /> <em>SIX5</em> on 19q13.32</td> <td><a href=\"http://www.omim.org/entry/113650\" target=\"_blank\">113650</a>, <a href=\"http://www.omim.org/entry/610896\" target=\"_blank\">610896</a></td> <td>Renal agenesis, hypoplasia, dysplasia</td> <td>Branchial defects with lateral cervical fistulas or cysts, ear pits, hearing loss</td> </tr> <tr class=\"divider_bottom\"> <td>Cenani-Lenz syndrome</td> <td>Autosomal recessive</td> <td><em>LRP4</em> on 11p11.2</td> <td><a href=\"http://www.omim.org/entry/212780\" target=\"_blank\">212780</a></td> <td>Renal agenesis, hypoplasia, dysplasia</td> <td>Distal limb abnormalities (syndactyly or oligodactyly), facial dysmorphism</td> </tr> <tr class=\"divider_bottom\"> <td>CHARGE syndrome</td> <td>Autosomal dominant</td> <td><em>CHD7</em> on 8q12.2</td> <td><a href=\"http://www.omim.org/entry/214800\" target=\"_blank\">214800</a></td> <td>Renal hypoplasia, solitary kidney, duplex kidneys, ureteropelvic junction obstruction, VUR</td> <td>Coloboma of the retina or the iris, heart anomalies, choanal atresia, mental retardation, genital and ear anomalies</td> </tr> <tr class=\"divider_bottom\"> <td>Kallmann syndrome</td> <td>&nbsp;</td> <td>Multiple genes, including <em>KAL1</em>, <em>FGFR1</em>, <em>FGF8</em>, <em>CHD7</em>, <em>PROK2</em>, <em>PROKR2</em></td> <td><a href=\"http://www.omim.org/entry/308700\" target=\"_blank\">308700</a></td> <td>Renal agenesis, renal dysplasia, hydronephrosis, VUR</td> <td>Hypogonadotrophic hypogonadism, anosmia, or hyposmia</td> </tr> <tr class=\"divider_bottom\"> <td>Pallister-Hall syndrome</td> <td>Autosomal dominant</td> <td><em>GLI3</em> on 7p14</td> <td><a href=\"http://www.omim.org/entry/146510\" target=\"_blank\">146510</a></td> <td>Renal agenesis, renal hypodysplasia</td> <td>Hypothalamic hamartoma, central and postaxial polydactyly, bifid epiglottis, imperforate anus</td> </tr> <tr class=\"divider_bottom\"> <td>Renal-coloboma syndrome (Papillorenal syndrome)</td> <td>Autosomal dominant</td> <td><em>PAX2</em> on 10q24</td> <td><a href=\"http://www.omim.org/entry/120330\" target=\"_blank\">120330</a></td> <td>Renal hypodysplasia, VUR</td> <td>Optic nerve coloboma</td> </tr> <tr class=\"divider_bottom\"> <td>Renal cysts and diabetes (RCAD) syndrome</td> <td>Autosomal dominant</td> <td><em>HNF1B </em>on 17q12</td> <td><a href=\"http://www.omim.org/entry/137920\" target=\"_blank\">137920</a></td> <td>Renal agenesis, renal cysts, renal dysplasia, multicystic kidney disease</td> <td>Diabetes, hypomagnesemia, hyperuricemia, genital tract anomalies, autism</td> </tr> <tr class=\"divider_bottom\"> <td>Renal tubular dysgenesis</td> <td>Autosomal recessive</td> <td><em>ACE</em> on 17q23.3<br /> <em>AGT</em> on 1q42.2<br /> <em>AGTR1</em> on 3q24<br /> <em>REN</em> on 1q32.1</td> <td><a href=\"http://www.omim.org/entry/267430\" target=\"_blank\">267430</a></td> <td>Renal tubular dysgenesis with oligohydramnios or anhydramnios</td> <td>Pulmonary hypoplasia, skull ossification defects, arterial hypotension</td> </tr> <tr class=\"divider_bottom\"> <td>Simpson-Golabi-Behmel syndrome</td> <td>X-linked</td> <td><em>GPC3</em> on Xq26</td> <td><a href=\"http://www.omim.org/entry/312870\" target=\"_blank\">312870</a></td> <td>Renal cysts, renal dysplasia</td> <td>Somatic overgrowth, increased risk of tumors, craniofacial and vertebral anomalies, cardiac defects, cryptorchidism</td> </tr> <tr class=\"divider_bottom\"> <td>Townes-Brocks syndrome (anus-hand-ear syndrome)</td> <td>Autosomal dominant</td> <td><em>SALL1</em> on 16q12.1</td> <td><a href=\"http://www.omim.org/entry/107480\" target=\"_blank\">107480</a></td> <td>Renal hypodysplasia, MCDK, VUR, posterior urethral valves</td> <td>Imperforate anus, preaxial polydactyly and triphalangeal thumbs, external ear anomalies, SNHL</td> </tr> <tr class=\"divider_bottom\"> <td>Fraser syndrome</td> <td>Autosomal recessive</td> <td><em>FRAS1</em><br /> <em>FREM2</em><br /> <em>GRIP1</em></td> <td><a href=\"http://www.omim.org/entry/219000\" target=\"_blank\">219000</a></td> <td>Renal agenesis, renal cystic dysplasia</td> <td>Cryptophthalmos, cutaneous syndactyly, genital malformations</td> </tr> <tr class=\"divider_bottom\"> <td>Bifid nose, renal agenesis, and anorectal malformations (BNAR) syndrome</td> <td>Autosomal recessive</td> <td><em>FREM2</em> on 9p22.2-p23</td> <td><a href=\"http://www.omim.org/entry/608980\" target=\"_blank\">608980</a></td> <td>Unilateral or bilateral renal agenesis</td> <td>Bifid nose, anorectal malformations</td> </tr> <tr> <td>Hypoparathyroidism, sensorineural deafness, and renal dysplasia (HDR; also known as Barakat syndrome)</td> <td>Autosomal dominant</td> <td><em>GATA3</em> on 10p14</td> <td><a href=\"http://www.omim.org/entry/146255\" target=\"_blank\">146255</a></td> <td>Renal dysplasia</td> <td>Hypoparathyroidism, SNHL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAKUT: congenital anomalies of the kidney and urinary tract; CHARGE: coloboma, heart anomaly, choanal atresia, retardation, genital and ear anomalies; MCDK: multicystic dysplastic kidney; OMIM: Online Mendelian Inheritance in Man; SNHL: sensorineural hearing loss; VUR: vesicoureteral reflux.</div><div id=\"graphicVersion\">Graphic 108138 Version 1.0</div></div></div>"},"108139":{"type":"graphic_figure","displayName":"PALM-COEIN AUB fibroid locations","title":"PALM-COEIN AUB leiomyoma locations","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">PALM-COEIN AUB leiomyoma locations</div><div class=\"cntnt\"><img style=\"width:764px; height:501px;\" src=\"images/OBGYN/108139_PALM-COEIN_AUB_fibroid_ltns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Submucous leiomyomas.<br />(B) Intramural and subserous leiomyomas, \"other\" or outside the endometrial cavity.<br />(C) Hybrid (transmural) leiomyomas.</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 108139 Version 1.0</div></div></div>"},"108140":{"type":"graphic_picture","displayName":"Condyloma acuminatum on vulva","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/108140_Condyloma_acuminatum_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Condyloma acuminatum on the vulva.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108140 Version 1.0</div></div></div>"},"108141":{"type":"graphic_picture","displayName":"Condyloma acuminatum on the penis","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108141_Condyloma_acuminatum_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules on the penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108141 Version 1.0</div></div></div>"},"108144":{"type":"graphic_picture","displayName":"Condyloma acuminatum on penis","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108144_Verrucous_plaque_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous plaque on the penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108144 Version 1.0</div></div></div>"},"108145":{"type":"graphic_picture","displayName":"Condyloma acuminatum at base of penis","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/108145_Condyloma_acuminatum_base_p.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous papules and plaque at base of penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108145 Version 1.0</div></div></div>"},"108146":{"type":"graphic_picture","displayName":"Perianal condyloma acuminatum","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108146_Perianal_condyloma_acuminat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perianal verrucous papules and plaques.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108146 Version 1.0</div></div></div>"},"108147":{"type":"graphic_picture","displayName":"Suprapubic condyloma acuminatum","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108147_Suprapubic_condyloma_acumin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Suprapubic condyloma acuminatum.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108147 Version 1.0</div></div></div>"},"108148":{"type":"graphic_picture","displayName":"Condyloma acuminatum at urethra","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108148_Condyloma_acuminatum_urethr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Condylomata involving the urethral meatus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108148 Version 1.0</div></div></div>"},"108149":{"type":"graphic_picture","displayName":"Nevus depigmentosus","title":"Nevus depigmentosus","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Nevus depigmentosus</div><div class=\"cntnt\"><img style=\"width:613px; height:648px;\" src=\"images/DERM/108149_Nevus_depigmentosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus depigmentosus presenting as a large hypopigmented patch involving the back and posterior aspect of the arm.</div><div id=\"graphicVersion\">Graphic 108149 Version 1.0</div></div></div>"},"108152":{"type":"graphic_table","displayName":"2015 WHO classification invasive lung tumors compared with 2004","title":"2015 WHO classification of invasive malignant epithelial lung tumors, with notable changes compared with the 2004 classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2015 WHO classification of invasive malignant epithelial lung tumors, with notable changes compared with the 2004 classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor type</td> <td class=\"subtitle1\">Changes from 2004 WHO classification</td> <td class=\"subtitle1\">2015 variants (if applicable)</td> </tr> <tr class=\"divider_bottom\"> <td>Adenocarcinoma</td> <td> <ul> <li>Discontinuation of terms bronchioalveolar carcinoma, mixed subtype adenocarcinoma, clear cell and signet ring adenocarcinoma (these subtypes are descriptive features in the 2015 system), and mucinous cystadenocarcinoma (these tumors are reclassified as colloid adenocarcinomas). </li> <li>Addition of adenocarcinoma in situ and minimally invasive adenocarcinoma. </li> <li>Classification of invasive adenocarcinoma according to predominant subtype. </li> <li>Introduction of the term lepidic for a noninvasive component of an invasive adenocarcinoma. </li> </ul> </td> <td> <ul> <li>Lepidic </li> <li>Acinar </li> <li>Papillary </li> <li>Micropapillary </li> <li>Solid </li> <li>Invasive mucinous (mixed invasive mucinous and non-mucinous) </li> <li>Colloid </li> <li>Fetal </li> <li>Enteric </li> <li>Minimally invasive </li> <li>Preinvasive (atypical adenomatous hyperplasia, adenocarcinoma in situ [non-mucinous and mucinous]) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Adenosquamous cell carcinoma</td> <td> <ul> <li>No significant changes. </li> </ul> </td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td>Squamous cell carcinoma</td> <td> <ul> <li>Papillary, clear cell, small cell, and basaloid carcinoma have been replaced. </li> <li>Clear cell change is now regarded as a cytologic feature. </li> </ul> </td> <td> <ul> <li>Keratinizing </li> <li>Non-keratinizing </li> <li>Basaloid </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Large cell carcinoma</td> <td> <ul> <li>The following have been reclassified from \"large cell carcinomas\" to other subgroups: basaloid carcinoma is a subgroup of squamous cell carcinomas, large cell neuroendocrine carcinoma is a neuroendocrine carcinoma, and lymphoepithelioma-like carcinoma belongs to \"other and unclassified carcinomas.\" </li> <li>Clear cell and rhabdoid are now descriptive features rather than subtypes. </li> </ul> </td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td>Sarcomatoid carcinoma</td> <td> <ul> <li>No significant changes, although molecular testing now recommended. </li> </ul> </td> <td> <ul> <li>Pleomorphic carcinoma </li> <li>Spindle cell carcinoma </li> <li>Giant cell carcinoma </li> <li>Carcinosarcoma </li> <li>Pulmonary blastoma </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Neuroendocrine carcinoma</td> <td> <ul> <li>Previously, small cell and large cell neuroendocrine tumors were in different categories and are now grouped together. </li> </ul> </td> <td> <ul> <li>Small cell carcinoma </li> <li>Large cell neuroendocrine carcinoma </li> <li>Carcinoid (typical and atypical) </li> </ul> </td> </tr> <tr> <td>Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia</td> <td> <ul> <li>No significant changes. </li> </ul> </td> <td>N/A</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Brambilla E, Travis WD. Lung cancer. In: World Cancer Report, Stewart BW, Wild CP (Eds), World Health Organization, Lyon 2014.</li>&#xD;&#xA;    <li>Travis WD, Brambilla EW, Burke AP, et al. WHO Classification of tumors of the lung, pleura, thymus, and heard, IARC Press, Lyon 2015.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 108152 Version 1.0</div></div></div>"},"108155":{"type":"graphic_picture","displayName":"Molluscum contagiosum on penis","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108155_Molluscum_contagiosum_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple umbilicated papules on the penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108155 Version 1.0</div></div></div>"},"108157":{"type":"graphic_picture","displayName":"Fordyce spots","title":"Fordyce spots on penis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fordyce spots on penis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108157_Fordyce_spots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, yellow papules on the penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108157 Version 1.0</div></div></div>"},"108158":{"type":"graphic_table","displayName":"Diagnostic criteria for TTTS","title":"Diagnostic criteria for twin-twin transfusion syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for twin-twin transfusion syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <ul> <li>Single monochorionic placenta </li> </ul> </td> </tr> <tr> <td> <ul> <li>Polyhydramnios/oligohydramnios sequence <ul> <li>Before 20 weeks of gestation, the maximum vertical pockets for oligohydramnios and polyhydramnios are &#60;2 cm and &#62;8 cm, respectively </li> <li>After 20 weeks, the maximum vertical pocket for polyhydramnios is defined as &#62;10 cm </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 108158 Version 1.0</div></div></div>"},"108159":{"type":"graphic_picture","displayName":"Lichen nitidus on penis","title":"Lichen nitidus","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Lichen nitidus</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/108159_Lichen_nitidus_on_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple pinhead-sized papules on the penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108159 Version 1.0</div></div></div>"},"108160":{"type":"graphic_picture","displayName":"Triquetrum palpation","title":"Triquetrum palpation","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Triquetrum palpation</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/SM/108160_Triquetrum_palpation_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The triquetrum can best be palpated by placing the wrist in radial deviation, finding the ulnar styloid, and palpating just distal to that. The first bony prominence encountered is the triquetrum (circled area).</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 108160 Version 1.0</div></div></div>"},"108161":{"type":"graphic_table","displayName":"Diagnostic criteria for TAPS","title":"Diagnostic criteria for twin anemia-polycythemia sequence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for twin anemia-polycythemia sequence</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Fetal criteria</strong> <ul class=\"decimal_heading\"> <li>MCA-PSV &#62;1.50 MoM in the donor and MCA-PSV &#60;0.80 MoM in the recipient </li> </ul> </td> </tr> <tr> <td><strong>Neonatal criteria</strong> <ul class=\"decimal_heading\"> <li>Intertwin hemoglobin difference &#62;8.0 g/dL and intertwin reticulocyte count ratio (donor/recipient) &#62;1.7 </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCA-PSV: middle cerebral artery peak systolic velocity; MoM: multiples of the median.</div><div id=\"graphicVersion\">Graphic 108161 Version 1.0</div></div></div>"},"108170":{"type":"graphic_table","displayName":"Diagnosis and classification of selective FGR","title":"Diagnosis and classification of selective fetal growth restriction in monochorionic twins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnosis and classification of selective fetal growth restriction in monochorionic twins</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Diagnosis:</strong> Estimated weight of one twin below the 10<sup>th</sup> percentile or discordance in estimated twin weights greater than 25 percent</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Type 1:</strong> Normal/positive Doppler flow in the umbilical artery <ul class=\"decimal_heading\"> <li>Mild intertwin weight discordance</li> <li>Usually favorable outcome for both twins: Very low risk of fetal demise of growth-restricted twin</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Type 2:</strong> Absent/reversed end-diastolic flow in the umbilical artery <ul class=\"decimal_heading\"> <li>Poorest prognosis: High risk of fetal demise of growth-restricted twin</li> <li>Mean gestational age at delivery: 29 weeks of gestation</li> </ul> </td> </tr> <tr> <td><strong>Type 3:</strong> Intermittent absent/reversed end-diastolic flow in the umbilical artery <ul class=\"decimal_heading\"> <li>Intermediate prognosis: 10 to 15 percent risk of fetal demise of growth-restricted twin</li> <li>Commonly survive to 32 weeks or more of gestation</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Gratacos E, Ortiz JU, Martinez JM. A systematic approach to the differential diagnosis and management of the complications of monochorionic twin pregnancies. Fetal Diagn Ther 2012; 32:145.</div><div id=\"graphicVersion\">Graphic 108170 Version 1.0</div></div></div>"},"108173":{"type":"graphic_table","displayName":"Key periods during cardiac surgery","title":"Key periods during cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key periods during cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Period</td> <td class=\"subtitle1_left\">Anesthetic goals</td> </tr> <tr class=\"divider_top\"> <td class=\"divider_bottom\" rowspan=\"12\">Prebypass period</td> <td>Induction and maintenance of anesthesia</td> <td> <ul> <li>Maintain optimal myocardial O<sub>2</sub> supply and minimize demand to prevent or treat ischemia </li> </ul> </td> </tr> <tr> <td>Antibiotic prophylaxis</td> <td> <ul> <li>Timely administration of selected antibiotics </li> </ul> </td> </tr> <tr> <td>Positioning</td> <td> <ul> <li>Careful arm, hand, and head positioning to avoid injuries </li> </ul> </td> </tr> <tr> <td>Fluid management</td> <td> <ul> <li>Restrict fluid administration since initiation of CPB causes significant hemodilution </li> </ul> </td> </tr> <tr> <td>Prebypass TEE examination</td> <td> <ul> <li>Assess regional LV wall motion abnormalities </li> <li>Assess global LV function </li> <li>Assess global RV function </li> <li>Assess structure and function of cardiac valves </li> <li>Evaluate thoracic aorta, interatrial septum, and left atrium&nbsp;with left atrial appendage </li> <li>Detect development of ischemia, hypovolemia, hypervolemia, or low SVR </li> </ul> </td> </tr> <tr> <td>Incision and sternotomy</td> <td> <ul> <li>Treat hypertension and tachycardia due to painful stimuli </li> <li>Briefly interrupt ventilation during sternotomy to avoid lung injury </li> </ul> </td> </tr> <tr> <td>Harvesting of the internal mammary artery</td> <td> <ul> <li>Reduce tidal volume </li> </ul> </td> </tr> <tr> <td>Anticoagulation for CPB</td> <td> <ul> <li>Administer heparin and ensure adequate anticoagulation (confirm with ACT) </li> </ul> </td> </tr> <tr> <td>Antifibrinolytic administration</td> <td> <ul> <li>Administer antifibrinolytic agent to minimize microvascular bleeding </li> </ul> </td> </tr> <tr> <td><span style=\"color: black;\">Perfusionist completes CPB circuit setup, priming, testing of alarms and circuit, adherence to checklist</span></td> <td> <ul id=\"_telerik_insertedList_id\"> <li><span style=\"color: black;\">Confer with perfusionist if indicated</span> </li> </ul> </td> </tr> <tr> <td>Aortic cannulation</td> <td> <ul> <li>Reduce systolic BP to &#60;100 mmHg to reduce risk of aortic dissection </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Venous cannulation</td> <td> <ul> <li>Treat hypotension or initiate CPB for malignant arrhythmias </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Initiation of CPB</td> <td>Retrograde autologous priming</td> <td> <ul> <li>Gradual onset of CPB to reduce hemodilution from crystalloid prime </li> </ul> </td> </tr> <tr> <td>Control of O<sub>2</sub> delivery, CO<sub>2</sub> removal, and pump flow assumed by perfusionist</td> <td> <ul> <li>Discontinue controlled ventilation and anesthetic administration via the anesthesia machine </li> <li>Discontinue cardiac support (eg, inotropic agents, IABP) </li> </ul> </td> </tr> <tr> <td>Anesthetic administration</td> <td> <ul> <li>Initiate volatile anesthetic administration via vaporizer attached to CPB circuit, or use TIVA technique </li> <li>Monitor raw and/or processed EEG and expired anesthetic gas from the oxygenator to prevent awareness </li> <li>Monitor neuromuscular function; administer NMBAs to prevent movement or shivering </li> </ul> </td> </tr> <tr> <td>Placement of aortic crossclamp and administration of cardioplegia</td> <td> <ul> <li>Ensure complete myocardial arrest (absence of ECG electrical activity) </li> <li>TEE monitoring for aortic insufficiency and LV distension during antegrade cardioplegia delivery </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Placement and monitoring of coronary sinus catheter and LV vent</td> <td> <ul> <li>TEE assessment of coronary sinus catheter placement for retrograde cardioplegia delivery </li> <li>Monitor coronary sinus pressure </li> <li>TEE assessment of&nbsp;correct LV vent placement and effective LV decompression </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Maintenance of CPB</td> <td>Cooling</td> <td> <ul> <li>Maintain temperature gradient between venous inflow and arterial outlet &#60;10&#176;C </li> </ul> </td> </tr> <tr> <td>Maintenance</td> <td> <ul> <li>Maintain MAP &#8805;65 mmHg (or &#8805;75 mmHg for patients with cerebrovascular disease or severe aortic atherosclerosis) </li> <li>Monitor temperature at oxygenator arterial outlet temperature (surrogate for cerebral temperature) and other sites (eg, nasopharyngeal, bladder, blood) </li> <li>Maintain Hgb &#8805;7.5 g/dL (Hct &#8805;22%); suggest hemoconcentration if Hgb &#60;7.5 g/dL, then transfuse PRBC if necessary </li> <li>Maintain SvO<sub>2</sub> &#8805;75%; suggest increase in pump flow if SvO<sub>2</sub> &#60;75% </li> </ul> </td> </tr> <tr> <td>Rewarming</td> <td> <ul> <li>Slow rewarming &#8804;0.5&#176;C/minute, with temperature gradient between venous inflow and arterial outlet &#8804;4&#176;C </li> <li>Avoid hyperthermia; target temperature is 37&#176;C at nasopharyngeal site and 35.5&#176;C at bladder site </li> <li>Monitor for awareness or return of neuromuscular function </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Removal of aortic crossclamp</td> <td> <ul> <li>Defibrillate and administer antiarrhythmic agents if necessary to treat ventricular fibrillation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Weaning from CPB</td> <td>&nbsp;</td> <td> <ul> <li>Refer to UpToDate topic on weaning from cardiopulmonary bypass (CPB) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Post-bypass</td> <td>Venous decannulation</td> <td> <ul> <li>Ensure initial reinfusion of blood drained from the venous tubing into the pump reservoir in 50- to 100-mL aliquots </li> <li>TEE assessment for adequate ventricular filling </li> </ul> </td> </tr> <tr> <td><span style=\"color: black;\">Anticoagulation reversal, pump suckers turned off, intravascular vents removed</span></td> <td> <ul> <li>Administer protamine slowly, treat protamine reactions </li> <li>Ensure complete reversal of anticoagulation </li> </ul> </td> </tr> <tr> <td>Aortic decannulation</td> <td> <ul> <li>Reduce systolic BP to &#60;100 mmHg to reduce risk of aortic dissection </li> </ul> </td> </tr> <tr> <td>Pacemaker management</td> <td> <ul> <li>Ensure optimal pacemaker settings </li> </ul> </td> </tr> <tr> <td>Postbypass TEE examination</td> <td> <ul> <li>Assess regional LV wall motion abnormalities </li> <li>Assess global LV function </li> <li>Assess global RV function </li> <li>Monitor LV and RV chamber sizes to assess intravascular volume status </li> <li>Evaluate the ascending aorta to rule out dissection </li> </ul> </td> </tr> <tr> <td>Hemostasis</td> <td> <ul> <li>Ensure absence of residual heparin </li> <li>Check point-of-care and laboratory tests of coagulation if bleeding persists </li> <li>Manage anemia, thrombocytopenia, and coagulopathy if necessary </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Chest closure</td> <td> <ul> <li>Observe for RV compression and dysfunction, coronary graft compromise, pacing wire displacement, or lung compression </li> </ul> </td> </tr> <tr> <td>Transport to ICU and handover</td> <td>&nbsp;</td> <td> <ul> <li>Ensure optimal patient condition prior to transport </li> <li>Immediate availability of airway equipment, emergency drugs, and defibrillator on the transport bed </li> <li>Continuous monitoring of ECG, SpO<sub>2</sub>, and intraarterial BP during transport </li> <li>Use of a formal protocol for communication and transfer of technology during handover to the ICU team </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">O<SUB>2</SUB>: oxygen; CPB: cardiopulmonary bypass;&nbsp;TEE: transesophageal echocardiography; LV: left ventricular; RV: right ventricular; SVR: systemic vascular resistance; ACT: activated clotting time; BP: blood pressure; CO<SUB>2</SUB>: carbon dioxide; IABP: intraaortic balloon pump; TIVA: total intravenous anesthesia; EEG: electroencephalography; MAP: mean arterial pressure; Hgb: hemoglobin; Hct: hematocrit; SVO<SUB>2</SUB>: mixed venous oxygen saturation; ECG: electrocardiogram; SpO<SUB>2</SUB>: peripheral oxygen saturation; ICU: intensive care unit.</div><div id=\"graphicVersion\">Graphic 108173 Version 2.0</div></div></div>"},"108174":{"type":"graphic_table","displayName":"Bivalirudin dosing for cardiac surgery","title":"Bivalirudin dosing for cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bivalirudin dosing for cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Bolus dosing</td> <td class=\"subtitle1\">Infusion dosing*</td> <td class=\"subtitle1\">Considerations</td> </tr> <tr> <td><strong>On pump</strong></td> <td>1 mg/kg</td> <td>2.5 mg/kg/hour</td> <td>50 mg added to CPB prime</td> </tr> <tr> <td><strong>Off pump</strong></td> <td>0.75 mg/kg</td> <td>1.75 mg/kg/hour</td> <td>If converting to CPB, an additional 0.25 mg/kg bolus is warranted with an increase in the infusion rate to 2.5 mg/kg/hour</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ACT values&nbsp;are not used to&nbsp;monitor the degree of anticoagulation during CPB. ACT values&nbsp;do not have a linear relationship with bivalirudin concentrations (in contrast to ecarin clotting time [ECT], which is rarely available).&nbsp;A doubling of&nbsp;baseline&nbsp;ACT is evidence that bivalirudin has circulated and is having an effect. The bolus and infusion dosing guidelines&nbsp;in the table are&nbsp;empiric.</div><div class=\"graphic_footnotes\">ACT: activated whole blood clotting time; CPB: cardiopulmonary bypass.<br />* If renal impairment, infusion dosing should be adjusted to maintain target ACT. Bolus dosing remains unchanged.</div><div id=\"graphicVersion\">Graphic 108174 Version 2.0</div></div></div>"},"108177":{"type":"graphic_table","displayName":"Diagnostic criteria for irregular sleep-wake rhythm disorder","title":"Diagnostic criteria for irregular sleep-wake rhythm disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for irregular sleep-wake rhythm disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Diagnostic criteria A-D must be met:</td> </tr> <tr> <td class=\"centered\">A</td> <td>The patient or caregiver reports a chronic or recurrent pattern of irregular sleep and wake episodes throughout the 24-hour period, characterized by symptoms of insomnia during the scheduled sleep period (usually at night), excessive sleepiness (napping) during the day, or both.</td> </tr> <tr> <td class=\"centered\">B</td> <td>Symptoms are present for at least three months.</td> </tr> <tr> <td class=\"centered\">C</td> <td>Sleep log and, whenever possible, actigraphy monitoring for at least seven days, preferably 14 days, demonstrate no major sleep period and multiple irregular sleep bouts (at least three) during a 24-hour period.</td> </tr> <tr> <td class=\"centered\">D</td> <td>The sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine, Darien, IL 2014. Copyright © 2014 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 108177 Version 1.0</div></div></div>"},"108178":{"type":"graphic_table","displayName":"Diagnostic criteria for non-24-hour sleep-wake rhythm disorder","title":"Diagnostic criteria for non-24-hour sleep-wake rhythm disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for non-24-hour sleep-wake rhythm disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Diagnostic criteria A-D must be met:</td> </tr> <tr> <td class=\"centered\">A</td> <td>There is a history of insomnia, excessive daytime sleepiness, or both, which alternate with asymptomatic episodes, due to misalignment between the 24-hour light-dark cycle and the non-entrained endogenous circadian rhythm of sleep-wake propensity.</td> </tr> <tr> <td class=\"centered\">B</td> <td>Symptoms persist over the course of at least three months.</td> </tr> <tr> <td class=\"centered\">C</td> <td>Daily sleep logs and actigraphy for at least 14 days, preferably longer for blind persons, demonstrate a pattern of sleep and wake times that typically delay each day, with a circadian period that is usually longer than 24 hours.</td> </tr> <tr> <td class=\"centered\">D</td> <td>The sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine, Darien, IL 2014. Copyright &copy; 2014 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 108178 Version 1.0</div></div></div>"},"108179":{"type":"graphic_table","displayName":"Diagnostic criteria for advanced sleep-wake phase disorder","title":"Diagnostic criteria for advanced sleep-wake phase disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for advanced sleep-wake phase disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Diagnostic criteria A-E must be met:</td> </tr> <tr> <td class=\"centered\">A</td> <td>There is an advance (early timing) in the phase of the major sleep episode in relation to the desired or required sleep time and wake-up time, as evidenced by a chronic or recurrent complaint of difficulty staying awake until the required or desired conventional bedtime, together with an inability to remain asleep until the required or desired time for awakening.</td> </tr> <tr> <td class=\"centered\">B</td> <td>Symptoms are present for at least three months.</td> </tr> <tr> <td class=\"centered\">C</td> <td>When patients are allowed to sleep in accordance with their internal biological clock, sleep quality and duration are improved with a consistent but advanced timing of the major sleep episode.</td> </tr> <tr> <td class=\"centered\">D</td> <td>Sleep log and, whenever possible, actigraphy monitoring for at least seven days (preferably 14 days) demonstrate a stable advance in the timing of the habitual sleep period. Both work/school days and free days must be included within this monitoring.</td> </tr> <tr> <td class=\"centered\">E</td> <td>The sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine, Darien, IL 2014. Copyright © 2014 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 108179 Version 1.0</div></div></div>"},"108180":{"type":"graphic_table","displayName":"Sleep timing questionnaire","title":"Sleep timing questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sleep timing questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Please think of a GOOD NIGHT TIME as the time at which you are finally in bed and trying to fall asleep</td> </tr> <tr> <td class=\"indent1\">On the night before a work day or school day, what is your <strong>earliest</strong> GOOD NIGHT TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\">On the night before a work day or a school day, what is your <strong>latest</strong> GOOD NIGHT TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\">On the night before a work day or school day, what is your <strong>usual</strong> GOOD NIGHT TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">How stable (ie, similar each night) are your GOOD NIGHT TIMES before a work day or school day? (circle one)</td> <td>0-15 m</td> <td>16-30 m</td> <td>31-45 m</td> <td>46-60 m</td> </tr> <tr> <td>61-75 m</td> <td>76-90 m</td> <td>91-105 m</td> <td>106-120 m</td> </tr> <tr> <td>2-3 h</td> <td>3-4 h</td> <td>&#62;4 h</td> <td>&nbsp;</td> </tr> <tr> </tr> <tr> <td class=\"indent1\">On a night before a day off (eg, a weekend), what is your <strong>earliest</strong> GOOD NIGHT TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\">On a night before a day off (eg, a weekend), what is your <strong>latest</strong> GOOD NIGHT TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\">On a night before a day off (eg, a weekend), what is your <strong>usual</strong> GOOD NIGHT TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"3\">How stable (ie, similar each night) are your GOOD NIGHT TIMES on a night before a day off (eg, a weekend)? (circle one)</td> <td>0-15 m</td> <td>16-30 m</td> <td>31-45 m</td> <td>46-60 m</td> </tr> <tr> <td>61-75 m</td> <td>76-90 m</td> <td>91-105 m</td> <td>106-120 m</td> </tr> <tr class=\"divider_bottom\"> <td>2-3 h</td> <td>3-4 h</td> <td>&#62;4 h</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Please think of GOOD MORNING TIME as the time at which you finally get out of bed and start your day</td> </tr> <tr> <td class=\"indent1\">Before a work day or school day, what is your <strong>earliest</strong> GOOD MORNING TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\">Before a work day or a school day, what is your <strong>latest</strong> GOOD MORNING TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\">Before a work day or school day, what is your <strong>usual</strong> GOOD MORNING TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">How stable (ie, similar each night) are your GOOD MORNING TIMES before a work day or school day? (circle one)</td> <td>0-15 m</td> <td>16-30 m</td> <td>31-45 m</td> <td>46-60 m</td> </tr> <tr> <td>61-75 m</td> <td>76-90 m</td> <td>91-105 m</td> <td>106-120 m</td> </tr> <tr> <td>2-3 h</td> <td>3-4 h</td> <td>&#62;4 h</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Before a day off (eg, a weekend), what is your <strong>earliest</strong> GOOD MORNING TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\">Before a day off (eg, a weekend), what is your <strong>latest</strong> GOOD MORNING TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"indent1\">Before a day off (eg, a weekend), what is your <strong>usual</strong> GOOD MORNING TIME?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">____:____ PM/AM</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"3\">How stable (ie, similar each night) are your GOOD MORNING TIMES on a night before a day off (eg, a weekend)? (circle one)</td> <td>0-15 m</td> <td>16-30 m</td> <td>31-45 m</td> <td>46-60 m</td> </tr> <tr> <td>61-75 m</td> <td>76-90 m</td> <td>91-105 m</td> <td>106-120 m</td> </tr> <tr class=\"divider_bottom\"> <td>2-3 h</td> <td>3-4 h</td> <td>&#62;4 h</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"5\">These questions are about how much sleep you lose to unwanted wakefulness:</td> </tr> <tr> <td class=\"indent1\">On most nights, how long, on average, does it take you to fall asleep after you start trying?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">________ minutes</td> </tr> <tr> <td class=\"indent1\">On most nights, how much sleep do you lose, on average, from waking up during the night (eg, to go to the bathroom)?</td> <td style=\"vertical-align: middle;\" colspan=\"4\">________ minutes</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Instructions: This questionnaire asks about when you normally sleep. We are interested in getting as accurate a picture as we can of the times when you normally go to bed and get up. Please think carefully before giving your answers and be as accurate and as specific as you can be. <strong>Please answer in terms of a recent \"normal average week,\" not one in which you traveled, vacationed, or had family crises.</strong></div><div class=\"graphic_footnotes\">h: hours; m: minutes.</div><div class=\"graphic_reference\">Republished with permission of the American Academy of Sleep Medicine, Monk TH, Buysse DJ, Kennedy K, et al. Measuring sleep habits without using a diary: The sleep timing questionnaire. Sleep 2003; 26:208. Copyright &copy; 2003; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 108180 Version 1.0</div></div></div>"},"108181":{"type":"graphic_table","displayName":"Diagnostic criteria for insufficient sleep syndrome","title":"Diagnostic criteria for insufficient sleep syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for insufficient sleep syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Diagnostic criteria A-F must be met:</td> </tr> <tr> <td class=\"centered\">A</td> <td>The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep or, in the case of prepubertal children, there is a complaint of behavioral abnormalities attributable to sleepiness.</td> </tr> <tr> <td class=\"centered\">B</td> <td>The patient's sleep time, established by personal or collateral history, sleep logs, or actigraphy, is usually shorter than expected for age.</td> </tr> <tr> <td class=\"centered\">C</td> <td>The curtailed sleep pattern is present most days for at least three months.</td> </tr> <tr> <td class=\"centered\">D</td> <td>The patient curtails sleep time by such measures as an alarm clock or being awakened by another person and generally sleeps longer when such measures are not used, such as on weekends or vacations.</td> </tr> <tr> <td class=\"centered\">E</td> <td>Extension of total sleep time results in resolution of the symptoms of sleepiness.</td> </tr> <tr> <td class=\"centered\">F</td> <td>The symptoms are not better explained by another untreated sleep disorder, the effects of medications or drugs, or other medical, neurologic, or mental disorders.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine, Darien, IL 2014. Copyright &copy; 2014 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 108181 Version 1.0</div></div></div>"},"108185":{"type":"graphic_picture","displayName":"Skeletal features of Marfan syndrome","title":"Skeletal features of Marfan syndrome","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Skeletal features of Marfan syndrome</div><div class=\"cntnt\"><img style=\"width:720px; height:480px;\" src=\"images/CARD/108185_Skeletal_features_Marfan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Individuals with Marfan syndrome have an increased arm span to height ratio. Arm span is measured from finger tip to finger tip with the arms abducted to 90 degree from the trunk as shown.</div><div class=\"graphic_reference\">Photographers: Rick Guidotti and Tim Joyce. Reproduced with permission from The Marfan Foundation (<a href=\"http://www.marfan.org/\" target=\"_blank\">Marfan.org</a>).</div><div id=\"graphicVersion\">Graphic 108185 Version 1.0</div></div></div>"},"108187":{"type":"graphic_diagnosticimage","displayName":"Hemorrhagic stroke subtypes","title":"Hemorrhagic stroke subtypes","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Hemorrhagic stroke subtypes</div><div class=\"cntnt\"><img style=\"width:872px; height:483px;\" src=\"images/NEURO/108187_Hemorrhagic_stroke_subtypes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic stroke subtypes.<br />(A) Axial head CT demonstrating large left temporal acute IPH (arrows) with surrounding edema and mass effect on the left lateral ventricle (arrowhead) with left to right midline shift. The underlying cause of hemorrhage in this patient was Factor VIII deficiency.<br />(B) Axial T2/FLAIR MRI sequence showing non-traumatic SAH visible as hyperintense signal within the cerebral convexities of the right frontal lobe (arrows).<br />(C) Axial head CT with isolated IVH in the third (C, left panel) and fourth (C, right panel) ventricles (arrows) associated with hydrocephalus.<br />(D) Axial (D, left panel) and sagittal (D, right panel) T1-weighted MRI sequence demonstrating a large right fronto-parietal IPH (arrows) with intraventricular extension into the entire right lateral ventricle (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography; IPH: intraparenchymal hemorrhage; FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance image; SAH: subarachnoid hemorrhage; IVH: intraventricular hemorrhage.</div><div id=\"graphicVersion\">Graphic 108187 Version 1.0</div></div></div>"},"108188":{"type":"graphic_diagnosticimage","displayName":"Hemorrhagic stroke etiologies","title":"Hemorrhagic stroke etiologies","html":"<div class=\"graphic\"><div style=\"width: 891px\" class=\"figure\"><div class=\"ttl\">Hemorrhagic stroke etiologies</div><div class=\"cntnt\"><img style=\"width:871px; height:486px;\" src=\"images/NEURO/108188_Hemorrhagic_stroke_etiolog.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lateral view of conventional cerebral angiogram demonstrating an extensive left parieto-occipital AVM (arrows) with feeding vessels from the left posterior cerebral, middle cerebral, and anterior cerebral arteries with early deep and superficial draining veins.<br />(B) Axial T2/FLAIR (B, left panel) and susceptibility-weighted (B, right panel) MRI sequences showing a left frontal cavernous malformation (arrows) with calcified components within the lesion (hyperintense punctate signals in (B, left panel) and increased susceptibility (B, right panel) consistent with blood products.<br />(C) Coronal views of a CT angiography (C, left panel) and conventional cerebral angiogram (C, right panel) demonstrating an irregular fusiform lobulated aneurysm of the mid-basilar artery (arrowheads).<br />(D) Sagittal (D, left panel) and axial (D, right panel) T2/FLAIR-weighted MRI sequence of a patient with a large pontine IPH (arrowheads) with associated IVH from a posterior fossa primitive neuroectodermal tumor.</div><div class=\"graphic_footnotes\">AVM: arteriovenous malformation; CT: computed tomography; IPH: intraparenchymal hemorrhage; FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance image; IVH: intraventricular hemorrhage.</div><div id=\"graphicVersion\">Graphic 108188 Version 1.0</div></div></div>"},"108209":{"type":"graphic_picture","displayName":"Davos shoulder reduction technique","title":"Davos technique to reduce anterior glenohumeral dislocation","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Davos technique to reduce anterior glenohumeral dislocation</div><div class=\"cntnt\"><img style=\"width:692px; height:666px;\" src=\"images/SM/108209_Davos_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the Davos technique, the patient relaxes their shoulder and arm muscles and then extends their head back, letting the shoulders roll forward with the arms extended.&nbsp;The technique&nbsp;is performed with the wrists bound together around the ipsilateral knee, and the foot braced, as shown in the photograph. </div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 108209 Version 1.0</div></div></div>"},"108210":{"type":"graphic_picture","displayName":"Reduction of posterior shoulder dislocation","title":"Reduction of posterior shoulder (glenohumeral) dislocation","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Reduction of posterior shoulder (glenohumeral)&nbsp;dislocation</div><div class=\"cntnt\"><img style=\"width:576px; height:720px;\" src=\"images/SM/108210_Reduct_post_shld_dislocatn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The basic technique for reduction of a posterior shoulder dislocation is shown above. Note the downward traction (black arrow), and internal rotation and adduction (white arrow) necessary to perform the technique. A sheet may be placed under the right axilla extending over the opposite shoulder for counter-traction (not pictured).</div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 108210 Version 1.0</div></div></div>"},"108211":{"type":"graphic_diagnosticimage","displayName":"CT posterior shoulder dislocation reverse Hill Sachs","title":"CT posterior shoulder dislocation reverse Hill Sachs","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">CT posterior shoulder dislocation reverse Hill Sachs</div><div class=\"cntnt\"><img style=\"width:453px; height:299px;\" src=\"images/SM/108211_CT_pst_shld_dislc_rvrs_Hill.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT image above shows a posterior glenohumeral dislocation complicated by a reverse Hill-Sachs impaction fracture of the anteriormedial aspect of the humeral head (arrow). The articular surface of the humeral head (arrowheads) has been forced posterior to the glenoid.</div><div class=\"graphic_footnotes\">CT: computed tomography; G: glenoid; H: humeral head.</div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 108211 Version 2.0</div></div></div>"},"108220":{"type":"graphic_picture","displayName":"Cutaneous ulceration in amyopathic dermatomyositis","title":"Cutaneous ulceration in amyopathic dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Cutaneous ulceration in amyopathic dermatomyositis</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/RHEUM/108220_Cutns_ulcrtn_amypthc_drmtms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaque with central crust and mild scale overlying the third metacarpal-phalangeal (MCP) joint in a patient with amyopathic dermatomyositis and antibodies to melanoma differentiation-associated gene 5 (MDA-5). The initial lesion was a spontaneous vasculopathic ulcer. The surrounding plaque developed as part of the healing process. A second healing plaque is present overlying the fifth MCP joint.</div><div id=\"graphicVersion\">Graphic 108220 Version 1.0</div></div></div>"},"108222":{"type":"graphic_algorithm","displayName":"Overview treatment rectal adenocarcinoma","title":"Algorithmic approach to management of rectal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 1410px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to management of rectal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:1390px; height:1151px;\" src=\"images/ONC/108222_Ovrvw_tx_rectl_adncrcnm_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an overview of our approach to the management of newly diagnosed nonmetastatic rectal adenocarcinoma. It should be used in conjunction with other UpToDate content on rectal adenocarcinoma.</div><div class=\"graphic_footnotes\">EUS: endoscopic ultrasound; MRI: magnetic resonance imaging; CT: computed tomography; LAR: low anterior resection; APR: abdominal perineal resection.<br />* CT of the torso (CT of the chest and abdomen if pelvic MRI has been done, and CT of the abdomen, chest, and pelvis if no pelvic MRI) is recommended for all except those with clinical T1N0 cancers with favorable histologic factors.<br />¶ A malignant polyp can be managed endoscopically if the following criteria are met: &#xD;&#xA;<UL>&#xD;&#xA;<LI>The polyp is considered to be completely excised by the endoscopist (ie, pT1) and is submitted in toto for pathological examination.</LI>&#xD;&#xA;<LI>The polyp is fixed and sectioned so that it is possible to accurately determine the depth of invasion, grade of differentiation, and completeness of excision of the carcinoma.</LI>&#xD;&#xA;<LI>The cancer is not poorly differentiated.</LI>&#xD;&#xA;<LI>There is no vascular or lymphatic involvement.</LI>&#xD;&#xA;<LI>The margin of the excision is not involved. Invasion of the stalk of pedunculated polyp, by itself, is not an unfavorable prognostic finding, as long as the cancer does not extend to the margin of stalk resection.</LI>&#xD;&#xA;<LI>No invasion beyond submucosa.</LI>&#xD;&#xA;<LI>Not a sessile polyp.</LI></UL>Δ Cases with all of the following features are amenable to local excision; just because the tumor is amenable to local excision does not mean it is the procedure of choice. The best choice may be a transabdominal surgery, especially in young individuals fit for surgery. There are other factors to consider (addressed in the discussion): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Superficial T1 cancer, limited to the submucosa.</LI>&#xD;&#xA;<LI>No radiographic evidence of metastatic disease to regional nodes.</LI>&#xD;&#xA;<LI>Tumor &lt;3 cm in diameter.</LI>&#xD;&#xA;<LI>Low risk of developing positive regional nodes (well-differentiated, no lymphovascular or neural invasion).</LI>&#xD;&#xA;<LI>Involves &lt;30% of the circumference of the lumen.</LI>&#xD;&#xA;<LI>Mobile, nonfixed.</LI>&#xD;&#xA;<LI>Margins clear (&gt;3 mm).</LI>&#xD;&#xA;<LI>Compliance with appropriate postoperative surveillance.</LI></UL><FONT class=lozenge>◊</FONT> In most centers, all patients who undergo neoadjuvant chemoradiotherapy are offered adjuvant chemotherapy due to difficulty in assessing nodal status in the treated surgical specimen. Postoperative chemotherapy is omitted for those with at least four months of chemotherapy prior to chemoradiotherapy.<br />§ Patients who refuse surgery or are considered poor surgical candidates after chemoradiotherapy may be managed by full-thickness local excision after chemoradiotherapy. Highly selected patients who appear to have a complete clinical response (scar only) may be considered for full-thickness local excision but should understand that transabdominal surgery represents a standard approach in this setting. More extensive residual disease at the time of local excision should prompt reconsideration for transabdominal surgery.<br />¥ Some guidelines suggest that local resection be limited to T1 tumors with limited submucosal excision only. Refer to UpToDate text on the overview&nbsp;of treatment of rectal cancer.</div><div id=\"graphicVersion\">Graphic 108222 Version 5.0</div></div></div>"},"108230":{"type":"graphic_diagnosticimage","displayName":"Triquetrum fracture plain radiographs and tomogram","title":"Triquetrum fracture plain radiographs and tomogram","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Triquetrum fracture plain radiographs and tomogram</div><div class=\"cntnt\"><img style=\"width:766px; height:726px;\" src=\"images/SM/108230_Triquetrum_fractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Oblique view of wrist shows a longitudinal fracture (arrows) through the body of the triquetrum.<br />(B) Avulsion fracture (arrow) from the ulnar border of the triquetrum.<br />(C) Tomogram of an undisplaced fracture on the body of the triquetrum (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Cooney III WP. Isolated carpal fractures. In: The Wrist: Diagnosis and Operative Treatment, 2nd ed, Cooney III WP (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Mayo Foundation for Medical Education and Research. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 108230 Version 1.0</div></div></div>"},"108231":{"type":"graphic_diagnosticimage","displayName":"Triquetrum fracture CT","title":"Triquetrum fracture CT","html":"<div class=\"graphic\"><div style=\"width: 684px\" class=\"figure\"><div class=\"ttl\">Triquetrum fracture CT</div><div class=\"cntnt\"><img style=\"width:664px; height:762px;\" src=\"images/SM/108231_TriquetrumfractureCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above are&nbsp;radiographic images of a&nbsp;triquetrum fracture. A lateral radiograph of the wrist (A) initially showed a displaced osseous fragment at the level of triquetral bone (arrow).&nbsp;Subsequently, a CT was performed and&nbsp;axial (B) and sagittal reformatted (C) images confirmed the diagnosis of a triquetrum fracture.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Upper limb III: Distal forearm, wrist, and hand. In: Orthopedic Imaging: A Practical Approach, 6th ed, Greenspan A, Beltran J (Eds), Wolters Kluwer Health, Philadelphia 2015. Copyright &copy; 2015 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 108231 Version 1.0</div></div></div>"},"108232":{"type":"graphic_algorithm","displayName":"Algorithmic approach to locally advanced cholangiocarcinoma","title":"Algorithmic approach to treatment of locally advanced or locally recurrent cholangiocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 1485px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to treatment of locally advanced or locally recurrent cholangiocarcinoma</div><div class=\"cntnt\"><img style=\"width:1465px; height:575px;\" src=\"images/ONC/108232_Approach_locally_adv_cholan.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BED: biologic equivalent dose; FU: fluorouracil; CRT: chemoradiotherapy; PDT: photodynamic therapy; SBRT: stereotactic body radiation therapy.<br />* Solitary site of unresectable disease, able to tolerate chemoradiotherapy.<br />¶ If local expertise is available, radioembolization may be preferred over CRT or systemic chemotherapy alone for patients with multiple hepatic lesions without extrahepatic spread.<br />Δ The role of orthotopic liver transplantation after neoadjuvant therapy for locally advanced initially unresectable disease is controversial; refer to text.<br /></div><div id=\"graphicVersion\">Graphic 108232 Version 1.0</div></div></div>"},"108233":{"type":"graphic_diagnosticimage","displayName":"Power Doppler duplex imaging","title":"Power Doppler duplex imaging","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Power Doppler duplex imaging</div><div class=\"cntnt\"><img style=\"width:603px; height:306px;\" src=\"images/ANEST/108233_Power_Doppler_duplex_imagng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Power Doppler duplex imaging identifies a blood vessel (arrows) adjacent to the brachial plexus in the groove between the anterior and middle scalene muscles in the posterior cervical triangle. In the interscalene region, the contributions to the brachial plexus are often monofascicular or oligofascicular (dashed arrows) and can be difficult to distinguish from adjacent muscle or blood vessels.</div><div id=\"graphicVersion\">Graphic 108233 Version 1.0</div></div></div>"},"108234":{"type":"graphic_diagnosticimage","displayName":"Posterior acoustic enhancement during femoral nerve block","title":"Posterior acoustic enhancement during femoral nerve block","html":"<div class=\"graphic\"><div style=\"width: 793px\" class=\"figure\"><div class=\"ttl\">Posterior acoustic enhancement during femoral nerve block</div><div class=\"cntnt\"><img style=\"width:773px; height:569px;\" src=\"images/ANEST/108234_Pst_acstc_enhncmnt_fmrl_nrv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior acoustic enhancement (arrow) observed deep to the femoral artery after femoral nerve block. These echoes can be mistaken for the adjacent femoral nerve (arrowhead) that typically lies lateral to the femoral artery.</div><div id=\"graphicVersion\">Graphic 108234 Version 1.0</div></div></div>"},"108236":{"type":"graphic_diagnosticimage","displayName":"Posterior acoustic enhancement and transducer compression","title":"Posterior acoustic enhancement and transducer compression during axillary block","html":"<div class=\"graphic\"><div style=\"width: 889px\" class=\"figure\"><div class=\"ttl\">Posterior acoustic enhancement and transducer compression during axillary block</div><div class=\"cntnt\"><img style=\"width:869px; height:272px;\" src=\"images/ANEST/108236_Post_acstc_enhncmnt_trnsdcr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior acoustic enhancement (circled) observed during axillary block at the level of the conjoint tendon (arrowheads) of the latissimus dorsi and teres major muscles. Images recorded (A) with and (B) without&nbsp;transducer compression. With light touch, the ulnar nerve (arrow) is identified just deep to an axillary vein (between the axillary vein and axillary artery).</div><div id=\"graphicVersion\">Graphic 108236 Version 1.0</div></div></div>"},"108237":{"type":"graphic_diagnosticimage","displayName":"Bone shadowing","title":"Bone shadowing","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">Bone shadowing</div><div class=\"cntnt\"><img style=\"width:840px; height:478px;\" src=\"images/ANEST/108237_Bone_shadowing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone shadowing from the fibular ridge in the mid-leg. This ridge points to the intermuscular septum and superficial peroneal nerve (arrow) for ultrasound-guided ankle block (the \"mountain\" sign). Note that the cortical surface of the fibula is echo-bright (\"snow on the mountain\").</div><div id=\"graphicVersion\">Graphic 108237 Version 1.0</div></div></div>"},"108238":{"type":"graphic_diagnosticimage","displayName":"Acoustic shadowing from plaque","title":"Acoustic shadowing from plaque","html":"<div class=\"graphic\"><div style=\"width: 969px\" class=\"figure\"><div class=\"ttl\">Acoustic shadowing from plaque</div><div class=\"cntnt\"><img style=\"width:949px; height:488px;\" src=\"images/ANEST/108238_Acoustic_shadowing_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acoustic shadowing from calcified plaque (arrows) observed within the superficial femoral artery in long-axis view.</div><div id=\"graphicVersion\">Graphic 108238 Version 1.0</div></div></div>"},"108239":{"type":"graphic_diagnosticimage","displayName":"Air shadowing","title":"Air shadowing","html":"<div class=\"graphic\"><div style=\"width: 849px\" class=\"figure\"><div class=\"ttl\">Air shadowing</div><div class=\"cntnt\"><img style=\"width:829px; height:448px;\" src=\"images/ANEST/108239_Air_shadowing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air shadowing (arrows) observed during ultrasound-guided regional anesthesia. A shallow layer of air obscures deeper anatomic structures.</div><div id=\"graphicVersion\">Graphic 108239 Version 1.0</div></div></div>"},"108240":{"type":"graphic_diagnosticimage","displayName":"Refractile shadowing","title":"Refractile shadowing artifact","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Refractile shadowing artifact</div><div class=\"cntnt\"><img style=\"width:757px; height:599px;\" src=\"images/ANEST/108240_Refractile_shadowing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refractile shadowing (arrows) and posterior acoustic enhancement observed deep to the second part of the axillary artery during infraclavicular block. The neurovascular bundle is seen deep to the pectoralis major and minor muscles. The large axillary vein is seen medially (caudal).</div><div id=\"graphicVersion\">Graphic 108240 Version 1.0</div></div></div>"},"108241":{"type":"graphic_diagnosticimage","displayName":"Needle reverberation artifact","title":"Needle reverberation artifact","html":"<div class=\"graphic\"><div style=\"width: 919px\" class=\"figure\"><div class=\"ttl\">Needle reverberation artifact</div><div class=\"cntnt\"><img style=\"width:899px; height:480px;\" src=\"images/ANEST/108241_Needle_reverberation_artfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Needle reverberation artifact (arrows). The block needle is placed within the plane of imaging nearly parallel to the active face of the transducer for optimal needle imaging. Note that the bevel faces the transducer, and that the reverberation artifact observed deep to the shaft does not extend to the bevel opening.</div><div id=\"graphicVersion\">Graphic 108241 Version 1.0</div></div></div>"},"108242":{"type":"graphic_diagnosticimage","displayName":"Bayonet artifact","title":"Bayonet artifact","html":"<div class=\"graphic\"><div style=\"width: 983px\" class=\"figure\"><div class=\"ttl\">Bayonet artifact</div><div class=\"cntnt\"><img style=\"width:963px; height:425px;\" src=\"images/ANEST/108242_Bayonet_artifact.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bayonet artifact (arrow) observed during axillary block with in-plane technique. The needle&nbsp;appears to bend away from the skin surface and transducer when it lies deep to the neurovascular bundle in the axilla. Note that there is also some difference in acoustic shadowing from the neurovascular bundle along the needle shaft.</div><div id=\"graphicVersion\">Graphic 108242 Version 1.0</div></div></div>"},"108243":{"type":"graphic_diagnosticimage","displayName":"Sciatic nerve and surrounding structures","title":"Sciatic nerve and surrounding structures","html":"<div class=\"graphic\"><div style=\"width: 963px\" class=\"figure\"><div class=\"ttl\">Sciatic nerve and surrounding structures</div><div class=\"cntnt\"><img style=\"width:943px; height:313px;\" src=\"images/ANEST/108243_Sciatic_nerve_structures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This image shows the polyfascicular echotexture of the sciatic nerve (arrow) in the proximal thigh after LA injection for regional block. LA can be seen surrounding the sciatic nerve in this short-axis view.&nbsp;The conjoint tendon of the biceps femoris and semitendinosus (arrowhead) points to the medial aspect of the sciatic nerve. The echogenic tendon of the semimembranosus is seen medial to the sciatic nerve (dashed arrow).<br />(B) LA appears dark (ie, hypoechoic), and tracks along&nbsp;both the superficial and deep surfaces of the nerve in long-axis view (arrows).</div><div class=\"graphic_footnotes\">LA: local anesthetic.</div><div id=\"graphicVersion\">Graphic 108243 Version 1.0</div></div></div>"},"108244":{"type":"graphic_diagnosticimage","displayName":"Tibial and common peroneal nerves","title":"Tibial and common peroneal nerves","html":"<div class=\"graphic\"><div style=\"width: 825px\" class=\"figure\"><div class=\"ttl\">Tibial and common peroneal nerves</div><div class=\"cntnt\"><img style=\"width:805px; height:541px;\" src=\"images/ANEST/108244_Tibial_common_peroneal_nrvs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polyfascicular echotexture of the tibial and common peroneal nerves in the popliteal fossa. Local anesthetic has been injected at the bifurcation of the sciatic nerve within the common investing fascial sheath and seen to track distally around and along these major branches. The common peroneal nerve (arrow) is smaller than the tibial nerve (dashed arrow) and lies closer to the posterior skin surface. The common peroneal nerve contains fewer but larger fascicles than the tibial nerve.</div><div id=\"graphicVersion\">Graphic 108244 Version 1.0</div></div></div>"},"108245":{"type":"graphic_diagnosticimage","displayName":"In-plane needle image","title":"In-plane needle image","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">In-plane needle image</div><div class=\"cntnt\"><img style=\"width:872px; height:311px;\" src=\"images/ANEST/108245_In_plane_needle_image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of in-plane technique for axillary block. Panel A shows&nbsp;a partial (incomplete) lineup, meaning that although some of the needle shaft is imaged, the needle tip does not lie within the plane of imaging. This is one of the most common problems during interventional ultrasound for regional anesthesia. Panel B shows a complete lineup, with the needle bevel identified (arrow). Note incidentally that there is some difference in acoustic shadowing from the neurovascular bundle along the needle shaft.</div><div id=\"graphicVersion\">Graphic 108245 Version 1.0</div></div></div>"},"108247":{"type":"graphic_diagnosticimage","displayName":"Needle enhancement","title":"Needle enhancement","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">Needle enhancement</div><div class=\"cntnt\"><img style=\"width:787px; height:420px;\" src=\"images/ANEST/108247_Needle_enhancement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Platform-based needle enhancement software. During this adductor canal block (ACB), needle enhancement was used to guide the needle-tip placement and injection deep to the sartorius muscle in the mid-thigh adjacent to the superficial femoral artery.</div><div id=\"graphicVersion\">Graphic 108247 Version 1.0</div></div></div>"},"108248":{"type":"graphic_diagnosticimage","displayName":"Echogenic needle","title":"Echogenic needle","html":"<div class=\"graphic\"><div style=\"width: 959px\" class=\"figure\"><div class=\"ttl\">Echogenic needle</div><div class=\"cntnt\"><img style=\"width:939px; height:530px;\" src=\"images/ANEST/108248_Echogenic_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echogenic needle used for short-axis in-plane approach to adductor canal block (ACB) deep to the sartorius muscle and adjacent superficial femoral artery. The last centimeter of the needle shaft is textured to enhance the received echoes (arrows).</div><div id=\"graphicVersion\">Graphic 108248 Version 1.0</div></div></div>"},"108249":{"type":"graphic_table","displayName":"Differential diagnosis of hemorrhagic stroke children","title":"Differential diagnosis of hemorrhagic stroke in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hemorrhagic stroke in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Arterial ischemic stroke with or without hemorrhagic transformation</td> </tr> <tr> <td>Bell's palsy</td> </tr> <tr> <td>Brain tumor</td> </tr> <tr> <td>Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)</td> </tr> <tr> <td>Cerebral infections including abscess, encephalitis, and meningitis</td> </tr> <tr> <td>Cerebral sinovenous thrombosis with or without venous infarction or hemorrhage</td> </tr> <tr> <td>Complications of migraine</td> </tr> <tr> <td>Conversion disorder</td> </tr> <tr> <td>Metabolic derangements such as hypoglycemia</td> </tr> <tr> <td>Methotrexate and other chemotherapeutic agent neurotoxicity</td> </tr> <tr> <td>Mitochondrial disease such as mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS)</td> </tr> <tr> <td>Musculoskeletal disorders</td> </tr> <tr> <td>Organic or amino acidurias </td> </tr> <tr> <td>Posterior reversible encephalopathy syndrome (PRES)</td> </tr> <tr> <td>Postictal (Todd) paralysis</td> </tr> <tr> <td>White matter diseases including multiple sclerosis, acute disseminated encephalomyelitis, and leukodystrophies</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 108249 Version 1.0</div></div></div>"},"108254":{"type":"graphic_form","displayName":"Hoarding Rating Scale - Interview","title":"Hoarding Rating Scale - Interview","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Hoarding Rating Scale - Interview</div><div class=\"cntnt\"><img style=\"width:604px; height:666px;\" src=\"images/PSYCH/108254_Hoarding_rating_scale_intrv.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Tolin DF, Frost RO, Steketee G. A brief interview for assessing compulsive hoarding: The Hoarding Rating Scale-Interview. Psychiatry Res 2010; 178:147. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108254 Version 1.0</div></div></div>"},"108257":{"type":"graphic_table","displayName":"Major toxicities of treatment regimens for relapsed MM","title":"Major toxicities of selected treatment regimens used for relapsed multiple myeloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major toxicities of selected treatment regimens used for relapsed multiple myeloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Major toxicities</td> <td class=\"subtitle1\">Adjunctives</td> <td class=\"subtitle1\">Clinical use</td> <td class=\"subtitle1\">Other/cost</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Options for initial relapse</td> </tr> <tr> <td class=\"indent1\">Daratumumab, lenalidomide, dexamethasone (DRd) </td> <td>Acute or delayed hypersensitivity reaction, opportunistic infections, diarrhea, fatigue</td> <td>Prophylaxis for infusion reactions; antiviral prophylaxis; thromboprophylaxis</td> <td>Preferred for patients relapsing off therapy or while on small doses of single agent lenalidomide or on bortezomib maintenance.</td> <td>Can interfere with cross-matching and red blood cell antibody screening. $$$$</td> </tr> <tr> <td class=\"indent1\">Daratumumab, bortezomib, dexamethasone (DVd) </td> <td>Peripheral neuropathy, transient cytopenias, acute or delayed hypersensitivity reaction, fatigue, nausea</td> <td>Prophylaxis for infusion reactions; antiviral prophylaxis</td> <td>Preferred if refractory to full doses of lenalidomide&nbsp;or refractory to a lenalidomide containing triplet.&nbsp;</td> <td>Can interfere with cross-matching and red blood cell antibody screening. $$$$</td> </tr> <tr> <td class=\"indent1\">Bortezomib, lenalidomide, dexamethasone (VRd)</td> <td>Peripheral neuropathy, transient cytopenias, fatigue, gastrointestinal distress</td> <td>Thromboprophylaxis; antiviral prophylaxis</td> <td>May be preferred for patients relapsing off therapy or on lenalidomide maintenance.</td> <td>Subcutaneous, once-weekly dosing of bortezomib decreases toxicity. $$$</td> </tr> <tr> <td class=\"indent1\">Bortezomib, cyclophosphamide, dexamethasone (VCD)</td> <td>Peripheral neuropathy, transient cytopenias</td> <td>Antiviral prophylaxis; PCP prophylaxis</td> <td>May be preferred for patients relapsing while off therapy or on lenalidomide maintenance.</td> <td>Subcutaneous, once-weekly dosing of bortezomib decreases toxicity. $$</td> </tr> <tr> <td class=\"indent1\">Carfilzomib, lenalidomide, dexamethasone (KRd)</td> <td>Gastrointestinal distress, transient cytopenias, fatigue, hypokalemia, hypertension, dyspnea, serious cardiac dysfunction (approximately 5 percent)</td> <td>Thromboprophylaxis; antiviral prophylaxis</td> <td>May be preferred for more aggressive relapse in fit patients.</td> <td>More cumbersome than weekly schedule of bortezomib or ixazomib-based regimens. $$$$</td> </tr> <tr> <td class=\"indent1\">Carfilzomib, pomalidomide, dexamethasone (off-label)</td> <td>Transient cytopenias, fatigue, hypokalemia, hypertension, dyspnea, potentially severe diarrhea, serious cardiac dysfunction (approximately 5 percent)</td> <td>Thromboprophylaxis; antiviral prophylaxis</td> <td>May be preferred for patients with aggressive disease relapsing on standard dose lenalidomide.</td> <td>$$$$$</td> </tr> <tr> <td class=\"indent1\">Bortezomib, pomalidomide, dexamethasone (off-label)</td> <td>Peripheral neuropathy, thrombocytopenia, lymphopenia, potentially severe diarrhea, asthenia/fatigue, peripheral neuropathy</td> <td>Thromboprophylaxis; antiviral prophylaxis</td> <td>May be preferred for patients relapsing on standard dose lenalidomide.</td> <td>$$$$</td> </tr> <tr> <td class=\"indent1\">Ixazomib, lenalidomide, dexamethasone (IRd)</td> <td>Diarrhea, constipation, nausea, vomiting, thrombocytopenia, peripheral neuropathy, peripheral edema, and back pain</td> <td>Thromboprophylaxis; antiviral prophylaxis</td> <td>May be preferred for frail patients or those with a clinically indolent relapse.</td> <td>Oral regimen. $$$</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Elotuzumab, lenalidomide, dexamethasone</td> <td>Acute or delayed hypersensitivity reaction, opportunistic infections, hepatic dysfunction, fatigue</td> <td>Prophylaxis for infusion reactions; thromboprophylaxis</td> <td>May be preferred for frail patients or those with a clinically indolent relapse.</td> <td>$$$$</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Options for multiply relapsed disease: Includes regimens above that have not yet been used</td> </tr> <tr> <td class=\"indent1\">Pomalidomide plus dexamethasone</td> <td>Thrombocytopenia, lymphopenia, potentially severe diarrhea, asthenia/fatigue</td> <td>Thromboprophylaxis</td> <td>Reserved for second or subsequent relapse.</td> <td>$$$</td> </tr> <tr> <td class=\"indent1\">Daratumumab</td> <td>Acute or delayed hypersensitivity reaction, fatigue, anemia, nausea</td> <td>Prophylaxis for infusion reactions; antiviral prophylaxis</td> <td>Reserved for third or subsequent relapse; may be preferred for clinically indolent relapse or frail patients.</td> <td>Can interfere with cross-matching and red blood cell antibody screening. $$$</td> </tr> <tr> <td class=\"indent1\">Daratumumab, pomalidomide, dexamethasone </td> <td>Hypersensitivity reaction, thrombocytopenia, lymphopenia, potentially severe diarrhea, asthenia/fatigue, peripheral neuropathy</td> <td>Prophylaxis for infusion reactions; antiviral prophylaxis; thromboprophylaxis</td> <td>Reserved for third or subsequent relapse; may be preferred for more aggressive relapse.</td> <td>Can interfere with cross-matching and red blood cell antibody screening. $$$$</td> </tr> <tr> <td class=\"indent1\">Panobinostat, bortezomib, dexamethasone</td> <td>Potentially fatal diarrhea, cardiac ischemic events, and severe arrhythmias</td> <td>Antiviral prophylaxis; prophylactic antidiarrheal medication</td> <td>Reserved for second or subsequent relapse; may be preferred for patients with aggressive disease.</td> <td>Must monitor electrolytes and hepatic function. $$$</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table provides information about select treatment regimens for relapsed or refractory multiple myeloma. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary. An autologous hematopoietic cell transplantation should be considered for eligible patients who have not had a transplant before. A second autologous hematopoietic cell transplantation may be considered for patients who progress more than 18 months after transplant without maintenance or more than 36 months after transplantation with maintenance therapy. The immunomodulatory derivatives lenalidomide, pomalidomide, and thalidomide are known teratogens.</div><div class=\"graphic_footnotes\">PCP: <EM>Pneumocystis</EM> pneumonia</div><div id=\"graphicVersion\">Graphic 108257 Version 6.0</div></div></div>"},"108259":{"type":"graphic_table","displayName":"Contraindications for cardiac rehabilitation","title":"Contraindications for cardiac rehabilitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications for cardiac rehabilitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Unstable angina </li> <li>Uncontrolled hypertension - resting systolic blood pressure (SBP) &#62;180 mmHg and/or resting diastolic BP (DBP) &#62;110 mmHg </li> <li>Orthostatic BP drop of &#62;20 mmHg with symptoms </li> <li>Significant aortic stenosis (aortic valve area &#60;1.0 cm<sup>2</sup>) </li> <li>Uncontrolled atrial or ventricular arrhythmias </li> <li>Uncontrolled sinus tachycardia (&#62;120 beats/min) </li> <li>Uncompensated heart failure </li> <li>Third degree atrioventricular (AV) block without pacemaker </li> <li>Active pericarditis or myocarditis </li> <li>Recent embolism </li> <li>Acute thrombophlebitis </li> <li>Acute systemic illness or fever </li> <li>Uncontrolled diabetes mellitus </li> <li>Severe orthopedic conditions that would prohibit exercise </li> <li>Other metabolic conditions, such as acute thyroiditis, hypokalemia, hyperkalemia, or hypovolemia (until adequately treated) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Pescatello LS. ACSM's Guidelines for Exercise Testing and Prescription, 9th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright &copy; 2014 American College of Sports Medicine.</div><div id=\"graphicVersion\">Graphic 108259 Version 1.0</div></div></div>"},"108260":{"type":"graphic_algorithm","displayName":"Diagnosis of HIDS in suspected periodic fever syndrome","title":"Diagnosis of hyperimmunoglobulin D syndrome in the patient with a suspected periodic fever syndrome*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnosis of hyperimmunoglobulin D syndrome in the patient with a suspected periodic fever syndrome*</div><div class=\"cntnt\"><img style=\"width:434px; height:494px;\" src=\"images/ALLRG/108260_Diagn_HIDS_periodc_fvr_synd.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic HIDS is due to compound heterozygous or homozygous mutation in the <em>MVK</em> gene. The underlying genetic defect is not known in variant HIDS.</div><div class=\"graphic_footnotes\">HIDS: hyperimmunoglobulin D syndrome; MKD: mevalonate kinase deficiency; MA: mevalonic aciduria; IgD: immunoglobulin D; <em>MVK</em>: mevalonate kinase; FMF: familial Mediterranean fever; CAPS: cryopyrin-associated periodic syndrome; TRAPS: tumor necrosis factor alpha receptor-1 associated periodic syndrome; PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis.<br />* A periodic fever syndrome should be suspected in a patient with childhood to early adulthood onset of fevers that recur over months to years in the absence of infection or malignancy.<br />&para; The Eurofever Classification Criteria scoring system screens for the most common periodic fever syndromes, including FMF, CAPS, and TRAPS. It does not include PFAPA. Refer to appropriate topic reviews for details on clinical manifestations of each periodic fever syndrome.<br />&Delta; Clinical features consistent with variant HIDS include onset at &ge;5 years of age, fever duration &gt;14 days, and lack of associated joint pain.</div><div id=\"graphicVersion\">Graphic 108260 Version 1.0</div></div></div>"},"108264":{"type":"graphic_form","displayName":"WHO maternal near-miss data collection tool","title":"WHO maternal near-miss data collection tool","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">WHO maternal near-miss data collection tool</div><div class=\"cntnt\"><img style=\"width:598px; height:1545px;\" src=\"images/OBGYN/108264_WHO_maternal_near-miss_data.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This data collection form can be used to standardize the evaluation of maternal near-miss events.</div><div class=\"graphic_footnotes\">bpm: beats per minute; HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Reprinted from Evaluating the quality of care for severe pregnancy complications: The WHO near-miss approach for maternal health, World Health Organization, Department of Reproductive Health and Research, p. 21, Copyright &copy; 2011. Available from: <a href=\"http://www.who.int/reproductivehealth/publications/monitoring/9789241502221/en/\" target=\"_blank\">http://www.who.int/reproductivehealth/publications/monitoring/9789241502221/en/</a> (accessed on August 10, 2016).</div><div id=\"graphicVersion\">Graphic 108264 Version 1.0</div></div></div>"},"108266":{"type":"graphic_table","displayName":"Grading severity of mitral stenosis by echocardiography","title":"Grading severity of mitral stenosis by echocardiography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading severity of mitral stenosis by echocardiography</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Progressive*</td> <td class=\"subtitle1\">Severe&#182;</td> <td class=\"subtitle1\">Very severe&#916;</td> </tr> <tr> <td><strong>Valve area (cm<sup>2</sup>)</strong></td> <td class=\"centered\">&#62;1.5</td> <td class=\"centered\">&#60;=1.5</td> <td class=\"centered\">&#8804;1</td> </tr> <tr> <td><strong>Diastolic pressure half-time (ms)</strong></td> <td class=\"centered\">&#60;150</td> <td class=\"centered\">&#8805;150&nbsp;</td> <td class=\"centered\">&#8805;220&nbsp;</td> </tr> <tr> <td><strong>Mean gradient&#9674; (mmHg)</strong></td> <td class=\"centered\">&#60;5</td> <td class=\"centered\">&#62;5 </td> <td class=\"centered\">&#62;10</td> </tr> <tr> <td><strong>Pulmonary artery systolic&nbsp;pressure (mmHg)</strong></td> <td class=\"centered\">&#60;30</td> <td class=\"centered\">&#62;30 </td> <td class=\"centered\">&#62;50</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*This category was previously labeled \"mild\".<br />¶This category was previously labeled \"moderate\".<br />ΔThis category was previously labeled \"severe\".<br />◊Transmitral mean pressure gradient ranges in sinus rhythm are shown, but these vary with heart rate and forward flow.</div><div id=\"graphicVersion\">Graphic 108266 Version 3.0</div></div></div>"},"108267":{"type":"graphic_algorithm","displayName":"Evaluation of children 3 to 16 years with an acute ankle injury","title":"Evaluation of children 3 to 16 years of age with an acute (≤72 hours) isolated ankle injury","html":"<div class=\"graphic\"><div style=\"width: 972px\" class=\"figure\"><div class=\"ttl\">Evaluation of children 3 to 16 years of age with an acute (&le;72 hours) isolated ankle injury</div><div class=\"cntnt\"><img style=\"width:952px; height:586px;\" src=\"images/EM/108267_Evl_chldrn_3_16_act_ank_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Plain radiographs of the ankle consist of anterior-posterior (AP), lateral, and mortise views.<br />&para; Clinically uncomplicated fractures of the ankle include fibular avulsion fractures and nondisplaced Salter-Harris I or II physeal fractures of the fibula.<br />&Delta; Refer to UpToDate topics on ankle fractures in children.</div><div id=\"graphicVersion\">Graphic 108267 Version 2.0</div></div></div>"},"108269":{"type":"graphic_diagnosticimage","displayName":"Biopsy of small renal mass","title":"Biopsy of small renal mass","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Biopsy of small renal mass</div><div class=\"cntnt\"><img style=\"width:692px; height:321px;\" src=\"images/ONC/108269_Biopsy_small_renal_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT contrast-enhanced coronal reformation image (A) shows homogeneously enhancing masses (arrows) in both kidneys. CT-guided biopsy (B) using a coaxial needle to obtain fine needle aspiration and core specimens diagnosed lymphoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 108269 Version 2.0</div></div></div>"},"108270":{"type":"graphic_table","displayName":"WHO inclusion criteria for assessment of pregnancy complications","title":"World Health Organization inclusion criteria for baseline assessment of severe complications of pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization inclusion criteria for baseline assessment of severe complications of pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Severe maternal complications</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Severe postpartum hemorrhage </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Severe preeclampsia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Eclampsia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sepsis or severe systemic infection </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ruptured uterus </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Severe complications of abortion </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Critical interventions or intensive care unit use</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Admission to intensive care unit </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Interventional radiology </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Laparotomy (includes hysterectomy, excludes cesarean section) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Use of blood products </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Life-threatening conditions (near-miss criteria)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cardiovascular dysfunction <ul> <li>Shock </li> <li>Cardiac arrest (absence of pulse/heart beat and loss of consciousness) </li> <li>Use of continuous vasoactive drugs </li> <li>Cardiopulmonary resuscitation </li> <li>Severe hypoperfusion (lactate &#62;5 mmol/L or &#62;45 mg/dL), severe acidosis (pH &#60;7.1) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Respiratory dysfunction <ul> <li>Acute cyanosis </li> <li>Gasping </li> <li>Severe tachypnea (respiratory rate &#62;40 breaths per minute) </li> <li>Severe bradypnea (respiratory rate &#60;6 breaths per minute) </li> <li>Intubation and ventilation not related to anesthesia </li> <li>Severe hypoxemia (O<sub>2</sub> saturation &#60;90% for &#8805;60 minutes or PAO<sub>2</sub>/FiO<sub>2</sub> &#60;200) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Renal dysfunction <ul> <li>Oliguria nonresponsive to fluids or diuretics </li> <li>Dialysis for acute renal failure </li> <li>Severe acute azotemia (creatinine &#8805;300 micromol/mL or &#8805;3.5 mg/dL) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Coagulation/hematological dysfunction <ul> <li>Failure to form clots </li> <li>Massive transfusion of blood or red cells (&#8805;5 units) </li> <li>Severe acute thrombocytopenia (&#60;50,000 platelets/mL) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hepatic dysfunction <ul> <li>Jaundice in the presence of preeclampsia </li> <li>Severe acute hyperbilirubinemia (bilirubin &#62;100 micromol/L or &#62;6.0 mg/dL) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Neurological dysfunction <ul> <li>Prolonged unconsciousness (lasting &#8805;12 hours)/coma (including metabolic coma) </li> <li>Stroke </li> <li>Uncontrollable fits/status epilepticus </li> <li>Total paralysis </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Uterine dysfunction <ul> <li>Uterine hemorrhage or infection leading to hysterectomy </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Maternal vital status</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Maternal death </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Inclusion criteria to identify women with severe complications of pregnancy.</div><div class=\"graphic_reference\">Reprinted from: World Health Organization, Department of Reproductive Health and Research. Evaluating the quality of care for severe pregnancy complications: The WHO near-miss approach for maternal health. Copyright &copy; 2011. <a href=\"http://www.who.int/reproductivehealth/publications/monitoring/9789241502221/en/\" target=\"_blank\">http://www.who.int/reproductivehealth/publications/monitoring/9789241502221/en/</a> (accessed on August 10th, 2016).</div><div id=\"graphicVersion\">Graphic 108270 Version 1.0</div></div></div>"},"108271":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of neonatal eventration of the diaphragm","title":"Chest radiographs of neonatal eventration of the diaphragm","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Chest radiographs of neonatal eventration of the diaphragm</div><div class=\"cntnt\"><img style=\"width:764px; height:351px;\" src=\"images/PEDS/108271_CR_neonatal_eventration_dph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiography of eventration of the diaphragm (arrows) in an 18-day-old infant demonstrated in anterior-posterior (AP) and lateral views. On the lateral view, the anterior and posterior diaphragmatic attachments are in the correct positions. With diaphragmatic paralysis, the elevated hemidiaphragm would be uniformly elevated.</div><div class=\"graphic_reference\">Courtesy of Christopher Cassady, MD, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 108271 Version 2.0</div></div></div>"},"108282":{"type":"graphic_diagnosticimage","displayName":"Loeffler syndrome chest x-ray","title":"Loeffler syndrome: Chest radiograph","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Loeffler syndrome: Chest radiograph</div><div class=\"cntnt\"><img style=\"width:756px; height:750px;\" src=\"images/ID/108282_Loeffler_syndrm_chest_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrating consolidation in mid-portion of left lung and infiltrates in right lung.</div><div class=\"graphic_reference\">This article was published in the Journal of the National Medical Association, Vol 39, Williams EB, Walker WH, Loeffler's syndrome: Report of a case with a brief review of the literature, 211-14, Copyright Elsevier (1947).</div><div id=\"graphicVersion\">Graphic 108282 Version 1.0</div></div></div>"},"108288":{"type":"graphic_picture","displayName":"Klippel-Trenaunay 1","title":"Klippel-Trenaunay syndrome","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Klippel-Trenaunay syndrome</div><div class=\"cntnt\"><img style=\"width:534px; height:620px;\" src=\"images/DERM/108288_Klippel_Trenaunay_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, sharply demarcated, dark red, geographic vascular patch on the left lateral hip and flank in a six-year-old boy with Klippel-Trenaunay syndrome.</div><div class=\"graphic_reference\">Courtesy of Ilona Frieden, MD.</div><div id=\"graphicVersion\">Graphic 108288 Version 1.0</div></div></div>"},"108289":{"type":"graphic_picture","displayName":"Klippel-Trenaunay 2","title":"Klippel-Trenaunay syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Klippel-Trenaunay syndrome</div><div class=\"cntnt\"><img style=\"width:422px; height:482px;\" src=\"images/DERM/108289_Klippel_Trenaunay_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, geographic, red-purple vascular stain involving the right lateral knee with many superimposed small vascular blebs and surrounding venous varicosities in a 10-year-old girl with Klippel-Trenaunay syndrome.</div><div class=\"graphic_reference\">Courtesy of Ilona Frieden, MD.</div><div id=\"graphicVersion\">Graphic 108289 Version 1.0</div></div></div>"},"108290":{"type":"graphic_picture","displayName":"Klippel-Trenaunay 3","title":"Klippel-Trenaunay syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Klippel-Trenaunay syndrome</div><div class=\"cntnt\"><img style=\"width:402px; height:473px;\" src=\"images/DERM/108290_Klippel_Trenaunay_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Significant overgrowth of the right lower extremity with prominent capillary-venous-lymphatic malformation in a 10-year-old girl with Klippel-Trenaunay syndrome.</div><div class=\"graphic_reference\">Courtesy of Ilona Frieden, MD.</div><div id=\"graphicVersion\">Graphic 108290 Version 1.0</div></div></div>"},"108292":{"type":"graphic_table","displayName":"Risk factors used to define treatment of intermediate-risk NMIBC","title":"Risk factors used to define treatment algorithm of intermediate-risk non-muscle invasive bladder cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors used to define treatment algorithm of intermediate-risk non-muscle invasive bladder cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">How many of the following risk factors does the patient have?</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Multiple tumors </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Tumor size &#62;3 cm </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Early recurrence (&#60;1 year) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Frequent recurrences (&#62;1 year) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Kamat AM, Witjes JA, Brausi M, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol 2014; 192:305.</div><div id=\"graphicVersion\">Graphic 108292 Version 1.0</div></div></div>"},"108293":{"type":"graphic_table","displayName":"Management of NMIBC recurrence by disease state","title":"Management of non-muscle invasive bladder cancer recurrence by disease state*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of&nbsp;non-muscle invasive bladder cancer&nbsp;recurrence by disease state*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease state at time of recurrence</td> <td class=\"subtitle1\">Prior management</td> <td class=\"subtitle1\">Second-line therapy</td> <td class=\"subtitle1\">Third-line therapy</td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"6\"> <p>Intermediate risk</p> <p>(LG Ta)</p> </td> <td rowspan=\"3\">TUR only</td> <td>Surveillance, office fulguration, or TURBT</td> <td>Same or intravesical therapy</td> </tr> <tr class=\"divider_bottom\"> <td>Intravesical chemotherapy</td> <td>Intravesical BCG</td> </tr> <tr class=\"divider_bottom\"> <td>Intravesical BCG</td> <td>Intravesical chemotherapy</td> </tr> <tr class=\"divider_bottom\"> <td>Prior intravesical chemotherapy</td> <td>Intravesical BCG</td> <td rowspan=\"2\">Clinical trial, other intravesical therapy, consider cystectomy only if&nbsp;unable to control disease</td> </tr> <tr class=\"divider_bottom\"> <td>Prior intravesical BCG, last dose &#8804;6 months</td> <td>Intravesical chemotherapy</td> </tr> <tr class=\"divider_bottom\"> <td>Prior intravesical BCG, last dose &#62;6 months</td> <td>Intravesical BCG</td> <td>Clinical trial, intravesical chemotherapy</td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"4\">High risk<br /> (HG Ta, CIS)</td> <td>TUR only</td> <td>Intravesical BCG</td> <td>Same as second-line post-BCG</td> </tr> <tr class=\"divider_bottom\"> <td>Prior intravesical chemotherapy</td> <td>Intravesical BCG</td> <td rowspan=\"2\">Cystectomy if recurrence within 6 months of last BCG dose, otherwise retreat with BCG; avoid more than 2 cycles of intravesical therapy if no interval response</td> </tr> <tr class=\"divider_bottom\"> <td>Prior intravesical BCG, last dose &#62;6 months</td> <td>Intravesical BCG</td> </tr> <tr class=\"divider_bottom\"> <td>Prior intravesical BCG, last dose &#8804;6 months</td> <td>Cystectomy most definitive with lowest risk of progression but risk of overtreatment; intravesical chemotherapy or BCG plus IFN reasonable option</td> <td>Cystectomy</td> </tr> <tr> <td rowspan=\"4\">Very high risk<br /> (HG T1)</td> <td class=\"divider_bottom\">TUR only</td> <td class=\"divider_bottom\">Intravesical BCG</td> <td class=\"divider_bottom\" rowspan=\"3\">Cystectomy</td> </tr> <tr class=\"divider_bottom\"> <td>Prior intravesical chemotherapy</td> <td>Immediate&nbsp;cystectomy or BCG</td> </tr> <tr class=\"divider_bottom\"> <td>Prior intravesical BCG, last dose &#62;6 months</td> <td>Immediate cystectomy or BCG</td> </tr> <tr> <td>Prior intravesical BCG, last dose &#8804;6 months</td> <td>Cystectomy</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LG: low grade; TUR: transurethral resection; TURBT: transurethral resection of bladder tumor; BCG: Bacillus Calmette-Guerin; HG: high grade; CIS: carcinoma in situ; IFN: interferon.<br />* Intravesical chemotherapy may include device-assisted therapies, such as hyperthermia and electromotive drug administration. Other intravesical therapy includes BCG plus interferon alpha-2b or alternative chemotherapeutic agents.</div><div id=\"graphicVersion\">Graphic 108293 Version 2.0</div></div></div>"},"108294":{"type":"graphic_table","displayName":"Parameters that determine EORTC recurrence and progression score","title":"Parameters that determine EORTC recurrence and progression scores","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parameters that determine EORTC recurrence and progression scores</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Recurrence</td> <td class=\"subtitle1\">Progression</td> </tr> <tr> <td colspan=\"3\"><strong>Number of tumors</strong></td> </tr> <tr> <td class=\"indent1\">Single</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">2 to 7</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;8</td> <td class=\"centered\">6</td> <td class=\"centered\">3</td> </tr> <tr> <td colspan=\"3\"><strong>Tumor size</strong></td> </tr> <tr> <td class=\"indent1\">&#60;3 cm</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;3 cm</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> </tr> <tr> <td colspan=\"3\"><strong>Prior recurrence rate</strong></td> </tr> <tr> <td class=\"indent1\">Primary</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">&#8804;1 recurrence/year</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;1 recurrence/year</td> <td class=\"centered\">4</td> <td class=\"centered\">2</td> </tr> <tr> <td colspan=\"3\"><strong>T category</strong></td> </tr> <tr> <td class=\"indent1\">Ta</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T1</td> <td class=\"centered\">1</td> <td class=\"centered\">4</td> </tr> <tr> <td colspan=\"3\"><strong>CIS</strong></td> </tr> <tr> <td class=\"indent1\">No</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Yes</td> <td class=\"centered\">1</td> <td class=\"centered\">6</td> </tr> <tr> <td colspan=\"3\"><strong>Grade</strong></td> </tr> <tr> <td class=\"indent1\">G1</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">G2</td> <td class=\"centered\">1</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">G3</td> <td class=\"centered\">2</td> <td class=\"centered\">5</td> </tr> <tr class=\"divider_top\"> <td><strong>Total score</strong></td> <td class=\"centered\"><strong>0 to 17</strong></td> <td class=\"centered\"><strong>0 to 23</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EORTC: European Organisation for Research and Treatment of Cancer; CIS: carcinoma in situ.</div><div class=\"graphic_reference\">Reproduced from: Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108294 Version 1.0</div></div></div>"},"108299":{"type":"graphic_algorithm","displayName":"Xpert and isolation","title":"Approach to the use of Xpert MTB/RIF assay to make decisions regarding need for airborne infection isolation in adults","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Approach to the use of Xpert MTB/RIF assay to make decisions regarding need for airborne infection isolation in adults</div><div class=\"cntnt\"><img style=\"width:772px; height:434px;\" src=\"images/ID/108299_Xpert_and_isolation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The Xpert MTB/RIF assay has been approved by the United States Food and Drug Administration for use in place of serial acid-fast sputum smears to aid in decisions regarding whether continued airborne infection isolation is warranted for patients with suspected tuberculosis. The approach described above should not be used alone to rule out tuberculosis; Xpert-negative or AFB smear-negative sputum may contain viable organisms and represent infectious tuberculosis. Interpretation of Xpert results must be made in the context of clinical and radiographic findings. In addition, at least three sputum specimens should be obtained for AFB smear and culture, which must be performed for detection of <EM>Mycobacterium tuberculosis</EM> complex and antimicrobial susceptibility testing.</LI>&#xD;&#xA;<LI>Negative Xpert results with positive AFB smear results should prompt consideration of nontuberculous mycobacteria infection (refer to related UpToDate content).</LI>&#xD;&#xA;<LI>Procedures must comply with state and local public health regulations; for questions, contact your local public health authority.</LI>&#xD;&#xA;<LI>Institutional infection control, in collaboration with the tuberculosis laboratory and public health authority, should collect and analyze data to determine and evaluate the effectiveness of the methods used to determine discharge from AII and modify this protocol as necessary.</LI></UL></div><div class=\"graphic_footnotes\">TB: tuberculosis; AII: airborne infection isolation; AFB: acid-fast bacilli.<br />* First morning sputum specimen is preferred to maximize diagnostic yield. Protocols for sputum collection are provided in the reference below. Sputum quality is critical for the performance of this assay. Spontaneously expectorated sputum obtained following deep coughing or sputum obtained following an approved procedure for sputum induction with deep inhalation of aerosolized hypertonic saline and deep coughing may be used. Saliva is not acceptable.<br />¶ An invaild Xpert result represents a failure of the assay; this is estimated to occur in 1 to 2 percent of specimen runs; in such cases, the presence or absence of <EM>M. tuberculosis</EM> complex cannot be determined.<br />Δ In such circumstances, a positive results suggests TB is likely, a negative result suggests infectious TB is not likely, and an invalid result indicates that the likelihood of infectious TB cannot be determined based on Xpert results. In such cases, AFB smear results and clinical judgment should be used to make decisions regarding likelihood of infectious TB and timeframe for discontinuation of AII.</div><div class=\"graphic_reference\">Modified from: National Tuberculosis Controllers Association and Association of Public Health Laboratories: Consensus statement on the use of Cepheid Xpert MTB/RIF assay in making decisions to discontinue airborne infection isolation in healthcare settings. Available at: <A href=\"http://www.tbcontrollers.org/docs/resources/NTCA_APHL_GeneXpert_Consensus_Statement_Final.pdf\" target=_blank>http://www.tbcontrollers.org/docs/resources/NTCA_APHL_GeneXpert_Consensus_Statement_Final.pdf</A> (Accessed on April 27, 2016).</div><div id=\"graphicVersion\">Graphic 108299 Version 2.0</div></div></div>"},"108302":{"type":"graphic_table","displayName":"Klippel-Trenaunay differential diagnosis","title":"Differential diagnosis of Klippel-Trenaunay syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Klippel-Trenaunay syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Klippel-Trenaunay syndrome<br /> (KTS)</td> <td class=\"subtitle1\">Diffuse capillary malformation with overgrowth<br /> (DCMO)</td> <td class=\"subtitle1\">Parkes Weber syndrome</td> <td class=\"subtitle1\">Congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal anomalies (CLOVES) syndrome</td> <td class=\"subtitle1\">Macrocephaly-capillary malformation<br /> (M-CM/MCAP)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Capillary malformation</strong>*</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Venous malformation and/or varicosities</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Arteriovenous malformation </strong></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lymphatic malformation</strong></td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Overgrowth</strong><sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Digital anomalies</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Epidermal nevus</strong></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The capillary malformation is often dark red/purple and geographic in KTS, compared with DCMO where the stain is pink, diffuse, and reticulated.<br />¶ Overgrowth is nonprogressive in DCMO but can be progressive in KTS. Lipomatous overgrowth is a prominent feature of CLOVES syndrome and can primarily involve the trunk.</div><div id=\"graphicVersion\">Graphic 108302 Version 2.0</div></div></div>"},"108305":{"type":"graphic_picture","displayName":"Diffuse capillary malformation with overgrowth","title":"Diffuse capillary malformation with overgrowth (DCMO)","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Diffuse capillary malformation with overgrowth (DCMO)</div><div class=\"cntnt\"><img style=\"width:727px; height:528px;\" src=\"images/DERM/108305_Diffuse_capil_malfrm_overgr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 15-month-old boy with diffuse capillary malformation with overgrowth (DCMO) presenting with extensive patchy and reticulated pink vascular stain involving the left chest, back, and upper and lower extremity with mild overgrowth of the left fingers.</div><div class=\"graphic_reference\">Courtesy of Ilona Frieden, MD.</div><div id=\"graphicVersion\">Graphic 108305 Version 1.0</div></div></div>"},"108306":{"type":"graphic_figure","displayName":"Timing of permanent tooth eruption ","title":"Timing of permanent tooth eruption","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Timing of permanent tooth eruption</div><div class=\"cntnt\"><img style=\"width:546px; height:444px;\" src=\"images/EM/108306_Timing_of_permanent_tooth_eruption.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 108306 Version 1.0</div></div></div>"},"108315":{"type":"graphic_figure","displayName":"Helmet interface","title":"Helmet interface for noninvasive ventilation","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Helmet interface for noninvasive ventilation</div><div class=\"cntnt\"><img style=\"width:530px; height:587px;\" src=\"images/PULM/108315_Helmet_interface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several types of helmets are commercially available, each with different features. This graphic shows a representative image of a typical helmet interface used to deliver noninvasive ventilation. All have ventilation ports for the administration and removal of gas flow and a rubber seal at the neck, while others have additional optional features including ports for the introduction of catheters and&nbsp;under-arm straps for extra security to ensure a tight seal.</div><div id=\"graphicVersion\">Graphic 108315 Version 1.0</div></div></div>"},"108316":{"type":"graphic_figure","displayName":"Types of hiatal hernia","title":"Types of hiatal hernia","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Types of hiatal hernia</div><div class=\"cntnt\"><img style=\"width:531px; height:698px;\" src=\"images/SURG/108316_Types_of_hiatal_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Panels C and D modified from: Jeur AS. Review of literatures on laparoscopic prosthetic repair of giant hiatal hernia than pure anatomical repair of Crura. World Journal of Laparoscopic Surgery 2010; 3:85.</div><div id=\"graphicVersion\">Graphic 108316 Version 1.0</div></div></div>"},"108318":{"type":"graphic_table","displayName":"Clinical manifestations SCD","title":"Overview of clinical manifestations of sickle cell disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of clinical manifestations of sickle cell disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Acute</td> <td class=\"subtitle1\">Chronic</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pain</strong></td> <td>Acute vaso-occlusive pain episodes, acute chest syndrome</td> <td>Pain from tissue infarction, osteonecrosis, ulcers</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Infection</strong></td> <td>Sepsis, pneumonia, meningitis</td> <td>Leg ulcers, osteomyelitis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Anemia</strong></td> <td>Aplastic crisis, splenic sequestration crisis, hyperhemolytic crisis</td> <td>Compensated hemolytic anemia, chronic hypersplenism</td> </tr> <tr class=\"divider_bottom\"> <td><strong>CNS</strong></td> <td>Ischemic stroke, hemorrhagic stroke, seizures, TIA</td> <td>Silent cerebral infarctions, cognitive delay, behavioral issues</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pulmonary</strong></td> <td>Acute chest syndrome, asthma, pulmonary fate embolism, pulmonary thromboembolism</td> <td>Pulmonary hypertension, sleep disordered breathing, chronic restrictive lung disease</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Renal</strong></td> <td>Renal infarction, medication toxicity, hematuria, acute renal failure, acute nephrotic syndrome</td> <td>Hypertension, chronic renal failure, concentrating defect, nephrogenic diabetes insipidus, renal medullary carcinoma</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Skeletal</strong></td> <td>Dactylitis, avascular necrosis</td> <td>Osteoporosis, osteomyelitis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cardiac</strong></td> <td>Myocardial infarction, dysrhythmia, sudden death, autonomic dysfunction</td> <td>Diastolic dysfunction, heart failure</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hepatobiliary</strong></td> <td>Hepatic sequestration crisis, cholecystitis, liver injury, acute intrahepatic cholestasis</td> <td>Pigment gallstones</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ocular</strong></td> <td>Retinal artery occlusion, hyphema, retinal detachment</td> <td>Proliferative retinopathy, blindness</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Obstetric</strong></td> <td>Fetal and maternal complications</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Genitourinary</strong></td> <td>Priapism</td> <td>Erectile dysfunction</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Endocrine</strong></td> <td>&nbsp;</td> <td>Delayed puberty, reduced growth</td> </tr> <tr> <td><strong>Other</strong></td> <td>Venous thromboembolism</td> <td>Functional asplenia</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on sickle cell disease for additional information on screening, diagnosis, and management of these complications.</div><div class=\"graphic_footnotes\">SCD: sickle cell disease; CNS: central nervous system; TIA: transient ischemic attack.</div><div id=\"graphicVersion\">Graphic 108318 Version 2.0</div></div></div>"},"108319":{"type":"graphic_picture","displayName":"Neonatal acrocyanosis","title":"Neonatal acrocyanosis","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Neonatal acrocyanosis</div><div class=\"cntnt\"><img style=\"width:545px; height:422px;\" src=\"images/PEDS/108319_Neonatal_acrocyanosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Janelle Aby, MD. Copyright &copy; 2016 Stanford University Well Newborn Nursery. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108319 Version 1.0</div></div></div>"},"108321":{"type":"graphic_algorithm","displayName":"Stepwise approach to treatment-resistant schizophrenia","title":"Stepwise approach to treatment-resistant schizophrenia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stepwise approach to treatment-resistant schizophrenia</div><div class=\"cntnt\"><img style=\"width:336px; height:602px;\" src=\"images/PSYCH/108321_Step_appr_tx_resist_schiz.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count.<br />* Pseudoresistance refers to lack of improvement due to causes other than failure of antipsychotic trial.<br />&para; Refer to UpToDate topic on treatment-resistant schizophrenia for additional approaches augmenting antipsychotic medications.</div><div id=\"graphicVersion\">Graphic 108321 Version 1.0</div></div></div>"},"108325":{"type":"graphic_algorithm","displayName":"Vaginal cytology","title":"Follow-up of results of vaginal cytology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follow-up of results of vaginal cytology</div><div class=\"cntnt\"><img style=\"width:412px; height:244px;\" src=\"images/OBGYN/108325_Vaginal_cytology.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ASC-US: atypical squamous cells of undetermined significance; LSIL: low-grade squamous intraepithelial lesion; NILM: negative for intraepithelial lesion or malignancy; HPV: human papillomavirus; HSIL: high-grade squamous intraepithelial lesion; ASC-H: atypical squamous cells cannot rule out high-grade; AGC: atypical glandular cells; hrHPV: high-risk HPV (HPV types that are high risk for causing cervical cancer).<br />​* If HPV genotyping is available, recommend immediate colposcopy for ASC-US/LSIL with HPV 16/18-positive and repeat testing in 1 year for those with NILM cytology/HPV 16/18-positive or HPV 16/18-negative.<br />¶ Cotesting = cervical cytology + hrHPV testing. Given the high negative predictive value of hrHPV testing, only 1 cotest is needed. If cytology alone is repeated, repeat cytology every year should be performed at least twice. If cotest negative once or cytology negative twice, then screening can stop.<br />Δ Cessation of screening if posthysterectomy for benign disease, OR<br /><FONT class=lozenge>◊</FONT> Continue routine surveillance if posttreatment for cervical HSIL or cervical cancer.</div><div class=\"graphic_reference\">From: Khan MJ, Massad LS, Kinney W, et al. A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. J Low Genit Tract Dis 2016; 20:119. DOI: <a href=\"http://journals.lww.com/jlgtd/pages/articleviewer.aspx?year=2016&amp;issue=04000&amp;article=00001&amp;type=abstract\" target=\"_blank\">10.1097/LGT.0000000000000185</a>. Copyright &copy; 2016 American Society for Colposcopy and Cervical Pathology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108325 Version 1.0</div></div></div>"},"108327":{"type":"graphic_table","displayName":"Classes of drugs associated with salivary hypofunction","title":"Classes of drugs associated with salivary hypofunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classes of drugs associated with salivary hypofunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Alpha and beta-adrenoreceptor blocking agents</td> </tr> <tr> <td>Antidepressant drugs</td> </tr> <tr> <td>Antihistamines</td> </tr> <tr> <td>Antipsychotic drugs</td> </tr> <tr> <td>Benzodiazepines</td> </tr> <tr> <td>Glucocorticoids</td> </tr> <tr> <td>Diuretics</td> </tr> <tr> <td>Histamine H2-receptor antagonists</td> </tr> <tr> <td>Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td>Opioid analgesics</td> </tr> <tr> <td>Proton pump inhibitors</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 108327 Version 1.0</div></div></div>"},"108328":{"type":"graphic_table","displayName":"Hemicraniectomy eligibility criteria","title":"General eligibility criteria for three major trials (DECIMAL, DESTINY, HAMLET) evaluating decompressive hemicraniectomy for malignant middle cerebral artery territory infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General eligibility criteria for three major trials (DECIMAL, DESTINY, HAMLET) evaluating decompressive hemicraniectomy for malignant middle cerebral artery territory infarction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inclusion criteria:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Age 18 to 60 years* </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Clinical deficits suggestive of infarction in the territory of the MCA with a NIHSS score &#8805;16 </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Decrease in the level of consciousness to a score of &#8805;1 on item 1a of the NIHSS </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Signs on brain CT of an infarct of &#8805;50 percent of the MCA territory, with or without additional infarction in the territory of the ipsilateral anterior or posterior cerebral artery, or infarct volume &#62;145 cm<sup>3</sup> on diffusion-weighted brain MRI </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Time from symptom onset to start of surgical decompression &#60;48 hours </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Written informed consent by the patient or a legal representative </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Exclusion criteria:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Prestroke mRS score &#8805;2 </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Both pupils fixed and dilated </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Contralateral ischemia or other brain lesion that could affect outcome </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Space-occupying hemorrhagic transformation of the infarct </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Life expectancy &#60;3 years </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Other serious illness that could affect outcome </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Known coagulopathy or systemic bleeding disorder </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Contraindication for anesthesia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">mRS: modified Rankin Scale; MCA: middle cerebral artery; NIHSS: National Institutes of Health Stroke Scale.<br />* Four other trials included patients over age 60.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Vahedi K, Vicaut E, Mateo J, et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke 2007; 38:2506.</li>&#xD;&#xA;    <li>J&uuml;ttler E, Schwab S, Schmiedek P, et al. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke 2007; 38:2518.</li>&#xD;&#xA;    <li>Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol 2009; 8:326.</li>&#xD;&#xA;    <li>Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007; 6:215.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 108328 Version 2.0</div></div></div>"},"108335":{"type":"graphic_algorithm","displayName":"Evaluation hemolysis","title":"Evaluation of unexplained hemolytic anemia","html":"<div class=\"graphic\"><div style=\"width: 1160px\" class=\"figure\"><div class=\"ttl\">Evaluation of unexplained hemolytic anemia</div><div class=\"cntnt\"><img style=\"width:1140px; height:816px;\" src=\"images/HEME/108335_Evaluation_hemolysis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an overview. Refer to UpToDate content on hemolytic anemia for further discussion and additional causes of hemolytic anemia.</div><div class=\"graphic_footnotes\">TMA: thrombotic microangiopathy (eg, thrombotic thrombocytopenic purpura [TTP], hemolytic uremic syndrome [HUS], drug-induced TMA); AIHA: autoimmune hemolytic anemia; DAT: direct antiglobulin [Coombs] test; G6PD: glucose-6-phosphate dehydrogenase; PK: pyruvate kinase; PNH: paroxysmal nocturnal hemoglobinuria; PCH: paroxysmal cold hemoglobinuria; DIC: disseminated intravascular coagulation; LDH: lactate dehydrogenase.<br />* Evidence of hemolysis includes increased reticulocyte count that is not due to active bleeding, recent correction of iron deficiency or nutritional anemia, or erythropoietin administration; spherocytosis; low haptoglobin; high LDH and indirect (unconjugated) bilirubin.<br />&para; Inherited intracorpuscular defects include hemoglobinopathies such as thalassemia or sickle cell disease; enzymopathies such as G6PD or PK deficiency; and membrane defects such as hereditary spherocytosis, elliptocytosis, or stomatocytosis.</div><div id=\"graphicVersion\">Graphic 108335 Version 1.0</div></div></div>"},"108339":{"type":"graphic_figure","displayName":"Diagnostic criteria for IBS subtypes","title":"Diagnostic criteria for irritable bowel syndrome subtypes","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Diagnostic criteria for irritable bowel syndrome subtypes</div><div class=\"cntnt\"><img style=\"width:708px; height:514px;\" src=\"images/GAST/108339_Diagn_criteria_IBS_subtypes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">IBS subtypes should be established according to stool consistency, using the BSFS. IBS subtyping is more accurate when patients have at least four days of abnormal bowel habits per month. Bowel habit subtypes should be based on BSFS for days with abnormal bowel habits. &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Predominant bowel habits are based on stool form on days with at least one abnormal bowel movement.*</LI>&#xD;&#xA;<LI>IBS with predominant constipation: More than one-fourth (25%) of bowel movements with Bristol stool form types 1 or 2 and less than one-fourth (25%) of bowel movements with Bristol stool form types 6 or 7.&nbsp;Alternative for epidemiology or clinical practice: Patient reports that abnormal bowel movements are usually constipation (like type 1 or 2 in the picture of BSFS).</LI>&#xD;&#xA;<LI>IBS with predominant diarrhea (IBS-D): More than one-fourth (25%) of bowel movements with Bristol stool form types 6 or 7 and less than one-fourth (25%) of bowel movements with Bristol stool form types 1 or 2. Alternative for epidemiology or clinical practice: Patient reports that abnormal bowel movements are usually diarrhea (like type 6 or 7 in the picture of BSFS).</LI>&#xD;&#xA;<LI>IBS with mixed bowel habits (IBS-M): More than one-fourth (25%) of bowel movements with Bristol stool form types 1 or 2 and more than one-fourth (25%) of bowel movements with Bristol stool form types 6 or 7. Alternative for epidemiology or clinical practice: Patient reports that abnormal bowel movements are usually both constipation and diarrhea (more than one-fourth of all the abnormal bowel movements were constipation and more than one-fourth were diarrhea, using picture of BSFS).</LI>&#xD;&#xA;<LI>IBS unclassified (IBS-U): Patients who meet diagnostic criteria for IBS but whose bowel habits cannot be accurately categorized into&nbsp;one of the&nbsp;three groups above should be categorized as having IBS unclassified.</LI>&#xD;&#xA;<LI>For clinical trials, subtyping based on at least&nbsp;two weeks of daily diary data is recommended, using the \"25% rule.\"</LI></UL></div><div class=\"graphic_footnotes\">BM: bowel movement; IBS: irritable bowel syndrome; BSFS: Bristol Stool Form Scale.<br />* IBS subtypes related to bowel habit abnormalities (IBSC, IBS-D, and IBS-M) can only be confidently established when the patient is evaluated off medications used to treat bowel habit abnormalities.</div><div class=\"graphic_reference\">Reproduced from: Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016; 150:1393. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108339 Version 1.0</div></div></div>"},"108340":{"type":"graphic_table","displayName":"Human trafficking: Red flags and indicators","title":"Human trafficking: Red flags and indicators","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human trafficking: Red flags and indicators</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>General indicators of human trafficking</strong> <ul class=\"decimal_heading\"> <li>Shares a scripted or inconsistent history </li> <li>Is unwilling or hesitant to answer questions about the injury or illness </li> <li>Is accompanied by an individual who does not let the patient speak for themselves, refuses to let the patient have privacy, or who interprets for them </li> <li>Evidence of controlling or dominating relationships (excessive concerns about pleasing a family member, romantic partner, or employer) </li> <li>Demonstrates fearful or nervous behavior or avoids eye contact </li> <li>Is resistant to assistance or demonstrates hostile behavior </li> <li>Is unable to provide his/her address </li> <li>Is not aware of his/her location, the current date, or time </li> <li>Is not in possession of his/her identification documents </li> <li>Is not in control of his or her own money </li> <li>Is not being paid or wages are withheld </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Labor trafficking indicators</strong> <ul class=\"decimal_heading\"> <li>Has been abused at work or threatened with harm by an employer or supervisor </li> <li>Is not allowed to take adequate breaks, food, or water while at work </li> <li>Is not provided with adequate personal protective equipment for hazardous work </li> <li>Was recruited for different work than he/she is currently doing </li> <li>Is required to live in housing provided by employer </li> <li>Has a debt to employer or recruiter that he/she cannot pay off </li> </ul> </td> <td><strong>Sex trafficking indicators</strong> <ul class=\"decimal_heading\"> <li>Patient is under the age of 18 and is involved in the commercial sex industry </li> <li>Has tattoos or other forms of branding, such as tattoos that say, \"Daddy,\" \"Property of...,\" \"For sale,\" etc </li> <li>Reports an unusually high numbers of sexual partners </li> <li>Does not have appropriate clothing for the weather or venue </li> <li>Uses language common in the commercial sex industry </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This is a list of potential red flags and indicators that medical providers may see in a patient who may be a victim of human trafficking. Please note that this list is not exhaustive. Each indicator taken individually may not imply a trafficking situation and not all victims of human trafficking will exhibit these signs. However, the recognition of several indicators may point to the need for referrals and further assessment.</div><div class=\"graphic_reference\">Reproduced with permission from: National Human Trafficking Resource Center. What to Look for in a Healthcare Setting, updated February 2016. Copyright &copy; 2010 National Human Trafficking Resource Center. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108340 Version 1.0</div></div></div>"},"108341":{"type":"graphic_table","displayName":"Human trafficking: Health indicators and consequences","title":"Human trafficking: Health indicators and consequences*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human trafficking: Health indicators and consequences*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td><strong>Physical health indicators</strong> <ul class=\"decimal_heading\"> <li>Signs of physical abuse or unexplained injuries <ul> <li>Bruising </li> <li>Burns </li> <li>Cuts or wounds </li> <li>Blunt force trauma </li> <li>Fractures </li> <li>Broken teeth </li> <li>Signs of torture </li> </ul> </li> <li>Neurologic conditions <ul> <li>Traumatic brain injury </li> <li>Headaches or migraines </li> <li>Unexplained memory loss </li> <li>Vertigo of unknown etiology </li> <li>Insomnia </li> <li>Difficulty concentrating </li> </ul> </li> <li>Cardiovascular/respiratory conditions that appear to be caused or worsened by stress, such as: <ul> <li>Arrhythmia </li> <li>High blood pressure </li> <li>Acute respiratory distress </li> </ul> </li> <li>Gastrointestinal conditions that appear to be caused or worsened by stress, such as: <ul> <li>Constipation </li> <li>Irritable bowel syndrome </li> </ul> </li> <li>Dietary health issues <ul> <li>Severe weight loss </li> <li>Malnutrition </li> <li>Loss of appetite </li> </ul> </li> <li>Reproductive issues <ul> <li>Sexually-transmitted infections </li> <li>Genitourinary issues </li> <li>Repeated unwanted pregnancies </li> <li>Forced or pressured abortions </li> <li>Genital trauma </li> <li>Sexual dysfunction </li> <li>Retained foreign body </li> </ul> </li> <li>Substance use disorders </li> <li>Other health issues <ul> <li>Effects of prolonged exposure to extreme temperatures </li> <li>Effects of prolonged exposure to industrial or agricultural chemicals </li> <li>Somatic complaints </li> </ul> </li> </ul> </td> <td><strong>Mental health indicators</strong> <ul class=\"decimal_heading\"> <li>Depression </li> <li>Suicidal ideation </li> <li>Self-harming behaviors </li> <li>Anxiety </li> <li>Post-traumatic stress disorder </li> <li>Nightmares </li> <li>Flashbacks </li> <li>Lack of emotional responsiveness </li> <li>Feelings of shame or guilt </li> <li>Hypervigilance </li> <li>Hostility </li> <li>Attachment disorders <ul> <li>Lack of or difficulty in engaging in social interactions </li> <li>Signs of withdrawal, fear, sadness, or irritability </li> </ul> </li> <li>Depersonalization or derealization <ul> <li>Feeling like an outside observer of themselves, as if watching themselves in a movie </li> <li>Emotional or physical numbness of senses </li> <li>Feeling alienated from or unfamiliar with their surroundings </li> <li>Distortions in perception of time </li> </ul> </li> <li>Dissociation disorders <ul> <li>Memory loss </li> <li>A sense of being detached from themselves </li> <li>A lack of a sense of self-identity, or switching between alternate identities </li> <li>A perception of the people and things around them as distorted or unreal </li> </ul> </li> </ul> <br /> <strong>Social or developmental indicators</strong> <ul class=\"decimal_heading\"> <li>Increased engagement in high-risk behaviors, such as running away or early sexual initiation if a minor </li> <li>Trauma bonding with trafficker or other victims (eg, Stockholm syndrome) </li> <li>Difficulty establishing or maintaining healthy relationships </li> <li>Delayed physical or cognitive development </li> <li>Impaired social skills </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This list of physical and mental health indicators of human trafficking is not exhaustive. Trafficking survivors may experience one or more of these indicators, none of these indicators, or health indicators not on this list. This list is intended to help you assess if a patient's condition may be a result of a trafficking-related trauma and should be considered in context.</div><div class=\"graphic_reference\">Reproduced with permission from: National Human Trafficking Resource Center. What to look for in a healthcare setting, updated February 2016. Copyright &copy; 2010 National Human Trafficking Resource Center. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108341 Version 1.0</div></div></div>"},"108342":{"type":"graphic_table","displayName":"Human trafficking: Questions to help identify victims","title":"Human trafficking: Questions to help identify victims","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human trafficking: Questions to help identify victims</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">International victims</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Who is the person who came with you today? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Can you tell me about them? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Were you ever promised something and it didn't happen? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Has anyone taken and kept your passport or other legal papers? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>What are your living conditions? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Are you able to leave your job and find another job if you desired to? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Are you able to leave your room when you want or are you locked in? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Do you have to ask permission to go to the bathroom? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Are you able to shower or take a bath as often as you would like? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Are you in any physical danger? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Has someone threatened you or your family? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Do you owe anyone any debts? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Do you have to work or do something you don't want to do to pay that debt? </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Have you ever been told to have sex with people you don't want to have sex with? </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Domestic victims</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Who is the person who came with you today? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Can you tell me about them? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Were you ever promised something and it didn't happen? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Does anyone monitor your conversations with family or friends? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Do you ever feel pressured to do something you don't want to do? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>How do you feel pressured? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Do you feel you were tricked or lied to? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Has anyone ever threatened you? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Has anyone ever physically abused you? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you ever had to trade sex for money or something else you needed? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Do you have to meet a quota of money each night before you return home? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you ever been told to have sex with people you don't want to have sex with? </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Hope for Justice. How to identify a victim of human trafficking. Available at <a href=\"http://hopeforjustice.org/professionals/\" target=\"_blank\">http://hopeforjustice.org/professionals/</a> (accessed July 6th, 2016). Copyright &copy; 2014 Hope for Justice. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108342 Version 1.0</div></div></div>"},"108343":{"type":"graphic_algorithm","displayName":"Human trafficking: Assessment tool","title":"Human trafficking: Assessment tool","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Human trafficking: Assessment tool</div><div class=\"cntnt\"><img style=\"width:530px; height:970px;\" src=\"images/OBGYN/108343_Human_trafficking_Assssmnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Report online or access resources and referrals: <a href=\"http://traffickingresourcecenter.org/\" target=\"_blank\">www.traffickingresourcecenter.org</a>.</li>&#xD;&#xA;    <li>Call: 1-888-373-7888 (24/7).</li>&#xD;&#xA;    <li>Email: <a href=\"mailto:nhtrc@polarisproject.org\" target=\"_blank\">nhtrc@polarisproject.org</a>.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">PTSD: post-traumatic stress disorder; HIPAA: Health Insurance Portability and Accountability Act.<br />* For more red flags and indicators, refer to the NHTRC's <a href=\"http://traffickingresourcecenter.org/resources/comprehensive-human-trafficking-assessment-tool\" target=\"_blank\">Comprehensive assessment tool</a> and <a href=\"http://traffickingresourcecenter.org/resources/what-look-healthcare-setting\" target=\"_blank\">Identifying victims of human trafficking</a> document for health care providers.</div><div class=\"graphic_reference\">Reproduced with permission from: National Human Trafficking Resource Center. Framework for a Human Trafficking Protocol in Healthcare Settings, updated February 2016. Copyright &copy; 2010 National Human Trafficking Resource Center. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108343 Version 1.0</div></div></div>"},"108356":{"type":"graphic_table","displayName":"Causes of transient microscopic hematuria in children","title":"Causes of transient microscopic hematuria in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of transient microscopic hematuria in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Exercise</td> </tr> <tr> <td>Fever</td> </tr> <tr> <td>Trauma to kidney and/or urinary tract</td> </tr> <tr> <td>Urinary tract infection</td> </tr> <tr> <td>Urethritis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 108356 Version 1.0</div></div></div>"},"108357":{"type":"graphic_figure","displayName":"Bristol stool form scale","title":"Bristol stool form scale","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Bristol stool form scale</div><div class=\"cntnt\"><img style=\"width:704px; height:568px;\" src=\"images/GAST/108357_Diagn_criteria_IBS_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Bristol stool form scale (BSFS) is a useful tool to evaluate bowel habits. Abnormal stool forms are types 1 to 2 (constipation) and types 6 to 7 (diarrhea). The BSFS has been shown to be a reliable surrogate marker for colonic transit.<sup>[1]</sup></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Patel P, Bercik P, Morgan DG, et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol 2015; 50:816.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016; 150:1393. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108357 Version 3.0</div></div></div>"},"108358":{"type":"graphic_diagnosticimage","displayName":"Large ascending aortic aneurysm with compression of RPA","title":"Large ascending aortic aneurysm causing compression of the right pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Large ascending aortic aneurysm causing compression of the right pulmonary artery</div><div class=\"cntnt\"><img style=\"width:726px; height:557px;\" src=\"images/ANEST/108358_Large_ascending_aortc_anrsm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">Intraoperative TEE image of the ascending&nbsp;aorta in short-axis in a patient with a 9-cm-diameter ascending aortic aneurysm causing a mediastinal mass effect and compression of the right pulmonary artery<STRONG innerHtml>.</STRONG></SPAN></div><div class=\"graphic_footnotes\">RPA: right pulmonary artery; Ao: ascending aorta; TEE: transesophageal echocardiography.</div><div id=\"graphicVersion\">Graphic 108358 Version 2.0</div></div></div>"},"108360":{"type":"graphic_table","displayName":"Empiric antibiotic treatment of acute cholecystitis","title":"Empiric antibiotic treatment of acute cholecystitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antibiotic treatment of acute cholecystitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infection</td> <td class=\"subtitle1\">Regimen</td> </tr> <tr class=\"divider_bottom\"> <td>Community-acquired acute cholecystitis of mild-to-moderate severity</td> <td>Cefazolin, cefuroxime, or ceftriaxone.</td> </tr> <tr class=\"divider_bottom\"> <td>Community-acquired acute cholecystitis of severe physiologic disturbance, advanced age, or immunocompromised state</td> <td>Imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin plus metronidazole, levofloxacin plus metronidazole, or cefepime plus metronidazole.*</td> </tr> <tr> <td>Health care-associated biliary infection of any severity</td> <td>Imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin plus metronidazole, levofloxacin plus metronidazole, or cefepime plus metronidazole, with vancomycin added to each regimen.*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Because of increasing resistance of <em>Escherichia coli</em> to fluoroquinolones, local population susceptibility profiles and, if available, isolate susceptibility should be reviewed.</div><div class=\"graphic_reference\">Reproduced from: Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. CID 2010; 50(2):133-64, by permission of Oxford University Press on behalf of The Infectious Diseases Society of America.</div><div id=\"graphicVersion\">Graphic 108360 Version 4.0</div></div></div>"},"108362":{"type":"graphic_table","displayName":"Interpretation of Zika and Dengue virus antibody testing","title":"Interpretation*<SUP>¶</SUP> of results of nucleic acid and antibody testing<SUP>Δ</SUP><SUP>◊</SUP> for suspected Zika virus infection – United States (including US territories), 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation*<SUP>¶</SUP> of results of nucleic acid and antibody testing<SUP>Δ</SUP><SUP>◊</SUP> for suspected Zika virus infection&nbsp;– United States (including US territories), 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Zika virus NAT (serum)<sup>&#167;</sup></td> <td class=\"subtitle1\">Zika virus NAT (urine)<sup>&#167;</sup></td> <td class=\"subtitle1\">Zika virus IgM<sup>&#165;</sup></td> <td class=\"subtitle1\">Zika virus PRNT</td> <td class=\"subtitle1\">Dengue virus PRNT</td> <td class=\"subtitle1\">Interpretation and recommendations</td> </tr> <tr> <td>Positive</td> <td>Positive</td> <td>Any result</td> <td>Not indicated</td> <td>Not indicated</td> <td><strong>Acute Zika virus infection.</strong></td> </tr> <tr> <td>Negative</td> <td>Positive</td> <td>Positive</td> <td>Not indicated</td> <td>Not indicated</td> <td><strong>Acute Zika virus infection.</strong></td> </tr> <tr> <td>Negative</td> <td>Positive</td> <td>Negative</td> <td>Not indicated</td> <td>Not indicated</td> <td><strong>Suggests acute Zika virus infection.</strong> <ul class=\"decimal_heading\"> <li>Repeat testing on original urine specimen. </li> <li>If repeat NAT result is positive, interpret as <strong>evidence of acute Zika virus infection</strong>. </li> <li>If repeat NAT result is negative, repeat Zika virus IgM testing on a serum specimen collected &#8805;2 weeks after symptom onset or possible exposure or specimen collection date. <ul> <li>If repeat IgM result is positive,<sup>&#135;</sup> interpret as <strong>evidence of acute Zika virus infection</strong>. </li> <li>If repeat IgM result is not positive, interpret as no evidence of Zika virus infection. </li> </ul> </li> </ul> </td> </tr> <tr> <td>Positive</td> <td>Negative or not performed</td> <td>Positive</td> <td>Not indicated</td> <td>Not indicated</td> <td><strong>Acute Zika virus infection.</strong></td> </tr> <tr> <td>Positive</td> <td>Negative or not performed</td> <td>Negative</td> <td>Not indicated</td> <td>Not indicated</td> <td><strong>Suggests acute Zika virus infection.</strong> <ul class=\"decimal_heading\"> <li>Repeat testing on original serum specimen. </li> <li>If repeat NAT result is positive, interpret as <strong>evidence of acute Zika virus infection</strong>. </li> <li>If repeat NAT result is negative, repeat Zika virus IgM testing on a serum specimen collected &#8805;2 weeks after symptom onset or possible exposure or specimen collection date. <ul> <li>If repeat IgM result is positive, interpret as <strong>evidence of acute Zika virus infection</strong>. </li> <li>If repeat IgM antibody result is not positive,<sup>&#135;</sup> interpret as no evidence of Zika virus infection. </li> </ul> </li> </ul> </td> </tr> <tr> <td>Negative</td> <td>Negative or not performed</td> <td>Any nonnegative result<sup>&#134;</sup></td> <td>&#8805;10</td> <td>&#60;10</td> <td><strong>Zika virus infection; timing of infection cannot be determined.</strong> <ul class=\"decimal_heading\"> <li>For persons without prior Zika virus exposure, a positive IgM result represents recent Zika virus infection. </li> </ul> </td> </tr> <tr> <td>Negative</td> <td>Negative or not performed</td> <td>Any nonnegative result<sup>&#134;</sup></td> <td>&#60;10</td> <td>Any result</td> <td><strong>No evidence of Zika virus infection.</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>Negative or not performed</td> <td>Any nonnegative result<sup>&#134;</sup></td> <td>&#8805;10</td> <td>&#8805;10</td> <td><strong>Flavivirus infection; specific virus cannot be identified; timing of infection cannot be determined.</strong> <ul class=\"decimal_heading\"> <li>For persons without prior Zika virus exposure, a positive IgM result represents recent unspecified flavivirus infection. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">For areas where PRNT is not recommended<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Negative</td> <td>Negative or not performed</td> <td>Positive for Zika virus AND negative for dengue virus</td> <td colspan=\"2\">Not performed because PRNT is not recommended</td> <td><strong>Presumptive Zika virus infection; timing of infection cannot be determined.</strong>**</td> </tr> <tr> <td class=\"indent1\">Negative</td> <td>Negative or not performed</td> <td>Positive for Zika virus AND positive for dengue virus</td> <td colspan=\"2\">Not performed because PRNT is not recommended</td> <td><strong>Presumptive flavivirus infection; specific virus cannot be identified; timing of infection cannot be determined.</strong>**</td> </tr> <tr> <td class=\"indent1\">Negative</td> <td>Negative or not performed</td> <td>Equivocal (either or both assays)</td> <td colspan=\"2\">Not performed because PRNT is not recommended</td> <td><strong>Insufficient information for interpretation.</strong> <ul class=\"decimal_heading\"> <li>Consider repeat testing. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Negative</td> <td>Negative or not performed</td> <td>Negative on both assays</td> <td colspan=\"2\">Not performed because PRNT is not recommended</td> <td><strong>No laboratory evidence of Zika virus infection.</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NAT: nucleic acid test; IgM: immunoglobulin M; PRNT: plaque reduction neutralization test.<br />​* Final interpretations of results of Zika virus tests should be performed after all testing is completed.<br />¶ Serology test results that indicate flavivirus infection should be interpreted in the context of circulating flaviviruses.<br />Δ Dengue virus IgM testing is recommended for symptomatic pregnant women as well as for asymptomatic pregnant women residing in areas where PRNT is not recommended.<br /><FONT class=lozenge>◊</FONT> Currently, PRNT confirmation is not routinely recommended for persons living in Puerto Rico.<br />§ Serum must be submitted for all persons tested for Zika virus infection; a urine specimen for Zika virus NAT testing should always be submitted concurrently with a serum specimen.<br />¥ For laboratory interpretation in the presence of dengue virus IgM results refer to <A href=\"https://www.cdc.gov/dengue/clinicallab/laboratory.html\" target=_blank>https://www.cdc.gov/dengue/clinicallab/laboratory.html</A>.<br />‡ <STRONG>Positive</STRONG> results include \"positive,\" \"presumptive Zika virus positive,\" or \"possible Zika virus positive.\" These are examples of assay interpretations that might accompany test results; positive serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the specific assay performed. Information on each assay can be found at <A href=\"https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika\" target=_blank>https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika</A> under the \"Labeling\" for the specific assay.<br />† <STRONG>Non-negative</STRONG> results include \"positive,\" \"equivocal,\" \"presumptive positive,\" or \"possible positive.\" These are examples of assay interpretations that might accompany test results; nonnegative serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the specific assay performed. Information on each assay can be found at <A href=\"https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika\" target=_blank>https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika</A> under \"Labeling\" for the specific assay.<br />** Zika virus IgM positive result is reported as \"presumptive positive or flavivirus infection\" to denote the need to perform confirmatory PRNT titers against Zika virus, dengue virus, and other flaviviruses to which the person might have been exposed to resolve potential false-positive results that might have been caused by crossreactivity or nonspecific reactivity. In addition, ambiguous test results (eg, inconclusive, equivocal, and indeterminate) that are not resolved by retesting also should have PRNT titers performed to rule out a false-positive result. However, PRNT confirmation is currently not routinely recommended for persons living in Puerto Rico.</div><div class=\"graphic_reference\">From: Oduyebo T, Polen KD, Walke HT, et al. Update: Interim guidance for health care providers caring for pregnant women with possible Zika virus exposure — United States (including U.S. territories), July 2017. MMWR 2017; 66:1.</div><div id=\"graphicVersion\">Graphic 108362 Version 3.0</div></div></div>"},"108363":{"type":"graphic_algorithm","displayName":"Vulvar ca staging surgery","title":"Vulvar cancer staging and surgical treatment algorithm","html":"<div class=\"graphic\"><div style=\"width: 1153px\" class=\"figure\"><div class=\"ttl\">Vulvar cancer staging and surgical treatment algorithm</div><div class=\"cntnt\"><img style=\"width:1133px; height:928px;\" src=\"images/ONC/108363_Vulvar_ca_staging_surgery.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LND: lymphadenectomy.<br />* If presence or extent of local extension cannot be determined on office examination, perform examination under anesthesia. This may include additional biopsies, cystoscopy, and/or proctoscopy.<br />¶ Pelvic/abdominal computed tomography or positron emission tomograpy, and chest radiograph.<br />Δ Stage IA: Lesions ≤2 cm in size, confined to the vulva or perineum with stromal invasion ≤1.0 mm.<br /><FONT class=lozenge>◊</FONT> Stage IB: Lesions &gt;2 cm in size OR any size with stromal invasion &gt;1.0 mm, confined to the vulva or perineum.<br />§ Stage II: Tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).<br />¥ Criteria for sentinel node biopsy (SLNB) are: &gt;1 mm depth, no palpable lymph nodes, unifocal disease, and sufficient surgical expertise. Institutions vary regarding tumor diameter from &lt;2 to &lt;4 cm. Patients should be counseled about the risk of a false negative with SLNB.<br />‡ Lateral is defined as &gt;2 cm from the vulvar midline.</div><div id=\"graphicVersion\">Graphic 108363 Version 1.0</div></div></div>"},"108369":{"type":"graphic_diagnosticimage","displayName":"Right ventricular strain","title":"Right ventricular strain","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Right ventricular strain</div><div class=\"cntnt\"><img style=\"width:800px; height:509px;\" src=\"images/CARD/108369_Right_ventricular_strain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four-chamber view demonstrating right ventricular strain assessed by two-dimensional speckle tracking. Both free wall and septal contours are traced for optimal algorithm functioning, but only the free wall segments are most commonly averaged. The average longitudinal strain of the RV free wall is –4% (normal &lt;-20%), suggesting significantly reduced longitudinal contractility (lower left panel). The regional strain is particularly impaired in the basal segment of the right ventricular free wall; a pattern frequently seen in post-cardiac surgery patients, such as this patient. Note the significant inhomogeneity in the time to peak strain (upper right panel).</div><div id=\"graphicVersion\">Graphic 108369 Version 1.0</div></div></div>"},"108370":{"type":"graphic_table","displayName":"Echo findings in acute and chronic pressure and volume overload","title":"Echocardiographic findings in acute and chronic pressure and volume overload","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiographic findings in acute and chronic pressure and volume overload</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"28%\"></colgroup><colgroup span=\"4\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Pressure overload</td> <td class=\"subtitle1\" colspan=\"2\">Volume overload</td> </tr> <tr> <td class=\"subtitle2\">Acute</td> <td class=\"subtitle2\">Chronic</td> <td class=\"subtitle2\">Acute</td> <td class=\"subtitle2\">Chronic</td> </tr> <tr class=\"divider_bottom\"> <td><strong>RV size</strong></td> <td class=\"centered\">N or <span style=\"font-size: larger;\">&#8593;</span> *</td> <td class=\"centered\">N or <span style=\"font-size: larger;\">&#8593;</span></td> <td class=\"centered\">N</td> <td class=\"centered\"><span style=\"font-size: larger;\">&#8593;</span><span style=\"font-size: larger;\">&#8593;</span></td> </tr> <tr class=\"divider_bottom\"> <td><strong>RV systolic function</strong></td> <td class=\"centered\">N or <span style=\"font-size: larger;\">&#8595;</span> <sup>&#182;</sup></td> <td class=\"centered\">N or <span style=\"font-size: larger;\">&#8595;</span> <sup>&#916;</sup></td> <td class=\"centered\">N or <span style=\"font-size: larger;\">&#8593;</span></td> <td class=\"centered\">N or <span style=\"font-size: larger;\">&#8595;</span></td> </tr> <tr class=\"divider_bottom\"> <td><strong>RA pressure</strong></td> <td class=\"centered\"><span style=\"font-size: larger;\">&#8593;</span></td> <td class=\"centered\">N or <span style=\"font-size: larger;\">&#8593;</span> <sup>&#9674;</sup></td> <td class=\"centered\"><span style=\"font-size: larger;\">&#8593;</span><span style=\"font-size: larger;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: larger;\">&#8593;</span></td> </tr> <tr> <td><strong>PA pressure</strong></td> <td class=\"centered\"><span style=\"font-size: larger;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: larger;\">&#8593;</span><span style=\"font-size: larger;\">&#8593;</span></td> <td class=\"centered\">N</td> <td class=\"centered\">N or <span style=\"font-size: larger;\">&#8593;</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RV: right ventricular; PA: pulmonary artery.<br />* RV size and systolic function may remain normal in the presence of mild-moderate acute increases in PA systolic pressure &lt;55 mmHg, whereas the normal RV cannot usually overcome acute increases in PA systolic pressure &gt;55 mmHg and thus fails. For chronic increases in PA pressure, the RV progressively adapts and remodels to tolerate higher pressures before failing.<br />¶ RV dysfunction may exhibit a pattern of apical sparring in acute pulmonary embolism, referred to as \"McConnell's sign\".<br />Δ RV dysfunction may exhibit a pattern of longitudinal sparing in pre-capillary pulmonary arterial hypertension, defined as normal tissue Doppler annular velocity (S') or tricuspid annular plane systolic excursion (TAPSE) in the presence of reduced fractional area change (FAC) or global RV ejection fraction.<br /><FONT class=lozenge>◊</FONT> RA dilation, indicative of elevated RA pressure, is a poor prognostic sign for survival in pulmonary arterial hypertension.</div><div id=\"graphicVersion\">Graphic 108370 Version 1.0</div></div></div>"},"108371":{"type":"graphic_figure","displayName":"Generation of a cross-reactive immune response in ARF","title":"Generation of a cross-reactive immune response in acute rheumatic fever","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Generation of a cross-reactive immune response in acute rheumatic fever</div><div class=\"cntnt\"><img style=\"width:712px; height:592px;\" src=\"images/ALLRG/108371_Cross-rctv_immune_rspns_ARF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following GAS adhesion to and invasion of the pharyngeal epithelium, GAS antigens activate both B and T cells. Molecular mimicry between GAS group A carbohydrate or serotype-specific M protein and the host heart, brain, or joint tissues can lead to an autoimmune response, which causes the major manifestations of ARF.</div><div class=\"graphic_footnotes\">GAS: group A <em>Streptococcus</em>; BCR: B cell receptor; TCR: T cell receptor; MHC: major histocompatibility complex; ARF: acute rheumatic fever.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Disease Primers. Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers 2016; 2:15084. Copyright &copy; 2016. <a href=\"http://www.nature.com/nrdp/\" target=\"_blank\">www.nature.com/nrdp/</a>.</div><div id=\"graphicVersion\">Graphic 108371 Version 1.0</div></div></div>"},"108372":{"type":"graphic_figure","displayName":"US data: Fetal, perinatal, neonatal mortality","title":"United States data on fetal, perinatal, and neonatal mortality","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">United States data on fetal, perinatal, and neonatal mortality</div><div class=\"cntnt\"><img style=\"width:480px; height:264px;\" src=\"images/PEDS/108372_US_Fetal_prntl_nntl_mortalit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal mortality, perinatal mortality, late-fetal mortality, and early NMRs: 2000, 2006, 2011, and 2012. Note: FMR indicates fetal deaths per 1000 live births plus fetal deaths; early FMR, early-fetal deaths (20 to 27 weeks) per 1000 live births plus fetal deaths; late FMR, late fetal deaths (≥28 weeks) per 1000 live births plus fetal deaths; PMR, late-fetal deaths and early neonatal (&lt;7 days of age) deaths per 1000 live births plus fetal deaths; early NMR, early-neonatal (&lt;7 days of age) deaths per 1000 live births.</div><div class=\"graphic_footnotes\">FMR: fetal mortality rate; PMR: perinatal mortality rate; NMR: neonatal mortality rate; NCHS: National Center for Health Statistics.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 135, Pages 1115-25, Copyright &copy; 2015 by the AAP.</div><div id=\"graphicVersion\">Graphic 108372 Version 2.0</div></div></div>"},"108373":{"type":"graphic_figure","displayName":"Effect of temperature on the EEG","title":"Effect of temperature on the EEG","html":"<div class=\"graphic\"><div style=\"width: 1018px\" class=\"figure\"><div class=\"ttl\">Effect of temperature on the EEG</div><div class=\"cntnt\"><img style=\"width:998px; height:658px;\" src=\"images/ANEST/108373_Effect_temperature_EEG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain temperature cannot be measured directly during deliberate hypothermia on cardiopulmonary bypass. Temperature measured within the NP or ear canal near the tympanic membrane is often used as a surrogate indicator of brain temperature. Hypothermia produces characteristic changes in the EEG that can also be used as a physiologic surrogate of the degree of suppression of cerebral metabolism. Electrocortical silence on the EEG occurs at an average NP temperature of 18°C in adults, but&nbsp;<FONT color=black>a</FONT> NP temperature of approximately 12°C is necessary to ensure electrocortical&nbsp;silence in &gt;95 percent of patients.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; NP: nasopharynx.</div><div class=\"graphic_reference\">Original figure modified for this publication. Stecker MM, Cheung AT, Pochettino A, et al. Deep hypothermic circulatory arrest: I. Effects of cooling on electroencephalogram and evoked potentials. Ann Thorac Surg 2001; 71:14. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108373 Version 2.0</div></div></div>"},"108374":{"type":"graphic_diagnosticimage","displayName":"Cerebral oximetry during carotid artery clamping","title":"Cerebral oximetry during carotid artery clamping","html":"<div class=\"graphic\"><div style=\"width: 756px\" class=\"figure\"><div class=\"ttl\">Cerebral oximetry during carotid artery clamping</div><div class=\"cntnt\"><img style=\"width:736px; height:597px;\" src=\"images/ANEST/108374_Cerebral_oximetry_carotid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">NIRS provides a means to assess cerebral oxygenation (and, by inference, cerebral&nbsp;blood flow) during operations involving the aortic arch.&nbsp;A</SPAN><FONT color=black><SPAN style=\"COLOR: black\"> decrease in the rSO<SUB>2</SUB> was noted in the ipsilateral frontal cortex (the left cortex) during temporary clamping of the LCCA and the&nbsp;innominate artery&nbsp;during a hybrid arch debranching procedure for repair of an aortic arch aneurysm.&nbsp;The image shows an initial decrease in rSO<SUB>2</SUB> over the left cortex following LCCA clamping and recovery after blood flow to the LCCA was restored (LCCA graft opened). Minutes later, a decrease in rSO<SUB>2</SUB> over the right cerebral cortex was recorded when the innominate artery was temporarily occluded; this was also followed by a recovery in&nbsp;rSO<SUB>2</SUB>&nbsp;after blood flow to the innominate artery was restored (Innom A graft opened). Continuous EEG monitoring during the procedure (not shown) was used to verify that the temporary reductions in rSO<SUB>2</SUB> were not associated with cerebral ischemia.</SPAN></FONT></div><div class=\"graphic_footnotes\">LCCA: left common carotid artery; Innom A: innominate artery; L: left; R: right; NIRS: near-infrared spectroscopy; rSO<SUB>2</SUB>: regional cerebral oxygen saturation; EEG: electroencephalogram.</div><div id=\"graphicVersion\">Graphic 108374 Version 5.0</div></div></div>"},"108376":{"type":"graphic_figure","displayName":"Orthopedic trauma table","title":"Orthopedic trauma table","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Orthopedic trauma table</div><div class=\"cntnt\"><img style=\"width:756px; height:544px;\" src=\"images/ANEST/108376_Orthopedic_trauma_table.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Schaerer Medical USA. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108376 Version 2.0</div></div></div>"},"108377":{"type":"graphic_diagnosticimage","displayName":"Two-dimensional echo-Simpson's method","title":"Two-dimensional echo-Simpson's method","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Two-dimensional echo-Simpson's method</div><div class=\"cntnt\"><img style=\"width:764px; height:536px;\" src=\"images/CARD/108377_Two_dmnsnl_echo_Simpsons.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional echocardiographic images in the apical four-chamber (upper panel) and apical two-chamber (lower panel) views at end diastolic (left panel) and end systolic (right panel) phases. The left ventricular endocardial cavity is traced on each of these views and phases to calculate left ventricular ejection fraction using the biplane method of discs (modified Simpson's method).</div><div id=\"graphicVersion\">Graphic 108377 Version 1.0</div></div></div>"},"108378":{"type":"graphic_diagnosticimage","displayName":"Two-dimensional echo strain","title":"Two-dimensional echo strain","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Two-dimensional echo strain</div><div class=\"cntnt\"><img style=\"width:752px; height:554px;\" src=\"images/CARD/108378_Two_dimensional_echo_strain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional echocardiographic image&nbsp;with tissue Doppler imaging in the apical four-chamber view for measurement of segmental and global longitudinal strain.</div><div id=\"graphicVersion\">Graphic 108378 Version 1.0</div></div></div>"},"108379":{"type":"graphic_diagnosticimage","displayName":"CMR disc summation method","title":"Cardiac magnetic resonance disc summation method","html":"<div class=\"graphic\"><div style=\"width: 928px\" class=\"figure\"><div class=\"ttl\">Cardiac magnetic resonance disc summation method</div><div class=\"cntnt\"><img style=\"width:908px; height:488px;\" src=\"images/CARD/108379_CMR_disc_summation_method.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiac magnetic resonance images in four- and two-chamber views&nbsp;showing&nbsp;positions of&nbsp;short axis slices from base to apex. The left ventricular endocardial cavity is traced on each short axis view at end-diastole and end-systole to calculate the left ventricular ejection fraction using the summation of discs method.</div><div id=\"graphicVersion\">Graphic 108379 Version 1.0</div></div></div>"},"108380":{"type":"graphic_diagnosticimage","displayName":"Cardiac CT disc summation method","title":"Cardiac computed tomography disc summation method","html":"<div class=\"graphic\"><div style=\"width: 714px\" class=\"figure\"><div class=\"ttl\">Cardiac computed tomography disc summation method</div><div class=\"cntnt\"><img style=\"width:694px; height:726px;\" src=\"images/CARD/108380_Cardiac_CT_disc_summtn_mthd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiac computed tomography short axis slices from base to apex at end-diastole and end-systole. The left ventricular endocardial cavity is traced on each short axis view at end-diastole and end-systole to calculate ventricular volumes and the left ventricular ejection fraction using the summation of discs method.</div><div id=\"graphicVersion\">Graphic 108380 Version 1.0</div></div></div>"},"108381":{"type":"graphic_diagnosticimage","displayName":"Cardiac CT threshold-based segmentation","title":"Cardiac computed tomography threshold-based segmentation","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Cardiac computed tomography threshold-based segmentation</div><div class=\"cntnt\"><img style=\"width:538px; height:728px;\" src=\"images/CARD/108381_Cardiac_CT_threshold_segmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiac computed tomography volumetric images are visualized in the four- and two-chamber views. Contiguous voxels of a predefined attenuation threshold are highlighted with set boundaries (mitral valve level) to determine left ventricular volume and left ventricular ejection fraction.</div><div id=\"graphicVersion\">Graphic 108381 Version 1.0</div></div></div>"},"108384":{"type":"graphic_table","displayName":"SOAPP-R tool","title":"Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"6\">The following are some questions given to patients who are on or being considered for medication for their pain. Please answer each question as honestly as possible. There are no right or wrong answers.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\">Never</td> <td class=\"subtitle1\">Seldom</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very often</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>How often do you have mood swings?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"2\"> <li>How often have you felt a need for higher doses of medication to treat your pain?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li>How often have you felt impatient with your doctors?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"4\"> <li>How often have you felt that things are just too overwhelming that you can't handle them?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"5\"> <li>How often is there tension in the home?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"6\"> <li>How often have you counted pain pills to see how many are remaining?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"7\"> <li>How often have you been concerned that people will judge you for taking pain medication?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"8\"> <li>How often do you feel bored?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"9\"> <li>How often have you taken more pain medication than you were supposed to?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"10\"> <li>How often have you worried about being left alone?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"11\"> <li>How often have you felt a craving for medication?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"12\"> <li>How often have others expressed concern over your use of medication?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"13\"> <li>How often have any of your close friends had a problem with alcohol or drugs?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"14\"> <li>How often have others told you that you had a bad temper?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"15\"> <li>How often have you felt consumed by the need to get pain medication?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"16\"> <li>How often have you run out of pain medication early?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"17\"> <li>How often have others kept you from getting what you deserve?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"18\"> <li>How often, in your lifetime, have you had legal problems or been arrested?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"19\"> <li>How often have you attended an AA or NA meeting?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"20\"> <li>How often have you been in an argument that was so out of control that someone got hurt?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"21\"> <li>How often have you been sexually abused?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"22\"> <li>How often have others suggested that you have a drug or alcohol problem?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"23\"> <li>How often have you had to borrow pain medications from your family or friends?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"24\"> <li>How often have you been treated for an alcohol or drug problem?</li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr> <td colspan=\"6\"><em>Please include any additional information you wish about the above answers.</em><br /> <em>Thank you.</em><br /> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">&copy;2015 Inflexxion, Inc. Permission granted solely for use in published format by individual practitioners in clinical practice. No other uses or alterations are authorized or permitted by copyright holder. Permissions questions: <a href=\"mailto:PainEDU@inflexxion.com\">PainEDU@inflexxion.com</a>. An online version of this tool is included in <a href=\"https://www.paincas.com/Welcome/Welcome\" target=\"_blank\">PainCAS</a>. The SOAPP&reg;-R was developed with a grant from the National Institutes of Health and an educational grant from Endo Pharmaceuticals.<br />Reproduced with permission. Copyright &copy; 2015 Inflexxion, Inc., Newton MA. All rights reserved. <a href=\"http://www.inflexxion.com/\" target=\"_blank\">www.Inflexxion.com</a>.</div><div id=\"graphicVersion\">Graphic 108384 Version 1.0</div></div></div>"},"108385":{"type":"graphic_table","displayName":"Current Opioid Misuse Measure (COMM)","title":"Current Opioid Misuse Measure (COMM)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Current Opioid Misuse Measure (COMM)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"6\">Please answer each question as honestly as possible. Keep in mind that we are only asking about the <strong>past 30 days</strong>. There are no right or wrong answers. If you are unsure about how to answer the question, please give the best answer you can.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">Please answer the questions using the following scale:</td> <td class=\"subtitle1\">Never</td> <td class=\"subtitle1\">Seldom</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very often</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>In the past 30 days, how often have you had trouble with thinking clearly or had memory problems? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"2\"> <li>In the past 30 days, how often do people complain that you are not completing necessary tasks? (i.e., doing things that need to be done, such as going to class, work or appointments) </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li>In the past 30 days, how often have you had to go to someone other than your prescribing physician to get sufficient pain relief from medications? (i.e., another doctor, the Emergency Room, friends, street sources) </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"4\"> <li>In the past 30 days, how often have you taken your medications differently from how they are prescribed? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"5\"> <li>In the past 30 days, how often have you seriously thought about hurting yourself? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"6\"> <li>In the past 30 days, how much of your time was spent thinking about opioid medications (having enough, taking them, dosing schedule, etc.)? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"7\"> <li>In the past 30 days, how often have you been in an argument? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"8\"> <li>In the past 30 days, how often have you had trouble controlling your anger (e.g., road rage, screaming, etc.)? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"9\"> <li>In the past 30 days, how often have you needed to take pain medications belonging to someone else? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"10\"> <li>In the past 30 days, how often have you been worried about how you're handling your medications? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"11\"> <li>In the past 30 days, how often have others been worried about how you're handling your medications? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"12\"> <li>In the past 30 days, how often have you had to make an emergency phone call or show up at the clinic without an appointment? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"13\"> <li>In the past 30 days, how often have you gotten angry with people? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"14\"> <li>In the past 30 days, how often have you had to take more of your medication than prescribed? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"15\"> <li>In the past 30 days, how often have you borrowed pain medication from someone else? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"16\"> <li>In the past 30 days, how often have you used your pain medicine for symptoms other than for pain (e.g., to help you sleep, improve your mood, or relieve stress)? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> <tr> <td> <ol start=\"17\"> <li>In the past 30 days, how often have you had to visit the Emergency Room? </li> </ol> </td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> <td class=\"centered\" style=\"font-size: 14px; vertical-align: middle;\">[&nbsp;]</td> </tr> </tbody></table></div><div class=\"graphic_reference\">&copy;2015 Inflexxion, Inc. Permission granted solely for use in published format by individual practitioners in clinical practice. No other uses or alterations are authorized or permitted by copyright holder. Permissions questions: <a href=\"mailto:PainEDU@inflexxion.com\">PainEDU@inflexxion.com</a>. An online version of this tool is included in <a href=\"https://www.paincas.com/Welcome/Welcome\" target=\"_blank\">PainCAS</a>. The SOAPP&reg;-R was developed with a grant from the National Institutes of Health and an educational grant from Endo Pharmaceuticals.<br />Reproduced with permission. Copyright &copy; 2015 Inflexxion, Inc., Newton MA. All rights reserved. <a href=\"http://www.inflexxion.com/\" target=\"_blank\">www.Inflexxion.com</a>.</div><div id=\"graphicVersion\">Graphic 108385 Version 1.0</div></div></div>"},"108386":{"type":"graphic_form","displayName":"Opioid Risk Tool (ORT)","title":"Opioid Risk Tool (ORT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid Risk Tool (ORT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Date:</strong><br /> &nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Patient name:</strong><br /> &nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\" colspan=\"2\">&nbsp;</td> <td class=\"centered\"><strong>Mark each box that applies</strong></td> <td class=\"centered\"><strong>Item score (female)</strong></td> <td class=\"centered\"><strong>Item score (male)</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"divider_bottom\" rowspan=\"3\"> <ol class=\"numbers_no_heading\"><strong> <li>Family history of substance abuse</li> </strong></ol> </td> <td> <ul> <li>Alcohol</li> </ul> </td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">1</td> <td class=\"centered\">3</td> </tr> <tr> <td> <ul> <li>Illegal drugs</li> </ul> </td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Prescription drugs</li> </ul> </td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"> <ol class=\"numbers_no_heading\" start=\"2\"><strong> <li>Personal history of substance abuse</li> </strong></ol> </td> <td> <ul> <li>Alcohol</li> </ul> </td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> </tr> <tr> <td> <ul> <li>Illegal drugs</li> </ul> </td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Prescription drugs</li> </ul> </td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">5</td> <td class=\"centered\">5</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"3\"><strong> <li>Age (mark box if 16 to 45)</li> </strong></ol> </td> <td>&nbsp;</td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"4\"><strong> <li>History of preadolescent sexual abuse</li> </strong></ol> </td> <td>&nbsp;</td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">3</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <ol class=\"numbers_no_heading\" start=\"5\"><strong> <li>Psychological disease</li> </strong></ol> </td> <td> <ul> <li>Attention deficit disorder</li> <li>Obsessive compulsive disorder</li> <li>Bipolar</li> <li>Schizophrenia</li> </ul> </td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Depression</li> </ul> </td> <td class=\"centered\"><strong>[&nbsp;]</strong></td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"highlight_gray_text\" rowspan=\"2\" colspan=\"2\">&nbsp;</td> <td class=\"centered divider_bottom highlight_green_text\"><strong>TOTAL:</strong></td> <td class=\"centered divider_bottom highlight_green_text\"><strong>_____</strong></td> <td class=\"centered divider_bottom highlight_green_text\"><strong>_____</strong></td> </tr> <tr class=\"divider_top\"> <td colspan=\"3\"><strong>Total score risk category:</strong> <ul class=\"decimal_heading\"> <li>Low risk: 0 to 3</li> <li>Moderate risk: 4 to 7</li> <li>High risk: &#8805;8</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Medicine 2005; 6(6):432-442, by permission of Oxford University Press on behalf of the American Academy of Pain Medicine, and Lynn R. Webster, MD, author of \"The Painful Truth: What Pain is Really Like and Why it Matters to Each of Us.\"</div><div id=\"graphicVersion\">Graphic 108386 Version 4.0</div></div></div>"},"108387":{"type":"graphic_table","displayName":"NOITULP classification Noma facial defects","title":"Classification of facial defects associated with Noma: NOITULP system*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of facial defects associated with Noma: NOITULP system*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Degree of tissue loss</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N</strong>ose</td> <td>None</td> <td>1/4</td> <td>1/2</td> <td>3/4</td> <td>Full tissue loss</td> </tr> <tr class=\"divider_bottom\"> <td><strong>O</strong>uter lining of cheek</td> <td>None</td> <td>1/4</td> <td>1/2</td> <td>3/4</td> <td>Full tissue loss</td> </tr> <tr class=\"divider_bottom\"> <td><strong>I</strong>nner lining of cheek</td> <td>None</td> <td>1/4</td> <td>1/2</td> <td>3/4</td> <td>Full tissue loss</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T</strong>rismus</td> <td>Full mouth opening</td> <td>&#60;40 mm</td> <td>&#60;30 mm</td> <td>&#60;20 mm</td> <td>&#60;10 mm</td> </tr> <tr class=\"divider_bottom\"> <td><strong>U</strong>pper lip</td> <td>None</td> <td>1/4</td> <td>1/2</td> <td>3/4</td> <td>Full tissue loss</td> </tr> <tr class=\"divider_bottom\"> <td><strong>L</strong>ower lip</td> <td>None</td> <td>1/4</td> <td>1/2</td> <td>3/4</td> <td>Full tissue loss</td> </tr> <tr> <td><strong>P</strong>articularities*</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOITULP is an acronym comprising the components of the classification scheme: Nose, Outer lining (of cheek), Inner lining (of cheek), Trismus, Upper lip, Lower lip, Particularities.</div><div class=\"graphic_footnotes\">* Particularities refers to pathologic findings relevant for surgical reconstruction (such as loss of orbital floor).</div><div class=\"graphic_reference\">From: Innovations in Plastic and Aesthetic Surgery, Hartman EHM, Van Damme PA, Suominen SHH. Innovative techniques in Noma reconstructive surgery, 2008, pages 177-92, Eisenmann-Klein M, Neuhann-Lorenz C (Eds), Copyright &copy; 2008 Springer-Verlag Berlin Heidelberg, with permission of Springer.</div><div id=\"graphicVersion\">Graphic 108387 Version 1.0</div></div></div>"},"108388":{"type":"graphic_table","displayName":"Dose and adverse effects of induction agents","title":"Dose and adverse effects of induction agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose and adverse effects of induction agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Premedications</td> <td class=\"subtitle1\">Dosing adjustment</td> <td class=\"subtitle1\">Adverse effects</td> </tr> <tr class=\"divider_bottom\"> <td>Basiliximab</td> <td>20 mg IV x 2 doses</td> <td>None</td> <td> <ul> <li>Pediatrics (&#60;35 kg give 10 mg) </li> </ul> </td> <td> <ul> <li>Hypersensitivity reactions (rare) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Rabbit anti-thymocyte globulin</td> <td>1.5 mg/kg IV x 3-14 days</td> <td>Yes</td> <td> <ul> <li>Decrease dose by one-half if the white cell count is between 2000 and 3000 cells/mm<sup>3</sup>, or if the platelet count is between 50,000 and 75,000 cells/mm<sup>3</sup>. </li> <li>Discontinue when white blood cell or platelet counts fall below the lower limits of these ranges. </li> </ul> </td> <td> <ul> <li>Rash </li> <li>Infusion reaction </li> <li>Thrombocytopenia </li> <li>Leukopenia </li> <li>Serum sickness </li> <li>Anaphylaxis (rare) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Horse anti-thymocyte globulin</td> <td>15 mg/kg IV x 3-14 days</td> <td>Yes</td> <td> <ul> <li>Adjust dose for leukopenia and thrombocytopenia </li> </ul> </td> <td> <ul> <li>Rash </li> <li>Infusion reaction </li> <li>Thrombocytopenia </li> <li>Leukopenia </li> <li>Hives </li> <li>Serum sickness </li> <li>Anaphylaxis (rare) </li> </ul> </td> </tr> <tr> <td>Alemtuzumab</td> <td>30 mg IV x 1 dose</td> <td>Yes</td> <td> <ul> <li>Adjust for neutropenia </li> </ul> </td> <td> <ul> <li>Infusion reaction </li> <li>Leukopenia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div class=\"graphic_reference\">From: Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy kidney transplantation. Transpl Int 2013; 26(7):662-72. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/tri.12043/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1111/tri.12043/abstract</a>. Copyright &copy; 2013 European Society for Organ Transplantation. Reproduced with permission of Blackwell Publishing Ltd. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 108388 Version 1.0</div></div></div>"},"108391":{"type":"graphic_figure","displayName":"Induction therapy choice based on risk assessment","title":"Induction therapy choice based on risk assessment","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Induction therapy choice based on risk assessment</div><div class=\"cntnt\"><img style=\"width:492px; height:260px;\" src=\"images/NEPH/108391_Induction_thrpy_risk_assess.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">From: Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int 2013; 26(7):662-72. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/tri.12043/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1111/tri.12043/abstract</a>. Copyright &copy; 2013 European Society for Organ Transplantation. Reproduced with permission of Blackwell Publishing Ltd. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 108391 Version 1.0</div></div></div>"},"108392":{"type":"graphic_algorithm","displayName":"Management of pregnant women with suspected acute pericarditis","title":"Algorithm for the initial management of pregnant women with suspected acute pericarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for the initial management of pregnant women with suspected acute pericarditis</div><div class=\"cntnt\"><img style=\"width:382px; height:474px;\" src=\"images/CARD/108392_Mmntprgnntwmnactprcrdts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Commonly used NSAID dosing regimens include: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Aspirin 500 to 750 mg every eight hours</LI>&#xD;&#xA;<LI>Ibuprofen 600 to 800 mg every eight hours </LI></UL>&nbsp;&nbsp;&nbsp;NSAID dosing should be continued until asymptomatic, then tapered weekly.<br />¶ Unlike idiopathic acute pericarditis in non-pregnant patients, colchicine is not used in pregnant patients due to unknown adverse effects and concerns about teratogenicity.<br />​Δ Typical glucocorticoid dosing regimen is prednisone 25 mg daily until asymptomatic (usually less than two to four weeks), then taper by 2.5 mg daily every two to four weeks.</div><div id=\"graphicVersion\">Graphic 108392 Version 3.0</div></div></div>"},"108394":{"type":"graphic_diagnosticimage","displayName":"Type A aortic dissection with aortic insufficiency","title":"Type A aortic dissection with aortic insufficiency","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Type A aortic dissection with aortic insufficiency</div><div class=\"cntnt\"><img style=\"width:730px; height:550px;\" src=\"images/ANEST/108394_Type_A_aortic_insufficiency.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative TEE image of the aortic valve, aortic root, and proximal ascending aorta in a long-axis view, with color-flow Doppler imaging in diastole demonstrating severe aortic regurgitation with an acute aortic dissection. The presence of an intimal flap in the aortic root (arrowheads) is diagnostic for Stanford type A aortic dissection. Severe aortic regurgitation is present as a mosaic regurgitant jet in the LVOT caused by acute enlargement of the aortic root due to the dissection.</div><div class=\"graphic_footnotes\">LVOT: left ventricular outflow tract; Ao: ascending aorta; TEE: transesophageal echocardiography.</div><div id=\"graphicVersion\">Graphic 108394 Version 2.0</div></div></div>"},"108395":{"type":"graphic_diagnosticimage","displayName":"TEE to guide aortic cannulation","title":"Intraoperative TEE to guide aortic cannulation","html":"<div class=\"graphic\"><div style=\"width: 864px\" class=\"figure\"><div class=\"ttl\">Intraoperative TEE to guide aortic cannulation</div><div class=\"cntnt\"><img style=\"width:844px; height:423px;\" src=\"images/ANEST/108395_TEE_guide_aortic_cannulatn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative TEE can be used to guide aortic cannulation for cardiopulmonary bypass in a patient with aortic dissection to ensure that the&nbsp;TL of the aorta is cannulated. TEE short-axis image of the aortic arch (left panel) showed that the arterial guidewire (arrow) was inadvertently inserted into the&nbsp;FL of the aortic dissection. TEE short-axis image of the descending thoracic aorta in another patient with an acute aortic dissection showed proper position of the arterial guidewire in the&nbsp;TL of the aortic dissection.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; TL:&nbsp;true lumen; FL: false lumen.</div><div id=\"graphicVersion\">Graphic 108395 Version 1.0</div></div></div>"},"108396":{"type":"graphic_diagnosticimage","displayName":"Ultrasound imaging of a carotid dissection","title":"Ultrasound imaging of a carotid dissection","html":"<div class=\"graphic\"><div style=\"width: 1021px\" class=\"figure\"><div class=\"ttl\">Ultrasound imaging of a carotid dissection</div><div class=\"cntnt\"><img style=\"width:1001px; height:415px;\" src=\"images/ANEST/108396_Carotid_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative Duplex ultrasound imaging of the right common carotid artery in short-axis in a patient with an acute Stanford type A aortic dissection demonstrating dissection extending into the right common carotid artery as evidenced by the presence of an intimal flap within the vessel (left panel, arrows). Doppler-flow imaging during cardiopulmonary bypass was used to confirm blood flow within the&nbsp;TL of the carotid artery dissection.</div><div class=\"graphic_footnotes\">TL: true lumen.</div><div id=\"graphicVersion\">Graphic 108396 Version 1.0</div></div></div>"},"108397":{"type":"graphic_figure","displayName":"Hypothermia and cerebral metabolism","title":"Hypothermia and cerebral metabolism","html":"<div class=\"graphic\"><div style=\"width: 824px\" class=\"figure\"><div class=\"ttl\">Hypothermia and cerebral metabolism</div><div class=\"cntnt\"><img style=\"width:804px; height:496px;\" src=\"images/ANEST/108397_Hypothermia_cerebral_mtblsm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship between O<SUB>2</SUB> consumption and body temperature in experimental studies involving dogs (smaller white&nbsp;circles) compared with the relation between cerebral metabolic O<SUB>2</SUB> consumption and body temperature based on the Q<SUB>10</SUB> ratio determined in adult humans (larger gray circles). Assuming the brain can tolerate a period of five minutes of ischemia at 37°C and that the ischemic tolerance of neurons is directly proportional to O<SUB>2</SUB> consumption, it is predicted that the brain can tolerate a period of 17 to 24 minutes of circulatory arrest under conditions of deliberate hypothermia at 20°C.</div><div class=\"graphic_footnotes\">O<SUB>2</SUB>: oxygen; Q<SUB>10</SUB> ratio: the ratio of the cerebral metabolic rate (CMRO<SUB innerHtml>2</SUB>) at a temperature (t) and at a temperature of t&nbsp;- 10°C&nbsp;(ie,&nbsp;the ratio of CMRO<SUB>2 </SUB>over a 10°C temperature difference).</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gordon AS, Meyer BW, Jones JC. Open-heart surgery using deep hypothermia without an oxygenator. J Thorac Cardiovasc Surg 1960; 40:787.</li>&#xD;&#xA;    <li>McCullough JN, Zhang N, Reich DL, et al. Cerebral metabolic suppression during hypothermic circulatory arrest in humans. Ann Thorac Surg 1999; 67:1895.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 108397 Version 1.0</div></div></div>"},"108398":{"type":"graphic_figure","displayName":"Oxygen extraction ratio during DHCA","title":"Oxygen extraction ratio during deep hypothermic circulatory arrest (DHCA)","html":"<div class=\"graphic\"><div style=\"width: 914px\" class=\"figure\"><div class=\"ttl\">Oxygen extraction ratio during deep hypothermic circulatory arrest (DHCA)</div><div class=\"cntnt\"><img style=\"width:894px; height:646px;\" src=\"images/ANEST/108398_Oxy_extraction_ratio_DHCA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">O<SUB>2</SUB> extraction ratio measured across the cerebral circulation during DHCA with RCP in adult patients at a temperature that produced electrocortical silence on the EEG. The O<SUB>2</SUB> extraction ratio increased over time to a maximum value of 0.6 between 30 and 40 minutes of DHCA with RCP. Simultaneously, the brainstem somatosensory evoked potential (N18) decreased in amplitude over time and disappeared approximately 30 to 40 minutes after the onset of circulatory arrest. Markers of cerebral ischemia, neuron-specific enolase, and astrocyte S-100 measured in the retrograde cerebral perfusate increased significantly at 21 to 30 minutes after the onset of circulatory arrest (not shown).</div><div class=\"graphic_footnotes\">DHCA: deep hypothermic circulatory arrest; RCP: retrograde cerebral perfusion; EEG: electroencephalogram; O<sub>2</sub>: oxygen.</div><div class=\"graphic_reference\">From: Cheung AT, Bavaria JE, Pochettino A, et al. Oxygen delivery during retrograde cerebral perfusion in humans. Anesth Analg 1999; 88:8. Copyright &copy; 1999 International Anesthesia Research Society. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108398 Version 1.0</div></div></div>"},"108399":{"type":"graphic_figure","displayName":"Selective antegrade cerebral perfusion","title":"Selective antegrade cerebral perfusion","html":"<div class=\"graphic\"><div style=\"width: 688px\" class=\"figure\"><div class=\"ttl\">Selective antegrade cerebral perfusion</div><div class=\"cntnt\"><img style=\"width:668px; height:450px;\" src=\"images/ANEST/108399_Sel_antegrad_cerebral_prfsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">Unilateral selective antegrade cerebral perfusion can be delivered by cannulation of the RAx or through an end-to-side prosthetic vascular graft sewn onto the RAx (not shown). The arch branch vessels are crossclamped during reconstruction of the aortic arch. Bilateral selective antegrade cerebral perfusion can be provided by direct cannulation of the IA and the LCA, or by perfusion of the RAx in combination with direct cannulation of the LCA. The LSA can be clamped or occluded by a Fogarty balloon catheter to achieve a bloodless operating field.</SPAN></div><div class=\"graphic_footnotes\">RAx: right axillary artery; IA: innominate artery; LCA: left carotid artery; LSA: left subclavian artery; XC: crossclamp.</div><div class=\"graphic_reference\">Reproduced from: Zierer A, El-Sayed Ahmad A, Papadopoulos N, et al. Selective antegrade cerebral perfusion and mild (28&deg;C-30&deg;C) systemic hypothermic circulatory arrest for aortic arch replacement: results from 1002 patients. J Thorac Cardiovasc Surg 2012; 144:1042. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108399 Version 2.0</div></div></div>"},"108400":{"type":"graphic_figure","displayName":"CPB circuit for retrograde cerebral perfusion","title":"CPB circuit for retrograde cerebral perfusion","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">CPB circuit for retrograde cerebral perfusion</div><div class=\"cntnt\"><img style=\"width:570px; height:672px;\" src=\"images/ANEST/108400_CPB_crct_rtrgrd_crbrl_prfsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retrograde cerebral perfusion can be provided by modifying the&nbsp;CPB circuit. After the initiation of DHCA, clamps are placed in the arterial and venous lines (A and B), the inferior vena cava cannula is clamped (C), a snare is placed around the superior vena cava cannula (D), and the arterial-venous bridge is opened (E) to infuse cold oxygenated blood into the superior vena cava.</div><div class=\"graphic_footnotes\">CPB: cardiopulmonary bypass; DHCA: deep hypothermic circulatory arrest.</div><div class=\"graphic_reference\">Reproduced from: Bavaria JE, Woo YJ, Hall RA, et al. Retrograde cerebral and distal aortic perfusion during ascending and thoracoabdominal aortic operations. Ann Thorac Surg 1995; 60:347. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108400 Version 2.0</div></div></div>"},"108401":{"type":"graphic_picture","displayName":"Struvite crystals in human urine","title":"Struvite crystals in human urine","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Struvite crystals in human urine</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/NEPH/108401_Struvite_crystals_human_uri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Struvite (magnesium ammonium phosphate/triple phosphate) crystals in a human urine sample with a pH of 9, as detected by an automated urinalysis system. Along with them, abundant amorphous phosphate crystals, several squamous and non-squamous epithelial cells, and a few leukocytes can be observed.</div><div class=\"graphic_reference\">Image provided by Doruk Salanci. Reproduced under the <a href=\"https://creativecommons.org/licenses/by-sa/3.0/deed.en\" target=\"_blank\">Creative Commons Attribution-Share Alike 3.0 Unported</a> license.</div><div id=\"graphicVersion\">Graphic 108401 Version 1.0</div></div></div>"},"108403":{"type":"graphic_figure","displayName":"Ventral mesh rectopexy","title":"Ventral mesh rectopexy","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Ventral mesh rectopexy</div><div class=\"cntnt\"><img style=\"width:532px; height:712px;\" src=\"images/SURG/108403_Ventral_mesh_rectopexy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In&nbsp;a ventral mesh rectopexy, the anterior wall of the rectum is sutured to a mesh that is affixed to the sacral promontory (shown) or Cooper’s ligament.&nbsp;Ventral mesh rectopexy is typically performed laparoscopically;&nbsp;either biologic or nonabsorbable meshes can be used. </div><div class=\"graphic_reference\">Modified from: Egglestone C. Laparoscopic ventral rectopexy (version 2). Gateshead&nbsp; Health NHS Foundation Trust 2014.</div><div id=\"graphicVersion\">Graphic 108403 Version 1.0</div></div></div>"},"108409":{"type":"graphic_picture","displayName":"Palmar palpation of the trapezium","title":"Palmar palpation of the trapezium","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Palmar palpation of the trapezium</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/SM/108409_Palmar_palpation_trapezium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palmar palpation of the trapezium can be accomplished by palpating at the base of the thenar eminence, just distal to the wrist crease (area outlined in photograph above).</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 108409 Version 1.0</div></div></div>"},"108410":{"type":"graphic_picture","displayName":"Dorsal palpation of the trapezium","title":"Dorsal palpation of the trapezium","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Dorsal palpation of the trapezium</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/SM/108410_Dorsal_palpation_trapezium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dorsal palpation of the trapezium can be accomplished by palpating the distal aspect of the snuffbox (outlined in photograph above), and by palpating&nbsp;the joint line&nbsp;between the trapezium and&nbsp;the first metacarpal during repetitive thumb abduction-adduction.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 108410 Version 2.0</div></div></div>"},"108411":{"type":"graphic_figure","displayName":"Sleep episode timing in circadian sleep-wake rhythm disorders","title":"Sleep episode timing in circadian sleep-wake rhythm disorders","html":"<div class=\"graphic\"><div style=\"width: 1102px\" class=\"figure\"><div class=\"ttl\">Sleep episode timing in circadian sleep-wake rhythm disorders</div><div class=\"cntnt\"><img style=\"width:1082px; height:298px;\" src=\"images/SLEEP/108411_Circadian_sleep_wake_rhythm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of sleep episode timing as seen in circadian sleep-wake rhythm disorders.</div><div class=\"graphic_footnotes\">N24SWRD: non-24-hour sleep-wake rhythm disorder; ISWRD: irregular sleep-wake rhythm disorder.</div><div id=\"graphicVersion\">Graphic 108411 Version 1.0</div></div></div>"},"108412":{"type":"graphic_table","displayName":"Drugs used for neuraxial labor analgesia","title":"Drugs used for neuraxial labor analgesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs used for neuraxial labor analgesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Epidural*</td> <td class=\"subtitle1\">Spinal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Local anesthetic</td> </tr> <tr> <td class=\"indent1\">Bupivacaine</td> <td>0.0625 to 0.125%</td> <td> <ul> <li>2.5 to 5 mg alone </li> <li>2 to 3 mg with opioid </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ropivacaine</td> <td>0.08 to 0.2%</td> <td> <ul> <li>3 to 4 mg alone </li> <li>2 to 4 mg with opioid </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Opioid</td> </tr> <tr> <td class=\"indent1\">Fentanyl</td> <td>1 to 3 mcg/mL</td> <td> <ul> <li>15 to 25 mcg alone </li> <li>10 to 15 mcg with LA </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Sufentanil</td> <td>0.2 to 0.5 mcg/mL</td> <td> <ul> <li>5 to 8 mcg alone </li> <li>2.5 to 5 mcg with LA </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LA: local anesthetic.<br />* Epidural analgesia is initiated with a bolus of 10 to 20 mL of a combination of an LA(either bupivacaine or ropivacaine, with or without a 3-mL lidocaine with epinephrine test dose) and an opioid (either fentanyl or sufentanil). Epidural analgesia is maintained with the same or a more dilute solution, administered by infusion and patient-controlled epidural analgesia.</div><div id=\"graphicVersion\">Graphic 108412 Version 2.0</div></div></div>"},"108417":{"type":"graphic_figure","displayName":"Impact of stages of human trafficking on health and well-being","title":"Impact of stages of human trafficking on health and well-being","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Impact of stages of human trafficking on health and well-being</div><div class=\"cntnt\"><img style=\"width:590px; height:278px;\" src=\"images/OBGYN/108417_Impact_trafficking_health.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from Zimmerman C, Stockl H. Understanding and addressing violence against women. Human trafficking. World Health Organization, Department of Reproductive Health and Pan American Health Organization, p. 3, Copyright &copy; 2012. Available from: <a href=\"http://www.who.int/reproductivehealth/publications/violence/en/index.html\" target=\"_blank\">http://www.who.int/reproductivehealth/publications/violence/en/index.html</a> (accessed on July 6, 2016).</div><div id=\"graphicVersion\">Graphic 108417 Version 1.0</div></div></div>"},"108419":{"type":"graphic_table","displayName":"Summary of health risks and consequences of human trafficking","title":"Summary of health risks and consequences of human trafficking","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of health risks and consequences of human trafficking</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Physical health</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Intentional traumatic injuries (eg, fractures, cuts, and disfigurement) and chemical/thermal burns </li> <li>Accidental traumatic and overuse injuries (eg, joint sprains, disc herniations, muscles tears, and eye strain) </li> <li>Chemical (eg, pesticides and industrial glues) and environmental exposures (eg, heat exhaustion and vision/hearing impairment) </li> <li>Communicable diseases (eg, hepatitis A virus, intestinal parasites, typhoid, and tuberculosis) </li> <li>Untreated chronic diseases (eg, anemia, cancer, chronic kidney disease, cardiovascular disease, diabetes mellitus, and hypertension) </li> <li>Poor oral health and injuries (eg, tooth decay/fractures and mandibular dislocations) </li> <li>Dehydration, malnutrition, and eating disorders </li> <li>Branding/tattooing and skin disorders (eg, lice, scabies, and mycoses) </li> <li>Complications from substance use disorders </li> <li>Homicide and accidental death (eg, fatal trauma) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Reproductive health</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Vaginal, perineal, and rectal injuries (eg, secondary/gang rape and use of foreign objects) </li> <li>Sexually transmitted infections (eg, HIV, human papillomavirus, <em>Neisseria gonorrhea</em>, chlamydia, and hepatitis B and C viruses) </li> <li>Diseases due to untreated sexually transmitted infections (eg, AIDS, cervical cancer, pelvic inflammatory disease, infertility, liver disease, and hepatocellular cancer) </li> <li>Poor access to barrier protection or other contraception </li> <li>Forced sterilization or use of contraceptive devices </li> <li>Unplanned and high-risk pregnancies </li> <li>Unsafe, forced abortions </li> <li>Abortion-related complications </li> <li>Forced pregnancy and childbirth </li> <li>Lack of prenatal care, including prevention of vertical HIV transmission </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Mental health</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Stockholm syndrome (ie, traumatic bonding with perpetrator) </li> <li>Affective disorders (eg, anxiety, depression, and panic attacks) </li> <li>Posttraumatic stress disorder (symptoms include flashbacks, intrusive thoughts, memory difficulties, and hypervigilance) and complex posttraumatic stress disorder </li> <li>Dissociative disorders involving varying degrees of detachment from self/reality </li> <li>Sleep disorders (eg, sleep disturbances, nightmares, and insomnia) </li> <li>Psychosomatic syndromes (eg, chronic pain, fatigue, gastrointestinal distress, headaches, and dizziness) </li> <li>Low self-esteem, shame, guilt, self-loathing, and hopelessness </li> <li>Forced or coerced substance use disorders </li> <li>High-risk and self-injurious behaviors </li> <li>Suicide and accidental death (eg, drug overdose) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome.</div><div class=\"graphic_reference\">From <em>Annals of Internal Medicine</em>, Macias-Konstantopoulos W. Human Trafficking: The Role of Medicine in Interrupting the Cycle of Abuse and Violence. Ann Intern Med 2016; 165(8):582-588. Copyright &copy; 2016 American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 108419 Version 2.0</div></div></div>"},"108422":{"type":"graphic_table","displayName":"Spinal local anesthetics","title":"Spinal local anesthetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spinal local anesthetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Local anesthetic</td> <td class=\"subtitle1\">Baricity</td> <td class=\"subtitle1\">Concentration (%)</td> <td class=\"subtitle1\">Dose* (mg)</td> <td class=\"subtitle1\">Duration<sup>&#182;</sup> (minutes)</td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"white-space: nowrap;\">2-chloroprocaine<sup>&#916;</sup><sup>[1]</sup></span></td> <td class=\"centered\">Isobaric<sup>&#9674;</sup></td> <td class=\"centered\">2, 3</td> <td class=\"centered\">20 to 60</td> <td class=\"centered\">30 to 50</td> </tr> <tr class=\"divider_bottom\"> <td>Lidocaine<sup>[2-4]</sup></td> <td class=\"centered\">Hyperbaric<sup>&#167;</sup></td> <td class=\"centered\">5</td> <td class=\"centered\">50 to 100</td> <td class=\"centered\">45 to 75</td> </tr> <tr class=\"divider_bottom\"> <td>Lidocaine<sup>&#916;</sup><sup>[5,6]</sup></td> <td class=\"centered\">Isobaric<sup>&#9674;</sup></td> <td class=\"centered\">2</td> <td class=\"centered\">40 to 80</td> <td class=\"centered\">45 to 75</td> </tr> <tr class=\"divider_bottom\"> <td>Mepivacaine<sup>&#916;</sup><sup>[7,8]</sup></td> <td class=\"centered\">Isobaric<sup>&#9674;</sup></td> <td class=\"centered\">1, 1.5, 2</td> <td class=\"centered\">50 to 70</td> <td class=\"centered\">45 to 75</td> </tr> <tr class=\"divider_bottom\"> <td>Bupivacaine<sup>[2,9,10]</sup></td> <td class=\"centered\">Hyperbaric<sup>&#167;</sup></td> <td class=\"centered\">0.75</td> <td class=\"centered\">6 to 15</td> <td class=\"centered\">90 to 150</td> </tr> <tr class=\"divider_bottom\"> <td>Bupivacaine<sup>&#916;</sup><sup>[11]</sup></td> <td class=\"centered\">Isobaric<sup>&#9674;</sup></td> <td class=\"centered\">0.5</td> <td class=\"centered\">6 to 15</td> <td class=\"centered\">90 to 150</td> </tr> <tr class=\"divider_bottom\"> <td>Ropivacaine<sup>&#916;</sup><sup>[12-14]</sup></td> <td class=\"centered\">Isobaric<sup>&#9674;</sup></td> <td class=\"centered\">0.5, 0.75, 1</td> <td class=\"centered\">15 to 20</td> <td class=\"centered\">75 to 120</td> </tr> <tr> <td>Tetracaine<sup>[2]</sup></td> <td class=\"centered\">Isobaric<sup>&#9674;</sup></td> <td class=\"centered\">1</td> <td class=\"centered\">5 to 20</td> <td class=\"centered\">90 to 150</td> </tr> <tr> <td>Prilocaine<sup>&#165;[15]</sup></td> <td class=\"centered\">Hyperbaric&nbsp;</td> <td class=\"centered\">2&nbsp;</td> <td class=\"centered\">30 to 60&nbsp;</td> <td class=\"centered\">60&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LA: local anesthetic.<br />* Spinal anesthetics are injected into the low- to mid-lumbar subarachnoid space. The primary determinants of the extent of dermatomal spread are dose and baricity (relative to the patient's body position). If baricity is held constant, the dose is directly related to extent of dermatomal spread: higher doses result in greater spread. Doses at the low end of the range will result in low-thoracic neuroblockade, and doses at the high end of the range will result in mid-thoracic neuroblockade. High doses of hyperbaric solution generally do not result in neuroblockade higher than T4 because the LA solution tends to layer in the thoracic kyphosis in a patient in the supine position. In practice, we use hyperbaric solutions if the desired sensory level is higher than T10 (eg, pelvic procedures), and we use isobaric (plain) solutions if the desired sensory level is lower than T10 (eg, lower extremity procedures). The addition of opioids to intrathecal LAs decreases the required dose and prolongs the duration of anesthesia.<br />¶ Two-dermatome regression.<br />Δ Not approved by the US Food and Drug Administration (FDA) for spinal injection.<br /><FONT class=lozenge>◊</FONT> Plain LA solutions (dissolved in normal saline solution) are actually slightly hypobaric, but are usually considered clinically to be isobaric solutions. In general, plain solutions have less dermatomal spread than hyperbaric solutions, and longer duration of anesthesia. Plain solutions of LA can be made hypobaric by the addition of sterile water (lidocaine 0.5%, bupivacaine 0.3%, and tetracaine 0.2% are reliably hypobaric).<br />§ LA solutions are made hyperbaric by the addition of dextrose (5 to 8.25%).<br />¥ Not approved by the US FDA for spinal injection. Approved for spinal injection in Europe.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Smith KN, Kopacz DJ, McDonald SB. Spinal 2-chloroprocaine: A dose-ranging study and the effect of added epinephrine. Anesth Analg 2004; 98:81.</LI>&#xD;&#xA;<LI>Frey K, Holman S, Mikat-Stevens M, et al. The recovery profile of hyperbaric spinal anesthesia with lidocaine, tetracaine, and bupivacaine. Reg Anesth Pain Med 1998; 23:159.</LI>&#xD;&#xA;<LI>Kito K, Kato H, Shibata M, et al. The effect of varied doses of epinephrine on duration od lidocaine spinal anesthesia in the thoracic and lumbosacral dermatomes. Anesth Analg 1998; 86:1018.</LI>&#xD;&#xA;<LI>Liu SS, Chiu AA, Carpenter RL, et al. Fentanyl prolongs lidocaine spinal anesthesia without prolonging recovery. Anesth Analg 1995; 80:730.</LI>&#xD;&#xA;<LI>Liam BL, Yim CF, Chong JL. Dose response study of 1% lidocaine for spinal anesthesia for lower limb and perineal surgery. Can J Anaesth 1998; 45:645.</LI>&#xD;&#xA;<LI>Liu SS, Pollock JE, Mulroy MF, et al. Comparison of 5% with dextrose, 1.5% with dextrose, and 1.5% dextrose-free lidocaine solutions for spinal anesthesia in human volunteers. Anesth Analg 1995; 81:697.</LI>&#xD;&#xA;<LI>Zayas VM, Liguori GA, Chisolm MF, et al. Dose response relationships for isobaric spinal mepivacaine using the combined spinal epidural technique. Anesth Analg 1999; 89:1167.</LI>&#xD;&#xA;<LI>Pawlowski J, Sukhani R, Pappas A, et al. The anesthetic and recovery profile of two doses (60 and 80 mg) of plain mepivacaine for ambulatory anesthesia. Anesth Analg 2000; 91:580.</LI>&#xD;&#xA;<LI>Kooger Infante NE, Van Gessel E, Forster A, et al. Extent of hyperbaric spinal anesthesia influences the duration of block. Anesthesiology 2000; 92:1319.</LI>&#xD;&#xA;<LI>Alley EA, Kopacz DJ, McDonald SB, et al. Hyperbaric spinal levobupivacaine: A comparison to racemic bupivacaine in volunteers. Anesth Analg 2002; 94:188.</LI>&#xD;&#xA;<LI>Malinovsky JM, Charles F, Kick O, et al. Intrathecal anesthesia: Ropivacaine vs. bupivacaine. Anesth Analg 2001; 91:1457.</LI>&#xD;&#xA;<LI>Kallio H, Snäll EV, Tuomas CA, Rosenberg PH. Comparison of hyperbaric and plain ropivacaine 15 mg in spinal anaesthesia for lower limb surgery. Br J Anaesth. 2004; 93:664.</LI>&#xD;&#xA;<LI>Gautier PE, De Kock M, Van Steenberge A, et al. Intrathecal ropivacaine for ambulatory surgery. Anesthesiology 1999; 91:1239.</LI>&#xD;&#xA;<LI>Boztuğ N, Bigat Z, Karsli B, et al. Comparison of ropivacaine and bupivacaine for intrathecal anesthesia during outpatient arthroscopic surgery. J Clin Anesth 2006; 18:521.</LI>&#xD;&#xA;<LI>Manassero A, Fanelli A. Prilocaine hydrochloride 2% hyperbaric solution for intrathecal injection: a clinical review. Local Reg Anesth 2017; 10:15.</LI></OL></div><div id=\"graphicVersion\">Graphic 108422 Version 2.0</div></div></div>"},"108423":{"type":"graphic_diagnosticimage","displayName":"US longitudinal view of medial head gastrocnemius","title":"US longitudinal view of medial head gastrocnemius","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">US longitudinal view of medial head gastrocnemius</div><div class=\"cntnt\"><img style=\"width:764px; height:321px;\" src=\"images/SM/108423_US_lng_view_mdl_hd_gstrcnms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph on the left shows the position of the ultrasound transducer for obtaining the image on the right, a longitudinal view of the medial gastrocnemius. Note the hypoechoic change (arrow) at the insertion of the medial gastrocnemius into the fascia consistent with a muscle tear. Localized edema, which also appears hypoechoic (arrowheads), is present in multiple sites within the gastrocnemius.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 108423 Version 4.0</div></div></div>"},"108424":{"type":"graphic_diagnosticimage","displayName":"US transverse view of medial head of gastrocnemius","title":"US transverse view of medial head of gastrocnemius","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">US transverse view of medial head of gastrocnemius</div><div class=\"cntnt\"><img style=\"width:763px; height:251px;\" src=\"images/SM/108424_US_transvrs_mdl_hd_gstrcnms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph on the left shows the position of the ultrasound transducer for obtaining the image on the right, a transverse view of the medial head of the gastrocnemius muscle. The ultrasound image shows hypoechoic change confined within the fascia (rectangle), which lies superficial to the muscle belly.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 108424 Version 4.0</div></div></div>"},"108425":{"type":"graphic_movie","displayName":"Elbow tap exercise for rotator cuff","title":"Elbow tap exercise for rotator cuff","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Elbow tap exercise for rotator cuff</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/108425_Elbowtaprotatorcuffvid.mp4\" style=\"width:560px;height:336px\"></div><img style=\"width:422px; height:316px;\" src=\"images/SM/108425_Elbowtaprotatorcuffimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The elbow tap exercise is performed on all fours, and can be used as part of a rehabilitation program for rotator cuff injuries.</div><div class=\"graphic_reference\">Courtesy of Michael Roberts, MPT, CSCS.</div><div id=\"graphicVersion\">Graphic 108425 Version 1.0</div></div></div>"},"108426":{"type":"graphic_diagnosticimage","displayName":"Medial elbow apophysitis (Little League elbow)","title":"Medial elbow apophysitis (Little League elbow)","html":"<div class=\"graphic\"><div style=\"width: 1045px\" class=\"figure\"><div class=\"ttl\">Medial elbow apophysitis (Little League elbow)</div><div class=\"cntnt\"><img style=\"width:1025px; height:514px;\" src=\"images/SM/108426_Medial_elbow_apophysitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both plain radiographs above are taken from the same adolescent baseball pitcher. The image on the right of the elbow in the boy's throwing arm&nbsp;shows signs of medial apophysitis, including widening of the physis and cortical irregularities (arrows). The other image&nbsp;on the left showing the elbow of the non throwing arm is normal (note this image was reversed to make comparison easier).</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 108426 Version 4.0</div></div></div>"},"108430":{"type":"graphic_figure","displayName":"TP53 mutations and treatment outcome in CLL","title":"TP53 mutations and treatment outcome in CLL","html":"<div class=\"graphic\"><div style=\"width: 1003px\" class=\"figure\"><div class=\"ttl\">TP53 mutations and treatment outcome in CLL</div><div class=\"cntnt\"><img style=\"width:983px; height:517px;\" src=\"images/HEME/108430_GenemutationstxoutcmCLL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) according to TP53 mutation status in patients with chronic lymphocytic leukemia (CLL)&nbsp;initially treated with fludarabine, cyclophosphamide, and rituximab.</div><div class=\"graphic_footnotes\">FCR: fludarabine, cyclophosphamide, and rituximab; PFS: progression-free survival; OS: overall survival;&nbsp;<EM>TP53</EM><SUP><EM>WT</EM></SUP>: wild-type <EM>TP53</EM>; <EM>TP53<SUP>mut</SUP></EM>: mutant <EM>TP53.</EM></div><div class=\"graphic_reference\">This research was originally published in Blood. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123:3247. Copyright &copy; 2014 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 108430 Version 1.0</div></div></div>"},"108431":{"type":"graphic_algorithm","displayName":"Treatment of HIDS","title":"Treatment of hyperimmunoglobulin D syndrome (HIDS)","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Treatment of hyperimmunoglobulin D syndrome (HIDS)</div><div class=\"cntnt\"><img style=\"width:658px; height:894px;\" src=\"images/ALLRG/108431_Treatment_of_HIDS_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HIDS primarily affects quality of life and rarely leads to severe physical complications. Thus, the main approach to management is symptomatic treatment of episodes if they significantly impact quality of life and the patient/family wishes to treat.</div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug.<br />* Symptomatic treatment is started at the onset of prodromal symptoms (eg, nasal congestion, sore throat, backache, fatigue, vertigo, headache, and behavioral changes) and continued for the anticipated duration of the attack (approximately four to seven days).<br />¶ Refer to UpToDate topic on management of hyperimmunoglobulin D syndrome for details on dosing options.<br />Δ Patient/family and clinician may opt for a trial of prophylactic therapy if ATTACKS ARE FREQUENT AND SEVERE OR IF symptoms are significantly diminishing quality of life even if attacks are less frequent and/or less severe.<br /><FONT class=lozenge>◊</FONT> Options for biologic agents for prophylactic therapy include anakinra, canakinumab, etanercept, and tocilizumab.</div><div id=\"graphicVersion\">Graphic 108431 Version 2.0</div></div></div>"},"108434":{"type":"graphic_algorithm","displayName":"Cerebral oximetry desaturation during CPB: Treatment algorithm","title":"Treatment algorithm for regional cerebral oxygen desaturation during cardiopulmonary bypass*","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for regional cerebral oxygen desaturation during cardiopulmonary bypass*</div><div class=\"cntnt\"><img style=\"width:666px; height:776px;\" src=\"images/ANEST/108434_Crbrl_oxmtry_dest_CPB_trtmt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">rO<SUB>2</SUB>: regional cerebral oxygen saturation; MAP: mean arterial pressure; SaO<SUB>2</SUB>: oxygen saturation of arterial blood; fiO<SUB>2</SUB>: fraction of inspired oxygen; PaCO<SUB>2</SUB>: partial pressure of carbon dioxide; Hgb: hemoglobin; RBC: red blood cells; CPB: cardiopulmonary bypass; O<SUB>2</SUB>: oxygen.<br />* When using this algorithm to treat cerebral oxygen desaturation, it is important to verify the accuracy of the monitoring equipment, particularly if unexpected values are encountered or sensor signal levels are inconsistent (suggesting a technical measurement problem).<br />¶ If rSO<SUB>2</SUB> has not returned to baseline, continue assessments and treat abnormalities, as noted in the algorithm.<br />Δ When low MAP is identified, always verify adequate CPB pump flow before administering pharmacologic treatment (ie, vasopressors).<br /><FONT class=lozenge>◊</FONT> Administering 100% O<SUB>2</SUB>, even if the SaO<SUB>2</SUB> is within normal limits, may improve O<SUB>2</SUB> delivery by increasing the O<SUB>2</SUB> content dissolved in arterial blood.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Subramanian B, Nyman C, Fritock M, et al. A multicenter pilot study assessing regional cerebral oxygen desaturation frequency during cardiopulmonary bypass and responsiveness to an intervention algorithm. Anesth Analg 2016; 122:1786.</LI>&#xD;&#xA;<LI>Denault A, Deschamps A, Murkin JM. A proposed algorithm for the intraoperative use of cerebral near-infrared spectroscopy. Semin Cardiothorac Vasc Anesth 2007; 11:274.</LI>&#xD;&#xA;<LI>Kara I, Erkin A, Sach H, et al. The effects of near-infrared spectroscopy on the neurocognitive functions in patients undergoing coronary artery bypass grafting with asymptomatic carotic artery disease: A randomized prospective study. Ann Thorac Cardiovasc Surg 2015; 21:544.</LI></OL></div><div id=\"graphicVersion\">Graphic 108434 Version 3.0</div></div></div>"},"108446":{"type":"graphic_diagnosticimage","displayName":"Prenatal MR of esophageal atresia","title":"Magnetic resonance image of fetal esophageal atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of fetal esophageal atresia</div><div class=\"cntnt\"><img style=\"width:224px; height:392px;\" src=\"images/OBGYN/108446_Prenatal_MR_esophageal_atrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T2w image at 28 weeks of gestation demonstrates a dilated fluid-filled proximal esophageal pouch (arrow). Polyhydramnios and a small stomach were also noted. Esophageal atresia was confirmed postnatally.</div><div id=\"graphicVersion\">Graphic 108446 Version 1.0</div></div></div>"},"108460":{"type":"graphic_diagnosticimage","displayName":"Trapezium body fracture with diastasis","title":"Trapezium body fracture with diastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trapezium body fracture with diastasis</div><div class=\"cntnt\"><img style=\"width:400px; height:612px;\" src=\"images/SM/108460_Trapezium_fractre_diastasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This oblique plain radiograph of the wrist reveals a comminuted fracture of the lateral portion of the trapezium. Significant widening of the first metacarpal trapezium articulation is present from&nbsp;severe ligamentous injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Rowe LJ, Yochum TR, Maola CJ. Trauma. In: Yochum and Rowe's Essentials of Skeletal Radiology, 3rd ed, Yochum TR, Rowe LJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 108460 Version 1.0</div></div></div>"},"108461":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph intra-articular trapezium fracture","title":"Plain radiograph of an intra-articular trapezium fracture","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of an intra-articular trapezium fracture</div><div class=\"cntnt\"><img style=\"width:662px; height:720px;\" src=\"images/SM/108461_Intraarticulartrpzmfrctr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is a close-up view taken from a plain radiograph showing a minimally displaced fracture of the trapezium (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Campbell RSD, Harris JH Jr. Wrist. In: Harris &amp; Harris' The Radiology of Emergency Medicine, 5th ed, Pope TL Jr, Harris JH Jr (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 108461 Version 2.0</div></div></div>"},"108463":{"type":"graphic_diagnosticimage","displayName":"CT trapezium palmar ridge fracture","title":"CT trapezium palmar ridge fracture","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">CT trapezium palmar ridge fracture</div><div class=\"cntnt\"><img style=\"width:604px; height:459px;\" src=\"images/PC/108463_Trapezium_palmar_rdg_fraxre.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transverse view CT (computed tomography) image above was obtained in a 28-year-old patient who trapped his left hand in a plastic molding press. The image shows flattening of the distal carpal row and a fracture (arrow) of the palmar ridge of the trapezium.</div><div class=\"graphic_reference\">Reproduced with permission from: Garcia-Elias M. Axial fracture dislocations. In: The Wrist: Diagnosis and Operative Treatment, 2nd ed, Cooney III WP (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Mayo Foundation for Medical Education and Research. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 108463 Version 2.0</div></div></div>"},"108484":{"type":"graphic_table","displayName":"TB drugs: Hematologic effects","title":"Hematologic abnormalities associated with anti-tuberculosis drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hematologic abnormalities associated with anti-tuberculosis drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"11\" width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">WBC&nbsp;<span style=\"font-size: 18px;\">&#8595;</span></td> <td class=\"subtitle1\">WBC&nbsp;<span style=\"font-size: 18px;\">&#8593;</span></td> <td class=\"subtitle1\">PMN&nbsp;<span style=\"font-size: 18px;\">&#8595;</span></td> <td class=\"subtitle1\">Eosinophil&nbsp;<span style=\"font-size: 18px;\">&#8593;</span></td> <td class=\"subtitle1\">Hemoglobin&nbsp;<span style=\"font-size: 18px;\">&#8595;</span></td> <td class=\"subtitle1\">Hemolytic anemia</td> <td class=\"subtitle1\">Red cell aplasia</td> <td class=\"subtitle1\">Aplastic anemia</td> <td class=\"subtitle1\">Platelet&nbsp;<span style=\"font-size: 18px;\">&#8595;</span></td> <td class=\"subtitle1\">Platelet&nbsp;<span style=\"font-size: 18px;\">&#8593;</span></td> <td class=\"subtitle1\">DIC or coagulation abnormal</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Amikacin</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Amoxicillin-clavulanate</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Capreomycin</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Clofazimine</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cycloserine</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ethambutol</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ethionamide</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Imipenem</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Isoniazid</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Kanamycin</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Levofloxacin</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Linezolid</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Moxifloxacin</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Para-aminosalicylic acid</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pyrazinamide</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Rifabutin</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Rifampin</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td><strong>Streptomycin</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC: white blood cell; PMN: polymorphonuclear leukocytes; DIC: disseminated intravascular coagulation.</div><div class=\"graphic_reference\">Modified with permission from: Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition, p. 260. Copyright &copy; 2016 Curry International Tuberculosis Center.</div><div id=\"graphicVersion\">Graphic 108484 Version 1.0</div></div></div>"},"108485":{"type":"graphic_table","displayName":"Commons signs and symptoms of chemical burns","title":"Commons signs and symptoms of chemical burns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commons signs and symptoms of chemical burns</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Sulfuric acid</strong></td> <td>Dark-brownish colored burns, mural perforation of the stomach, cardiovascular collapse, dyspnea, pneumonia, sialorrhea, fever, rapid decrease of blood pressure, tachypnea, severe pain in the mouth and throat, hematemesis, blindness, chest pain (tightness), cough, dizziness.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hydrofluoric acid</strong></td> <td>Whitish tissue with surrounding erythema, immediate abdominal, mouth and throat pain, skin edema, ulcers and necrosis, vomiting, fever, dyspnea, stridor, laryngeal edema, wheezing, tachypnea, vomiting, tetany, cardiac arrhythmias.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Acetic acid and derivatives</strong><br /> (glacial acetic, trifluoroacetic, &#38;&nbsp;monochloroacetic acids)</td> <td>Cough, tachypnea, wheezing, headache, nausea, vomiting, impaired vision, abdominal pain, diarrhea, eye, nose and throat irritation, tooth erosion, conjunctivitis, pharyngeal and pulmonary edema, whitish discoloration of the skin (exposure to trifluoroacetic acid).</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Nitric acid</strong></td> <td>Yellowish discoloration of the skin and mucosas, whitish tinge of teeth, eye, mouth, throat and abdominal burns and pain, dyspnea, hematemesis, dizziness, cough, tachypnea, pneumonia, laryngospasm.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hydrochloric acid</strong></td> <td>White or grayish discoloration of the skin and mucosas, eye, mouth, throat and abdominal burns and pain, hematemesis, vomiting, dizziness, dyspnea, cough, tachypnea, pneumonia, laryngospasm, headache, respiratory failure.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hydrogen sulphide</strong></td> <td>Greenish color of gray matter, \"cherry-red\" or pink lividity, green patches in the skin, irritant of conjunctivae, sclera and the upper respiratory tract, serous and hemorrhagic pulmonary edema, visceral congestion, bronchial secretions, scattered petechiae, anorexia, headache, amnesia, dizziness, photophobia, tearing, pain and blurred vision.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sodium hydroxide</strong></td> <td>Skin burns, oropharyngeal pain, dysphagia, vomiting, drooling and excessive salivation, ulcerative mucosal burns, dyspnea, stridor, perforation, and strictures can involve the entire gastrointestinal tract, often in the upper esophagus, severe ocular injury, opacification and perforation of cornea, microstomia, contracture of tongue and trismus, diarrhea, severe abdominal pain, hematemesis, laryngeal edema.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Calcium hydroxide</strong></td> <td>Allergic dermatitis, abrasions, eye and skin burns, erythema and vesicles, ulcers covered with black necrosis, pulmonary edema, cough, nausea, vomiting or severe abdominal pain.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Airbags inflation</strong></td> <td>Skin abrasions and erythema, respiratory problems, sneezing, sore throat and rhinorrhea.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Paraquat</strong></td> <td>Skin burn, nails white discoloration, and ulcerated lesions in the lips, tongue, oropharynx, esophagus (including perforation), stomach, scrotum and trachea, pulmonary edema and fibrosis, multiorganic failure, seizures, hematemesis.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vesicant &ndash; sulfur mustard</strong></td> <td>Skin burn, pruritus, erythema, xerosis, purpura, hypopigmentation, hyperpigmentation and blistering, chronic respiratory disease, repeated respiratory infections, eye pain, swelling, and tearing, abdominal pain, diarrhea, fever, nausea and vomiting.</td> </tr> <tr> <td><strong>White phosphorus</strong></td> <td>Eye and respiratory tract irritation, sensation of a foreign body in the eye, lacrimation, blepharospasm, photophobia, cornea perforation, endophthalmitis, blindness, skin partial (second degree) to full thickness burns.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Dinis-Oliveira RJ, Carvalho F, Moreira R, et al. Clinical and forensic signs related to chemical burns: a mechanistic approach. Burns 2015; 41:658. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108485 Version 1.0</div></div></div>"},"108487":{"type":"graphic_table","displayName":"Human trafficking: Sample messages for clinicians","title":"Human trafficking: Sample messages for clinicians","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human trafficking: Sample messages for clinicians</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Sample messages to convey to victims of human trafficking to help gain trust</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>We are here to help you </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Our first priority is your safety </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Under the Trafficking Victims Protection Act of 2000, victims of trafficking can apply for special visas or could receive other forms of immigration relief </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>We will give you the medical care that you need </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>We can help find you a safe place to stay </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>You have a right to live without being abused </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>You deserve the chance to become self-sufficient and independent </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>We can help you get what you need </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>We can help you protect your family </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>You can trust me </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>We want to make sure that what happened to you doesn't happen to anyone else </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>You have rights </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>You are entitled to assistance; we can help you get assistance </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If you are a victim of trafficking, you can receive help to rebuild your life safely in this country </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Sample messages to convey to victims of human trafficking to help establish trust.</div><div class=\"graphic_reference\">Reproduced from: United States Department of Health and Human Services, Administration for Children and Families. Messages for communicating with victims of human trafficking. Available at: <a href=\"http://www.acf.hhs.gov/sites/default/files/orr/communicating_with_victims_of_human_trafficking.pdf\" target=\"_blank\">http://www.acf.hhs.gov/sites/default/files/orr/communicating_with_victims_of_human_trafficking.pdf</a> (Accessed on July 6, 2016).</div><div id=\"graphicVersion\">Graphic 108487 Version 1.0</div></div></div>"},"108490":{"type":"graphic_figure","displayName":"Nasopharyngeal temperature during cooling to achieve EEG silence","title":"Nasopharyngeal temperature during cooling to achieve electrocortical inactivity on the EEG in patients undergoing DHCA","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Nasopharyngeal temperature during cooling to achieve electrocortical inactivity on the EEG in patients undergoing DHCA</div><div class=\"cntnt\"><img style=\"width:692px; height:278px;\" src=\"images/ANEST/108490_Nsphryngl_temp_cool_EEG_sil.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nasopharyngeal temperature (A) and cooling time (B) required to achieve electrocortical&nbsp;inactivity on the EEG in a series of 325 adult patients undergoing thoracic aortic surgery with DHCA.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECI: electrocortical inactivity; DHCA: deep hypothermic circulatory arrest.</div><div class=\"graphic_reference\">Reproduced from: James ML, Anderson MD, Swaminathan M, et al. Predictors of electrocerebral inactivity with deep hypothermia, J Thorac Cardiovasc Surg 2014; 147:1002. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108490 Version 2.0</div></div></div>"},"108491":{"type":"graphic_table","displayName":"Orthopedic injury/surgery and anesthetic and analgesic choices","title":"Orthopedic injury/surgery and anesthetic and analgesic choices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Orthopedic injury/surgery and anesthetic and analgesic choices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Injury/surgery</td> <td class=\"subtitle1\">Anesthesia technique</td> <td class=\"subtitle1\">Analgesic technique</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Clavicle fracture</strong></td> <td>General</td> <td>Interscalene block (C5/6 nerve distribution) + superficial cervical plexus block (C4 nerve distribution)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Shoulder dislocation</strong></td> <td>General</td> <td>Systemic</td> </tr> <tr> <td colspan=\"3\"><strong>Humerus fracture</strong></td> </tr> <tr> <td class=\"indent1\">Proximal</td> <td>General</td> <td>Interscalene, supraclavicular, or infraclavicular block (C5 to C7 nerve distribution)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Distal</td> <td>Supraclavicular or infraclavicular + intercostobrachial nerve block</td> <td>Supraclavicular or single-injection or continuous infraclavicular block (C5 to T1 nerve distribution)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Forearm fracture or hand fracture</strong></td> <td>Regional or general</td> <td>Supraclavicular, infraclavicular, or axillary block (C5 to T1 nerve distribution)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pelvic fracture</strong></td> <td>General</td> <td>Lumbar epidural (caution spine injury)</td> </tr> <tr> <td colspan=\"3\"><strong>Hip fracture</strong></td> </tr> <tr> <td class=\"indent1\">Intramedullary nail or ORIF</td> <td>General or neuraxial</td> <td>Femoral block (single-injection or continuous with catheter tunneled away from surgical field)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bipolar/total hip arthroplasty</td> <td>General or neuraxial</td> <td>Continuous high lumbar epidural or lumbar plexus or paravertebral catheter +/&ndash; proximal single-injection sciatic nerve block</td> </tr> <tr> <td colspan=\"3\"><strong>Femur fracture</strong></td> </tr> <tr> <td class=\"indent1\">Proximal</td> <td>General or neuraxial</td> <td>Continuous femoral block +/&ndash; single-injection or continuous sciatic nerve block</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Midfemoral or distal</td> <td>General, neuraxial, or peripheral nerve blocks</td> <td>Continuous femoral block +/&ndash; single-injection or continuous sciatic nerve block</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Patella fracture</strong></td> <td>General or neuraxial</td> <td>Femoral nerve block</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tibial plateau fracture</strong></td> <td>General or neuraxial</td> <td>Femoral catheter AND continuous sciatic (avoid boluses of local anesthetic to provide consistent and constant analgesia, to facilitate monitoring for compartment syndrome)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tibial shaft fracture</strong></td> <td>General, neuraxial, or regional (femoral/sciatic nerve block)</td> <td>Sciatic catheter and femoral block (single-injection or continuous catheter)</td> </tr> <tr> <td><strong>Ankle fracture</strong></td> <td>General, neuraxial, or regional</td> <td>Sciatic nerve block (popliteal or subgluteal) + saphenous nerve block (adductor canal or femoral), single-injection or continuous catheters depending on severity of injury and duration of hospital stay</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ORIF: open reduction internal fixation.</div><div id=\"graphicVersion\">Graphic 108491 Version 2.0</div></div></div>"},"108519":{"type":"graphic_table","displayName":"Categories of LVEF","title":"Categories of left ventricular ejection fraction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of left ventricular ejection fraction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">LVEF (%)</td> <td class=\"subtitle1\">Qualitative assessment</td> </tr> <tr> <td class=\"centered\">&#62;70</td> <td class=\"centered\">Hyperdynamic</td> </tr> <tr> <td class=\"centered\">50-70</td> <td class=\"centered\">Normal</td> </tr> <tr> <td class=\"centered\">40-49</td> <td class=\"centered\">Mild dysfunction</td> </tr> <tr> <td class=\"centered\">30-39</td> <td class=\"centered\">Moderate dysfunction</td> </tr> <tr> <td class=\"centered\">&#60;30</td> <td class=\"centered\">Severe dysfunction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LVEF: left ventricular ejection fraction.</div><div class=\"graphic_reference\">Data from: American College of Cardiology. Left Ventricular Ejection Fraction LVEF Assessment (Outpatient Setting). Available at: <a href=\"https://www.acc.org/tools-and-practice-support/clinical-toolkits/heart-failure-practice-solutions/left-ventricular-ejection-fraction-lvef-assessment-outpatient-setting\" target=\"_blank\">https://www.acc.org/tools-and-practice-support/clinical-toolkits/heart-failure-practice-solutions/left-ventricular-ejection-fraction-lvef-assessment-outpatient-setting</a> (Accessed on August 9, 2016).</div><div id=\"graphicVersion\">Graphic 108519 Version 1.0</div></div></div>"},"108520":{"type":"graphic_table","displayName":"Categories of fractional shortening","title":"Categories of fractional shortening","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of fractional shortening</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Women</td> <td class=\"subtitle1\">Men</td> </tr> <tr> <td><strong>Reference range</strong></td> <td class=\"centered\">27 to 45%</td> <td class=\"centered\">25 to 43%</td> </tr> <tr> <td><strong>Mildly abnormal</strong></td> <td class=\"centered\">22 to 26%</td> <td class=\"centered\">20 to 24%</td> </tr> <tr> <td><strong>Moderately abnormal</strong></td> <td class=\"centered\">17 to 21%</td> <td class=\"centered\">15 to 19%</td> </tr> <tr> <td><strong>Severely abnormal</strong></td> <td class=\"centered\">&#8804;16%</td> <td class=\"centered\">&#8804;15%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Lang RM, Bieri M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiography 2006; 7:79.</div><div id=\"graphicVersion\">Graphic 108520 Version 1.0</div></div></div>"},"108521":{"type":"graphic_figure","displayName":"G6PD distribution map","title":"G6PD distribution map","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">G6PD distribution map</div><div class=\"cntnt\"><img style=\"width:766px; height:427px;\" src=\"images/HEME/108521_G6PD_distribution_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glucose-6-phosphate dehydrogenase (G6PD) deficiency occurs worldwide. It is most common in the tropical and subtropical zones of the Eastern hemisphere (eg, Africa, Europe, Asia). Refer to UpToDate for additional information.</div><div class=\"graphic_reference\">Reprinted from Glucose-6-phosphate dehydrogenase deficiency, Bull World Health Organ 1989; 67:601, Copyright © 1989. Available from: <A spellcheck=true href=\"http://apps.who.int/iris/bitstream/10665/47019/1/bulletin_1989_67(6)_601-611.pdf\" target=_blank>http://apps.who.int/iris/bitstream/10665/47019/1/bulletin_1989_67(6)_601-611.pdf</A> (accessed on June 13, 2016).</div><div id=\"graphicVersion\">Graphic 108521 Version 1.0</div></div></div>"},"108522":{"type":"graphic_diagnosticimage","displayName":"Paramedian sagittal PVB post-injectate","title":"Paramedian sagittal PVB post-injectate","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Paramedian sagittal PVB post-injectate</div><div class=\"cntnt\"><img style=\"width:640px; height:452px;\" src=\"images/ANEST/108522_Paramdn_sgttl_PVB_pst_injct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After injection of LA&nbsp;for thoracic paravertebral block, the LA expands the space between the internal intercostal membrane and the pleura. For further details, refer to UpToDate content on ultrasound-guided thoracic paravertebral block.</div><div class=\"graphic_footnotes\">LA: local anesthetic. IIM: internal intercostal membrane</div><div id=\"graphicVersion\">Graphic 108522 Version 1.0</div></div></div>"},"108523":{"type":"graphic_diagnosticimage","displayName":"Transverse intercostal PVB with needle","title":"Transverse intercostal PVB with needle","html":"<div class=\"graphic\"><div style=\"width: 661px\" class=\"figure\"><div class=\"ttl\">Transverse intercostal PVB with needle</div><div class=\"cntnt\"><img style=\"width:641px; height:453px;\" src=\"images/ANEST/108523_Trnsvrs_intrcstl_PVB_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The block needle is visualized with the tip in the paravertebral space, between the IIM and the pleura. For further details, refer to UpToDate content on ultrasound-guided thoracic paravertebral block.</div><div class=\"graphic_footnotes\">IIM: internal intercostal membrane.</div><div id=\"graphicVersion\">Graphic 108523 Version 1.0</div></div></div>"},"108525":{"type":"graphic_diagnosticimage","displayName":"Transverse intercostal PVB post-injectate","title":"Transverse intercostal PVB post-injectate","html":"<div class=\"graphic\"><div style=\"width: 662px\" class=\"figure\"><div class=\"ttl\">Transverse intercostal PVB post-injectate</div><div class=\"cntnt\"><img style=\"width:642px; height:452px;\" src=\"images/ANEST/108525_Trnsvr_intrcstl_PVB_pst_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After injection, the local anesthetic expands below the IIM, and often pushes the pleura anteriorly. For further details, refer to UpToDate content on ultrasound-guided thoracic paravertebral block.</div><div class=\"graphic_footnotes\">IIM: internal intercostal membrane.</div><div id=\"graphicVersion\">Graphic 108525 Version 1.0</div></div></div>"},"108538":{"type":"graphic_table","displayName":"Challenge protocol for anti-TB drugs (adult)","title":"Dosing for oral* rechallenges with antituberculosis drugs following nonanaphylactic allergic reactions (adults)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing for oral* rechallenges with antituberculosis drugs following nonanaphylactic allergic reactions (adults)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose &ndash; Day 1</td> <td class=\"subtitle1\">Dose &ndash; Day 2<sup>&#182;</sup></td> <td class=\"subtitle1\">Dose &ndash; Day 3</td> </tr> <tr class=\"centered\"> <td>Isoniazid</td> <td>50 mg </td> <td>300 mg</td> <td>Usual daily dose<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>Rifampin</td> <td>75 mg<sup>&#9674;</sup></td> <td>300 mg</td> <td>600 mg</td> </tr> <tr class=\"centered\"> <td>Pyrazinamide</td> <td>250 mg</td> <td>1 g</td> <td>Usual daily dose<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>Ethionamide</td> <td>125 mg</td> <td>375 mg</td> <td>500 to 750 mg</td> </tr> <tr class=\"centered\"> <td>Cycloserine</td> <td>125 mg<sup>&#167;</sup></td> <td>250 mg</td> <td>500 to 750 mg</td> </tr> <tr class=\"centered\"> <td>Ethambutol</td> <td>100 mg</td> <td>400 mg</td> <td>Usual daily dose<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>Para-aminosalicylic acid</td> <td>1 g<sup>&#165;</sup></td> <td>4 g</td> <td>6 to 8 g</td> </tr> <tr class=\"divider_bottom centered\"> <td>Streptomycin*</td> <td>125 mg</td> <td>500 mg</td> <td>Usual daily dose<sup>&#916;</sup></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_single centered\" colspan=\"4\">Doses for the following drugs were not supplied by the Philadelphia program but have been extrapolated (based on the doses above) to the following:</td> </tr> <tr class=\"centered\"> <td>Amikacin*</td> <td>125 mg</td> <td>500 mg</td> <td>Usual daily dose<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>Capreomycin*</td> <td>125 mg</td> <td>500 mg</td> <td>Usual daily dose<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>Levofloxacin</td> <td>50 mg<sup>&#135;</sup></td> <td>200 to 250 mg</td> <td>Usual daily dose<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Reintroducing antituberculosis drugs (rechallenge) should only be considered in patients who have experienced a nonanaphylactic reaction, such as isolated hives (urticaria) or rash without systemic symptoms or organ involvement. Reintroduction would <strong>not</strong> be appropriate for a patient who had symptoms of possible anaphylaxis (ie, the rapid onset of some combination of hives, angioedema, airway compromise, bronchospasm, nausea and vomiting, hypotension) or of a more serious systemic hypersensitivity reaction, such as Stevens-Johnson syndrome or toxic epidermal necrolysis (ie, blistering or peeling of the skin, high fever, flu-like symptoms, or involvement of mucous membranes).</li>&#xD;&#xA;    <li>Drugs should be reintroduced one at a time. If the patient was taking several drugs at the time of the reaction and all were stopped, the most important one should be reintroduced first. If the first drug causes no adverse reaction, then it is continued and challenge to the second drug is performed, etc, until the patient is again taking all the required meds and/or the drug causing the reaction is identified.</li>&#xD;&#xA;    <li>The patient can be premedicated with oral diphenhydramine 25 mg with or without a small dose of oral glucocorticoid (eg, prednisone 10 to 20 mg) given 30 minutes before the first dose. If the initial dose is well-tolerated, give diphenhydramine 30 minutes before the second dose, without the prednisone. If that is well-tolerated, give the third dose without premedication.</li>&#xD;&#xA;    <li>Premedication may not prevent cutaneous symptoms entirely but typically makes the reaction less severe. Patients who develop a mild rash as a result of reintroduction may benefit from a short course of low-dose glucocorticoids, allowing the drug to be continued.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* All rechallenge regimens are based upon oral administration except for streptomycin, amikacin, capreomycin which may be administered intramuscularly.<br />¶ If the day 2 dose is less than the normal recommended dose based on the patient's weight, increase the day 3 dose to the correct weight-based dose (eg, dose of ethambutol for a 70 kg patient: day 1 = 100 mg, day 2 = 500 mg, and day 3 = 1000 mg).<br />Δ Usual daily dose means the daily dose that the individual patient in question will require, which may vary by regimen and patient characteristics.<br /><FONT class=lozenge>◊</FONT> Rifampin is available in 150 mg capsules. Empty capsule contents into a small amount of applesauce or jelly and administer one-half.<br />§ Cycloserine comes in 250 mg capsules. Empty capsule contents into a small amount of no sugar added chocolate pudding or grape jelly and administer one-half.<br />¥ Para-aminosalicylic acid comes in 4 gram packets. Suspended in orange juice and administer one-quarter.<br />‡ Levofloxacin is available in an oral solution of 25 mg/mL.</div><div class=\"graphic_reference\">Adapted from: Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition, p. 255.<br />Additional data from:</P>&#xD;&#xA;<OL>&#xD;&#xA;<LI>​Philadelphia Tuberculosis Control Program, Lawrence Flick Memorial Tuberculosis Clinic. Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents. Philadelphia: Philadelphia Tuberculosis Control Program, 1998. </LI>&#xD;&#xA;<LI>Peloquin CA, Durbin D, Childs J, et al. Stability of antituberculosis drugs mixed in food. Clin Infect Dis 2007; 45:521.</LI></OL></div><div id=\"graphicVersion\">Graphic 108538 Version 3.0</div></div></div>"},"108543":{"type":"graphic_algorithm","displayName":"Algorithm for evaluation for HAE - Negative family history","title":"Evaluation of a patient with symptoms suggestive of hereditary angioedema but NEGATIVE family history (or family history not known)","html":"<div class=\"graphic\"><div style=\"width: 1099px\" class=\"figure\"><div class=\"ttl\">Evaluation of a patient with symptoms suggestive of hereditary angioedema but NEGATIVE family history (or family history not known)</div><div class=\"cntnt\"><img style=\"width:1079px; height:554px;\" src=\"images/ALLRG/108543_SymptHAEnegatfamilyhist.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; NSAIDs: nonsteroidal anti-inflammatory drugs; C1INH: C1 inhibitor; SERPING1: the gene for C1 inhibitor.<br />* C4: In patients with C1INH-HAE, C4 is usually &lt;50% of normal. If results are not reported as a percentage of normal, then 25 mg is a normal value in adults, C4 &lt;10 mg is definitely pathologic, C4 of 10 to 15 mg is possibly pathologic, and C4 &gt;15 is not pathologic.<br />¶ In the presence of normal C4, low C1INH protein levels are usually due to laboratory error.<br />Δ Identified variants include those in the genes for factor XII, angiopoietin-1, and plasminogen.</div><div id=\"graphicVersion\">Graphic 108543 Version 4.0</div></div></div>"},"108544":{"type":"graphic_algorithm","displayName":"Algorithm for diagnosis of HAE - Positive family history","title":"Evaluation of a patient with symptoms and family history suggestive of hereditary angioedema","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Evaluation of a patient with symptoms and family history suggestive of hereditary angioedema</div><div class=\"cntnt\"><img style=\"width:762px; height:348px;\" src=\"images/ALLRG/108544_SymptHAEpositfamilyhist.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; NSAIDs: nonsteroidal anti-inflammatory drugs; C1INH: C1 inhibitor.<br />* C4: In patients with C1INH-HAE, C4 is &lt;50% of normal. If results are not reported as a percentage of normal, then 25 mg is a normal value in adults,&nbsp;C4 &lt;10 mg is definitely pathologic, C4 of 10 to 15 mg is possibly pathologic, and C4 &gt;15 is not pathologic.<br />&para; In the presence of normal C4, low C1INH protein levels are usually due to laboratory error.<br />&Delta; Identified variants include those in the genes for factor XII, angiopoietin-1, and plasminogen.</div><div id=\"graphicVersion\">Graphic 108544 Version 3.0</div></div></div>"},"108607":{"type":"graphic_table","displayName":"Human trafficking: Warning signs","title":"Human trafficking: Warning signs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human trafficking: Warning signs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Warning signs of human trafficking</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Delayed presentation for medical care </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sudden or dramatic change in behavior (eg, a minor stops attending school) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Discrepancy between the stated history and the clinical presentation or observed pattern of injury </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Scripted, memorized, or mechanically recited history </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Stated age older than visual appearance </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Lack of documentation or identification (eg, driver's license, passport) or documents in possession of accompanying individual(s) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Reluctance to speak on own behalf or presence of accompanying individual(s) who answers for patient </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Fearful, suspicious, or distrustful demeanor </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Inappropriate attire for a visit (ie, lingerie) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Signs of malnourishment, substance abuse, or poor dental hygiene </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Signs the person is being controlled by someone who is accompanying him/her to the visit (eg, companion who refuses to leave) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Signs the person does not have freedom to exit a job or relocate </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Frequent relocation or lack of knowledge of surroundings (victims may be moved frequently to avoid detection) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Evidence of isolation from the public or from religious/ethnic community </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Warning signs of sex trafficking</td> </tr> <tr> <td class=\"decimal_heading indent1\"> <ul> <li><strong>All genders:</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li type=\"disc\">Multiple sexual partners </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li type=\"disc\">Multiple sexually transmitted infections </li> </ul> </td> </tr> <tr> <td class=\"decimal_heading indent1\"> <ul> <li><strong>For postpubertal girls and women:</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li type=\"disc\">Multiple pregnancies </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li type=\"disc\">Multiple miscarriages </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li type=\"disc\">Multiple terminations </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Alpert EJ, Ahn R, Albright E, et al. Human trafficking: Guidebook on identification, assessment, and response in the health care setting. MGH Human Trafficking Initiative and Committee on Violence Intervention and Prevention, September 2014. <A href=\"http://www.massmed.org/Patient-Care/Health-Topics/Violence-Prevention-and-Intervention/Human-Trafficking/#.V2hMhqPD-Um\" target=_blank>http://www.massmed.org/Patient-Care/Health-Topics/Violence-Prevention-and-Intervention/Human-Trafficking/#.V2hMhqPD-Um</A> (Accessed on June 21, 2016).</LI>&#xD;&#xA;<LI>Tracy EE, Konstantopoulos WM. Human trafficking: A call for heightened awareness and advocacy by obstetrician-gynecologists. Obstet Gynecol 2012; 119:1045.</LI>&#xD;&#xA;<LI>American College of Obstetricians and Gynecologists. Committee opinion no. 507: Human trafficking. Obstet Gynecol 2011; 118:767.</LI>&#xD;&#xA;<LI>Macy RJ, Graham LM. Identifying domestic and international sex-trafficking victims during human service provision. Trauma Violence Abuse 2012; 13:59.</LI>&#xD;&#xA;<LI>United States Department of Health and Human Services. Administration for Children and Families. Identifying and interacting with victims of human trafficking.</LI>&#xD;&#xA;<LI><A href=\"http://www.acf.hhs.gov/sites/default/files/orr/tips_for_identifying_and_helping_victims_of_human_trafficking.pdf\" target=_blank>http://www.acf.hhs.gov/sites/default/files/orr/tips_for_identifying_and_helping_victims_of_human_trafficking.pdf</A> (Accessed on June 21, 2016).</LI>&#xD;&#xA;<LI>United States Department of Homeland Security. Blue Campaign. Indicators of Human Trafficking. <A href=\"https://www.dhs.gov/blue-campaign/indicators-human-trafficking\" target=_blank>https://www.dhs.gov/blue-campaign/indicators-human-trafficking</A> (Accessed on June 21, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 108607 Version 1.0</div></div></div>"},"108608":{"type":"graphic_figure","displayName":"Achondroplasia growth curves height","title":"Achondroplasia growth curves (height)","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Achondroplasia growth curves (height)</div><div class=\"cntnt\"><img style=\"width:494px; height:792px;\" src=\"images/ALLRG/108608_Achondroplasia_grwth_height.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Height (mean &plusmn;SD) for males with achondroplasia (shaded area) compared with normal male standard height curve (3<sup>rd</sup>, 50<sup>th</sup>, and 97<sup>th</sup> percentile).<br />(B) Height (mean &plusmn;SD) for females with achondroplasia (shaded area) compared with normal female standard height curve.</div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Reproduced from: Horton WA, Rotter JI, Rimoin DL, et al. Standard growth curves for achondroplasia. J Pediatr 1978; 93:435. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108608 Version 1.0</div></div></div>"},"108609":{"type":"graphic_figure","displayName":"Achondroplasia growth curves head circumference","title":"Achondroplasia growth curves (head circumference)","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Achondroplasia growth curves (head circumference)</div><div class=\"cntnt\"><img style=\"width:514px; height:742px;\" src=\"images/ALLRG/108609_Achondroplasia_head_crcmfrn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Head circumference (mean &plusmn;2 SD) for males with achondroplasia (shaded area) compared with normal male head circumference (mean &plusmn;2 SD).<br />(B) Head circumference (mean &plusmn;2 SD) for females with achondroplasia (shaded area) compared with normal female head circumference (mean &plusmn;SD).</div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Reproduced from: Horton WA, Rotter JI, Rimoin DL, et al. Standard growth curves for achondroplasia. J Pediatr 1978; 93:435. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108609 Version 1.0</div></div></div>"},"108610":{"type":"graphic_figure","displayName":"Developmental screening tests in achondroplasia","title":"Developmental screening tests in achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Developmental screening tests in achondroplasia</div><div class=\"cntnt\"><img style=\"width:764px; height:596px;\" src=\"images/ALLRG/108610_Dvlpmntl_scrning_achondrpls.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Developmental screening tests in achondroplasia. The 25<SUP>th</SUP>, 50<SUP>th</SUP>, 75<SUP>th</SUP>, and 90<SUP>th</SUP> centiles are determined by linear interpolation.</div><div class=\"graphic_reference\">From: Todorov AB, Scott CI Jr, Waren AE, Leeper JD. Development screening tests in achondroplastic children. Am J Med Genet A 1981; 9(1):19-23. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/ajmg.1320090105/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/ajmg.1320090105/abstract</a>. Copyright &copy; 1981 Wiley-Liss, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 108610 Version 1.0</div></div></div>"},"108612":{"type":"graphic_diagnosticimage","displayName":"Paramedian sagittal PVB pre-injectate","title":"Paramedian sagittal PVB pre-injectate","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Paramedian sagittal PVB pre-injectate</div><div class=\"cntnt\"><img style=\"width:602px; height:454px;\" src=\"images/ANEST/108612_Paramdn_sgttl_PVB_pre_injct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The paravertebral space (blue oval) lies between the superior costotransverse ligament and the pleura. For further details, refer to UpToDate content on ultrasound-guided thoracic paravertebral nerve block.</div><div class=\"graphic_footnotes\">SCTL: Superior costotransverse ligament</div><div id=\"graphicVersion\">Graphic 108612 Version 1.0</div></div></div>"},"108615":{"type":"graphic_picture","displayName":"Paramedian sagittal TPVB approach","title":"Paramedian sagittal TPVB approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paramedian sagittal TPVB approach</div><div class=\"cntnt\"><img style=\"width:412px; height:576px;\" src=\"images/ANEST/108615_Paramedian_sagttl_TPVB_appr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the paramedian, sagittal approach to thoracic paravertebral block, the ultrasound probe is placed lateral to the midline at the chosen spinal level. The needle can be inserted in plane or out of plane</div><div class=\"graphic_footnotes\">OOP: out of plane</div><div id=\"graphicVersion\">Graphic 108615 Version 1.0</div></div></div>"},"108639":{"type":"graphic_table","displayName":"Human trafficking: Sample screening questions","title":"Human trafficking: Sample screening questions for adult and minor victims","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Human trafficking: Sample screening questions for adult and minor victims</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle2_left\">General screening questions to identify victims of human trafficking</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>What are your working or living conditions like? </li> <li>Where do you sleep and eat? </li> <li>Do you sleep in a bed, on a cot, or on the floor? </li> <li>Have you ever been deprived of food, water, sleep, or medical care? </li> <li>Do you have to ask permission to eat, sleep, or go to the bathroom? </li> <li>Have you been harmed in any way? </li> <li>Can you leave your job or situation if you want? </li> <li>Can you come and go as you please? </li> <li>Are there locks on your doors and windows so you cannot get out? </li> <li>Have you been threatened if you try to leave? </li> <li>Has anyone threatened your family? </li> <li>Has your identification or documentation been taken from you? </li> <li>Is anyone forcing you to do anything that you do not want to do? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Additional screening questions for minor victims of sex trafficking</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is there a previous history of drug and/or alcohol use? </li> <li>Has the youth ever run away from home? </li> <li>Has the youth ever been involved with law enforcement? </li> <li>Has the youth ever broken a bone, had traumatic loss of consciousness, or sustained a significant wound? </li> <li>Has the youth ever had a sexually transmitted infection? </li> <li>Does the youth have a history of sexual activity with more than five partners? </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists sample questions and is not meant to be exhaustive.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>United States Department of Health and Human Services, Administration for Children and Families. Screening tool for victims of human trafficking. Available at: <a href=\"http://www.acf.hhs.gov/sites/default/files/orr/screening_questions_to_assess_whether_a_person_is_a_trafficking_victim_0.pdf\" target=\"_blank\">http://www.acf.hhs.gov/sites/default/files/orr/screening_questions_to_assess_whether_a_person_is_a_trafficking_victim_0.pdf</a> (Accessed on July 7, 2016).</li>&#xD;&#xA;    <li>Greenbaum VJ, Dodd M, McCracken C. A short screening tool to identify victims of child sex trafficking in the health care setting. Pediatr Emerg Care 2015. DOI: <a href=\"http://journals.lww.com/pec-online/pages/articleviewer.aspx?year=9000&amp;issue=00000&amp;article=99067&amp;type=abstract\" target=\"_blank\">10.1097/PEC.0000000000000602</a>. Copyright &copy; 2015. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 108639 Version 1.0</div></div></div>"},"108641":{"type":"graphic_table","displayName":"Laboratory monitoring for children with SBS","title":"Suggested laboratory monitoring for infants and children with short bowel syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested laboratory monitoring for infants and children with short bowel syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laboratory test</td> <td class=\"subtitle1\">When on parenteral nutrition (PN)</td> <td class=\"subtitle1\">When on full enteral feeds</td> </tr> <tr> <td class=\"divider_bottom\">CBC with RBC indices/differential, and reticulocyte count</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Every&nbsp;1 to 3&nbsp;months, or as clinically indicated.</p> (More frequent monitoring with blood loss, microcytic anemia, abnormal iron studies, or parenteral iron use).</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>After PN is discontinued,<sup>&#182;</sup> then every 6 to 12 months.</p> (More frequent monitoring with blood loss, microcytic anemia, abnormal iron studies, or enteral iron use).</td> </tr> <tr class=\"divider_bottom\"> <td>Iron studies (iron, ferritin, TIBC, transferrin saturation), with CRP*</td> </tr> <tr class=\"divider_bottom\"> <td>PN profile: <ul class=\"decimal_heading\"> <li>Electrolytes, BUN, creatinine, glucose </li> <li>Phosphorus, calcium, magnesium </li> <li>Albumin, prealbumin </li> <li>Triglycerides </li> </ul> (may use a comprehensive metabolic panel instead of a PN profile)</td> <td> <p>When PN is initiated, weekly until stable, and then with significant changes in PN formulation or volume.</p> For patients on stable PN, these labs should be monitored every&nbsp;1 to 3 months.</td> <td>After PN is discontinued,<sup>&#182;</sup> then every&nbsp;6 to 8&nbsp;months, depending on clinical status.</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatic panel: <ul class=\"decimal_heading\"> <li>Total and direct bilirubin </li> <li>AST, ALT </li> <li>GGTP </li> </ul> </td> <td> <p>When PN is initiated, then weekly until stable.</p> For patients on stable PN, monitor every&nbsp;1 to 3 months.</td> <td>Annually for patients with history of intestinal failure-associated liver disease (IFALD).</td> </tr> <tr class=\"divider_bottom\"> <td>Copper, zinc, selenium (measure in conjunction with CRP)</td> <td> <p>Measure 30 days after PN initiation, then every&nbsp;6 months.</p> <p>(If level is low, or if making changes to dosing of these trace minerals in PN, repeat every&nbsp;2 to 3 months. Monitor more frequently in patients with persistent neutropenia or anemia).</p> Measure copper and ceruloplasmin with CRP and CBC in patients with signs of copper deficiency.<sup>&#916;</sup></td> <td> <p>Measure zinc after PN is discontinued,<sup>&#182;</sup> then at least annually.</p> Measure copper and ceruloplasmin with CRP in patients with signs of copper deficiency.<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>PT, INR (as an index of vitamin K sufficiency)<sup>&#9674;</sup></td> <td> <p>Every&nbsp;6 months.</p> (Monitor more frequently in patients with GI bleeding, bacterial overgrowth, or cholestasis).</td> <td> <p>After PN is discontinued,<sup>&#182;</sup> then at least annually.</p> (Monitor more frequently in patients with GI bleeding, bacterial overgrowth, or cholestasis).</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Monitor fat-soluble vitamin status:&nbsp;</p> <ul> <li>Vitamin D (as 25-hydroxyvitamin D) </li> <li>Vitamin A </li> <li>Vitamin E (as alpha-tocopherol) </li> </ul> </td> <td> <p>Annually.</p> (Check every&nbsp;3 to 6 months in patients with evidence of deficiency, on enteral supplementation, or with chronic liver disease or cholestasis).</td> <td> <p>After PN is discontinued,<sup>&#182;</sup> then at least annually.</p> (Check every&nbsp;3 to 6 months in patients with evidence of deficiency, on enteral supplementation, or with chronic liver disease or cholestasis).</td> </tr> <tr class=\"divider_bottom\"> <td>Serum vitamin B12</td> <td>Annually.</td> <td>After PN is discontinued,<sup>&#182;</sup> then every 6 to 12 months, especially in patients who had resection of the distal ileum or persistent macrocytic anemia.<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>RBC folate</td> <td>Annually in patients with extensive intestinal resection.</td> <td>Annually in patients with extensive intestinal resection.</td> </tr> <tr class=\"divider_bottom\"> <td>Essential fatty acid panel</td> <td>Measure every 3 to 6 months in&nbsp;patients on lipid restriction (ie, total fat intake &#8804;1 g/kg/day for &#62;10 to 14&nbsp;days).</td> <td>Measure if there are clinical signs of essential fatty acid deficiency such as poor growth or rash.</td> </tr> <tr class=\"divider_bottom\"> <td>Aluminum, carnitine profile</td> <td>Measure 30 days after PN initiation, then every 6 months.</td> <td>Not necessary.</td> </tr> <tr class=\"divider_bottom\"> <td>Alpha-fetoprotein level</td> <td>Annually for patients with a history of cirrhosis related&nbsp;to IFALD.</td> <td>Annually for patients with history of cirrhosis related to IFALD.</td> </tr> <tr class=\"divider_bottom\"> <td>Chromium, manganese</td> <td> <p>Annually.</p> (Measure more frequently in patients with poor glycemic control [which may be caused by chromium deficiency]).</td> <td>Generally not necessary.</td> </tr> <tr> <td>Urine sodium</td> <td>Consider every&nbsp;6 months, or more frequently in patients with poor weight gain, high ostomy output, or who are on enteral NaCl supplementation.</td> <td>Consider every&nbsp;6 months, or more frequently in patients with poor weight gain, high ostomy output, or who are on enteral NaCl supplementation.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table reflects the authors' approach to monitoring nutritional status in patients with short bowel syndrome. For frequency of laboratory testing, the upper end of the range reflects their approach to a stable patient with good nutritional status on home parenteral nutrition. </div><div class=\"graphic_footnotes\">PN: parenteral nutrition; CBC: complete blood count; RBC: red blood cell; TIBC: total iron binding capacity; CRP: C-reactive protein; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGTP: gamma glutamyl transpeptidase; IFALD: intestinal failure-associated liver disease; PT: prothrombin time; INR: international normalized ratio; GI: gastrointestinal; NaCl: sodium chloride; MMA: methylmalonic acid.<br />* Serum ferritin is an index of iron stores, but is also increased in the setting of inflammation. Measurement of CRP concurrently with iron studies helps to determine if an acute phase response is present and permits accurate interpretation of the results. An acute phase response also tends to increase serum concentrations of copper, and decrease serum concentrations of zinc.<br />&para; Measure vitamin and mineral/trace element levels four to eight weeks after parenteral nutrition is discontinued, and then a second time 4 to 6 months after parenteral nutrition is discontinued.<br />&Delta; Signs of copper deficiency include a microcytic anemia unresponsive to iron intake, neutropenia, or osteopenia.<br /><span class=\"lozenge\">&loz;</span> For patients with elevated PT/INR, measurement of PIVKA-II is helpful to assess for vitamin K deficiency.<br />&sect; Vitamin B12 levels should be monitored particularly closely in patients who have had the distal ileum resected and are on partial or full enteral feeds. Concentrations of methylmalonic acid (MMA) also reflect vitamin B12 deficiency, and measurements of MMA in urine or serum may be useful for patients with abnormal vitamin B12 levels, with distal ileal resection, or on treatment for vitamin B12 deficiency.</div><div class=\"graphic_reference\">Courtesy of Drs. Chistopher Duggan, Alexandra Carey, and Danielle Stamm.</div><div id=\"graphicVersion\">Graphic 108641 Version 2.0</div></div></div>"},"108643":{"type":"graphic_table","displayName":"Major trials of MgSO4 rx in pregnancy for neuroprotection","title":"Major placebo-controlled randomized trials of treatment of pregnant women with magnesium sulfate for neuroprotection of offspring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major placebo-controlled randomized trials of treatment of pregnant women with magnesium sulfate for neuroprotection of offspring</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup span=\"5\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Trial</td> <td class=\"subtitle1\">Number of subjects</td> <td class=\"subtitle1\">Gestational age at randomization (weeks)</td> <td class=\"subtitle1\">Magnesium sulfate dose</td> <td class=\"subtitle1\">Death</td> <td class=\"subtitle1\">Cerebral palsy</td> <td class=\"subtitle1\">Composite outcome</td> <td class=\"subtitle1\">Other outcomes</td> </tr> <tr class=\"divider_bottom\"> <td>ACTOMgSO4</td> <td class=\"centered\">1062</td> <td class=\"centered\">&#60;30</td> <td>4 g loading dose followed by 1 g/hour for maximum of 24 hours</td> <td>Total pediatric mortality: <ul class=\"decimal_heading\"> <li>13.8 versus 17.1% </li> <li>RR 0.83 </li> <li>95% CI 0.64-1.09 </li> </ul> </td> <td>Cerebral palsy: <ul class=\"decimal_heading\"> <li>6.8 versus 8.2% </li> <li>RR 0.83 </li> <li>95% CI 0.54-1.27 </li> </ul> </td> <td>Death or cerebral palsy: <ul class=\"decimal_heading\"> <li>19.8 versus 24.0% </li> <li>RR 0.83 </li> <li>95% CI 0.66-1.03 </li> </ul> </td> <td>Substantial gross motor dysfunction: <ul class=\"decimal_heading\"> <li>3.4 versus 6.6% </li> <li>RR 0.51 </li> <li>95% CI 0.29-0.91 </li> </ul> Death or substantial gross motor dysfunction: <ul class=\"decimal_heading\"> <li>17.0 versus 22.7% </li> <li>RR 0.75 </li> <li>95% CI 0.59-0.96 </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>BEAM</td> <td class=\"centered\">2241</td> <td class=\"centered\">24 to 31</td> <td>6 g loading dose followed by 2 g/hour for maximum of 12 hours</td> <td>Death: <ul class=\"decimal_heading\"> <li>9.5 versus 8.5% </li> <li>RR 1.12 </li> <li>95% CI 0.85-1.47 </li> </ul> </td> <td>Moderate to severe cerebral palsy: <ul class=\"decimal_heading\"> <li>1.9 versus 3.5% </li> <li>RR 0.55 </li> <li>95% CI 0.32-0.95* </li> </ul> </td> <td>Stillbirth or infant death by one year of corrected age or moderate or severe cerebral palsy at or beyond two years of corrected age: <ul class=\"decimal_heading\"> <li>11.3 versus 11.7% </li> <li>RR 0.97 </li> <li>95% CI 0.77-1.23 </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td>PREMAG</td> <td class=\"centered\">573</td> <td class=\"centered\">&#60;33</td> <td>4 g loading dose, no maintenance dose</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Cerebral palsy or death: <ul class=\"decimal_heading\"> <li>OR 0.65 </li> <li>95% CI 0.42-1.03 </li> </ul> Severe motor dysfunction or death: <ul class=\"decimal_heading\"> <li>OR 0.62 </li> <li>95% CI 0.41-0.93 </li> </ul> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTOMgSO4: Australasian Collaborative Trial of Magnesium Sulphate; RR: relative risk; BEAM: Beneficial Effects of Antenatal Magnesium Sulfate; OR: odds ratio.<br />* When evaluated in terms of gestational age at randomization (&lt;28 weeks versus &ge;28 weeks), only infants of pregnancies randomized at &lt;28 weeks had a significant reduction in moderate or severe cerebral palsy.</div><div id=\"graphicVersion\">Graphic 108643 Version 2.0</div></div></div>"},"108644":{"type":"graphic_picture","displayName":"Chronic irritant contact derm PI","title":"Chronic irritant contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Chronic irritant contact dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/PI/108644_Chronc_irritnt_cntct_drm_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If you have dermatitis, your skin might be red, dry, itchy, or cracked.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108644 Version 1.0</div></div></div>"},"108645":{"type":"graphic_figure","displayName":"Arteries of the foot - Branching and communicating","title":"Arteries of the foot: Branching and communicating","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Arteries of the foot: Branching and communicating</div><div class=\"cntnt\"><img style=\"width:730px; height:343px;\" src=\"images/SM/108645_Arteries_foot_Branchng_comm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arteries of the midfoot and forefoot resemble those of the hand in that (1) arches on the two aspects give rise to metatarsal (metacarpal) arteries, which in turn give rise to digital arteries; (2) the dorsal arteries are exhausted before reaching the distal ends of the toes or digits, so the plantar (palmar) digital arteries send branches dorsally to supply the distal dorsal aspects of the digits, including the nail beds; and (3) perforating branches extend between the metatarsals (metacarpals) forming anastomoses between the arches of each side.</div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 108645 Version 1.0</div></div></div>"},"108646":{"type":"graphic_figure","displayName":"Surface anatomy of the foot - Lateral and superolateral views","title":"Surface anatomy of the foot: Lateral and superolateral views","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Surface anatomy of the foot: Lateral and superolateral views</div><div class=\"cntnt\"><img style=\"width:661px; height:773px;\" src=\"images/SM/108646_Srfc_antmy_ft_Lat_suplat_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In these images of the foot, numbers and letters following structures in the anatomic diagram below correspond to surface structures with the same labels in the photograph above. </div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 108646 Version 1.0</div></div></div>"},"108647":{"type":"graphic_figure","displayName":"Surface anatomy of the foot - Medial view","title":"Surface anatomy of the foot: Medial view","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Surface anatomy of the foot: Medial view</div><div class=\"cntnt\"><img style=\"width:754px; height:416px;\" src=\"images/SM/108647_Srfc_antmy_foot_Med_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 108647 Version 2.0</div></div></div>"},"108648":{"type":"graphic_figure","displayName":"Surface anatomy and underlying structures of dorsal foot","title":"Surface anatomy and underlying structures of the dorsal foot","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Surface anatomy&nbsp;and underlying structures of the dorsal foot</div><div class=\"cntnt\"><img style=\"width:754px; height:525px;\" src=\"images/SM/108648_Srfc_antmy_foot_V_U_strctrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The surface anatomy of the foot is shown in photograph A.&nbsp;The arrow indicates&nbsp;the tuberosity of the navicular. Photograph B shows underlying structures.</div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 108648 Version 1.0</div></div></div>"},"108662":{"type":"graphic_algorithm","displayName":"Management of possible exposure to HIV","title":"Management of possible exposure to HIV","html":"<div class=\"graphic\"><div style=\"width: 976px\" class=\"figure\"><div class=\"ttl\">Management of possible exposure to HIV</div><div class=\"cntnt\"><img style=\"width:956px; height:902px;\" src=\"images/ID/108662_Mngmnt_possible_exposur_HIV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The HIV status of the source should be classified as HIV-positive or unknown at the time of the initial evaluation. Thus, treatment decisions should be made based upon the nature of the exposure and when the exposure occurred. Once the need for nPEP has been identified, the patient should receive a dose as soon as possible (and within 72 hours of the exposure), even if HIV testing of the exposed patient and source have not yet been performed. After the initial dose has been administered, HIV testing and a more detailed history can be obtained. At that time, patients should also be assessed for hepatitis B and C virus, and sexually transmitted infections (depending upon the type of exposure).</div><div class=\"graphic_footnotes\">ART: antiretroviral therapy; EVG/c/FTC/TDF: Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; FTC: emtricitabine; nPEP: nonoccupational post-exposure prophylaxis; TDF: tenofovir disoproxil fumarate. Antiretroviral abbreviations separated by \"/\" (eg, TAF/FTC) are available in single-tablet coformulations.<br />* High-risk exposure includes: Having condomless receptive or insertive vaginal or anal intercourse with a source who is HIV-infected, or a source whose HIV status is unknown, but it is at high risk for HIV (eg, men who have sex with men, injection drug users, sex workers); having a percutaneous exposure to blood (or body fluids contaminated with blood) from a patient who is HIV-infected or with the risk factors described above; or having been sexually assaulted.<br />&para; Preferred regimens: The coformulated tablet TDF/FTC in combination with raltegravir or dolutegravir. Alternative regimens include: EVG/c/FTC/TDF, TDF/FTC plus a pharmacologically-boosted PI (eg, darunavir plus ritonavir or darunavir/cobicistat), or rilpivirine/emtricitabine/TDF. There is an increased risk of drug interactions if a pharmacologic boosting agent (cobicistat or ritonavir) is used.<br />&Delta; For individuals with reduced kidney function, TDF and FTC cannot be administered as a coformulated tablet and the dosage must be adjusted according to the patient's renal function. In addition, TDF and cobicistat should only be administered together if the eGFR is &gt;70 mL/min/1.73 m<sup>2</sup>.<br /><span class=\"lozenge\">&loz;</span> If the source patient is at risk for having drug-resistant virus (eg, those who have failed multiple regimens as well as those with known non-adherence), our preferred nPEP regimen is the coformulated tablet TDF/FTC in combination with dolutegravir. An alternative regimen is TDF/FTC plus a pharmacologically-boosted PI (eg, darunavir plus ritonavir or darunavir/cobicistat). Such patients are best managed in conjunction with an experienced HIV provider.<br />&sect; Refer to the topic that discusses the clinical manifestations of acute HIV infection.<br />&yen; HIV-infected patients with a stably suppressed viral load are unlikely to transmit HIV. Decisions to continue nPEP should be made on a case-by-case basis. Refer to the topic that discusses HIV prevention.</div><div id=\"graphicVersion\">Graphic 108662 Version 1.0</div></div></div>"},"108663":{"type":"graphic_table","displayName":"Differential diagnoses for maternal early warning criteria","title":"Differential diagnoses for maternal early warning criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnoses for maternal early warning criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Blood pressure &#62;160 systolic or &#62;100 diastolic</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Chronic hypertension </li> <li>Preeclampsia </li> <li>Sympathomimetic medications (methylergonovine, phenylephrine, other vasopressors) </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Illicit substances (eg, cocaine, amphetamines) </li> <li>Endocrine disorders (pheochromocytoma, hyperthyroidism, renal artery stenosis) </li> <li>Hypoventilation with hypercarbia (eg, opiate-related, obstructive sleep apnea, respiratory muscle weakness) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Blood pressure &#60;90 systolic</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Dehydration </li> <li>Supine hypotension syndrome </li> <li>Regional anesthesia side-effect <ul> <li>Hypotension solely due to regional anesthesia is unusual if the cephalad anesthetic level is at T10 or below </li> </ul> </li> <li>Hemorrhage </li> <li>Medication side-effects (beta-blockers, calcium channel blockers) </li> <li>Vasovagal reaction (in presence of bradycardia) </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Sepsis </li> <li>Cardiac (cardiomyopathy, right or left heart failure, myocardial ischemia, pericarditis, cardiac tamponade, arrhythmia) </li> <li>Thromboembolism (PE) </li> <li>Concealed hemorrhage (retroperitoneal hemorrhage, abruption, uterine rupture) </li> <li>Amniotic fluid embolism </li> <li>Anaphylaxis </li> <li>Diabetic ketoacidosis </li> <li>Drug toxicity (magnesium, local anesthetic) </li> <li>High spinal or epidural block </li> <li>Tension pneumothorax </li> <li>Vascular emergency (splanchnic arterial dissection, aortic dissection) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Heart rate &#62;120 bpm</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Dehydration </li> <li>Hemorrhage </li> <li>Infection </li> <li>Medication side effects (sympathomimetics, beta-2 agonists) </li> <li>Anxiety/pain/panic attack </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Cardiac (cardiomyopathy, right or left heart failure, myocardial ischemia, pericarditis, pericardial tamponade, tachyarrhythmia) </li> <li>Illicit drugs (eg, cocaine, amphetamines) </li> <li>Thromboembolism (PE) </li> <li>Concealed hemorrhage (retroperitoneal hemorrhage, abruption, uterine rupture) </li> <li>Amniotic fluid embolism </li> <li>Anaphylaxis </li> <li>Endocrine disorders (pheochromocytoma, hyperthyroidism/thyroid storm) </li> <li>Malignant hyperthermia </li> <li>Vascular emergency (splanchnic arterial dissection, aortic dissection) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Heart rate &#60;50</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Vasovagal reaction (in presence of hypotension) </li> <li>Medication side-effects (beta-blockers) </li> <li>Hypertension (reflex bradycardia) </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Heart block from cardiac disease (eg, myocardial infarction, myocarditis, or hemochromatosis) </li> <li>Hypoventilation or hypoxemia (eg, obstructive sleep apnea) </li> <li>Electrolyte disturbances (K, Na, Ca, Mg) </li> <li>Medication toxicity (magnesium) </li> <li>Stroke/increased intracranial pressure </li> <li>High spinal or epidural block </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory rate &#62;30</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Hypoxia (eg, asthma) </li> <li>Hemorrhage </li> <li>Infection (eg, sepsis, pneumonia) </li> <li>Anxiety/panic attack/exertion </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Cardiac (cardiomyopathy, right or left heart failure, myocardial ischemia) </li> <li>Thromboembolism (PE) </li> <li>Aspiration </li> <li>Metabolic acidosis including diabetic ketoacidosis </li> <li>Concealed hemorrhage (retroperitoneal hemorrhage, abruption, uterine rupture) </li> <li>Amniotic fluid embolism </li> <li>Stroke </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory rate &#60;10</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Medication toxicity (opioids, benzodiazepines, magnesium) </li> <li>Obstructive sleep apnea </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Airway obstruction </li> <li>Asthma with respiratory failure </li> <li>High spinal or epidural block </li> <li>Cerebrovascular accident </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Oxygen saturation &#60;95% or increasing oxygen requirements to maintain oxygen saturation &#8805;95%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Atelectasis (following anesthesia, obesity, supine position at the end of pregnancy) </li> <li>Bronchospasm (asthma) </li> <li>Hemorrhage </li> <li>Hypoventilation (obstructive sleep apnea, opiate or benzodiazepine effect) </li> <li>Infection (eg, pneumonia) </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Airway obstruction (asphyxia, laryngospasm) </li> <li>Pulmonary edema </li> <li>Thromboembolic disease (PE) </li> <li>Cardiac disease (cardiomyopathy, right or left heart failure, intracardiac shunt) </li> <li>Concealed hemorrhage (retroperitoneal hemorrhage, abruption, uterine rupture) </li> <li>Amniotic fluid embolism </li> <li>Anaphylaxis </li> <li>Aspiration </li> <li>Acute chest syndrome (sickle cell disease) </li> <li>Pneumothorax </li> <li>Venous air embolism </li> <li>Blood product reaction (TACO, TRALI, anaphylaxis) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Maternal confusion, agitation, or unresponsiveness</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Hypoxemia </li> <li>Hemorrhage/hypotension </li> <li>Illicit substances (either intoxication or withdrawal) </li> <li>Seizure/postictal state/posterior reversible encephalopathy syndrome (PRES) </li> <li>Psychosis is a diagnosis of exclusion </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Diabetic ketoacidosis, hypoglycemia </li> <li>Sepsis </li> <li>Concealed hemorrhage (retroperitoneal hemorrhage, abruption, uterine rupture) </li> <li>Thromboembolic disease (PE) </li> <li>Amniotic fluid embolism </li> <li>Anesthesia complications </li> <li>Cardiomyopathy </li> <li>Cerebrovascular accident, cavernous sinus thrombosis </li> <li>Increased intracranial pressure </li> <li>Electrolyte abnormality (hypermagnesemia) </li> <li>Hyperthyroidism/thyroid storm, myxedema coma </li> <li>Medication toxicity </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Oliguria &#60;35 mL/hour over a two-hour period</td> </tr> <tr> <td><strong>Common diagnoses</strong> <ul class=\"decimal_heading\"> <li>Severe dehydration </li> <li>Hemorrhage </li> <li>Obstructed urinary catheter </li> </ul> <br /> <strong>Rare but life-threatening diagnoses</strong> <ul class=\"decimal_heading\"> <li>Surgical complications </li> <li>Genitourinary tract injury </li> <li>Preeclampsia with severe features </li> <li>Sepsis </li> <li>Concealed hemorrhage (retroperitoneal hemorrhage, abruption, uterine rupture) </li> <li>Acute renal failure </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PE: pulmonary embolism; bpm: beats per minute; TACO: transfusion-associated circulatory overload; TRALI: transfusion-related acute lung injury.</div><div class=\"graphic_reference\">From: Myhre JM, D'Oria R, Hameed AB, et al. The maternal early warning criteria: A proposal from the National Partnership for Maternal Safety. Obstet Gynecol 2014; 124:782. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2014&amp;issue=10000&amp;article=00019&amp;type=abstract\" target=\"_blank\">10.1097/AOG.0000000000000480</a>. Copyright &copy; 2014 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108663 Version 1.0</div></div></div>"},"108664":{"type":"graphic_table","displayName":"Sideroblastic anemia classification by MCV","title":"Sideroblastic anemia classification by MCV","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sideroblastic anemia classification by MCV</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sideroblastic anemia</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Diagnostic testing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">MCV decreased</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> <td>History of use</td> <td>Response to discontinuation and/or vitamin B6 supplementation</td> </tr> <tr> <td class=\"indent1\">X-linked sideroblastic anemia (XLSA) in males</td> <td>Family history (no syndromic features); usually adult presentation</td> <td><em>ALAS2</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">XLSA/A</td> <td>Family history; ataxia; childhood presentation</td> <td><em>ABCB7</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive congenital sideroblastic anemia (ARCSA)</td> <td>Family history; infancy, childhood or adult presentation (no syndromic features)</td> <td><em>SLC25A38,</em> <em>HSPA9,</em> <em>GLRX5</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">SIFD (ARCSA with immunodeficiency)</td> <td>Family history; infancy or childhood presentation; immunodeficiency; fevers; developmental delay</td> <td><em>TRNT1</em> mutation analysis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Erythropoietic protoporphyria (EPP)</td> <td>Family history; photosensitivity; hepatobiliary complications</td> <td>Total and metal-free erythrocyte protoporphyrin level; <em>FECH</em> mutation analysis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">MCV normal or increased (microcytic RBCs may also be present)</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> <td>History of alcohol abuse; stigmata of liver disease</td> <td>Response to discontinuation; exclude nutrient deficiencies</td> </tr> <tr> <td class=\"indent1\">Certain medications</td> <td>History of use</td> <td>Response to discontinuation</td> </tr> <tr> <td class=\"indent1\">Copper deficiency</td> <td>Malabsorption; gastrointestinal surgery; zinc ingestion</td> <td>Serum copper and ceruloplasmin levels; zinc level</td> </tr> <tr> <td class=\"indent1\">XLSA in females</td> <td>Family history (no syndromic features)</td> <td><em>ALAS2</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">MLASA and MLASA variants</td> <td>Family history; +/&ndash; infancy or childhood presentation; myopathy; lactic acidosis</td> <td><em>PUS1,</em> <em>YARS2,</em> <em>LARS2,</em>&nbsp;<em>MTATP6</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">X-linked MLASA variant</td> <td>Family history; childhood presentation; variable syndromic features</td> <td><em>NDUFB11</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">Pearson marrow-pancreas syndrome</td> <td>Infancy or childhood presentation; pancreatic insufficiency; acidosis</td> <td>Mitochondrial DNA mutation analysis</td> </tr> <tr> <td class=\"indent1\">TRMA</td> <td>Family history; infancy or childhood presentation; diabetes mellitus; deafness</td> <td><em>SLC19A2</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">MDS-RS-SLD</td> <td>Anemia without other cytopenias</td> <td>Exclusion of other causes; <em>SF3B1</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">MDS-RS-MLD</td> <td>Anemia with leukopenia&nbsp;and/or&nbsp;thrombocytopenia</td> <td>Exclusion of other causes; <em>SF3B1</em> mutation analysis</td> </tr> <tr> <td class=\"indent1\">MDS/MPN-RS-T</td> <td>Anemia with thrombocytosis</td> <td>Exclusion of other causes; <em>SF3B1</em> and <em>JAK2</em> V617F mutation analysis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table applies to patients for whom ring sideroblasts are present in a Prussian blue stained smear of the bone marrow aspirate. The MCV is most accurate before the patient has received any transfusion. Additional forms of sideroblastic anemia exist for which the cause has not yet been identified. Refer to UpToDate for discussions of the evaluation and management of sideroblastic anemia.</div><div class=\"graphic_footnotes\">MCV: mean corpuscular volume; XLSA: X-linked sideroblastic anemia; ARCSA: autosomal recessive congenital sideroblastic anemia; SIFD: sideroblastic anemia with B cell immunodeficiency, periodic fevers, and developmental delay; MLASA: myopathy, lactic acidosis and sideroblastic anemia; TRMA: thiamine-responsive megaloblastic anemia; MDS-RS-SLD:&nbsp;myelodysplastic syndrome&nbsp;with ring sideroblasts and single lineage dysplasia; MDS-RS-MLD: myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia; MDS/MPN-RS-T: myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.</div><div id=\"graphicVersion\">Graphic 108664 Version 1.0</div></div></div>"},"108672":{"type":"graphic_algorithm","displayName":"IV fluids for crush victims","title":"Initial IV fluids for crush victims of high-casualty disasters such as earthquakes","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Initial IV fluids for crush victims of high-casualty disasters such as earthquakes</div><div class=\"cntnt\"><img style=\"width:512px; height:634px;\" src=\"images/NEPH/108672_IV_fluids_crush_victims.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* The rate is reduced because patients cannot be closely monitored when they are under the rubble and there is a risk of giving too much fluid.<br />&para; Generally, up to 12 L/day IV fluid can be administered in patients with good urine output (ie, &gt;300 mL/hour). We give 4 to 4.5 L more than total fluid loss from the prior day.<br />&Delta; The actual amount depends on extent of injuries, body mass index, ambient temperature, urine production, amount of overall estimated fluid losses, and age. Patients with severe injuries usually require more fluid and may receive up to 6 L. Older patients who are not as severely injured may be given only 3 L.</div><div class=\"graphic_reference\">Adapted from: Sever MS, Vanholder R, RDRTF of ISN Work Group on Recommendations for the Management of Crush Victims in Mass Disasters. Recommendations for the management of crush victims in mass disasters. Nephrol Dial Transplant 2012; 27 (Suppl 1):i1.</div><div id=\"graphicVersion\">Graphic 108672 Version 1.0</div></div></div>"},"108680":{"type":"graphic_diagnosticimage","displayName":"Comminuted fracture great toe","title":"Comminuted fracture great toe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted fracture great toe</div><div class=\"cntnt\"><img style=\"width:363px; height:612px;\" src=\"images/SM/108680_Comminutd_fractre_great_toe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The antero-posterior (AP) plain radiograph above shows a&nbsp;comminuted fracture through the shaft of the proximal phalanx of the great toe, extending immediately distal to the proximal articular surface of the phalanx.</div><div class=\"graphic_reference\">Reproduced with permission from: Rowe LJ, Yochum TR, Maola CJ. Trauma. In: Yochum and Rowe's Essentials of Skeletal Radiology, 3rd ed, Yochum TR, Rowe LJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 108680 Version 2.0</div></div></div>"},"108692":{"type":"graphic_table","displayName":"Principal manifestations of osteoarthritis","title":"Principal manifestations of osteoarthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principal manifestations of osteoarthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Patient characteristics</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Age of onset</td> <td> <ul> <li>&#62;40 years* </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Symptoms</td> </tr> <tr> <td class=\"indent1\">Pain</td> <td> <ul> <li>Affects one or a few joints at a time </li> <li>Insidious onset - slow progression over years </li> <li>Variable intensity </li> <li>May be intermittent </li> <li>Increased by joint use and relieved by rest </li> <li>Night pain in severe&nbsp;osteoarthritis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Stiffness</td> <td> <ul> <li>Short-lived (&#60;30 minutes) and early morning- or inactivity-related </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Swelling</td> <td> <ul> <li>Some (eg, nodal osteoarthritis) patients present with swelling and/or deformity </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Constitutional symptoms</td> <td> <ul> <li>Absent </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Physical exam findings</td> </tr> <tr> <td class=\"indent1\">Appearance</td> <td> <ul> <li>Swelling (bony overgrowth &#177; fluid/synovial hypertrophy) </li> <li>Attitude </li> <li>Deformity </li> <li>Muscle wasting (global - all muscles acting over the joint) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Palpation</td> <td> <ul> <li>Absence of warmth </li> <li>Swelling (effusion if present is usually small and cool) </li> <li>Joint line tenderness </li> <li>Periarticular tenderness (especially knee, hip) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Range of motion </td> <td> <ul> <li>Crepitus (knee, thumb bases) </li> <li>Reduced range of movement </li> <li>Weak local muscles </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OA: osteoarthritis.<br />* Major joint injury and certain rare conditions may predispose to OA before the age of 40 years.</div><div class=\"graphic_reference\">Adapted from: OARSI Primer (<a href=\"http://primer.oarsi.org/\" target=\"_blank\">http://primer.oarsi.org</a>).</div><div id=\"graphicVersion\">Graphic 108692 Version 1.0</div></div></div>"},"108696":{"type":"graphic_diagnosticimage","displayName":"Pelvic radiograph osteopetrosis type II","title":"Pelvic radiograph in a patient with osteopetrosis type II","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Pelvic radiograph in a patient with osteopetrosis type II</div><div class=\"cntnt\"><img style=\"width:658px; height:566px;\" src=\"images/ALLRG/108696_Pelvc_osteopetrosis_type_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior pelvis views of a patient with autosomal dominant osteopetrosis type II. Note the concentric rims around the iliac wing secondary to areas of increased bone density often known as bone-in-bone image. There is increased bone density inside the lumbar vertebral bodies. The proximal femurs showed a generalized increase in bone density and decrease of intramedullary spaces.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108696 Version 1.0</div></div></div>"},"108698":{"type":"graphic_diagnosticimage","displayName":"Thigh radiograph osteopetrosis type II","title":"Thigh radiograph in a patient with osteopetrosis type II","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Thigh radiograph in a patient with osteopetrosis type II</div><div class=\"cntnt\"><img style=\"width:534px; height:658px;\" src=\"images/ALLRG/108698_Thigh_osteopetrosis_type_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased bone density and widening of the distal femoral diaphysis and metaphysis in autosomal dominant osteopetrosis type II.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108698 Version 1.0</div></div></div>"},"108699":{"type":"graphic_diagnosticimage","displayName":"Hand radiograph osteopetrosis type II","title":"Hand radiograph in a patient with osteopetrosis type II","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hand radiograph in a patient with osteopetrosis type II</div><div class=\"cntnt\"><img style=\"width:590px; height:658px;\" src=\"images/ALLRG/108699_Hand_osteopetrosis_type_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized increased density in the metacarpals and phalanges in autosomal dominant osteopetrosis type II.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108699 Version 1.0</div></div></div>"},"108700":{"type":"graphic_table","displayName":"Causes AUB adolescents","title":"Causes of abnormal uterine bleeding in nonpregnant adolescents according to bleeding pattern","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of abnormal uterine bleeding in nonpregnant adolescents according to bleeding pattern</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Bleeding pattern</td> <td class=\"subtitle1\">Associated clinical features</td> <td class=\"subtitle1\">Suggested evaluation</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Amenorrhea</strong></td> </tr> <tr> <td class=\"indent1\">Primary amenorrhea</td> <td> <ul> <li>Absence of menarche by age 15 years </li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on primary amenorrhea </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Secondary amenorrhea</td> <td> <ul> <li>Absence of menses for: <ul> <li>&#8805;90 days in adolescents who had regular menstrual cycles, or </li> <li>&#8805;6 months in adolescents who had irregular menstrual cycles </li> </ul> </li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on secondary amenorrhea </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Irregular bleeding</strong> (unpredictable in timing and volume)</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Common causes</strong></td> </tr> <tr> <td class=\"indent2\">Anovulatory uterine bleeding due to immature HPO axis</td> <td> <ul> <li>First year or two after menarche </li> <li>Absence of premenstrual symptoms (eg, breast tenderness, weight gain, mood swings, cramping) </li> <li>Absence of clinical features associated with other causes </li> </ul> </td> <td> <ul> <li>Evaluation to exclude other possible causes of anovulatory uterine bleeding as indicated clinically </li> </ul> </td> </tr> <tr> <td class=\"indent2\">PCOS</td> <td> <ul> <li>Hyperandrogenism (hirsutism, acne, clitoromegaly) </li> <li>Obesity </li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on diagnosis of PCOS in adolescents </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Less common causes</strong></td> </tr> <tr> <td class=\"indent2\">Hypothyroidism or hyperthyroidism</td> <td> <ul> <li>Recent weight gain or loss </li> <li>Heat or cold intolerance </li> <li>Family history of thyroid dysfunction </li> </ul> </td> <td> <ul> <li>Thyroid-stimulating hormone </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Hyperprolactinemia</td> <td> <ul> <li>Galactorrhea, headache, visual changes </li> </ul> </td> <td> <ul> <li>Prolactin </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Hypothalamic dysfunction</td> <td> <ul> <li>Poor nutrition </li> <li>Intense exercise </li> <li>Psychosocial stress </li> </ul> </td> <td> <ul> <li>Follicle-stimulating hormone </li> <li>Luteinizing hormone </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Intermittent nonuterine bleeding mimicking irregular menses</td> <td> <ul> <li>Clinical features of sexually transmitted infection (eg, vaginal discharge, vulvovaginal lesions, post-coital bleeding) </li> </ul> </td> <td> <ul> <li>Examination of external genitalia </li> <li>Testing for sexually transmitted infection as indicated </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Regular menses with excessive flow</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Common causes</strong></td> </tr> <tr> <td class=\"indent2\">Bleeding disorder</td> <td> <ul> <li>Heavy bleeding with first period </li> <li>Symptoms of bleeding disorder (eg, bruising, epistaxis, gum bleeding) </li> <li>Family history of bleeding disorder </li> </ul> </td> <td> <ul> <li>Complete blood count with platelets </li> <li>Evaluation of peripheral blood smear </li> <li>aPTT and PT </li> <li>von Willebrand panel </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Less common causes</strong></td> </tr> <tr> <td class=\"indent2\">Medications that affect hemostasis</td> <td> <ul> <li>Anticoagulant therapy </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Hypothyroidism or hyperthyroidism</td> <td> <ul> <li>Recent weight gain or loss </li> <li>Heat or cold intolerance </li> <li>Family history of thyroid dysfunction </li> </ul> </td> <td> <ul> <li>Thyroid-stimulating hormone </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Structural lesions (eg, endometrial polyp, uterine leiomyoma [fibroid], congenital uterine anomaly)</td> <td> <ul> <li>Often asymptomatic </li> <li>May be associated with pelvic pressure and pain </li> </ul> </td> <td> <ul> <li>Pelvic ultrasonography </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Regular menses with intermenstrual bleeding</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Common causes</strong></td> </tr> <tr> <td class=\"indent2\">Hormonal contraception or intrauterine device</td> <td> <ul> <li>Recent initiation or poor adherence </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Sexually transmitted infection</td> <td> <ul> <li>High-risk behaviors (eg, unprotected sexual activity, multiple partners) </li> <li>Vaginal discharge </li> <li>Vulvar lesions </li> <li>Post-coital bleeding </li> </ul> </td> <td> <ul> <li>Testing for sexually transmitted infection as indicated </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Extrauterine causes of intermittent bleeding that may mimic intermenstrual uterine bleeding</strong></td> </tr> <tr> <td class=\"indent2\">Ectropion (eversion of the endocervix)</td> <td>&nbsp;</td> <td> <ul> <li>Speculum examination </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Perineal trauma</td> <td> <ul> <li>History of perineal trauma or forced sexual activity </li> </ul> </td> <td> <ul> <li>Examination of external genitalia </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Cervical polyps</td> <td> <ul> <li>Chronic inflammation of the cervical canal </li> </ul> </td> <td> <ul> <li>Speculum examination </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Medications</td> <td> <ul> <li>Anticoagulant therapy </li> </ul> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPO: hypothalamic-pituitary-ovarian; PCOS: polycystic ovary syndrome; aPTT: activated partial thromboplastin time; PT: prothrombin time.</div><div id=\"graphicVersion\">Graphic 108700 Version 1.0</div></div></div>"},"108702":{"type":"graphic_algorithm","displayName":"RB Rx algorithm","title":"Algorithmic overview of initial treatment options for children with newly diagnosed retinoblastoma based on disease classification*","html":"<div class=\"graphic\"><div style=\"width: 1240px\" class=\"figure\"><div class=\"ttl\">Algorithmic overview of initial treatment options for children with newly diagnosed retinoblastoma based on disease classification*</div><div class=\"cntnt\"><img style=\"width:1220px; height:926px;\" src=\"images/PEDS/108702_RB_Rx_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* This algorithm is intended for use in conjunction with additional UpToDate content on retinoblastoma in children. Refer to UpToDate topics on retinoblastoma for additional details of the approach to treatment and the overall efficacy of these treatments.<br />&para; Enucleation may be required for some group D tumors.<br />&Delta; Adjuvant chemotherapy and radiotherapy are provided following enucleation if there are microscopic residua at the cut section of the optic nerve or sclera, or if there are other pathologic risk factors.<br /><span class=\"lozenge\">&loz;</span> For patients who have undergone enucleation of one eye, systemic or intra-arterial chemotherapy can be used in attempt to salvage the other eye. These therapies may also be used in patients with bilateral advanced disease in attempt to salvage both eyes.<br />&sect; Some group B tumors can be treated with focal therapies (eg, laser photocoagulation, cryotherapy); however, for larger tumors and those that impinge on the fovea, local or systemic chemotherapy is typically used to shrink the tumor before performing focal therapy.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of Retinoblastoma in 2015: Agreement and Disagreement. JAMA Ophthalmol 2015; 133:1341.</li>&#xD;&#xA;    <li>Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005; 18:41.</li>&#xD;&#xA;    <li>Shields CL, Mashayekhi A, Au AK. The International Classification of Retinoblastoma Predicts Chemoreduction Success. Ophthalmology 2006; 113:2276.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 108702 Version 2.0</div></div></div>"},"108706":{"type":"graphic_figure","displayName":"Inferior alveolar nerve and branches","title":"Inferior alveolar nerve and branches","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Inferior alveolar nerve and branches</div><div class=\"cntnt\"><img style=\"width:536px; height:582px;\" src=\"images/NEURO/108706_Inferior_alveolar_nerve_and_branches.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inferior alveolar nerve travels through the medial surface of the mandible though the mandibular canal, dividing into the incisive and mental branches just anterior to the first premolar tooth. The incisive branch innervates the first premolar, canine, and incisor teeth along with the associated vestibular gingiva. The mental nerve passes through the mental foramen on the anterior mandible, typically below the second premolar tooth, before dividing into two or three branches that supply sensation to the skin of the chin, the mucous membrane of the lower lip, and the buccal gingivae of the mandibular teeth and premolars.</div><div class=\"graphic_reference\">Modified from: Smith RM, Hassan A, Robertson CE. Numb Chin Syndrome. Curr Pain Headache Rep 2015; 19:44.</div><div id=\"graphicVersion\">Graphic 108706 Version 1.0</div></div></div>"},"108707":{"type":"graphic_figure","displayName":"Origin supraorbital, infraorbital, and mental nerves","title":"Origin of the supraorbital, infraorbital, and mental nerves ","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Origin of the supraorbital, infraorbital, and mental nerves </div><div class=\"cntnt\"><img style=\"width:509px; height:597px;\" src=\"images/NEURO/108707_Origin_supraorbital_infraorbital_and_mental_nerves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The origin of the supraorbital, infraorbital, and mental nerves all lie in approximately the same vertical plane, which passes through the mid-pupil.</div><div class=\"graphic_reference\">Modified from: Smith RM, Hassan A, Robertson CE. Numb Chin Syndrome. Curr Pain Headache Rep 2015; 19:44.</div><div id=\"graphicVersion\">Graphic 108707 Version 1.0</div></div></div>"},"108708":{"type":"graphic_table","displayName":"VBAC prediction score","title":"VBAC prediction score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">VBAC prediction score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Calculated VBAC score</td> <td class=\"subtitle1\">Estimated chance of successful vaginal birth,<br /> %&nbsp;(95% CI)</td> </tr> <tr class=\"centered\"> <td>4</td> <td>11.7 (6.4-20.5)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>5</td> <td>14.7 (8.5-24.3)</td> </tr> <tr class=\"centered\"> <td>6</td> <td>19.0 (11.8-29.1)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>7</td> <td>24.7 (16.7-35.0)</td> </tr> <tr class=\"centered\"> <td>8</td> <td>31.9 (23.3-41.9)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>9</td> <td>40.2 (31.8-49.2)</td> </tr> <tr class=\"centered\"> <td>10</td> <td>49.1 (41.6-56.6)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>11</td> <td>57.7 (51.6-63.6)</td> </tr> <tr class=\"centered\"> <td>12</td> <td>65.6 (61.0-69.9)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>13</td> <td>72.2 (68.7-75.4)</td> </tr> <tr class=\"centered\"> <td>14</td> <td>77.5 (74.7-80.1)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>15</td> <td>81.6 (79.1-83.8)</td> </tr> <tr class=\"centered\"> <td>16</td> <td>84.7 (82.3-86.8)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>17</td> <td>87.0 (84.6-89.0)</td> </tr> <tr class=\"centered\"> <td>18</td> <td>88.6 (86.3-90.6)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>19</td> <td>89.8 (87.6-91.8)</td> </tr> <tr class=\"centered\"> <td>20</td> <td>90.7 (88.5-92.6)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>21</td> <td>91.4 (89.1-93.2)</td> </tr> <tr class=\"centered\"> <td>22</td> <td>91.9 (89.6-93.7)</td> </tr> <tr class=\"centered highlight_gray_text\"> <td>23</td> <td>92.3 (90.1-94.0)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VBAC: vaginal birth after cesarean delivery.</div><div class=\"graphic_reference\">Data from: Metz TD, Stoddard GJ, Henry E, et al. Simple, validated vaginal birth after cesarean delivery prediction model for use at the time of admission. Obstet Gynecol 2013; 122:571.</div><div id=\"graphicVersion\">Graphic 108708 Version 2.0</div></div></div>"},"108710":{"type":"graphic_algorithm","displayName":"Algorithm for BRUE in an infant","title":"Diagnosis, risk classification, and recommended management of a brief resolved unexplained event (BRUE) in an infant","html":"<div class=\"graphic\"><div style=\"width: 918px\" class=\"figure\"><div class=\"ttl\">Diagnosis, risk classification, and recommended management of a brief resolved unexplained event (BRUE) in an infant</div><div class=\"cntnt\"><img style=\"width:898px; height:1170px;\" src=\"images/PEDS/108710_Algorithm_BRUE_infant.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnosis, risk classification, and recommended management of a BRUE.</div><div class=\"graphic_footnotes\">BRUE: brief resolved unexplained event; ALTE: apparent life-threatening event; PE: physical examination; GER: gastroesophageal reflux; FH: family history; CPR: cardiopulmonary resuscitation; ECG: electrocardiogram; WBC: white blood cell; CSF: cerebrospinal fluid; EEG: electroencephalogram.<br />* Refer to source reference or UpToDate topic text for determination of an appropriate and negative family history and physical examination.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 137, Pages pii: e20160590, Copyright © 2016 by the AAP.</div><div id=\"graphicVersion\">Graphic 108710 Version 3.0</div></div></div>"},"108711":{"type":"graphic_table","displayName":"Neoplastic etiologies NCS","title":"Neoplastic etiologies of numb chin syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neoplastic etiologies of numb chin syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Oral cavity/oropharyngeal cancer including salivary gland malignancies </li> <li>Nasopharyngeal cancer </li> <li>Malignant melanoma </li> <li>Esophageal/gastric cancer </li> <li>Glioblastoma </li> <li>Medulloblastoma </li> <li>Ependymoma </li> <li>Neuroblastoma </li> <li>Leptomeningeal carcinomatosis </li> <li>Lymphoma/leukemia </li> <li>Waldenstr&#246;m macroglobulinemia </li> <li>Post-transplant lymphoproliferative disorder </li> <li>Multiple myeloma </li> <li>Osteosarcoma </li> <li>Rhabdomyosarcoma </li> <li>Liposarcoma </li> <li>Reticulum cell sarcoma </li> <li>Thyroid cancer </li> <li>Renal cell cancer </li> <li>Small and non-small cell lung cancer </li> <li>Hepatocellular cancer </li> <li>Chordoma </li> <li>Breast cancer </li> <li>Colon/rectal cancer </li> <li>Ovarian cancer </li> <li>Uterine/endometrial cancer </li> <li>Testicular cancer </li> <li>Prostate cancer </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">​Reprinted by permission from: Springer: Current Pain and Headache Reports. Smith RM, Hassan A, Robertson CE. Numb Chin Syndrome. Curr Pain Headache Rep 2015; 19:44. Copyright © 2015. <A spellcheck=true href=\"https://link.springer.com/journal/11916\" target=_blank>https://link.springer.com/journal/11916</A>.</div><div id=\"graphicVersion\">Graphic 108711 Version 2.0</div></div></div>"},"108712":{"type":"graphic_table","displayName":"Inflammatory/immune etiologies NCS","title":"Inflammatory and immune-mediated etiologies of numb chin syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inflammatory and immune-mediated etiologies of numb chin syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Systemic lupus erythematosus </li> <li>Giant cell arteritis </li> <li>Primary arteritis nodosa </li> <li>Sj&#246;gren syndrome </li> <li>Post-vaccination </li> <li>Anti-GQ1b antibody </li> <li>Sarcoidosis </li> <li>Multiple sclerosis </li> <li>Amyloidosis </li> <li>Sensorimotor mononeuritis multiplex </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Current Pain and Headache Reports. Smith RM, Hassan A, Robertson CE. Numb Chin Syndrome. Curr Pain Headache Rep 2015; 19:44. Copyright © 2015. <A spellcheck=true href=\"https://link.springer.com/journal/11916\" target=_blank>https://link.springer.com/journal/11916</A>. Table adaptation permitted by authors.</div><div id=\"graphicVersion\">Graphic 108712 Version 2.0</div></div></div>"},"108713":{"type":"graphic_table","displayName":"Infectious-traumatic-toxic-other etiologies NCS","title":"Infectious, traumatic, toxic and other etiologies of numb chin syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious, traumatic, toxic and other etiologies of numb chin syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>HIV (with Burkitt lymphoma) </li> <li>Herpes simplex virus </li> <li>Syphilis </li> <li>Lyme disease </li> <li>Sickle cell disease </li> <li>Mandibular osteomyelitis </li> <li>Periapical dental infection/abscess </li> <li>Dental procedures/anesthesia </li> <li>Odontogenic cysts and benign masses </li> <li>Orthognathic surgery </li> <li>Facial trauma </li> <li>Salivary gland biopsy </li> <li>Mandibular atrophy in the edentulous with or without denture trauma over mental foramen </li> <li>Temporomandibular joint synovial cyst </li> <li>Denture compression </li> <li>Elongated styloid process </li> <li>Bisphosphonate therapy </li> <li>Mefloquine </li> <li>Thermal (scald) injury </li> <li>Trichloroethylene/dichloroacetylene </li> <li>Stilbamidine </li> <li>Interferon alpha </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Current Pain and Headache Reports. Smith RM, Hassan A, Robertson CE. Numb Chin Syndrome. Curr Pain Headache Rep 2015; 19:44. Copyright © 2015. <A spellcheck=true href=\"https://link.springer.com/journal/11916\" target=_blank>https://link.springer.com/journal/11916</A>. Table adaptation permitted by authors.</div><div id=\"graphicVersion\">Graphic 108713 Version 3.0</div></div></div>"},"108717":{"type":"graphic_movie","displayName":"Hyponasal speech","title":"Evaluating a child for hyponasal speech","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluating a child for hyponasal speech</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/108717_Hyponasalspeechvid.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:476px; height:240px;\" src=\"images/PEDS/108717_Hyponasalspeechimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyponasality occurs in nasal obstruction due to adenoidal hypertrophy or intrinsic intranasal obstruction. An affected child will have difficulty saying words or phrases containing the nasal consonants \"m\" and \"n.\" A useful test phrase is \"my name means money.\"</div><div id=\"graphicVersion\">Graphic 108717 Version 1.0</div></div></div>"},"108718":{"type":"graphic_movie","displayName":"Hypernasal speech","title":"Evaluating a child for hypernasal speech","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluating a child for hypernasal speech</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/108718_Hypernasalspeechvid.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:421px; height:240px;\" src=\"images/PEDS/108718_Hypernasalspeechimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypernasality occurs in velopharyngeal insufficiency (eg, due to submucous [covert] or overt cleft of the palate). Hypernasality is demonstrated by air escape when the child says words or phrases that contain plosive consonants, especially \"b\" and \"p\" (eg, \"puppy\" or \"Bobby\"), or sibilant fricatives such as \"s,\" \"z,\" or \"sh.\" A useful test phrase is \"Suzie sells sea shells.\"</div><div id=\"graphicVersion\">Graphic 108718 Version 1.0</div></div></div>"},"108719":{"type":"graphic_algorithm","displayName":"Genetic evaluation of the fetus with a structural abnormality","title":"Genetic evaluation of the fetus with a structural abnormality identified on ultrasound examination","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Genetic evaluation of the fetus with a structural abnormality identified on ultrasound examination</div><div class=\"cntnt\"><img style=\"width:792px; height:467px;\" src=\"images/OBGYN/108719_Gntcevalftsstrctrlabnrm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Structural anatomic abnormalities identified by ultrasound are associated with an increased risk of fetal genetic abnormality. Structural anatomic abnormalities do not include \"soft markers,\" such as echogenic intracardiac focus, choroid plexus cyst, slightly short humerus or femur, nuchal thickening, mild pyelectasis, echogenic bowel, and absent or hypoplastic nasal bone.</div><div class=\"graphic_footnotes\">CVS: chorionic villus sampling; FISH: fluorescence in situ hybridization.<br />* For invasive testing, CVS is offered through 14 weeks of gestation; amniocentesis is offered at 15 weeks of gestation and beyond.<br />¶ Offer an invasive procedure for diagnostic testing when \"no result\" is reported due to increased association of test failures and fetal aneuploidy.<br />Δ A positive cell-free DNA screening test must be confirmed with a diagnostic test, particularly if pregnancy termination is planned based on test results.<br /><FONT class=lozenge>◊</FONT> FISH test panel should include chromosomes 13, 18, 21, X, and Y. Although FISH provides a rapid result, it also adds to the cost of the fetal evaluation, so it is also reasonable to proceed directly to chromosomal microarray.</div><div id=\"graphicVersion\">Graphic 108719 Version 2.0</div></div></div>"},"108720":{"type":"graphic_algorithm","displayName":"Genetic evaluation of fetus with two or more soft markers on U/S","title":"Genetic evaluation of the fetus with two or more soft markers for aneuploidy on ultrasound examination and before serum or blood aneuploidy screening","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Genetic evaluation of the fetus with two or more soft markers for aneuploidy on ultrasound examination and before serum or blood aneuploidy screening</div><div class=\"cntnt\"><img style=\"width:781px; height:447px;\" src=\"images/OBGYN/108720_GntcevalftssoftmrkrsUS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Soft markers\" are a common finding in the second-trimester ultrasound. They are not structural anomalies but are indicators of an increased risk for chromosomal aneuploidy. Examples of soft markers include echogenic intracardiac focus, choroid plexus cyst, slightly short humerus or femur, nuchal thickening, mild pyelectasis, echogenic bowel, and absent or hypoplastic nasal bone.</div><div class=\"graphic_footnotes\">CVS: chorionic villus sampling; FISH: fluorescence in situ hybridization.<br />* For invasive testing, CVS is offered through 14 weeks of gestation; amniocentesis is offered at 15 weeks of gestation and beyond.<br />¶ FISH may be performed but is often omitted to save time.<br />Δ A positive cell-free DNA screening test must be confirmed with a diagnostic test, particularly if pregnancy termination is planned based on test results.<br /><FONT class=lozenge>◊</FONT> FISH test panel should include chromosome 13, 18, 21, X, and Y. Although FISH provides a rapid result, it also adds to the cost of the fetal evaluation, so it is also reasonable to proceed directly to chromosomal microarray.<br />§ Echogenic bowel has been associated with disorders other than aneuploidy, including blood in bowel lumen, cystic fibrosis, growth restriction, infection, and gastrointestinal obstruction. For evaluation, refer to the UpToDate topic on fetal echogenic bowel. First-trimester nuchal thickening has also been associated with congenital heart disease. For evaluation, refer to the UpToDate topic on cystic hygroma and increased nuchal translucency.</div><div id=\"graphicVersion\">Graphic 108720 Version 4.0</div></div></div>"},"108723":{"type":"graphic_picture","displayName":"Endometrial ca grade 1","title":"Endometrioid endometrial carcinoma, grade 1","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Endometrioid endometrial carcinoma, grade 1</div><div class=\"cntnt\"><img style=\"width:752px; height:563px;\" src=\"images/ONC/108723_Endometrial_ca_grade_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Margaret M. Steinhoff, MD.</div><div id=\"graphicVersion\">Graphic 108723 Version 1.0</div></div></div>"},"108724":{"type":"graphic_picture","displayName":"Endometrial ca grade 3","title":"Endometrioid endometrial carcinoma, grade 3","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Endometrioid endometrial carcinoma, grade 3</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/ONC/108724_Endometrial_ca_grade_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Margaret M. Steinhoff, MD.</div><div id=\"graphicVersion\">Graphic 108724 Version 1.0</div></div></div>"},"108725":{"type":"graphic_picture","displayName":"Serous endometrial ca","title":"Serous endometrial carcinoma","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Serous endometrial carcinoma</div><div class=\"cntnt\"><img style=\"width:752px; height:563px;\" src=\"images/ONC/108725_Serous_endometrial_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Margaret M. Steinhoff, MD.</div><div id=\"graphicVersion\">Graphic 108725 Version 1.0</div></div></div>"},"108726":{"type":"graphic_picture","displayName":"Clear cell endometrial ca","title":"Clear cell endometrial carcinoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Clear cell endometrial carcinoma</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/ONC/108726_Clear_cell_endometrial_car.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Margaret M. Steinhoff, MD.</div><div id=\"graphicVersion\">Graphic 108726 Version 1.0</div></div></div>"},"108727":{"type":"graphic_picture","displayName":"Uterine carcinosarcoma","title":"Uterine carcinosarcoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Uterine carcinosarcoma</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/ONC/108727_Uterine_carcinosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Margaret M. Steinhoff, MD.</div><div id=\"graphicVersion\">Graphic 108727 Version 1.0</div></div></div>"},"108729":{"type":"graphic_table","displayName":"Risk factors for drug-resistant tuberculosis","title":"Risk factors for drug-resistant tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for drug-resistant tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patients with history of tuberculosis</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Persistent or progressive clinical and/or radiographic findings while on&nbsp;antituberculous therapy </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Lack of conversion of cultures to negative during first three months of antituberculous&nbsp;therapy </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Incomplete adherence to prescribed antituberculous therapy </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Lack of directly observed therapy or poorly supervised antituberculous therapy </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Documented treatment failure or relapse </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>History of an inappropriate treatment regimen, including too few effective drugs or inadequate drug dosing </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Patients without prior history of tuberculosis</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Exposure to an individual with known or suspected drug-resistant TB </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Residence in or travel to a region with high prevalence of drug-resistant tuberculosis </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Residence in or work in an institution or setting with documented drug-resistant tuberculosis </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Among foreign-born individuals: Emigration within the previous two years </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: tuberculosis.</div><div class=\"graphic_reference\">Data from: Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition.</div><div id=\"graphicVersion\">Graphic 108729 Version 1.0</div></div></div>"},"108730":{"type":"graphic_table","displayName":"Rx drug-resistant latent TB","title":"Suggested regimens for treatment of drug-resistant latent tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for treatment of drug-resistant latent tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pattern of drug resistance</td> <td class=\"subtitle1\">Suggested regimen</td> <td class=\"subtitle1\">Duration of treatment*</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF</td> <td>Fluoroquinolone (levofloxacin or moxifloxacin) with or without EMB</td> <td>6 to 12 months</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF, EMB</td> <td>Fluoroquinolone (levofloxacin or moxifloxacin) with or without ETA</td> <td>6 to 12 months</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF, PZA</td> <td>Fluoroquinolone (levofloxacin or moxifloxacin) with or without ENB</td> <td>6 to 12 months</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF, PZA, EMB +/&ndash; injectable</td> <td>Fluoroquinolone (levofloxacin or moxifloxacin) with or without ETA</td> <td>6 to 12 months</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF, PZA, EMB, injectable, ETA</td> <td>Fluoroquinolone (levofloxacin or moxifloxacin) with or without CS</td> <td>6 to 12 months</td> </tr> <tr> <td>INH, RIF, PZA, EMB, fluoroquinolone (levofloxacin or moxifloxacin)</td> <td>See note<sup>&#182;</sup></td> <td>6 to 12 months</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The term \"drug-resistant tuberculosis\" refers to tuberculosis caused by an isolate of <em>Mycobacterium tuberculosis</em> that is resistant to one of the first-line anti-tuberculosis drugs: isoniazid, rifampin, pyrazinamide, ethambutol, or streptomycin.</div><div class=\"graphic_footnotes\">INH: isoniazid; EMB: ethambutol; PZA: pyrazinamide; RIF: rifampin; ETA: ethionamide; CS: cycloserine; PAS: para-aminosalicyclic acid.<br />* Longer duration (12 months) of therapy is warranted for patients with immunosuppression, children &lt;5 years, and individuals with other substantial risk for progression to active TB disease; shorter duration (6 months) is appropriate for other individuals.<br />¶ When the resistance pattern limits options for treatment of latent tuberculosis to toxic combinations, clinical monitoring (symptom review every three to six months for two years with chest radiographs and/or sputum collection as clinically indicated) in the absence of treatment is reasonable. Prompt pursuit of treatment is warranted for patients with immunosuppression, children &lt;5 years, and individuals with other substantial risk for progression to active TB disease; in such cases, possible regimens include two of the following agents: CS, PAS, and ETA.</div><div id=\"graphicVersion\">Graphic 108730 Version 3.0</div></div></div>"},"108731":{"type":"graphic_table","displayName":"Rx poly-resistant tuberculosis","title":"Suggested regimens for treatment of poly-resistant tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for treatment of poly-resistant tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pattern of drug resistance</td> <td class=\"subtitle1\">Suggested regimen</td> <td class=\"subtitle1\">Minimum duration of treatment</td> </tr> <tr class=\"divider_bottom\"> <td>INH and EMB</td> <td>RIF, PZA, and fluoroquinolone</td> <td>6 to 9 months*</td> </tr> <tr class=\"divider_bottom\"> <td>INH and PZA</td> <td>RIF, EMB, and fluoroquinolone</td> <td>9 to 12 months*</td> </tr> <tr class=\"divider_bottom\"> <td>INH, EMB, PZA (+/&ndash; SM)</td> <td>RIF, fluoroquinolone, oral second-line agent, plus an injectable agent for first 2 to 3 months<sup>&#182;</sup></td> <td>9 to 12 months</td> </tr> <tr class=\"divider_bottom\"> <td>RIF and EMB (+/&ndash; SM)</td> <td>INH, PZA, fluoroquinolone, plus an injectable agent for first 2 to 3 months<sup>&#182;</sup></td> <td>12 to 18 months</td> </tr> <tr> <td>RIF and PZA (+/&ndash; SM)</td> <td>INH, EMB, fluoroquinolone, plus an injectable agent for first 2 to 3 months<sup>&#182;</sup></td> <td>18 months</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The term \"poly-resistant tuberculosis\" refers to&nbsp;tuberculosis caused by an isolate of <EM>Mycobacterium tuberculosis </EM>that is resistant to more than one antituberculous agent; the isolate may be resistant to either isoniazid or rifampin but not both.</div><div class=\"graphic_footnotes\">INH: isoniazid; EMB: ethambutol; PZA: pyrazinamide; SM: streptomycin; RIF: rifampin.<br />* A longer duration of therapy should be used for patients with extensive disease.<br />&para; A longer course of the injectable agent (6 months) may strengthen the regimen for patients with extensive disease.</div><div id=\"graphicVersion\">Graphic 108731 Version 3.0</div></div></div>"},"108732":{"type":"graphic_table","displayName":"Technique induced sputum collection","title":"Nebulized sputum induction for tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nebulized sputum induction for tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Purpose</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>To obtain sputum specimens for AFB smear microscopy and culture from a patient who has a dry, non-productive cough.</p> <strong>Ensure that the patient is placed in an appropriate negative air pressure room with the door shut. The air in the negative air pressure room should be drawn out of the room and vented outside of the building.</strong></td> </tr> <tr> <td class=\"subtitle1_single\">Materials and equipment required</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Sterile, filtered water or normal saline (150 to 250 mL)</li> <li> <p>Hand-held nebulizer with mouthpiece and 15 mL vial of 3% saline</p> <p class=\"indent1\"><strong>NOTE:</strong> A mask may be used if a patient absolutely cannot use the mouthpiece; 3% saline may be available from the pharmacy if not available in department stock.</p> </li> <li>N95 mask (particulate respirator) for AFB</li> <li>Gloves</li> <li>Box of tissues</li> <li>Sterile specimen container approved by the laboratory for sputum collection and transport</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Procedure</td> </tr> <tr> <td class=\"subtitle2_single\">Preparation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol> <li> <p>Assure that the patient is NPO for three hours prior to sputum induction.</p> <p class=\"indent1\"><strong>NOTE:</strong> Three hours NPO reduces the potential risk of vomiting and aspiration.</p> </li> <li> <p>Instruct the patient to gently brush his/her teeth, gingival margins, tongue, and buccal surfaces using sterile, filtered water or normal saline to rinse.</p> <p class=\"indent1\"><strong>Do not</strong> use toothpaste, commercial mouth wash preparations, nose drops, or any medications containing alcohol, or oil. Instruct the patient to avoid taking oral antibiotics immediately before the sputum collection procedure.</p> </li> <li> <p>Instruct the patient to gargle several times with sterile, filtered water or normal saline after brushing.</p> <p class=\"indent1\"><strong>Do not</strong> use tap water or bottled water, as it may contain nontuberculous mycobacteria that may alter findings.</p> </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Sputum collection</td> </tr> <tr> <td class=\"indent1\"> <ol> <li> <p>Observe standard precautions at all times.</p> <p class=\"indent1\"><strong>NOTE:</strong> N95 masks must worn by healthcare personnel for AFB cough-producing procedures.</p> </li> <li>The patient must be in an appropriate negative air pressure room.</li> <li> <p>Place approximately 5 mL of 3% saline into the hand-held nebulizer. Set the flow at 6 to 8 L/min and nebulize saline for 7 to 10 minutes or until sputum is expectorated. The maximum nebulization time is 20 minutes.</p> <p class=\"indent1\"><strong>NOTE:</strong> More saline may be added to the nebulizer if more than 10 minutes is needed to produce an adequate cough.</p> </li> <li> <p>Ask the patient to inhale the nebulized 3% saline deeply 2 to 3 times followed by a vigorous cough. This will assist in expectorating quality sputum. Collect the sputum into a sterile specimen container.</p> <p class=\"indent1\"><strong>NOTE:</strong> Coaching the patient is very important in order to get quality results in a timely manner.</p> <p class=\"indent1\"><strong>NOTE:</strong> High-quality sputum is required for smear, culture, and NAA testing. For AFB NAA testing alone, a minimum of 1 mL of raw sputum (or 0.5 mL of sputum sediment) is needed. It is preferred to collect 5 to 10 mL of raw sputum.</p> </li> <li>Label the specimen with time and date of its collection and place it in a specimen bag. Attach a laboratory request form, if applicable.</li> <li> <p>Document the procedure in the appropriate flow sheet or medical record.</p> <p class=\"indent1\"><strong>NOTE:</strong> Documentation also is required for unsuccessful procedures.</p> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AFB: acid-fast bacilli; NPO: nothing by mouth; NAA: nucleic acid amplification.</div><div class=\"graphic_reference\">Reproduced with permission from: National Tuberculosis Controllers Association. Consensus statement on the use of Cepheid Xpert MTB/RIF assay in making decisions to discontinue airborne infection isolation in healthcare settings, April 2016. Copyright &copy; 2016 National TB Controllers Association. Available at: <a href=\"http://www.tbcontrollers.org/docs/resources/NTCA_APHL_GeneXpert_Consensus_Statement_Final.pdf\" target=\"_blank\">http://www.tbcontrollers.org/docs/resources/NTCA_APHL_GeneXpert_Consensus_Statement_Final.pdf</a> (Accessed on June 21, 2016).</div><div id=\"graphicVersion\">Graphic 108732 Version 1.0</div></div></div>"},"108733":{"type":"graphic_table","displayName":"Technique expectorated sputum collection","title":"Spontaneously produced sputum collection for tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spontaneously produced sputum collection for tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Purpose</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>To obtain sputum specimens for AFB smear microscopy and culture from a patient who has a productive cough.</p> <strong>Ensure that the patient is outdoors or placed in an airborne isolation room or negative-pressure sputum collection booth with the door shut. The air in the negative-pressure room or booth should be drawn out of the space and vented outside of the building.</strong></td> </tr> <tr> <td class=\"subtitle1_single\">Materials and equipment required</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Sterile, filtered water or normal saline (150 to 250 mL) </li> <li>N95 mask (particulate respirator) for AFB </li> <li>Gloves </li> <li>Box of tissues </li> <li>Sterile specimen container approved by the laboratory for sputum collection and transport </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Procedure</td> </tr> <tr> <td class=\"subtitle2_single\">Preparation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol> <li> <p>Instruct the patient to gently brush his/her teeth, gingival margins, tongue, and buccal surfaces using sterile, filtered water or normal saline to rinse.</p> <p class=\"indent1\"><strong>Do not</strong> use toothpaste, commercial mouth wash preparations, nose drops, any medications containing alcohol, or oil. Instruct the patient to avoid taking oral antibiotics immediately before the sputum collection procedure.</p> </li> <li> <p>Instruct the patient to gargle several times with sterile, filtered water or normal saline after brushing.</p> <p class=\"indent1\"><strong>Do not</strong> use tap water or bottled water, as it may contain nontuberculous mycobacteria that may alter findings.</p> </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Sputum collection</td> </tr> <tr> <td class=\"indent1\"> <ol> <li> <p>Observe standard precautions at all times.</p> <p class=\"indent1\"><strong>NOTE:</strong> N95 masks must worn by healthcare personnel for AFB cough-producing procedures.</p> </li> <li>The patient must be outdoors or in an appropriate negative air pressure room or booth. </li> <li> <p>Coach the patient and supervise the first sputum collection, at a minimum, in order to obtain a good quality sputum sample that represents secretions from the lower respiratory tract.</p> <p class=\"indent1\"><strong>NOTE:</strong> The patient should understand that sputum is material that is brought up from the lungs and that <strong>nasal secretions and saliva or spit are not acceptable</strong>.</p> </li> <li>Instruct the patient to inhale deeply, as far as possible, and then exhale slowly three times. </li> <li>After the third breath, direct the patient to inhale completely and try to cough hard to produce sputum from deep in the lungs. The patient may feel a rattle or tickle as the sputum moves up from the lungs into the throat. </li> <li>Instruct the patient to expectorate the sputum into a sterile specimen container. </li> <li> <p>When there is at least 5 mL (1 teaspoon) of sputum, replace the lid on the container and tighten it so it does not leak.</p> <p class=\"indent1\"><strong>NOTE:</strong> High-quality sputum is required for smear, culture, and NAA testing. For AFB NAA testing alone, a minimum of 1 mL of raw sputum (or 0.5 mL of sputum sediment) is needed. It is preferred to collect 5 to 10 mL of raw sputum.</p> </li> <li>If the patient is in a negative air pressure room or booth, ask the patient remain in the booth or room until cleared to leave. </li> <li>Label the specimen with time and date of its collection and place it in a specimen bag. Attach a laboratory request form, if applicable. </li> <li> <p>Document the procedure in the appropriate flow sheet or medical record.</p> <p class=\"indent1\"><strong>NOTE:</strong> Documentation also is required for unsuccessful procedures.</p> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AFB: acid-fast bacilli; NAA: nucleic acid amplification. </div><div class=\"graphic_reference\">Reproduced with permission from: National Tuberculosis Controllers Association. Consensus statement on the use of Cepheid Xpert MTB/RIF assay in making decisions to discontinue airborne infection isolation in healthcare settings, April 2016. Copyright &copy; 2016 National TB Controllers Association. Available at: <a href=\"http://www.tbcontrollers.org/docs/resources/NTCA_APHL_GeneXpert_Consensus_Statement_Final.pdf\" target=\"_blank\">http://www.tbcontrollers.org/docs/resources/NTCA_APHL_GeneXpert_Consensus_Statement_Final.pdf</a> (Accessed on June 21, 2016).</div><div id=\"graphicVersion\">Graphic 108733 Version 1.0</div></div></div>"},"108735":{"type":"graphic_figure","displayName":"Hematogones in copper deficiency","title":"Hematogones in copper deficiency","html":"<div class=\"graphic\"><div style=\"width: 739px\" class=\"figure\"><div class=\"ttl\">Hematogones in copper deficiency</div><div class=\"cntnt\"><img style=\"width:719px; height:568px;\" src=\"images/HEME/108735_Hematogones_copper_defcncy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An increase in hematogones (lymphoid precursor cells) in the bone marrow aspirate smear is characteristic of copper deficiency and has been proposed to be helpful in distinguishing copper deficiency from myelodysplastic syndromes (MDS). The figure shows a bone marrow aspirate from a boy with leukopenia and macrocytic anemia. Copper deficiency was diagnosed and&nbsp;attributed to small bowel resection with enteral feedings that probably did not contain adequate copper supplementation. Dashed arrow: Hematogone. Arrow: Cytoplasmic vacuolization in a granulocytic precursor. Arrowhead: Cytoplasmic vacuolization in an erythroid precursor.</div><div class=\"graphic_reference\">From: Pirruccello E, Luu HS, Chen W. Haematogone hyperplasia in copper deficiency. Br J Haematol 2016; 173(3):335. <A href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.13964/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1111/bjh.13964/abstract</A>. Copyright © 2016. Reproduced with permission of Blackwell Publishing Ltd. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\">permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 108735 Version 3.0</div></div></div>"},"108737":{"type":"graphic_table","displayName":"Staging breast implant-related ALCL","title":"Staging breast implant-related anaplastic large cell lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging breast implant-related anaplastic large cell lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr class=\"divider_bottom highlight_gray_text\" style=\"font-size:1.2em;\"> <td class=\"highlight_gray_text\" rowspan=\"2\"><strong>Tumor extent (T)</strong></td> <td class=\"centered\"><strong>T1</strong></td> <td class=\"centered\"><strong>T2</strong></td> <td class=\"centered\"><strong>T3</strong></td> <td class=\"centered\"><strong>T4</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Confined to effusion or a layer on luminal side of capsule</td> <td>Early capsule infiltration</td> <td>Cell aggregates or sheets infiltrating the capsule</td> <td>Lymphoma infiltrates beyond the capsule</td> </tr> <tr class=\"divider_top divider_bottom highlight_gray_text\" style=\"font-size:1.2em;\"> <td rowspan=\"2\"><strong>Lymph nodes (N)</strong></td> <td class=\"centered\"><strong>N0</strong></td> <td class=\"centered\"><strong>N1</strong></td> <td class=\"centered\"><strong>N2</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"divider_bottom\"> <td>No lymph node involvement</td> <td>One regional lymph node (+)</td> <td>Multiple regional lymph nodes (+)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top divider_bottom highlight_gray_text\" style=\"font-size:1.2em;\"> <td rowspan=\"2\"><strong>Metastasis (M)</strong></td> <td class=\"centered\"><strong>M0</strong></td> <td class=\"centered\"><strong>M1</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"divider_bottom\"> <td>No distant spread</td> <td>Spread to other organs/distant sites</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Stages:</td> </tr> <tr> <td class=\"indent1\">IA</td> <td colspan=\"4\">T(1)N(0)M(0)</td> </tr> <tr> <td class=\"indent1\">IB</td> <td colspan=\"4\">T(2)N(0)M(0)</td> </tr> <tr> <td class=\"indent1\">IC</td> <td colspan=\"4\">T(3)N(0)M(0)</td> </tr> <tr> <td class=\"indent1\">IIA</td> <td colspan=\"4\">T(4)N(0)M(0)</td> </tr> <tr> <td class=\"indent1\">IIB</td> <td colspan=\"4\">T(1-3)N(1)M(0)</td> </tr> <tr> <td class=\"indent1\">III</td> <td colspan=\"4\">T(4)N(1-2)M(0)</td> </tr> <tr> <td class=\"indent1\">IV</td> <td colspan=\"4\">T(any)N(any)M(1)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large cell lymphoma. J Clin Oncol 2016; 34:160. Reprinted with permission. Copyright &copy; 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108737 Version 1.0</div></div></div>"},"108738":{"type":"graphic_table","displayName":"Infant antiretroviral prophylaxis dosing","title":"Infant antiretroviral prophylaxis dosing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infant antiretroviral prophylaxis dosing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infant age</td> <td class=\"subtitle1\">Dosing of nevirapine (NVP)</td> <td class=\"subtitle1\">Dosing of zidovudine (AZT)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Birth to 6 weeks</td> </tr> <tr> <td class=\"indent1\">Birth weight 2000 to 2499 grams*</td> <td>10 mg once daily<br /> (1 mL of syrup once daily)</td> <td>10 mg twice daily<br /> (1 mL of syrup twice daily)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Birth weight &#8805;2500 grams</td> <td>15 mg once daily<br /> (1.5 mL of syrup once daily)</td> <td>15 mg twice daily<br /> (1.5 mL of syrup twice daily)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">&#62;6 weeks to 12 weeks</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>20 mg once daily<br /> (2 mL of syrup once daily or half a 50 mg tablet once daily)</td> <td>60 mg twice daily<sup>&#182;</sup><br /> (6 mL of syrup twice daily or a 60 mg tablet twice daily)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For infants older than 35 weeks gestational age who weigh &lt;2000 grams, the suggested doses are: NVP 2 mg/kg per dose once daily and AZT 4 mg/kg per dose twice daily. Premature infants younger than 35 weeks of gestational age should be dosed using expert guidance.<br />¶&nbsp;The prophylaxis dose for zidovudine in these infants has not been established;&nbsp;the treatment dose is recommended.</div><div class=\"graphic_reference\">Reprinted from Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach - Second edition, World Health Organization, Annex 11, p. 388, Copyright &copy; 2011. Available from: <a href=\"http://www.who.int/hiv/pub/arv/arv-2016/en/\" target=\"_blank\">http://www.who.int/hiv/pub/arv/arv-2016/en/</a> (Accessed on June 21, 2016).</div><div id=\"graphicVersion\">Graphic 108738 Version 1.0</div></div></div>"},"108739":{"type":"graphic_figure","displayName":"Ras pathway","title":"Ras pathway","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Ras pathway</div><div class=\"cntnt\"><img style=\"width:541px; height:551px;\" src=\"images/HEME/108739_Ras_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram showing ligand-stimulated Ras activation, the Ras-Erk pathway, and the gene mutations found to date contributing to the neuro-cardio-facio-cutaneous congenital disorders and JMML. </div><div class=\"graphic_footnotes\">NL/MGCL: Noonan-like/multiple giant cell lesion; CFC: Cardia-facio-cutaneous; JMML: juvenile myelomonocytic leukemia.</div><div class=\"graphic_reference\">Modified from: Chan RJ, Cooper T, Kratz CP, et al. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res 2009; 33:355.</div><div id=\"graphicVersion\">Graphic 108739 Version 1.0</div></div></div>"},"108741":{"type":"graphic_picture","displayName":"Granular parakeratosis in the axilla","title":"Granular parakeratosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Granular parakeratosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108741_Granular_parakeratosis_axil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic plaque in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108741 Version 1.0</div></div></div>"},"108742":{"type":"graphic_picture","displayName":"Granular parakeratosis involving axilla","title":"Granular parakeratosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Granular parakeratosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108742_Granlr_parakeratosis_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic plaque in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108742 Version 1.0</div></div></div>"},"108744":{"type":"graphic_table","displayName":"USPSTF CRC screening summary","title":"USPSTF screening for colorectal cancer: Clinical summary","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">USPSTF screening for colorectal cancer: Clinical summary</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Population</strong></td> <td><strong>Adults aged 50 to 75 years</strong></td> <td><strong>Adults aged 76 to 85 years</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Recommendation</strong></td> <td> <p><strong>Screen for colorectal cancer starting at age 50 years.</strong></p> <strong>Grade: A</strong></td> <td> <p><strong>The decision to screen for colorectal cancer is an individual one.</strong></p> <strong>Grade: C</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1 highlight_gray_text divider_bottom\" colspan=\"3\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Risk assessment</strong></td> <td colspan=\"2\">For the vast majority of adults, the most important risk factor for colorectal cancer is older age. Other associated risk factors include family history of colorectal cancer, male sex, and black race.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Screening tests</strong></td> <td colspan=\"2\">There are numerous screening tests to detect early-stage colorectal cancer, including stool-based tests (gFOBT, FIT, and FIT-DNA), direct visualization tests (flexible sigmoidoscopy, alone or combined with FIT; colonoscopy; and CT colonography), and serology tests (<em>SEPT9</em> DNA test). The USPSTF found no head-to-head studies demonstrating that any of these screening strategies are more effective than others, although they have varying levels of evidence supporting their effectiveness, as well as different strengths and limitations.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Starting and stopping ages</strong></td> <td colspan=\"2\">The USPSTF concluded that the evidence best supports a starting age of 50 years for the general population. The age at which the balance of benefits and harms of colorectal cancer screening becomes less favorable varies based on a patient's life expectancy, health status, comorbid conditions, and prior screening status. The USPSTF does not recommend routine screening for colorectal cancer in adults 86 years and older.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Treatment and interventions</strong></td> <td colspan=\"2\">Treatment of early-stage colorectal cancer generally consists of local excision or simple polypectomy for tumors limited to the colonic mucosa or surgical resection (via laparoscopy or open approach) with anastomosis for larger, localized lesions.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Balance of benefits and harms</strong></td> <td>The USPSTF concludes with high certainty that the net benefit of screening for colorectal cancer is substantial.</td> <td>The USPSTF concludes with moderate certainty that the net benefit of screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened is small. Adults who have never been screened are more likely to benefit. Screening is most appropriate for those healthy enough to undergo treatment and those without comorbid conditions that significantly limit their life expectancy.</td> </tr> <tr> <td><strong>Other relevant USPSTF recommendations</strong></td> <td colspan=\"2\">The USPSTF has made a recommendation on aspirin use for the primary prevention of cardiovascular disease and colorectal cancer in average-risk adults. This recommendation is available on the USPSTF website (http://www.uspreventiveservicestaskforce.org).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org.</div><div class=\"graphic_footnotes\">gFOBT: guaiac-based fecal occult blood test; FIT: fecal immunochemical test; FIT-DNA: multitargeted stool DNA test; CT: computed tomography; USPSTF: United States Preventive Services Task Force.</div><div class=\"graphic_reference\">Reproduced with permission from: US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016; 315(23):2564-75. Copyright &copy; 2016 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108744 Version 3.0</div></div></div>"},"108745":{"type":"graphic_table","displayName":"Characteristics of colorectal cancer screening strategies","title":"Characteristics of colorectal cancer screening strategies*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of colorectal cancer screening strategies*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Screening method</td> <td class=\"subtitle1\">Frequency<sup>&#182;</sup></td> <td class=\"subtitle1\">Evidence of efficacy</td> <td class=\"subtitle1\">Other considerations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stool-based tests</td> </tr> <tr> <td class=\"indent1\">gFOBT</td> <td>Every year</td> <td>RCTs with mortality end points: <ul class=\"decimal_heading\"> <li>High-sensitivity versions (eg, Hemoccult SENSA) have superior test performance characteristics than older tests (eg, Hemoccult II) </li> </ul> </td> <td> <ul> <li>Does not require bowel preparation, anesthesia, or transportation to and from the screening examination (test is performed at home) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">FIT<sup>&#916;</sup></td> <td>Every year</td> <td>Test characteristic studies: <ul class=\"decimal_heading\"> <li>Improved accuracy compared with gFOBT </li> <li>Can be done with a single specimen </li> </ul> </td> <td> <ul> <li>Does not require bowel preparation, anesthesia, or transportation to and from the screening examination (test is performed at home) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">FIT-DNA</td> <td>Every one or three years<sup>&#9674;</sup></td> <td>Test characteristic studies: <ul class=\"decimal_heading\"> <li>Specificity is lower than for FIT, resulting in more false-positive results, more diagnostic colonoscopies, and more associated adverse events per screening test </li> <li>Improved sensitivity compared with FIT per single screening test </li> </ul> </td> <td> <ul> <li>There is insufficient evidence about appropriate longitudinal follow-up of abnormal findings after a negative diagnostic colonoscopy; may potentially lead to overly intensive surveillance due to provider and patient concerns over the genetic component of the test </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Direct visualization tests</td> </tr> <tr> <td class=\"indent1\">Colonoscopy<sup>&#916;</sup></td> <td>Every 10 years</td> <td>Prospective cohort study with mortality end point</td> <td> <ul> <li>Requires less frequent screening </li> <li>Screening and diagnostic follow-up of positive findings can be performed during the same examination </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CT colonography<sup>&#167;</sup></td> <td>Every five years</td> <td>Test characteristic studies</td> <td> <ul> <li>There is insufficient evidence about the potential harms of associated extracolonic findings, which are common </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Flexible sigmoidoscopy</td> <td>Every five years</td> <td>RCTs with mortality end points: <ul class=\"decimal_heading\"> <li>Modeling suggests it provides less benefit than when combined with FIT or compared with other strategies </li> </ul> </td> <td> <ul> <li>Test availability has declined in the United States </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Flexible sigmoidoscopy with FIT<sup>&#916;</sup></td> <td>Flexible sigmoidoscopy every 10 years plus FIT every year</td> <td>RCT with mortality end point (subgroup analysis)</td> <td> <ul> <li>Test availability has declined in the United States </li> <li>Potentially attractive option for patients who want endoscopic screening but want to limit exposure to colonoscopy </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FIT: fecal immunochemical test; FIT-DNA: multitargeted stool DNA test; gFOBT: guaiac-based fecal occult blood test; RCT: randomized clinical trial.<br />* Although a serology test to detect methylated <EM>SEPT9</EM> DNA was included in the systematic evidence review, this screening method currently has limited evidence evaluating its use (a single published test characteristic study met inclusion criteria, which found it had a sensitivity to detect colorectal cancer of &lt;50%).<SUP>[1]</SUP> It is therefore not included in this table.<br />¶ Applies to persons with negative findings (including hyperplastic polyps) and is not intended for persons in surveillance programs. Evidence of efficacy is not informative of screening frequency, with the exception of gFOBT and flexible sigmoidoscopy alone.<br />Δ Strategy yields comparable life-years gained (ie, the life-years gained with the noncolonoscopy strategies were within 90% of those gained with the colonoscopy strategy) and an efficient balance of benefits and harms in CISNET modeling.<SUP>[2]</SUP><br /><FONT class=lozenge>◊</FONT> Suggested by manufacturer.<br />§ Strategy yields comparable life-years gained (ie, the life-years gained with the noncolonoscopy strategies were within 90% of those gained with the colonoscopy strategy) and an efficient balance of benefits and harms in CISNET modeling when lifetime number of colonoscopies is used as the proxy measure for the burden of screening, but not if lifetime number of cathartic bowel preparations is used as the proxy measure.<SUP>[2]</SUP></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lin JS, Piper M, Perdue LA, et al. Screening for Colorectal Cancer: A Systematic Review for the US Preventive Services Task Force: Evidence Synthesis No. 135. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14-05203-EF-1.</li>&#xD;&#xA;    <li>Zauber A, Knudsen A, Rutter CM, Lansdorp-Vogelaar I, Kuntz KM. Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach. Rockville, MD: Agency for Healthcare Research and Quality; 2015. AHRQ publication 14-05203-EF-2.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016; 315(23):2564-75. Copyright &copy; 2016 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108745 Version 2.0</div></div></div>"},"108746":{"type":"graphic_picture","displayName":"Toddler with achondroplasia","title":"Toddler with achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toddler with achondroplasia</div><div class=\"cntnt\"><img style=\"width:415px; height:758px;\" src=\"images/ALLRG/108746_Toddler_achondroplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with achondroplasia soon after ambulation started. Notice lumbar lordosis and residual thoracic kyphosis. There is shortening visible in the arms and legs, more so in the proximal segments. The child also exhibits macrocephaly.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108746 Version 2.0</div></div></div>"},"108747":{"type":"graphic_picture","displayName":"Hand of an infant with achondroplasia","title":"Hand of an infant with achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Hand of an infant with achondroplasia</div><div class=\"cntnt\"><img style=\"width:684px; height:474px;\" src=\"images/ALLRG/108747_Hand_infant_achondroplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brachydactyly and short hand evident by a single transverse palmar crease.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108747 Version 1.0</div></div></div>"},"108748":{"type":"graphic_diagnosticimage","displayName":"Hand radiograph of a newborn with achondroplasia","title":"Hand radiograph of a newborn with achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand radiograph of a newborn with achondroplasia</div><div class=\"cntnt\"><img style=\"width:317px; height:315px;\" src=\"images/ALLRG/108748_Hnd_rdgrph_nwbrn_achondropl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hand AP film of newborn with achondroplasia. There is generalized shortening of metacarpals and all phalanges. The spaces between the second and fourth digits with the middle finger suggest the presence of the trident deformity.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108748 Version 1.0</div></div></div>"},"108749":{"type":"graphic_diagnosticimage","displayName":"Radiograph of thorax and pelvis in an infant with achondroplasia","title":"Radiograph of thorax and pelvis in an infant with achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of thorax and pelvis in an infant with achondroplasia</div><div class=\"cntnt\"><img style=\"width:374px; height:700px;\" src=\"images/ALLRG/108749_Rdgrph_thorx_plvs_achndrpls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP view of young three-month-old female with achondroplasia. The iliac wings are round, there is lack of caudal widening of the interpedicular distances, the femurs are short, and the proximal ends (metaphyses) have a scooped appearance.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108749 Version 1.0</div></div></div>"},"108750":{"type":"graphic_diagnosticimage","displayName":"Standing leg radiograph in a young child with achondroplasia","title":"Standing leg radiograph in a young child with achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standing leg radiograph in a young child with achondroplasia</div><div class=\"cntnt\"><img style=\"width:349px; height:482px;\" src=\"images/ALLRG/108750_Stndng_leg_rdgrph_achndrpls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP leg standing films on a three-year-old female with achondroplasia. Femus and tibiae are short.&nbsp;There is fibular overgrowth and&nbsp;marked bowing of the tibial-fibular region.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108750 Version 2.0</div></div></div>"},"108753":{"type":"graphic_diagnosticimage","displayName":"Radiograph of leg bowing surgical correction in achondroplasia","title":"Radiograph of surgical correction of leg bowing in a young child with achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of surgical correction of leg bowing in a young child with achondroplasia</div><div class=\"cntnt\"><img style=\"width:437px; height:631px;\" src=\"images/ALLRG/108753_Rdgrph_lg_bwng_srgcl_corrct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical correction of leg bowing in a child with achondroplasia.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108753 Version 1.0</div></div></div>"},"108754":{"type":"graphic_diagnosticimage","displayName":"Radiograph of pelvis in a young child with achondroplasia","title":"Radiograph of pelvis in a young child with achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 755px\" class=\"figure\"><div class=\"ttl\">Radiograph of pelvis in a young child with achondroplasia</div><div class=\"cntnt\"><img style=\"width:735px; height:606px;\" src=\"images/ALLRG/108754_Radiograph_pelvis_achondrpl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP pelvis view of a three-year-old female with achondroplasia. Abnormal proximal scooping of the femurs. Small round pelvis and small sacrosciatic notches.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Carlos A Bacino, MD, FACMG.</div><div id=\"graphicVersion\">Graphic 108754 Version 2.0</div></div></div>"},"108755":{"type":"graphic_table","displayName":"Remote CIED monitoring recommendations","title":"Remote monitoring recommendations for cardiac implantable electronic devices (CIEDs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Remote monitoring recommendations for cardiac implantable electronic devices (CIEDs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Device follow-up paradigm</td> <td class=\"subtitle1\">Class of recommendation</td> <td class=\"subtitle1\">Level of evidence</td> </tr> <tr class=\"divider_bottom\"> <td>A strategy of remote CIED monitoring and interrogation, combined with at least annual in-person examination, is recommended over a calendar-based schedule of in-person CIED evaluation alone (when technically feasible).</td> <td class=\"centered\">I</td> <td class=\"centered\">A</td> </tr> <tr class=\"divider_bottom\"> <td>All patients with CIEDs should be offered RM as part of the standard follow-up management strategy.</td> <td class=\"centered\">I</td> <td class=\"centered\">A</td> </tr> <tr class=\"divider_bottom\"> <td>Before implementing RM, it is recommended that each patient be educated about the nature of RM, their responsibilities and expectations, potential benefits, and limitations. The occurrence of this discussion should be documented in the medical record.</td> <td class=\"centered\">I</td> <td class=\"centered\">E</td> </tr> <tr class=\"divider_bottom\"> <td>It is recommended that all CIEDs be checked through direct patient contact 2 to 12 weeks postimplantation.</td> <td class=\"centered\">I</td> <td class=\"centered\">E</td> </tr> <tr class=\"divider_bottom\"> <td>It may be beneficial to initiate RM within the two weeks of CIED implantation.</td> <td class=\"centered\">IIa</td> <td class=\"centered\">C</td> </tr> <tr class=\"divider_bottom\"> <td>All patients with an implantable loop recorder with wireless data transfer capability should be enrolled in an RM program, given the daily availability of diagnostic data.</td> <td class=\"centered\">I</td> <td class=\"centered\">E</td> </tr> <tr class=\"divider_bottom\"> <td>It is recommended that allied health care professionals responsible for interpreting RM transmissions and who are involved in subsequent patient management decisions have the same qualifications as those performing in-clinic assessments and should ideally possess IBHRE certification for device follow-up or equivalent experience.</td> <td class=\"centered\">I</td> <td class=\"centered\">E</td> </tr> <tr> <td>It is recommended that RM programs develop and document appropriate policies and procedures to govern program operations, the roles and responsibilities of those involved in the program, and the expected timelines for providing service.</td> <td class=\"centered\">I</td> <td class=\"centered\">E</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CIED: cardiac implantable electronic device; HRS: Heart Rhythm Society; IBHRE: International Board of Heart Rhythm Examiners; RM: remote monitoring.</div><div class=\"graphic_reference\">Reproduced from: Slotwiner D, Varma N, Akar JG, et al. HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm 2015; 12:e69. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108755 Version 1.0</div></div></div>"},"108756":{"type":"graphic_algorithm","displayName":"Protocol for feeding advancement in SBS","title":"Protocol for advancing feeds during inpatient care of an infant with short bowel syndrome","html":"<div class=\"graphic\"><div style=\"width: 872px\" class=\"figure\"><div class=\"ttl\">Protocol for advancing feeds during inpatient care of an infant with short bowel syndrome</div><div class=\"cntnt\"><img style=\"width:852px; height:516px;\" src=\"images/PEDS/108756_Protocol_fdng_advncmnt_SBS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Contraindications to enteral feeding: Ileus, grossly bloody stools or ostomy output, or radiologic changes suggesting intestinal ischemia; shock/poor perfusion due to cardiac or respiratory insufficiency; bilious and/or persistent vomiting (&gt;3 episodes in 12 hours); clinical suspicion of obstruction or ileus (severe distension, decreased ostomy output and/or radiologic changes suggesting obstruction or ileus).<br />&para; Assess tolerance one to two times in each 24-hour period. Advance feeds no more than once in each 24-hour period.<br />&Delta; Depending on the patient and clinical setting, stool output can be monitored as number of stools each day, or stool weight (grams/day), or ostomy output (mL/kg/hour). Any one of these measures can be used for this algorithm.<br /><span class=\"lozenge\">&loz;</span> To hold feeds; the usual approach is to stop feeds for 8 hours, then restart at 75 percent of the previous rate.</div><div class=\"graphic_reference\">Adapted from: Brenn M, Gura K, Duggan C. Intestinal failure. In: Manual of Pediatric Nutrition, 5th ed, Sonneville K, Duggan C (Eds), People's Medical Publishing House, Shelton, CT 2013.</div><div id=\"graphicVersion\">Graphic 108756 Version 1.0</div></div></div>"},"108757":{"type":"graphic_picture","displayName":"Angioedema PI","title":"Angioedema of the face","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Angioedema of the face</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PI/108757_Angioedema_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows angioedema (swelling) of the face, including the eyelids.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108757 Version 2.0</div></div></div>"},"108758":{"type":"graphic_figure","displayName":"Distal forearm ultrasound technique","title":"Distal forearm ultrasound: Six-view technique","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Distal forearm ultrasound: Six-view&nbsp;technique</div><div class=\"cntnt\"><img style=\"width:537px; height:478px;\" src=\"images/EM/108758_Distal_forearm_ultrasound_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Place the arm to be examined&nbsp;on an arm table in a pronated position. Apply transducer gel to the distal forearm. With the ultrasound transducer in contact with the gel but not the underlying skin, examine the&nbsp;radius and ulna&nbsp;in 6 standardized planes using a linear probe, as shown. Ultrasound fracture findings include the presence of cortical gap, cortical bulging, cortical deviation, or a positive hematoma covering the cortex in all views.</div><div class=\"graphic_reference\">Modified from: Herren C, Sobottke R, Ringe MJ, et al. Ultrasound-guided diagnosis of fractures of the distal forearm in children. Orthop Traumatol Surg Res 2015; 101:501.</div><div id=\"graphicVersion\">Graphic 108758 Version 1.0</div></div></div>"},"108759":{"type":"graphic_diagnosticimage","displayName":"Ovarian cancer on ultrasound","title":"Sonographic appearance of ovarian cystadenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Sonographic appearance of ovarian cystadenocarcinoma</div><div class=\"cntnt\"><img style=\"width:607px; height:653px;\" src=\"images/OBGYN/108759_Ovarian_cancer_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Gray-scale.<br />(B) Color Doppler.</div><div class=\"graphic_reference\">Reproduced with permission from Maitray Patel, MD.</div><div id=\"graphicVersion\">Graphic 108759 Version 1.0</div></div></div>"},"108778":{"type":"graphic_algorithm","displayName":"Algorithm for the diagnosis and management of colonic ischemia","title":"Algorithm for the diagnosis and management of colonic ischemia","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis and management of colonic ischemia</div><div class=\"cntnt\"><img style=\"width:710px; height:766px;\" src=\"images/SURG/108778_Dx_mgmt_colonic_ischemia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SBP: systolic blood pressure; HR: heart rate; WBC: white blood cell count; Hgb: hemoglobin; BUN: blood urea nitrogen; LDH: lactate dehydrogenase; CT: computed tomography; IV: intravenous.<br />* Abdominal pain, cramping, urgent desire to defecate, lower gastrointestinal bleeding, diarrhea.<br />¶ Severe colonic ischemia includes any of the following: peritoneal signs on physical examination; pneumoperiteonum, pneumatosis, or portal venous gas on radiologic imaging; gangrene on colonoscopic examination; pancolonic ischemia or colon involvement isolated to the right side on imaging by colonoscopy or CT; or more than three of the risk factors commonly associated with a poorer outcome (refer to central box of algorithm).<br />Δ CT with IV (and oral contrast, if tolerated) is the initial imaging study. Multiphase CT angiography is indicated for patients with suspected vascular occlusion (eg, colonic involvement isolated to the right indicating possible superior mesenteric artery occlusion). Bowel findings include mural thickening, edema, and thumbprinting.<br /><FONT class=lozenge>◊</FONT> Examples include intestinal obstruction or inflammatory bowel disease.<br />§ Mild disease includes that with typical symptoms of colon ischemia but none of the risk factors commonly associated with a poorer outcome (refer to central box of algorithm).<br />¥ Moderate colonic ischemia includes that with typical symptoms and one to three risk factors commonly associated with a poorer outcome (refer to central box of algorithm).<br />‡ Colonoscopy should be performed in suspected cases to confirm the diagnosis. The colon should be insufflated minimally.&nbsp;For moderate-to-severe disease, limited sigmoidoscopy or colonoscopy is appropriate to confirm disease prior to exploration, stopping at the distal-most extent of the disease. Biopsies of the colonic mucosa should be obtained except in cases of gangrene.<br />† Conventional catheter-based arteriography may be indicated if vascular occlusion is demonstrated or strongly suspected, such as with colonic involvement isolated to the right side.<br />** The approach to revascularization, if indicated, may be endovascular or open depending upon the nature of the lesion.</div><div class=\"graphic_reference\">Adapted from: Brandt LJ, Feuerstadt P, Longstreth GF, et al. ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). Am J Gastroenterol 2015; 110:18.</div><div id=\"graphicVersion\">Graphic 108778 Version 1.0</div></div></div>"},"108779":{"type":"graphic_figure","displayName":"Timeline of published cases of BIA-ALCL","title":"Timeline of published cases of BIA-ALCL","html":"<div class=\"graphic\"><div style=\"width: 695px\" class=\"figure\"><div class=\"ttl\">Timeline of published cases of BIA-ALCL</div><div class=\"cntnt\"><img style=\"width:675px; height:449px;\" src=\"images/SURG/108779_Timeline_pub_cases_BI-ALCL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Timeline of published cases of BIA-ALCL.</div><div class=\"graphic_footnotes\">BIA-ALCL: breast implant-associated anaplastic large cell lymphoma.</div><div id=\"graphicVersion\">Graphic 108779 Version 2.0</div></div></div>"},"108781":{"type":"graphic_picture","displayName":"Wright-Giemsa staining from a malignant effusion of BIA-ALCL","title":"Wright-Giemsa staining from a malignant effusion of BIA-ALCL","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Wright-Giemsa staining from a malignant effusion of BIA-ALCL</div><div class=\"cntnt\"><img style=\"width:764px; height:512px;\" src=\"images/SURG/108781_WG_malig_effusion_BI-ALCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Wright-Giemsa staining from a malignant effusion demonstrating pleomorphic cells with horseshoe-shaped nuclei, nuclear folding, and abundant vacuolated cytoplasm consistent with BIA-ALCL (1000x magnification).<br />(B) Tissue section demonstrates sheets of large cells positive for CD30 staining on immunohistochemistry (440x magnification).<br /><br /></div><div class=\"graphic_footnotes\">BIA-ALCL: breast implant-associated anaplastic large cell lymphoma.</div><div class=\"graphic_reference\">Original figure modified for this publication. Clemens MW, Miranda RN. Coming of Age, Breast Implant–Associated Anaplastic Large Cell Lymphoma After 18 Years of Investigation. Clin Plast Surg 2015; 42:605. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108781 Version 2.0</div></div></div>"},"108782":{"type":"graphic_picture","displayName":"Lymphoma cells on textured silicone implant","title":"Lymphoma cells on textured silicone implant","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Lymphoma cells on textured silicone implant</div><div class=\"cntnt\"><img style=\"width:756px; height:472px;\" src=\"images/SURG/108782_Lymphoma_txtrd_silicone_imp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning electron micrograph at 300x magnification demonstrating aggregates of lymphoma cells clustered on the surface of a textured silicone implant.</div><div id=\"graphicVersion\">Graphic 108782 Version 2.0</div></div></div>"},"108783":{"type":"graphic_figure","displayName":"Survival curves according to Ann Arbor stage","title":"Survival curves according to Ann Arbor stage","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Survival curves according to Ann Arbor stage</div><div class=\"cntnt\"><img style=\"width:749px; height:372px;\" src=\"images/SURG/108783_Ann_Arbor_survival_curves.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival curves according to Ann Arbor stage.<br />(A) Event-free survival.<br />(B) Overall survival.</div><div class=\"graphic_reference\">From: Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for patients with breast implant-associated anaplastic large cell lymphoma. J Clin Oncol 2016; 34:160. Reprinted with permission. Copyright © 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108783 Version 1.0</div></div></div>"},"108784":{"type":"graphic_figure","displayName":"BIA-ALCL survival curves according to treatment approaches","title":"BIA-ALCL survival curves according to treatment approaches","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">BIA-ALCL survival curves according to treatment approaches</div><div class=\"cntnt\"><img style=\"width:749px; height:372px;\" src=\"images/SURG/108784_BI-ALCL_srvvl_crvs_trtmnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival curves according to treatment approaches.<br />(A) Event-free survival.<br />(B) Overall survival.</div><div class=\"graphic_footnotes\">BIA-ALCL: breast implant-associated anaplastic large cell lymphoma.</div><div class=\"graphic_reference\">From: Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for patients with breast implant-associated anaplastic large cell lymphoma. J Clin Oncol 2016; 34:160. Reprinted with permission. Copyright © 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108784 Version 2.0</div></div></div>"},"108785":{"type":"graphic_figure","displayName":"Survival curves according to BIA-ALCL TNM staging","title":"Survival curves according to BIA-ALCL TNM staging","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Survival curves according to BIA-ALCL TNM staging</div><div class=\"cntnt\"><img style=\"width:749px; height:372px;\" src=\"images/SURG/108785_BI-ALCL_TNM_stgg_srvvl_crvs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival curves according to BIA-ALCL TNM Staging.<br />(A) Event-free survival.<br />(B) Overall survival.</div><div class=\"graphic_footnotes\">BIA-ALCL: breast implant-associated anaplastic large cell lymphoma; TNM: Tumor, Node, Metastasis.</div><div class=\"graphic_reference\">From: Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for patients with breast implant-associated anaplastic large cell lymphoma. J Clin Oncol 2016; 34:160. Reprinted with permission. Copyright © 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108785 Version 2.0</div></div></div>"},"108788":{"type":"graphic_algorithm","displayName":"First-line systemic chemo for metastatic panc adenocarcinoma","title":"First-line systemic chemotherapy for metastatic pancreatic adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">First-line systemic chemotherapy for metastatic pancreatic adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:788px; height:417px;\" src=\"images/ONC/108788_Syst_chmo_pancr_adncarcm_E1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>ECOG PS:</strong>&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>0: Fully active, no performance restrictions.</li>&#xD;&#xA;    <li>1: Strenuous physical activity restricted; fully ambulatory and able to carry out light work.</li>&#xD;&#xA;    <li>2: Capable of self-care but unable to carry out any work activities. Up and about &gt;50% of waking hours.</li>&#xD;&#xA;    <li>3: Capable of only limited self-care; confined to bed or chair &gt;50% of waking hours.</li>&#xD;&#xA;    <li>4: Completely disabled; cannot carry out any self-care; totally confined to bed to chair.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">ECOG PS: Eastern Cooperative Oncology Group performance status; ULN: upper limit of normal; FOLFIRINOX: leucovorin plus short-term infusional fluorouracil plus oxaliplatin and irinotecan; FOLFOX: leucovorin plus short term fluorouracil and oxaliplatin.<br />* In addition to ECOG PS, comorbidity, and serum bilirubin, goals of care, patient preference, symptom burden, and psychosocial issues (including the patient's support system) should guide treatment decisions.<br />&para; Adequate comorbidity: Adequate hepatic and renal function, and hematologic status; able to tolerate potentially myelosuppressive antineoplastic chemotherapy.<br />&Delta; For patients whose tumors harbor a known <em>BRCA</em> mutation, a platinum-based chemotherapy regimen is preferred.<br /><span class=\"lozenge\">&loz;</span> Highly selected patients with an ECOG PS 2 because of heavy tumor burden could be considered for gemcitabine plus nabpaclitaxel because of the higher likelihood of an objective antitumor response.</div><div id=\"graphicVersion\">Graphic 108788 Version 4.0</div></div></div>"},"108793":{"type":"graphic_table","displayName":"Estimated caloric needs of nonpregnant women","title":"Estimated caloric needs of reproductive-aged women (nonpregnant, nonlactating)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated caloric needs of reproductive-aged women (nonpregnant, nonlactating)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age<br /> (years)</td> <td class=\"subtitle1\">Sedentary*<br /> (kcal/day)</td> <td class=\"subtitle1\">Moderately active<sup>&#182;</sup><br /> (kcal/day)</td> <td class=\"subtitle1\">Active<sup>&#916;</sup><br /> (kcal/day)</td> </tr> <tr class=\"centered\"> <td>15 to 18</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr class=\"centered\"> <td>19 to 25</td> <td>2000</td> <td>2200</td> <td>2400</td> </tr> <tr class=\"centered\"> <td>26 to 30</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr class=\"centered\"> <td>31 to 50</td> <td>1800</td> <td>2000</td> <td>2200</td> </tr> <tr class=\"centered\"> <td>51 to 55</td> <td>1600</td> <td>1800</td> <td>2200</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These estimates are based on the Estimated Energy Requirements (EER) equations, using reference heights (average) and reference weights (healthy) for each age group. These estimates apply to women who are not pregnant or breastfeeding.</div><div class=\"graphic_footnotes\">kcal: kilocalories.<br />* Sedentary means a lifestyle that includes only the physical activity of independent living.<br />&para; Moderately active means a lifestyle that includes physical activity equivalent to walking about 1.5 to 3 miles per day at three to four miles per hour, in addition to the activities of independent living.<br />&Delta; Active means a lifestyle that includes physical activity equivalent to walking more than three miles per day at three to four miles per hour, in addition to the activities of independent living.</div><div class=\"graphic_reference\">Data from: U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015&ndash;2020 Dietary Guidelines for Americans, 8th Edition, December 2015. Available at: <a href=\"http://health.gov/dietaryguidelines/2015/guidelines/\" target=\"_blank\">http://health.gov/dietaryguidelines/2015/guidelines/</a> (Accessed on June 28, 2016).</div><div id=\"graphicVersion\">Graphic 108793 Version 2.0</div></div></div>"},"108795":{"type":"graphic_table","displayName":"Objectives and strategies for anesthesia for head & neck surgery","title":"Objectives and strategies for anesthesia for head and neck surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Objectives and strategies for anesthesia for head and neck surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Expert airway management</td> </tr> <tr> <td class=\"indent1\">Shared airway precautions</td> </tr> <tr> <td class=\"indent1\">Surgery-specific airway management requirements</td> </tr> <tr> <td class=\"indent1\">Versatility with difficult airway devices and techniques</td> </tr> <tr> <td class=\"indent1\">Proficiency with different ventilation techniques and strategies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Team-centered approach</td> </tr> <tr> <td class=\"subtitle1_single\">Provision of a stable plane of anesthesia and a clear surgical field</td> </tr> <tr> <td class=\"indent1\">Opioid-based techniques</td> </tr> <tr> <td class=\"indent1\">TIVA</td> </tr> <tr> <td class=\"indent1\">Moderate controlled hypotension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypnotic monitoring</td> </tr> <tr> <td class=\"subtitle1_single\">Immobility of the surgical field</td> </tr> <tr> <td class=\"indent1\">Absence of patient movement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Avoidance of iatrogenic motion interference</td> </tr> <tr> <td class=\"subtitle1_single\">Smooth and rapid emergence from anesthesia</td> </tr> <tr> <td class=\"indent1\">Remifentanil emergence</td> </tr> <tr> <td class=\"indent1\">Bailey maneuver</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">SGA as the primary ventilatory device</td> </tr> <tr> <td class=\"subtitle1_single\">Fast-tracking patients for discharge</td> </tr> <tr> <td class=\"indent1\">Stratified opioid use</td> </tr> <tr> <td class=\"indent1\">Multimodal analgesia</td> </tr> <tr> <td class=\"indent1\">Adjuvant techniques</td> </tr> <tr> <td class=\"indent1\">Prophylaxis of PONV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TIVA: total intravenous anesthesia; SGA: supraglottic airway device; PONV: postoperative nausea and vomiting.</div><div class=\"graphic_reference\">Courtesy of Dr. Vladimir Nekhendzy.</div><div id=\"graphicVersion\">Graphic 108795 Version 2.0</div></div></div>"},"108796":{"type":"graphic_table","displayName":"AMSTERDAM classification of sternal reconstruction","title":"AMSTERDAM classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AMSTERDAM classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Sternal stability</td> <td class=\"subtitle1\">Bone viability and stock</td> <td class=\"subtitle1\">Reconstruction</td> <td class=\"subtitle1\">Staging of reconstruction</td> </tr> <tr> <td>1</td> <td>Stable</td> <td>Reasonable</td> <td>TNP*</td> <td>(class I, level B)</td> </tr> <tr> <td>2a</td> <td>Stable</td> <td>Reasonable</td> <td>Local muscle flap<sup>&#182;</sup></td> <td>Primary <br /> (class II, level B) </td> </tr> <tr> <td>2b</td> <td>Stable</td> <td>Reasonable</td> <td>Muscle<sup>&#916;</sup> <strong>or</strong> omentum flap</td> <td>Delayed<br /> (class I, level B)</td> </tr> <tr> <td>3a</td> <td>Unstable</td> <td>Viable and sufficient</td> <td>Rewiring/osteosynthesis</td> <td>Primary<sup>&#9674;</sup>Delayed<sup>&#167;</sup><br /> (class IIb, level B)</td> </tr> <tr> <td>3b</td> <td>Unstable</td> <td>Viable and sufficient</td> <td>Rewiring/osteosynthesis <strong>and</strong> muscle<sup>&#916;</sup> <strong>or</strong> omentum flap</td> <td> <p>Primary<sup>&#9674;</sup></p> <p><sup></sup>Delayed<sup>&#167;</sup><br /> (class IIb, level B)</p> </td> </tr> <tr> <td>4a</td> <td>Unstable</td> <td>Necrotic and insufficient</td> <td>Muscle flap</td> <td>Primary/delayed</td> </tr> <tr> <td>4b</td> <td>Unstable</td> <td>Necrotic and insufficient</td> <td>Omentum flap</td> <td>(class IIb, level B)</td> </tr> <tr> <td>4c</td> <td>Unstable</td> <td>Necrotic and insufficient</td> <td>Muscle <strong>and</strong> omentum flap</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AMSTERDAM: Assiduous Mediastinal Sternal Debridement&nbsp;and Aimed Management; TNP: topical negative pressure.<br />*Important: When definite reconstruction is \"delayed\", time interval and temporizing procedure (eg, TNP) should be specified.<br />​¶ Always, unilateral or bilateral pectoralis muscle advancement.<br />Δ Frequently, unilateral or bilateral pectoralis muscle advancement.<br />◊ Rewiring.<br />§ Osteosynthesis (plates, clips, etc).</div><div class=\"graphic_reference\">From: van Wingerden JJ, Ubbink DT, van der Horst CM, de Mol BA. Poststernotomy mediastinitis: a classification to initiate and evaluate reconstructive management based on evidence from a structured review. J Cardiothorac Surg 2014; 9:179. Copyright &copy; 2014 van Wingerden et al. Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 108796 Version 1.0</div></div></div>"},"108797":{"type":"graphic_table","displayName":"Airway management considerations for head and neck surgery","title":"Airway management considerations for head and neck surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Airway management considerations for head and neck surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <ul> <li><strong>Expert airway management</strong> <ul> <li>Shared airway precautions and coordination with surgeon</li> <li>Surgery-specific airway management requirements</li> <li>Versatility with difficult airway devices and techniques</li> <li>Versatility with different ventilatory techniques and strategies</li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li><strong>Team-centered approach</strong></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li><strong>Airway management during induction of anesthesia</strong> <ul> <li>Increased risks of: <ul> <li>Difficult airway management</li> <li>Airway management failure</li> <li>Need for emergency airway management</li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Airway management during extubation</strong> <ul> <li>Extubation strategies &ndash; Increased risks of: <ul> <li>Laryngospasm</li> <li>Postextubation airway edema</li> <li>Postoperative airway obstruction</li> <li>Reintubation</li> </ul> </li> <li>Requirement for smooth extubation</li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dr. Vladimir Nekhendzy.</div><div id=\"graphicVersion\">Graphic 108797 Version 2.0</div></div></div>"},"108798":{"type":"graphic_table","displayName":"Predictors of difficult videolaryngoscopy","title":"Predictors of difficult videolaryngoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of difficult videolaryngoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Otolaryngologic and cardiac surgery </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sniffing head positioning </li> </ul> </td> </tr> <tr> <td> <ul> <li>Abnormal neck anatomy (a neck scar, a neck mass, neck radiation changes) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Decreased cervical spine motion </li> </ul> </td> </tr> <tr> <td> <ul> <li>Decreased oral entry (obesity, decreased mouth opening, decreased jaw mobility) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Restricted oropharyngeal space (edema, bleeding, retrognathia) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Aziz MF, Bayman EO, Van Tienderen MM, et al. Predictors of difficult videolaryngoscopy with GlideScope&reg; or C-MAC&reg; with D-blade: secondary analysis from a large comparative videolaryngoscopy trial. Br J Anaesth 2016; 117:118.</li>&#xD;&#xA;    <li>Stroumpoulis K, Pagoulatou A, Violari M, et al. Videolaryngoscopy in the management of the difficult airway: a comparison with the Macintosh blade. Eur J Anaesthesiol 2009; 26:218.</li>&#xD;&#xA;    <li>Asai T, Liu EH, Matsumoto S, et al. Use of the Pentax-AWS in 293 patients with difficult airways. Anesthesiology 2009; 110:898.</li>&#xD;&#xA;    <li>Aziz MF, Healy D, Kheterpal S, et al. Routine clinical practice effectiveness of the Glidescope in difficult airway management: an analysis of 2,004 Glidescope intubations, complications, and failures from two institutions. Anesthesiology 2011; 114:34.</li>&#xD;&#xA;    <li>Lai HY, Chen IH, Chen A, et al. The use of the GlideScope for tracheal intubation in patients with ankylosing spondylitis. Br J Anaesth 2006; 97:419.</li>&#xD;&#xA;    <li>Tremblay MH, Williams S, Robitaille A, Drolet P. Poor visualization during direct laryngoscopy and high upper lip bite test score are predictors of difficult intubation with the GlideScope videolaryngoscope. Anesth Analg 2008; 106:1495. </li>&#xD;&#xA;    <li>Savoldelli GL, Schiffer E, Abegg C, et al. Comparison of the Glidescope, the McGrath, the Airtraq and the Macintosh laryngoscopes in simulated difficult airways. Anaesthesia 2008; 63:1358.</li>&#xD;&#xA;    <li>Narang AT, Oldeg PF, Medzon R, et al. Comparison of intubation success of video laryngoscopy versus direct laryngoscopy in the difficult airway using high-fidelity simulation. Simul Healthc 2009; 4:160.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Dr. Vladimir Nekhendzy.</div><div id=\"graphicVersion\">Graphic 108798 Version 4.0</div></div></div>"},"108799":{"type":"graphic_table","displayName":"The advantages of opioid-based anesthesia for H&N surgery","title":"The advantages of opioid-based anesthesia for head and neck surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The advantages of opioid-based anesthesia for head and neck surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Powerful intraoperative analgesia </li> </ul> </td> </tr> <tr> <td> <ul> <li>Excellent postoperative pain control </li> </ul> </td> </tr> <tr> <td> <ul> <li>Superior maintenance of controlled hypotension </li> </ul> </td> </tr> <tr> <td> <ul> <li>Decreased general anesthetic requirements </li> </ul> </td> </tr> <tr> <td> <ul> <li>Promotion of patient immobility </li> </ul> </td> </tr> <tr> <td> <ul> <li>Improved hypnotic monitoring </li> </ul> </td> </tr> <tr> <td> <ul> <li>Improved intraoperative neurophysiologic monitoring </li> </ul> </td> </tr> <tr> <td> <ul> <li>Potent suppression of upper airway reflexes </li> </ul> </td> </tr> <tr> <td> <ul> <li>Promotion of smooth and rapid emergence from anesthesia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dr. Vladimir Nekhendzy.</div><div id=\"graphicVersion\">Graphic 108799 Version 2.0</div></div></div>"},"108801":{"type":"graphic_table","displayName":"Stratification and doses of opioids for head and neck procedures","title":"Stratification and doses of opioids for head and neck procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stratification and doses of opioids for head and neck procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Stratification of opioid infusions for head and neck surgery</td> </tr> <tr> <td class=\"subtitle2_left\">Degree of postoperative pain</td> <td class=\"subtitle2_left\" colspan=\"2\">Opioid regimen</td> </tr> <tr> <td class=\"indent1\">None to mild</td> <td colspan=\"2\">Remifentanil infusion +/&ndash; fentanyl 1 mcg/kg total dose</td> </tr> <tr> <td class=\"indent1\">Mild to moderate</td> <td colspan=\"2\"> <p>Remifentanil infusion + fentanyl 1 to 3 mcg/kg total dose</p> <p class=\"indent1\">OR</p> Alfentanil infusion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Moderate to severe</td> <td colspan=\"2\"> <p>Sufentanil infusion +/&ndash; remifentanil infusion*</p> <p class=\"indent1\">OR</p> Fentanyl infusion +/&ndash; remifentanil infusion*</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"3\">Opioid doses for head and neck surgery<sup>&#182;</sup><sup>[1-23]</sup></td> </tr> <tr> <td class=\"subtitle2_left\">Opioid</td> <td class=\"subtitle2_left\">IV load</td> <td class=\"subtitle2_left\">IV infusion</td> </tr> <tr> <td class=\"indent1\">Fentanyl</td> <td>3 to 7 mcg/kg<sup>&#916;</sup></td> <td>0.7 to 2.5 mcg/kg/hour<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Sufentanil</td> <td>0.25 to 1.5 mcg/kg<sup>&#916;</sup><br /> TCI: 0.4 to 0.5 ng/mL</td> <td>0.2 to 0.3 mcg/kg/hour<br /> TCI: 0.2 to 0.65 ng/mL</td> </tr> <tr> <td class=\"indent1\">Alfentanil</td> <td>20 to 40 mcg/kg<br /> TCI: 100 to 200 ng/mL</td> <td>0.25 to 1.5 mcg/kg/minute<br /> TCI: 60 to 150 ng/mL</td> </tr> <tr> <td class=\"indent1\">Remifentanil</td> <td>0.5 to 2 mcg/kg<br /> TCI: 4 ng/mL</td> <td>0.05 to 0.3 mcg/kg/minute<br /> TCI: 1.5 to 9 ng/mL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">TCI with opioids and propofol allows for easier and more rapid titration of drugs to patient responses and facilitates intraoperative hemodynamic control, as well as rapid recovery from anesthesia.</div><div class=\"graphic_footnotes\">IV: intravenous; TCI: target-controlled infusion; TIVA: total IV anesthesia; N<sub>2</sub>O: nitrous oxide.<br />* May be additionally required during highly stimulating parts of the surgical procedure.<br />&para; Assumes: IV induction with propofol 1 to 2 mg/kg, maintenance of TIVA with propofol 80 to 180 mcg/kg/minute (TCI 3 to 5 mcg/mL), and no N<sub>2</sub>O administration.<br />&Delta; We titrate the loading dose of fentanyl or sufentanil using the clinical endpoints during induction, such as either a decrease of respiratory rate or onset of sedation.<br /><span class=\"lozenge\">&loz;</span> Fentanyl infusion should be used with caution and adjusted accordingly due to its long, context-sensitive half-life.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Erhan E, Ugur G, Gunusen I, et al. Propofol - not thiopental or etomidate - with remifentanil provides adequate intubating conditions in the absence of neuromuscular blockade. Can J Anaesth 2003; 50:108.</li>&#xD;&#xA;    <li>Jellish WS, Leonetti JP, Avramov A, et al. Remifentanil-based anesthesia versus a propofol technique for otologic surgical procedures. Otolaryngol Head Neck Surg 2000; 122:222.</li>&#xD;&#xA;    <li>Eberhart LH, Eberspaecher M, Wulf H, et al. Fast-track eligibility, costs and quality of recovery after intravenous anaesthesia with propofol-remifentanil versus balanced anaesthesia with isoflurane-alfentanil. Eur J Anaesthesiol 2004; 21:107.</li>&#xD;&#xA;    <li>Philip BK, Kallar SK, Bogetz MS, et al. A multicenter comparison of maintenance and recovery with sevoflurane or isoflurane for adult ambulatory anesthesia. The Sevoflurane Multicenter Ambulatory Group. Anesth Analg 1996; 83:314.</li>&#xD;&#xA;    <li>Wuesten R, Van Aken H, Glass PS, et al. Assessment of depth of anesthesia and postoperative respiratory recovery after remifentanil- versus alfentanil-based total intravenous anesthesia in patients undergoing ear-nose-throat surgery. Anesthesiology 2001; 94:211.</li>&#xD;&#xA;    <li>Montes FR, Trillos JE, Rinc&oacute;n IE, et al. Comparison of total intravenous anesthesia and sevoflurane-fentanyl anesthesia for outpatient otorhinolaryngeal surgery. J Clin Anesth 2002; 14:324.</li>&#xD;&#xA;    <li>Jellish WS, Leonetti JP, Buoy CM, et al. Facial nerve electromyographic monitoring to predict movement in patients titrated to a standard anesthetic depth. Anesth Analg 2009; 109:551.</li>&#xD;&#xA;    <li>Vuyk J. Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. Acta Anaesth Belg 2001; 52:445.</li>&#xD;&#xA;    <li>Stanski DR, Shafer SL. Quantifying anesthetic drug interaction. Implications for drug dosing. Anesthesiology 1995; 83:1.</li>&#xD;&#xA;    <li>Twersky RS, Jamerson B, Warner DS, et al. Hemodynamics and emergence profile of remifentanil versus fentanyl prospectively compared in a large population of surgical patients. J Clin Anesth 2001; 13:407.</li>&#xD;&#xA;    <li>Miller DR, Martineau RJ, O'Brien H, et al. Effects of alfentanil on the hemodynamic and catecholamine response to tracheal intubation. Anesth Analg 1993; 76:1040.</li>&#xD;&#xA;    <li>Thompson JP, Hall AP, Russell J, et al. Effect of remifentanil on the haemodynamic response to orotracheal intubation. Br J Anaesth 1998; 80:467.</li>&#xD;&#xA;    <li>McAtamney D, O'Hare R, Hughes D, et al. Evaluation of remifentanil for control of haemodynamic response to tracheal intubation. Anaesthesia 1998; 53:1223.</li>&#xD;&#xA;    <li>Jeon YT, Oh AY, Park SH, et al. Optimal remifentanil dose for lightwand intubation without muscle relaxants in healthy patients with thiopental coadministration: a prospective randomised study. Eur J Anaesthesiol 2012; 29:520.</li>&#xD;&#xA;    <li>Demirkaya M, Kelsaka E, Sarihasan B, et al. The optimal dose of remifentanil for acceptable intubating conditions during propofol induction without neuromuscular blockade. J Clin Anesth 2012; 24:392.</li>&#xD;&#xA;    <li>Stefanutto TB, Feiner J, Krombach J, et al. Hemoglobin desaturation after propofol/remifentanil-induced apnea: a study of the recovery of spontaneous ventilation in healthy volunteers. Anesth Analg 2012; 114:980.</li>&#xD;&#xA;    <li>Gulhas N, Topal S, Erdogan Kayhan G, et al. Remifentanil without muscle relaxants for intubation in microlaryngoscopy: a double blind randomised clinical trial. Eur Rev Med Pharmacol Sci 2013; 17:1967.</li>&#xD;&#xA;    <li>Mencke T, Jacobs RM, Machmueller S, et al. Intubating conditions and side effects of propofol, remifentanil and sevoflurane compared with propofol, remifentanil and rocuronium: a randomised, prospective, clinical trial. BMC Anesthesiol 2014; 14:39.</li>&#xD;&#xA;    <li>Derrode N, Lebrun F, Levron JC, et al. Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. Br J Anaesth 2003; 9:842.</li>&#xD;&#xA;    <li>De Baerdemaeker LE, Jacobs S, Pattyn P, et al. Influence of intraoperative opioid on postoperative pain and pulmonary function after laparoscopic gastric banding: remifentanil TCI vs sufentanil TCI in morbid obesity. Br J Anaesth 2007; 99:404.</li>&#xD;&#xA;    <li>Bidgoli J, Delesalle S, De Hert SG, et al. A randomised trial comparing sufentanil versus remifentanil for laparoscopic gastroplasty in the morbidly obese patient. Eur J Anaesthesiol 2011; 28:120.</li>&#xD;&#xA;    <li>Vuyk J. TCI: supplementation and drug interactions. Anaesthesia 1998; 53 Suppl 1:35.</li>&#xD;&#xA;    <li>P&eacute;rus O, Marsot A, Ramain E, et al. Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. Br J Anaesth 2012; 109:551.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Dr. Vladimir Nekhendzy.</div><div id=\"graphicVersion\">Graphic 108801 Version 4.0</div></div></div>"},"108802":{"type":"graphic_table","displayName":"Centers for disease control definitions for mediastinitis","title":"Centers for disease control definitions for mediastinitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Centers for disease control definitions for mediastinitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Mediastinitis must meet at least one of the following criteria:</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Patient has organisms identified from mediastinal tissue or fluid by a culture or nonculture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (eg, not active surveillance culture/testing). </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"2\"> <li>Patient has evidence of mediastinitis on gross anatomic or histopathologic exam. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li>Patient has at least one of the following signs or symptoms: <ul> <li>Fever (&#62;38.0&#176;C), </li> <li>Chest pain*, or </li> <li>Sternal instability* </li> </ul> <strong>And at least one of the following:</strong> <ol style=\"list-style-type: lower-alpha;\"> <li>Purulent drainage from mediastinal area </li> <li>Mediastinal widening on imaging test </li> </ol> </li> </ol> </td> </tr> <tr> <td> <ol start=\"4\"> <li>Patient &#8804;1 year of age has at least one of the following signs or symptoms: <ul> <li>Fever (&#62;38.0&#176;C), </li> <li>Hypothermia (&#60;36.0&#176;C), </li> <li>Apnea*, </li> <li>Bradycardia*, or </li> <li>Sternal instability* </li> </ul> <strong>And at least one of the following:</strong> <ol style=\"list-style-type: lower-alpha;\"> <li>Purulent drainage from mediastinal area </li> <li>Mediastinal widening on imaging test </li> </ol> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Reporting instruction: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Mediastinal space is the area under the sternum and in front of the vertebral column, containing the heart and its large vessels, trachea, esophagus, thymus, lymph nodes, and other structures and tissues. It is divided into anterior, middle, posterior, and superior regions.</LI>&#xD;&#xA;<LI>Report mediastinitis (MED) following cardiac surgery that is accompanied by osteomyelitis as SSI-MED, rather than SSI-BONE.</LI></UL></div><div class=\"graphic_footnotes\">SSI: surgical site infection.<br />* With no other recognized cause.</div><div class=\"graphic_reference\">Modified from: CDC/NHSN Surveillance Definitions for Specific Types of Infections, January 2016. Available at: <a href=\"http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf\" target=\"_blank\">http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf</a> (Accessed on June 10, 2016).</div><div id=\"graphicVersion\">Graphic 108802 Version 1.0</div></div></div>"},"108807":{"type":"graphic_figure","displayName":"Physiology prone positioning","title":"Physiology of prone positioning in acute respiratory distress syndrome","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Physiology of prone positioning in acute respiratory distress syndrome</div><div class=\"cntnt\"><img style=\"width:536px; height:406px;\" src=\"images/PULM/108807_Physiology_prone_positioning.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown in this figure are axial (left) and sagittal views (right) of the thoracic cage representing the changes that occur as a consequence of prone positioning compared with supine positioning. Distending pressure of lung is determined by the transpulmonary pressure (PTP). When an individual is supine, the ventral PTP (+++) significantly exceeds the dorsal PTP (---) resulting in greater expansion of the ventral alveoli than the dorsal alveoli; this effect is exaggerated in acute respiratory distress syndrome (ARDS) such that ventral alveoli become overdistended and dorsal alveoli become atelectatic (dark purple). Prone positioning reduces the difference between the dorsal and ventral PTP, making ventilation more homogeneous, leading to a decrease in ventral alveolar overinflation and dorsal alveolar collapse and recruitment of alveoli that had collapsed during the supine ventilation. In ARDS, there is substantial ventilation-perfusion mismatch in the supine position, since blood flow and alveolar collapse are both greatest in the dependent portions of the lung. When prone, ventilation/perfusion matching improves since the previously dependent lung continues to receive the majority of the blood flow as alveoli reopen, while the newly dependent lung continues to receive the minority of the blood flow as alveoli begin to collapse.</div><div id=\"graphicVersion\">Graphic 108807 Version 1.0</div></div></div>"},"108808":{"type":"graphic_algorithm","displayName":"RLS infant prophylaxis","title":"Antiretroviral prophylaxis in infants born to HIV-infected mothers in resource-limited settings","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Antiretroviral prophylaxis in infants born to HIV-infected mothers in resource-limited settings</div><div class=\"cntnt\"><img style=\"width:692px; height:480px;\" src=\"images/ID/108808_RLS_infant_prophylaxis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm reflects the World Health Organization recommendations for infant antiretroviral prophylaxis to prevent mother-to-child transmission of HIV infection. Prophylaxis should start as soon as possible after birth, preferably within 6 to 12 hours. Refer to other UpToDate content for dosing details. In addition to infant prophylaxis, initiation of lifelong ART is recommended for all HIV-infected pregnant and breastfeeding women.</div><div class=\"graphic_footnotes\">ART: antiretroviral therapy.<br />* If indicated, antiretroviral prophylaxis should be initiated prior to the availability of results of virologic testing. If the virologic test is positive, any prophylaxis regimen should be discontinued and the infant should start a combination ART regimen.<br />&para; If the mother interrupts ART during breastfeeding, the infant should be managed as indicated for an infant with HIV exposure identified more than 48 hours postpartum.<br />&Delta; If the mother cannot tolerate or declines ART, then the infant should continue nevirapine prophylaxis throughout the duration of breastfeeding, until one week following breastfeeding cessation (if nevirapine is not tolerated, daily lamivudine can be used).<br /><span class=\"lozenge\">&loz;</span> Uninfected infants who are using replacement feeding do not need antiretroviral prophylaxis because there is no ongoing risk of transmission through breast milk, and the period for effective prophylaxis of intrapartum transmission may be passed (ie, infant prophylaxis initiated 48 hours or more after birth is unlikely to affect intrapartum transmission).</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach - Second edition. http://www.who.int/hiv/pub/arv/arv-2016/en/ (Accessed on July 8, 2016).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 108808 Version 2.0</div></div></div>"},"108810":{"type":"graphic_table","displayName":"Classification of cystic lung diseases","title":"Classification of cystic lung disease in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of cystic lung disease in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Description</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\"> <li>Neoplastic </li> </ol> </td> <td> <ul> <li>Lymphangioleiomyomatosis &ndash; sporadic as well as associated with tuberous sclerosis </li> <li>Pulmonary Langerhans cell histiocytosis, and non-Langerhans cell histiocytoses, including Erdheim Chester disease </li> <li>Other primary and metastatic neoplasms, such as sarcomas, adenocarcinomas, pleuropulmonary blastoma, etc </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Genetic/developmental/congenital </li> </ol> </td> <td> <ul> <li>Birt-Hogg-Dub&#233; syndrome </li> <li>Proteus syndrome, neurofibromatosis, Ehlers-Danlos syndrome </li> <li>Congenital pulmonary airway malformation, bronchopulmonary dysplasia, etc </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Associated with lymphoproliferative disorders </li> </ol> </td> <td> <ul> <li>Lymphocytic interstitial pneumonia </li> <li>Follicular bronchiolitis </li> <li>Sj&#246;gren syndrome </li> <li>Amyloidosis </li> <li>Light-chain deposition disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Infectious </li> </ol> </td> <td> <ul> <li><em>Pneumocystis jiroveci</em></li> <li>Staphylococcal pneumonia </li> <li>Recurrent respiratory papillomatosis </li> <li>Endemic fungal diseases, especially coccidioidomycosis </li> <li>Paragonimiasis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\" start=\"5\"> <li>Associated with interstitial lung diseases </li> </ol> </td> <td> <ul> <li>Hypersensitivity pneumonitis </li> <li>Desquamative interstitial pneumonia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\" start=\"6\"> <li>Smoking related </li> </ol> </td> <td> <ul> <li>Pulmonary Langerhans cell histiocytosis </li> <li>Desquamative interstitial pneumonia </li> <li>Respiratory bronchiolitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\" start=\"7\"> <li>Other/miscellaneous </li> </ol> </td> <td> <ul> <li>Post-traumatic pseudocysts </li> <li>Fire-eater's lung </li> <li>Hyper-IgE syndrome </li> </ul> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"8\"> <li>DCLD mimics </li> </ol> </td> <td> <ul> <li>Emphysema </li> <li>Alpha-1 antitrypsin deficiency </li> <li>Bronchiectasis </li> <li>Honeycombing seen in late-stage scarring interstitial lung diseases </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Many DCLDs have overlapping features and can be classified in more than one category. Pulmonary Langerhans cell histiocytosis is classified as both a neoplasm and a smoking-related cystic lung disease. Similarly, desquamative interstitial pneumonia is an interstitial lung disease as well as a smoking-related cystic lung disease. Although classified as a lymphoproliferative disorder, light-chain deposition disease could also be considered under the neoplastic category. Similarly, hyper-IgE syndrome, although classified as other/miscellaneous, could also be classified under the category of infections causing cystic lung disease.</div><div class=\"graphic_footnotes\">DCLD: diffuse cystic lung disease.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2015 American Thoracic Society. Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse Cystic Lung Disease. Part I. Am J Respir Crit Care Med 2015; 191(12):1354-66. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 108810 Version 2.0</div></div></div>"},"108830":{"type":"graphic_algorithm","displayName":"Hypopigmentation differential diagnosis","title":"Differential diagnosis of acquired hypopigmentation disorders","html":"<div class=\"graphic\"><div style=\"width: 1026px\" class=\"figure\"><div class=\"ttl\">Differential diagnosis of acquired hypopigmentation disorders</div><div class=\"cntnt\"><img style=\"width:1006px; height:541px;\" src=\"images/DERM/108830_Hypopigmentation_Ddx.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 108830 Version 1.0</div></div></div>"},"108831":{"type":"graphic_algorithm","displayName":"Initial treatment of SMVT in responsive patients with a pulse","title":"Algorithm for initial treatment of SMVT in responsive patients with a pulse","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Algorithm for initial treatment of SMVT in responsive patients with a pulse</div><div class=\"cntnt\"><img style=\"width:688px; height:508px;\" src=\"images/CARD/108831_Intl_tx_SMVT_rspns_px_pulse.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SMVT: sustained monomorphic ventricular tachycardia; CV: cardioversion.<br />* Hemodynamically unstable patients have evidence of hemodynamic compromise, such as hypotension, altered mental status, chest pain, or heart failure. Hemodynamically stable patients should have none of these findings.<br />&para; Initial choice of pharmacologic agents includes:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Intravenous lidocaine (1 to 1.5 mg/kg [typically 75 to 100 mg] at a rate of 25 to 50 mg/minute; lower doses of 0.5 to 0.75 mg/kg can be repeated every 5 to 10 minutes as needed), which may be more effective in the setting of acute myocardial ischemia or infarction</li>&#xD;&#xA;    <li>Intravenous procainamide (20 to 50 mg/minute until arrhythmia terminates or a maximum dose of 17 mg/kg is administered)</li>&#xD;&#xA;    <li>Intravenous amiodarone (150 mg IV over 10 minutes, followed by 1 mg/minute for the next six hours; bolus can be repeated if VT recurs)</li>&#xD;&#xA;</ul>&#xD;&#xA;&Delta; Electrical cardioversion should be synchronized if possible, using 100-joule biphasic shock or 200-joule monophasic shock. If first shock is unsuccessful, energy level should be escalated on subsequent shocks.<br /><span class=\"lozenge\">&loz;</span> Conditions associated with SMVT include myocardial ischemia, electrolyte disturbances (eg, hypokalemia, hypomagnesemia), drug-related proarrhythmia, and heart failure.</div><div id=\"graphicVersion\">Graphic 108831 Version 1.0</div></div></div>"},"108833":{"type":"graphic_picture","displayName":"Normal liver lobule biopsy","title":"Normal liver lobule","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Normal liver lobule</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108833_Normal_liver_lobule_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this photomicrograph, the portal tracts are at the periphery (PT), and the terminal hepatic venule (C) is located in the center. The hepatocytes are arranged in cords or trabeculae. Periportal (zone 1) hepatocytes receive the most oxygenated blood, while centrilobular (zone 3) receive the least oxygenated blood.</div><div id=\"graphicVersion\">Graphic 108833 Version 1.0</div></div></div>"},"108834":{"type":"graphic_picture","displayName":"EBV hepatitis biopsy","title":"Epstein-Barr virus (EBV) hepatitis (mononucleosis hepatitis)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Epstein-Barr virus (EBV) hepatitis (mononucleosis hepatitis)</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108834_EBV_hepatitis_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In contrast to acute lobular hepatitis (in which there are many scattered areas of liver cell necrosis throughout the parenchyma), the most prominent finding in mononucleosis hepatitis are the slightly atypical lymphoid cells filling the sinusoids.</div><div id=\"graphicVersion\">Graphic 108834 Version 1.0</div></div></div>"},"108835":{"type":"graphic_picture","displayName":"Drug-induced ALF biopsy","title":"Acute liver failure from drug-induced liver injury","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Acute liver failure from drug-induced liver injury</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108835_Drug_induced_ALF_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most of the parenchyma has been destroyed and collapsed (confluent necrosis) with only a few viable hepatocytes remaining. There is a mild infiltrate of inflammatory cells in the areas of necrosis. Arrows point to ceroid-containing macrophages.</div><div id=\"graphicVersion\">Graphic 108835 Version 1.0</div></div></div>"},"108836":{"type":"graphic_picture","displayName":"Refractory AIH biopsy","title":"Steroid-resistant (refractory) autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Steroid-resistant (refractory) autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108836_Refractory_AIH_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy showing bridging necrosis as characterized by necrotic hepatocytes (delineated by arrows) that link two vascular structures. In this case, a sprinkling of plasma cells is seen.</div><div id=\"graphicVersion\">Graphic 108836 Version 1.0</div></div></div>"},"108837":{"type":"graphic_picture","displayName":"AIH with cirrhosis biopsy","title":"Liver biopsy two years after the start of treatment for autoimmune hepatitis showing cirrhosis (trichrome stain)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Liver biopsy two years after the start of treatment for autoimmune hepatitis showing cirrhosis (trichrome stain)</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108837_AIH_cirrhosis_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is extensive scarring and nodule formation as highlighted by the broad bands of collagen (blue color) that surround regenerative nodules.</div><div id=\"graphicVersion\">Graphic 108837 Version 1.0</div></div></div>"},"108838":{"type":"graphic_picture","displayName":"Postmortem AIH biopsy","title":"Postmortem section of liver in a patient with autoimmune hepatitis (trichrome stain)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Postmortem section of liver in a patient with autoimmune hepatitis (trichrome stain)</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108838_Postmortem_AIH_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This section shows uniformly nodular liver parenchyma. Each nodule is completely surrounded by dense fibrous tissue, indicative of established cirrhosis.</div><div id=\"graphicVersion\">Graphic 108838 Version 1.0</div></div></div>"},"108839":{"type":"graphic_picture","displayName":"AIH confluent necrosis biopsy","title":"Autoimmune hepatitis with confluent necrosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis with confluent necrosis</div><div class=\"cntnt\"><img style=\"width:756px; height:521px;\" src=\"images/GAST/108839_AIH_confluent_necrosis_biop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is parenchymal collapse occupying 50 percent of the photomicrograph. Note the dense lymphoplasmacytic infiltrate replacing the area of collapse. Arrows point to interface hepatitis as characterized by spillage of inflammatory cells (in this case, plasma cells) into the adjacent parenchyma.</div><div id=\"graphicVersion\">Graphic 108839 Version 1.0</div></div></div>"},"108840":{"type":"graphic_picture","displayName":"AIH with 16 months treatment biopsy","title":"Liver biopsy after 16 months of therapy for autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Liver biopsy after 16 months of therapy for autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108840_AIH_16_months_tx_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is minimal to absent inflammation noted in portal tracts (PT), which show no evidence of scarring (absence of fibrosis).</div><div id=\"graphicVersion\">Graphic 108840 Version 1.0</div></div></div>"},"108841":{"type":"graphic_picture","displayName":"AIH 21-year-old man","title":"Autoimmune hepatitis in a 21-year-old man with advanced fibrosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis in a 21-year-old man with advanced fibrosis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108841_AIH_25_year_old_man.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichrome stain showing bridging fibrous septa that partially enclose nodules.</div><div id=\"graphicVersion\">Graphic 108841 Version 1.0</div></div></div>"},"108842":{"type":"graphic_picture","displayName":"AIH after one year treatment biopsy","title":"Autoimmune hepatitis in a 21-year-old after one year of therapy","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis in a 21-year-old after one year of therapy</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108842_AIH_after_one_year_tx_biop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power view of the liver with no evidence of fibrosis or active inflammation and appearing almost normal. Portal tracts are quiet, as are the lobules.</div><div id=\"graphicVersion\">Graphic 108842 Version 1.0</div></div></div>"},"108843":{"type":"graphic_picture","displayName":"Heart failure liver biopsy trichome","title":"Liver biopsy from a patient with left-sided heart failure (trichrome stain)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Liver biopsy from a patient with left-sided heart failure (trichrome stain)</div><div class=\"cntnt\"><img style=\"width:756px; height:569px;\" src=\"images/GAST/108843_Heart_flr_lvr_bpsy_trichome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo shows bands of fibrosis that are deposited within the sinusoids. Within the fibrous tissue are entrapped red blood cells (arrows).</div><div id=\"graphicVersion\">Graphic 108843 Version 1.0</div></div></div>"},"108844":{"type":"graphic_picture","displayName":"Heart failure liver biopsy high power","title":"Liver biopsy from a patient with left-sided heart failure","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Liver biopsy from a patient with left-sided heart failure</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108844_Heart_failure_lvr_bpsy_high.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is congestion in centrilobular zones as exemplified by pools of red blood cells present in the sinusoids (arrows).</div><div id=\"graphicVersion\">Graphic 108844 Version 1.0</div></div></div>"},"108845":{"type":"graphic_picture","displayName":"Heart failure liver biopsy low power","title":"Liver biopsy of patient with left-sided heart failure","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Liver biopsy of patient with left-sided heart failure</div><div class=\"cntnt\"><img style=\"width:753px; height:569px;\" src=\"images/GAST/108845_Heart_failure_livr_bpsy_low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power view of extensive congestion affecting most of the lobule. Extravasation of red blood cells as well as dropout and necrosis of the hepatocytes can be seen (arrowhead). This is particularly prominent in centrilobular zones (arrows).</div><div id=\"graphicVersion\">Graphic 108845 Version 1.0</div></div></div>"},"108846":{"type":"graphic_picture","displayName":"Budd-Chiari recanalized venule","title":"Chronic Budd-Chiari syndrome with recanalized hepatic venule","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Chronic Budd-Chiari syndrome with recanalized hepatic venule</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108846_Budd_Chiari_recanlzd_venule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large intrahepatic vein shows an old thrombus with partial recanalization. Arrows point to areas with pinpoint lumina indicative of recanalization.</div><div id=\"graphicVersion\">Graphic 108846 Version 1.0</div></div></div>"},"108847":{"type":"graphic_picture","displayName":"Hemochromatosis cirrhosis biopsy","title":"Hemochromatosis with cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis with cirrhosis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/108847_Hemochromatosis_cirrhosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo shows part of a cirrhotic nodule. The hypocellular fibrous band is indicated by the arrowhead. Arrows point to periportal hepatocytes that contain iron granules. The iron deposition has extended to include zone 2 (base of the arrows).</div><div id=\"graphicVersion\">Graphic 108847 Version 1.0</div></div></div>"},"108849":{"type":"graphic_figure","displayName":"Type A and Type B nuchal cords","title":"Type A and Type B nuchal cords","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Type A and Type B nuchal cords</div><div class=\"cntnt\"><img style=\"width:523px; height:307px;\" src=\"images/OBGYN/108849_Type_A_and_Type_B_nuchal_cords.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type A: The placental end crosses over the umbilical end, entangling the neck in an unlocked pattern. This pattern can become undone with fetal movement.<br />Type B: The placental end crosses under the umbilical end, entangling the neck in a locked pattern.&nbsp;This pattern cannot undo itself and can form a true knot when it passes caudally over the fetal body.</div><div class=\"graphic_reference\">Modified from: Collins JH. Nuchal cord type A and type B. Am J Obstet Gynecol 1997; 177:94.</div><div id=\"graphicVersion\">Graphic 108849 Version 1.0</div></div></div>"},"108850":{"type":"graphic_picture","displayName":"Tobramycin inhaler","title":"Tobramycin dry powder inhaler","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Tobramycin dry powder inhaler</div><div class=\"cntnt\"><img style=\"width:574px; height:162px;\" src=\"images/PULM/108850_Tobramycin_inhaler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TOBI Podhaler is a dry powder inhaler (DPI)&nbsp;for oral inhalation of tobramycin by patients with cystic fibrosis and chronic<EM>&nbsp;Pseudomonas aeruginosa</EM>&nbsp;colonization of their airways. It is not used for&nbsp;acute infection or pneumonia.&nbsp;The inhaler&nbsp;uses capsules that each contain 28 mg of tobramycin powder. Patients typically&nbsp;inhale the contents of 4 capsules twice a day for 28 days followed by 28 days off the drug.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Novartis Pharma AG. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108850 Version 1.0</div></div></div>"},"108867":{"type":"graphic_algorithm","displayName":"T4 replacement for subclinical hypothyroidism","title":"Indications for thyroid hormone replacement in nonpregnant adults with subclinical hypothyroidism*","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Indications for thyroid hormone replacement in nonpregnant adults with subclinical hypothyroidism*</div><div class=\"cntnt\"><img style=\"width:700px; height:306px;\" src=\"images/ENDO/108867_T4_rplcmnt_sbcln_hypthyrdsm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; T4: levothyroxine;&nbsp;free T4: free thyroxine.<br />* Subclinical hypothyroidism is defined by a TSH above the normal reference range with a normal free T4, confirmed with repeat measurement.<br />¶ For patients not treated with T4, monitor TSH and free T4 initially at six months and, if stable, yearly thereafter.<br />Δ Convincing symptoms of hypothyroidism (new or worsening fatigue, constipation, cold intolerance) or growing goiter.</div><div id=\"graphicVersion\">Graphic 108867 Version 2.0</div></div></div>"},"108868":{"type":"graphic_table","displayName":"CMV prevention kidney transplant","title":"CMV prevention strategies for adult kidney transplant recipients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CMV prevention strategies for adult kidney transplant recipients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">Recommendation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">CMV D+/R&ndash;</td> <td><strong>Prophylaxis</strong> is strongly preferred <ul class=\"decimal_heading\"> <li>Valganciclovir 900 mg orally daily (adjust for renal function) for six months following transplant </li> </ul> <strong>Preemptive treatment</strong> is an alternative <ul class=\"decimal_heading\"> <li>Weekly CMV PCR testing for three months following transplant, then valganciclovir 900 mg orally twice daily (adjust for renal function) or ganciclovir 5 mg/kg IV every 12 hours (adjust for renal function) upon detection of active CMV infection by PCR (thresholds vary) until repeat CMV PCR testing is negative and for a minimum of 21 days </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">CMV R+</td> <td><strong>Prophylaxis</strong> is preferred <ul class=\"decimal_heading\"> <li>Valganciclovir 900 mg orally daily (adjust for renal function) for three months following transplant </li> </ul> <strong>Preemptive treatment</strong> is an alternative <ul class=\"decimal_heading\"> <li>Weekly CMV PCR testing for three months following transplant, then valganciclovir 900 mg orally twice daily or ganciclovir 5 mg/kg IV every 12 hours (adjust for renal function) upon detection of active CMV infection by PCR (thresholds vary) until repeat CMV PCR testing is negative and for a minimum of 14 days </li> </ul> </td> </tr> <tr> <td class=\"centered\">CMV D&ndash;/R&ndash;</td> <td><strong>No specific CMV prevention strategies</strong> are recommended, but herpes simplex virus prophylaxis is recommended <ul class=\"decimal_heading\"> <li>Acyclovir 200 mg orally twice daily for three months following transplant </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Preventive strategies shown in the table are based upon recommendations used at centers with experience caring for kidney transplant recipients; protocols will vary by institution and patient condition. For additional information, refer to UpToDate topics on cytomegalovirus infection and disease in kidney transplant recipients, including discussion of hybrid prophylactic and preemptive approaches.</div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; D+: donor seropositive; R–: recipient seronegative; R+: recipient seropositive; D–: donor seronegative; IV: intravenous; PCR: polymerase chain reaction.</div><div class=\"graphic_reference\">Reference: Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96:333.<br />Courtesy of Drs. Carlos AQ Santos, MD; John Vella, MD, FACP, FRCP, FASN; and Daniel C Brennan, MD, FACP.</div><div id=\"graphicVersion\">Graphic 108868 Version 2.0</div></div></div>"},"108889":{"type":"graphic_table","displayName":"Clinical manifestations of pertussis","title":"Clinical manifestations of pertussis among infants, children, adolescents, and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of pertussis among infants, children, adolescents, and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Clinical sign</td> <td class=\"subtitle1\" colspan=\"2\">Frequency in: (%)</td> </tr> <tr> <td class=\"subtitle2\">Infants and children*</td> <td class=\"subtitle2\">Adolescents and adults</td> </tr> <tr> <td>Coughing paroxysms<sup>[1-5]</sup></td> <td class=\"centered\">89 to 93</td> <td class=\"centered\">70 to 99</td> </tr> <tr> <td>Inspiratory whoops<sup>[1-8]</sup></td> <td class=\"centered\">69 to 92</td> <td class=\"centered\">8 to 82</td> </tr> <tr> <td>Nocturnal cough<sup>[2,3,6,9,10]</sup></td> <td class=\"centered\">41</td> <td class=\"centered\">61 to 87</td> </tr> <tr> <td>Posttussive vomiting<sup>[1-9]</sup></td> <td class=\"centered\">48 to 60</td> <td class=\"centered\">17 to 65</td> </tr> <tr> <td>No or low-grade fever<sup>[4,8]</sup></td> <td class=\"centered\">87 to 96</td> <td class=\"centered\">13</td> </tr> <tr> <td>Coryza<sup>[4]</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">58</td> </tr> <tr> <td>Pharyngitis<sup>[4]</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">31</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: data not available.<br />* Ages 6 days to 9 years.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001; 183:1353.</li>&#xD;&#xA;    <li>Gilberg S, Njamkepo E, Du Chatelet IP, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. J Infect Dis 2002; 186:415.</li>&#xD;&#xA;    <li>Postels-Multani S, Schmitt HJ, Wirsing von Konig CH, et al. Symptoms and complications of pertussis in adults. Infection 1995; 23:139.</li>&#xD;&#xA;    <li>Schmitt-Grohe S, Cherry JD, Heininger U, et al. Pertussis in German adults. Clin Infect Dis 1995; 21:860. </li>&#xD;&#xA;    <li>De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182:174&ndash;179.</li>&#xD;&#xA;    <li>Mertens PL, Stals FS, Schellekens JF, et al. An epidemic of pertussis among elderly people in a religious institution in The Netherlands. Eur J Clin Microbiol Infect Dis 1999; 18:242.</li>&#xD;&#xA;    <li>Trollfors B, Rabo E. 1981. Whooping cough in adults. Br Med J (Clin Res ed) 1981; 283:696.</li>&#xD;&#xA;    <li>Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 1997; 100:E10.</li>&#xD;&#xA;    <li>Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001; 32:1691.</li>&#xD;&#xA;    <li>Wirsing von Konig CH, Finger H. Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection. Eur J Clin Microbiol Infect Dis 1994; 13:455.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Kilgore PE, Salim AM, Zervos MJ, Schmitt H-J. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev 2016; 29:449&ndash;486. DOI: 10.1128/CMR.00083-15. Reproduced with permission from American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 108889 Version 2.0</div></div></div>"},"108899":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of semimembranosus bursa","title":"Ultrasound image of semimembranosus bursa","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of semimembranosus bursa</div><div class=\"cntnt\"><img style=\"width:764px; height:300px;\" src=\"images/RHEUM/108899_US_semimembranosus_bursa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph on left shows the position of the ultrasound transducer (on a patient in the prone position)&nbsp;for obtaining the image on the right. The gastrocnemius muscle is indicated by an arrow. Beneath the gastrocnemius is the semimembranosus bursa, which appears as a hypoechoic (fluid-filled) area marked by an asterisk. The semimembranosus is labeled; there is some hypoechoic change adjacent to the muscle, suggesting injury.</div><div class=\"graphic_reference\">Courtesy of Karl Fields, MD.</div><div id=\"graphicVersion\">Graphic 108899 Version 1.0</div></div></div>"},"108900":{"type":"graphic_picture","displayName":"Supplies needed for long leg cast","title":"Supplies needed for making a long leg cast","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Supplies needed for making a long leg cast</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/SM/108900_Long_leg_casting_supplies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The supplies needed to make a long leg cast are pictured above. From the top left moving&nbsp;clockwise these include: stockinette sized for the upper leg, stockinette sized for the lower leg, cotton padding, tepid water, gloves, casting tape (may use either fiberglass–black or plaster–white).</div><div class=\"graphic_reference\">Courtesy of Jesse DeLuca, DO.</div><div id=\"graphicVersion\">Graphic 108900 Version 1.0</div></div></div>"},"108901":{"type":"graphic_picture","displayName":"Stockinette application for long leg cast","title":"Stockinette application for long leg cast","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Stockinette application for long leg cast</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/SM/108901_Stockinette_application.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first step in applying a long leg cast is to&nbsp;position the&nbsp;knee and ankle properly. The degree of flexion at the knee and ankle, and the placement of leg support during casting, depend on the type of fracture type and&nbsp;whether&nbsp;closed&nbsp;reduction is required.&nbsp;Keep the stockinette unstretched when determining the needed length. The stockinette&nbsp;should extend&nbsp;from the proximal greater trochanter to a point just distal to the toes.&nbsp;The size of the&nbsp;stockinette segments for the upper and lower leg should be such that the material is flush&nbsp;against the skin but not constrictive and without folds.</div><div class=\"graphic_reference\">Courtesy of Jesse DeLuca, DO.</div><div id=\"graphicVersion\">Graphic 108901 Version 1.0</div></div></div>"},"108902":{"type":"graphic_table","displayName":"Clinical complications of pertussis","title":"Clinical complications of pertussis among infants, adolescents, and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical complications of pertussis among infants, adolescents, and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Complication</td> <td class=\"subtitle1\" colspan=\"2\">Frequency in: (%)</td> </tr> <tr> <td class=\"subtitle2\">Infants</td> <td class=\"subtitle2\">Adolescents and adults</td> </tr> <tr> <td>Apnea<sup>[1-4]</sup></td> <td class=\"centered\">50 to 67</td> <td class=\"centered\">27 to 86</td> </tr> <tr> <td>Pnemonia<sup>[1-5]</sup></td> <td class=\"centered\">20 to 23</td> <td class=\"centered\">0.6 to 8</td> </tr> <tr> <td>Convulsions<sup>[2-4]</sup></td> <td class=\"centered\">1</td> <td class=\"centered\">0 to 0.6</td> </tr> <tr> <td>Death<sup>[1,2,6,7]</sup></td> <td class=\"centered\">1 to 1.6</td> <td class=\"centered\">0.01</td> </tr> <tr> <td>Insomnia<sup>[3]</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">77</td> </tr> <tr> <td>Sinusitis<sup>[5]</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">13</td> </tr> <tr> <td>Otitis media<sup>[5,8]</sup></td> <td class=\"centered\">6</td> <td class=\"centered\">4</td> </tr> <tr> <td>Weight loss<sup>[2,3,5,8]</sup></td> <td class=\"centered\">12</td> <td class=\"centered\">3 to 33</td> </tr> <tr> <td>Urinary incontinence<sup>[1,3,5]</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">3 to 28</td> </tr> <tr> <td>Syncope<sup>[1,2,5,9]</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">2 to 6</td> </tr> <tr> <td>Rib fracture<sup>[1-5]</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">1 to 4</td> </tr> <tr> <td>Loss of consciousness<sup>[3]</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">1</td> </tr> <tr> <td>Hospitalization<sup>[1,3,4]</sup></td> <td class=\"centered\">Approximately 50</td> <td class=\"centered\">0 to 12</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: data not available.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention. Pregnancy and whooping cough: vaccinating pregnant patients. CDC, Atlanta, GA 2014. http: //www.cdc.gov/pertussis/pregnant/hcp/pregnant-patients.html.</li>&#xD;&#xA;    <li>Cortese MM, Bisgard KM. Pertussis. Maxcy-Rosenau-Last Public Health and Preventive Medicine, 15th ed, Wallace RB (Ed). McGraw-Hill Medical, New York, NY 2008. p 111.</li>&#xD;&#xA;    <li>Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.</li>&#xD;&#xA;    <li>Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55:1.</li>&#xD;&#xA;    <li>De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182:174.</li>&#xD;&#xA;    <li>Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992; 14:708.</li>&#xD;&#xA;    <li>Thampi N, Gurol-Urganci I, Crowcroft NS, Sander B. Pertussis post-exposure prophylaxis among household contacts: a cost-utility analysis. PLoS One 2015; 10:e0119271.</li>&#xD;&#xA;    <li>Stojanov S, Liese J, Belohradsky BH. Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection. Infection 2000; 28:106.</li>&#xD;&#xA;    <li>Jenkins P, Clarke SW. Cough syncope: a complication of adult whooping cough. Br J Dis Chest 1981; 75:311.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Kilgore PE, Salim AM, Zervos MJ, Schmitt H-J. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev 2016; 29:449&ndash;486. DOI: 10.1128/CMR.00083-15. Reproduced with permission from American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 108902 Version 2.0</div></div></div>"},"108903":{"type":"graphic_picture","displayName":"Padding application for long leg cast","title":"Padding application for long leg cast","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Padding application for long leg cast</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/SM/108903_Padding_application.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apply padding from distal to proximal with about a 50 percent&nbsp;overlap. Make certain to add&nbsp;extra layers of padding over bony prominences and to&nbsp;limit any&nbsp;folding of the material, which can cause pressure sores.</div><div class=\"graphic_reference\">Courtesy of Jesse DeLuca, DO.</div><div id=\"graphicVersion\">Graphic 108903 Version 1.0</div></div></div>"},"108904":{"type":"graphic_picture","displayName":"Applying fiberglass or plaster to lower leg for long leg cast","title":"Applying fiberglass or plaster to lower leg for long leg cast","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Applying fiberglass or plaster to lower leg for long leg cast</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/SM/108904_Fiberglass_cast_tape_plaste.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When making a long leg cast, cast tape (or plaster)&nbsp;is applied to the lower leg first.&nbsp;The cast tape is wrapped&nbsp;over the padding, moving&nbsp;from distal to proximal. Before the final layer is applied, the distal portion of the stockinette is folded back over the top of the cast tape, and then&nbsp;a final&nbsp;layer of cast tape is applied. A total of 8 to 12 layers of plaster or 5 to 6 layers of fiberglass should be applied.</div><div class=\"graphic_reference\">Courtesy of Jesse DeLuca, DO.</div><div id=\"graphicVersion\">Graphic 108904 Version 1.0</div></div></div>"},"108905":{"type":"graphic_picture","displayName":"Applying fiberglass or plaster to thigh for long leg cast","title":"Applying fiberglass or plaster to thigh for long leg cast","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Applying fiberglass or plaster to thigh for long leg cast</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/SM/108905_FG_cast_application_up_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once lower leg casting material&nbsp;has set (5 to 10 minutes), apply&nbsp;casting material to the thigh. Before the last layer of casting material&nbsp;is applied, fold the stockinette back over the proximal portion of the cast and then add&nbsp;the final&nbsp;layer.</div><div class=\"graphic_reference\">Courtesy of Jesse DeLuca, DO.</div><div id=\"graphicVersion\">Graphic 108905 Version 1.0</div></div></div>"},"108906":{"type":"graphic_picture","displayName":"Completion of long leg fiberglass cast","title":"Completion of long leg fiberglass cast","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Completion of long leg fiberglass cast</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/SM/108906_Fin_FG_cast_uniform_color.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After&nbsp;the final layer of casting material is applied, the clinician can use the flat surface of their palms to smoothen the cast tape and mold it to the bony contours.</div><div class=\"graphic_reference\">Courtesy of Jesse DeLuca, DO.</div><div id=\"graphicVersion\">Graphic 108906 Version 1.0</div></div></div>"},"108907":{"type":"graphic_picture","displayName":"Urticating spider hairs 1","title":"Urticating spider hairs 1","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Urticating spider hairs 1</div><div class=\"cntnt\"><img style=\"width:756px; height:293px;\" src=\"images/EM/108907_Urticatinghairs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When threatened, tarantulas dislodge small (about 1 mm long) barbed hairs at the posterior of their abdomens and launch them at their attacker. These urticating hairs, as well as airborne material from crushed tarantulas, may cause irritation if they come in contact with skin, eyes, or mucous membranes.</div><div class=\"graphic_reference\">Courtesy of Rick Vetter, MS.</div><div id=\"graphicVersion\">Graphic 108907 Version 2.0</div></div></div>"},"108909":{"type":"graphic_table","displayName":"PUQE score","title":"Pregnancy Unique-Quantification of Emesis (PUQE) score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pregnancy Unique-Quantification of Emesis (PUQE) score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">1 point</td> <td class=\"subtitle1\">2 points</td> <td class=\"subtitle1\">3 points</td> <td class=\"subtitle1\">4 points</td> <td class=\"subtitle1\">5 points</td> </tr> <tr> <td><strong>Duration of nausea in the past 12 hours</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">&#8804;1 hour</td> <td class=\"centered\">2 to 3 hours</td> <td class=\"centered\">4 to 6 hours</td> <td class=\"centered\">&#62;6 hours</td> </tr> <tr> <td><strong>Number of vomiting episodes in the past 12 hours</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">1 to 2</td> <td class=\"centered\">3 to 4</td> <td class=\"centered\">5 to 6</td> <td class=\"centered\">&#8805;7</td> </tr> <tr> <td><strong>Number of episodes of dry heaves in the past 12 hours</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">1 to 2</td> <td class=\"centered\">3 to 4</td> <td class=\"centered\">5 to 6</td> <td class=\"centered\">&#8805;7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Total score 4 to 6: mild nausea and vomiting of pregnancy. Total score 7 to 12: moderate nausea and vomiting of pregnancy. Total score &ge;13: severe nausea and vomiting of pregnancy.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Koren G, Boskovic R, Hard M, et al. Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am J Obstet Gynecol 2002; 186:S228.</LI>&#xD;&#xA;<LI>Koren G, Piwko C, Ahn E, et al. Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. J Obstet Gynaecol 2005; 25:241.</LI></OL></div><div id=\"graphicVersion\">Graphic 108909 Version 2.0</div></div></div>"},"108910":{"type":"graphic_diagnosticimage","displayName":"Entry into epidural space (lateral view)","title":"Entry into epidural space (lateral view)","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Entry into epidural space (lateral view)</div><div class=\"cntnt\"><img style=\"width:509px; height:644px;\" src=\"images/ANEST/108910_Entry_in_epidural_space_lat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tip of the epidural needle is shown in the epidural space in this lateral radiograph, which was&nbsp;obtained with fluoroscopy during spinal cord stimulator placement.</div><div id=\"graphicVersion\">Graphic 108910 Version 1.0</div></div></div>"},"108911":{"type":"graphic_diagnosticimage","displayName":"Correct posterior position of the stimulator lead (lateral view)","title":"Correct posterior position of the stimulator lead (lateral view)","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Correct posterior position of the stimulator lead (lateral view)</div><div class=\"cntnt\"><img style=\"width:490px; height:490px;\" src=\"images/ANEST/108911_Posterior_position_lead_lat.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 108911 Version 1.0</div></div></div>"},"108912":{"type":"graphic_diagnosticimage","displayName":"Two percutaneous leads (AP view)","title":"Two percutaneous leads (AP view)","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Two percutaneous leads (AP view)</div><div class=\"cntnt\"><img style=\"width:753px; height:675px;\" src=\"images/ANEST/108912_TwoleadsAPview.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 108912 Version 3.0</div></div></div>"},"108913":{"type":"graphic_diagnosticimage","displayName":"2 percutaneous leads in posterior epidural space (lateral view)","title":"Two percutaneous leads in posterior epidural space (lateral view)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two percutaneous leads in posterior epidural space (lateral view)</div><div class=\"cntnt\"><img style=\"width:307px; height:402px;\" src=\"images/ANEST/108913_Leads_posterior_epidurl_lat.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 108913 Version 2.0</div></div></div>"},"108914":{"type":"graphic_diagnosticimage","displayName":"Surgical paddle leads","title":"Surgical paddle leads","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical paddle leads</div><div class=\"cntnt\"><img style=\"width:406px; height:478px;\" src=\"images/ANEST/108914_Surgical_paddle_leads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiographic image shows a surgically placed paddle lead with two sets of eight electrodes.</div><div id=\"graphicVersion\">Graphic 108914 Version 2.0</div></div></div>"},"108915":{"type":"graphic_diagnosticimage","displayName":"Trial failure due to lead migration out of the epidural space","title":"Trial failure due to lead migration out of the epidural space","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trial failure due to lead migration out of the epidural space</div><div class=\"cntnt\"><img style=\"width:316px; height:482px;\" src=\"images/ANEST/108915_Trial_fail_lead_mig_epidurl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spinal cord stimulator lead has migrated outward, such that the lower electrodes are outside the epidural space.</div><div id=\"graphicVersion\">Graphic 108915 Version 1.0</div></div></div>"},"108917":{"type":"graphic_table","displayName":"Procedural anticoagulation management checklist","title":"Procedural anticoagulation management checklist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedural anticoagulation management checklist</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Evaluate baseline patient-specific risk factors for perioperative bleeding</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>History and physical examination signs suggestive of a bleeding disorder: <ul> <li>History of unexplained nosebleeds (epistaxis) or menorrhagia </li> <li>Examination signs include petechiae, mucosal bleeding, purpura, or ecchymoses </li> </ul> </li> <li>Family history of bleeding disorders </li> <li>Screen for antiplatelet, antithrombotic, or thrombolytic therapy </li> <li>Screen for SNRIs, SSRIs, and herbal therapies that may influence coagulation status </li> <li>Order coagulation tests when needed based on history and physical examination and/or medication use </li> <li>Identify aspirin and non-aspirin NSAIDs utilization </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">For individuals on aspirin, categorize reason for utilization</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Primary prophylaxis: Absence of established cardiovascular disease or risk factor </li> <li>Secondary prophylaxis: Presence of cardiovascular disease </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Process the anatomical location of procedural intervention into decision-making</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Intracanal versus extracanal spinal procedures </li> <li>Cervicothoracic neuraxial or lumbosacral neuraxial area </li> <li>Surrounding vascular structures at risk for penetration </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Review appropriate radiographic imaging to identify and understand anatomic challenges</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Cervical, thoracic, and lumbar spinal stenosis that alter spinal canal anatomy </li> <li>Epidural fibrosis and significant scar tissue from previous surgical intervention </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Identify and manage pharmacologic coagulopathies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Understand drug elimination and appropriate discontinuation time </li> <li>Determine appropriate timing for reinitiation of anticoagulation and antiplatelet therapy </li> <li>Practice informed decision-making involving procedural physician, prescribing medical physician, and patient </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\" style=\"font-size:1.2em;\"> <td><strong>Employ post-procedure surveillance for the detection of bleeding complications</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SNRIs: serotonin and&nbsp;norepinephrine reuptake inhibitors; SSRIs: selective serotonin reuptake inhibitors; NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div class=\"graphic_reference\">From: Narouze S, Benzon HT, Provenzano DA, et al. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications: Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2015; 40:182. DOI: <A href=\"http://journals.lww.com/rapm/pages/articleviewer.aspx?year=2015&amp;issue=05000&amp;article=00002&amp;type=abstract\" target=_blank>10.1097/AAP.0000000000000223</A>. Copyright © 2015 ESRA, AOSRA, and LASRA. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108917 Version 1.0</div></div></div>"},"108918":{"type":"graphic_table","displayName":"Periprocedural management of anticoagulants & antiplatelet meds","title":"Summary of periprocedural management of anticoagulants and antiplatelet medications for interventional pain procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of periprocedural management of anticoagulants and antiplatelet medications for interventional pain procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"3\">When to stop</td> <td class=\"subtitle1\" rowspan=\"2\">When to restart</td> </tr> <tr> <td class=\"subtitle2\">High-risk procedures</td> <td class=\"subtitle2\">Intermediate-risk procedures</td> <td class=\"subtitle2\">Low-risk procedures</td> </tr> <tr class=\"divider_bottom\"> <td>ASA and ASA combinations</td> <td> <p>Primary prophylaxis: six days</p> Secondary prophylaxis: shared assessment and risk stratification</td> <td>Shared assessment and risk stratification*<sup>&#182;</sup></td> <td>No</td> <td>24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">NSAIDs</td> <td>Five half-lives</td> <td>No<sup>&#916;</sup></td> <td>No</td> <td>24 hours</td> </tr> <tr> <td class=\"indent1\">Diclofenac</td> <td>One day</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ketorolac</td> <td>One day</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> <td>One day</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Etodolac</td> <td>Two days</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Indomethacin</td> <td>Two days</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Naproxen</td> <td>Four days</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Meloxicam</td> <td>Four days</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Nabumetone</td> <td>Six days</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Oxaprozin</td> <td>10 days</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Piroxicam</td> <td>10 days</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Phosphodiesterase inhibitors</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cilostazol</td> <td>Two days</td> <td>No</td> <td>No</td> <td>24 hours</td> </tr> <tr> <td class=\"indent1\">Dipyridamole</td> <td>Two days</td> <td>No</td> <td>No</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ASA combinations</td> <td>Follow ASA recommendations</td> <td>Shared assessment and risk stratification*</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Anticoagulants</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Coumadin</td> <td>Five days, normal INR</td> <td>Five days, normal INR</td> <td>No; shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr> <td class=\"indent1\">Acenocoumarol</td> <td>Three days, normal INR</td> <td>Three days, normal INR</td> <td>No; shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr> <td class=\"indent1\">IV heparin</td> <td>Four hours</td> <td>Four hours</td> <td>Four hours</td> <td>Two hours<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Subcutaneous heparin, BID, and TID</td> <td>8 to 10 hours</td> <td>8 to 10 hours</td> <td>8 to 10 hours</td> <td>Two hours</td> </tr> <tr> <td class=\"indent1\">LMWH: prophylactic</td> <td>12 hours</td> <td>12 hours</td> <td>12 hours</td> <td>Four hours after low-risk procedures; 12 to 24 hours after medium-/high-risk pain procedures</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">LMWH: therapeutic</td> <td>24 hours</td> <td>24 hours</td> <td>24 hours</td> <td>Four hours after low-risk procedures; 12 to 24 hours after medium-/high-risk pain procedures</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Fibrinolytic agents</td> <td>48 hours</td> <td>48 hours</td> <td>48 hours</td> <td>48 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fondaparinux</td> <td>Four days</td> <td>Four days</td> <td>Shared assessment and risk stratification</td> <td>24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">P2Y12 inhibitors</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Clopidogrel</td> <td>Seven days</td> <td>Seven days</td> <td>No</td> <td>12 to 24 hours</td> </tr> <tr> <td class=\"indent1\">Prasugrel</td> <td>7 to 10 days</td> <td>7 to 10 days</td> <td>No</td> <td>12 to 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ticagrelor</td> <td>Five days</td> <td>Five days</td> <td>No</td> <td>12 to 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">New anticoagulants</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Dabigatran</td> <td>Four to five days; six days (impaired renal function)</td> <td>Four to five days; six days (impaired renal function)</td> <td>Shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr> <td class=\"indent1\">Rivaroxaban</td> <td>Three days</td> <td>Three days</td> <td>Shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Apixaban</td> <td>Three to five days</td> <td>Three to five days</td> <td>Shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Glycoprotein IIb/IIIa inhibitors</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Abciximab</td> <td>Two to five days</td> <td>Two to five days</td> <td>Two to five days</td> <td>8 to 12 hours</td> </tr> <tr> <td class=\"indent1\">Eptifibatide</td> <td>8 to 24 hours</td> <td>8 to 24 hours</td> <td>8 to 24 hours</td> <td>8 to 12 hours</td> </tr> <tr> <td class=\"indent1\">Tirofiban</td> <td>8 to 24 hours</td> <td>8 to 24 hours</td> <td>8 to 24 hours</td> <td>8 to 12 hours</td> </tr> <tr> <td class=\"indent1\">Antidepressants and SRIs</td> <td>Individualized<sup>&#167;</sup></td> <td>No</td> <td>No</td> <td>Individualized<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">ASA: American Society of Anesthesiologists; INR: international normalized ratio; IV: intravenous; BID: two times per day; TID: three times per day; LMWH: low-molecular-weight heparin; SRIs: serotonin reuptake inhibitors.<br />* Refer to detailed text in the corresponding section of the source article.<br />¶ Consideration should be given to the discontinuation of aspirin for certain intermediate-risk procedures including interlaminar cervical epidural steroid injections and stellate ganglion blocks where specific anatomical configurations may increase the risk and consequences of procedural bleeding.<br />Δ Consideration should be given to the discontinuation of NSAIDs for certain intermediate-risk procedures including interlaminar cervical epidural steroid injections and stellate ganglion blocks where specific anatomical configurations may increase the risk and consequences of procedural bleeding (refer to the section entitled \"Anatomical Considerations for the Development of a Hematoma in Spinal and Non‐spinal Areas\" in the source article).<br />◊ If a moderate- or high-risk procedure was bloody, then a 24-hour interval should be observed.<br />§ For more information, refer to the section entitled \"SRIs and Anticoagulants\" and table 6 in the source article, as well as the UpToDate content on the pharmacology and side effects of selective serotonin reuptake inhibitors. </SPAN></div><div class=\"graphic_reference\">From: Narouze S, Benzon HT, Provenzano DA, et al. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications: Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2015; 40:182. DOI: <a href=\"http://journals.lww.com/rapm/pages/articleviewer.aspx?year=2015&amp;issue=05000&amp;article=00002&amp;type=abstract\" target=\"_blank\">10.1097/AAP.0000000000000223</a>. Copyright &copy; 2015 ESRA, AOSRA, and LASRA. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108918 Version 2.0</div></div></div>"},"108922":{"type":"graphic_form","displayName":"Current Opioid Misuse Measure (scoring instructions)","title":"Current Opioid Misuse Measure (scoring instructions)","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Current Opioid Misuse Measure (scoring instructions)</div><div class=\"cntnt\"><img style=\"width:607px; height:838px;\" src=\"images/ANEST/108922_COMM_scoring_instructions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Inflexxion, Inc., Newton MA. All rights reserved. <a href=\"http://www.inflexxion.com/\" target=\"_blank\">www.Inflexxion.com</a>.</div><div id=\"graphicVersion\">Graphic 108922 Version 1.0</div></div></div>"},"108923":{"type":"graphic_form","displayName":"SOAPP-R (scoring instructions)","title":"Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R) (scoring instructions)","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R) (scoring instructions)</div><div class=\"cntnt\"><img style=\"width:550px; height:788px;\" src=\"images/ANEST/108923_SOAPPR_scoring_instructions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2016 Inflexxion, Inc., Newton MA. All rights reserved. <A href=\"http://www.inflexxion.com/\" target=_blank>www.Inflexxion.com</A>.</div><div id=\"graphicVersion\">Graphic 108923 Version 2.0</div></div></div>"},"108925":{"type":"graphic_picture","displayName":"Erythema nodosum multiple nodules","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108925_Erythema_nodosum_multi_ndls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous nodules on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108925 Version 1.0</div></div></div>"},"108926":{"type":"graphic_picture","displayName":"Erythema nodosum nodules","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108926_Erythema_nodosum_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous nodules on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108926 Version 1.0</div></div></div>"},"108927":{"type":"graphic_picture","displayName":"Erythema nodosum on arm","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108927_Erythema_nodosum_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous nodule on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108927 Version 1.0</div></div></div>"},"108928":{"type":"graphic_picture","displayName":"Erythema nodosum pathology","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108928_Erythema_nodosum_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Septal panniculitis with limited extension into the fat lobules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108928 Version 1.0</div></div></div>"},"108929":{"type":"graphic_algorithm","displayName":"Evaluation for neonatal Graves' disease","title":"Evaluation and management of infants at risk for neonatal Graves' disease","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of infants at risk for neonatal Graves' disease</div><div class=\"cntnt\"><img style=\"width:690px; height:490px;\" src=\"images/PEDS/108929_Evl_neonatal_Graves_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TSHR-Ab: thyroid stimulating hormone receptor antibodies; fT4: free thyroxine; T3: triiodothyronine; TSH: thyroid stimulating hormone; DOL: day of life; MMI: methimazole.<br />* For infants coming to medical attention after birth, thyroid function tests are performed as soon as the possibility of neonatal Graves' disease is recognized, and repeated during the first two weeks of life, as shown. Results of maternal TSHR-Ab tests, if available, may be helpful to estimate the infant's risk of developing neonatal Graves' disease.<br />¶ Follow-up is recommended because some TSH-R antibody tests may have false-negative results.<br />Δ Thyroid function tests should be interpreted in the context of the infant's age because the normal values for these tests are higher during the first few weeks of life compared with values in older infants (refer to UpToDate topic text for details).<br /><FONT class=lozenge>◊</FONT> In most of these infants, the hypothyroidism is transient, and is due to maternal antithyroid drug treatments, although some cases are caused by maternal TSH-R blocking antibodies. The infant may become euthyroid or hyperthyroid anytime during the first few weeks of life. As neonatal Graves' disease resolves, some infants may develop <STRONG>central</STRONG> hypothyroidism (low fT4 and low TSH). Central hypothyroidism also may be transient, but should be treated with levothyroxine until the hypothyroidism resolves.</div><div id=\"graphicVersion\">Graphic 108929 Version 2.0</div></div></div>"},"108930":{"type":"graphic_figure","displayName":"Types and etiologies of valvular heart disease","title":"Types and etiologies of valvular heart disease","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Types and etiologies of valvular heart disease</div><div class=\"cntnt\"><img style=\"width:615px; height:441px;\" src=\"images/ANEST/108930_Type_valvular_heart_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of etiologies of valvular heart disease according to the type of single native valve disease in a European population.</div><div class=\"graphic_footnotes\">AR: aortic regurgitation; AS: aortic stenosis; MR: mitral regurgitation; MS: mitral stenosis.</div><div class=\"graphic_reference\">Reproduced from: Lung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol 2014; 30:962. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108930 Version 1.0</div></div></div>"},"108934":{"type":"graphic_table","displayName":"Pre-treatment immunity evaluation for IBD","title":"Baseline evaluation of vaccine preventable infections in pediatric patients with inflammatory bowel disease (IBD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Baseline evaluation of vaccine preventable infections in pediatric patients with inflammatory bowel disease (IBD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Baseline evaluation*</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Pathogen or vaccine</td> <td class=\"subtitle1\">Review risk factors, vaccine records, and prior infections</td> <td class=\"subtitle1\">Check serologic status</td> <td class=\"subtitle1\">Offer vaccine if not up to date, or nonimmune, and age-appropriate</td> <td class=\"subtitle1\">Subsequent annual evaluation</td> </tr> <tr> <td><em>Haemophilus influenza</em> type b</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>Hepatitis A virus</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Consider</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>Hepatitis B virus</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes (HBsAg, anti-HBc, and anti-HBs)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Repeat series once if inadequate serologic response; recheck anti-HBs (2 months after 3rd dose)</td> </tr> <tr> <td>HPV</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Encourage gynecologic/anal examination if age appropriate</td> <td class=\"centered\">Yes, minimum age 9 years</td> <td class=\"centered\">Yes, if appropriate</td> </tr> <tr> <td>Influenza, inactivated vaccine</td> <td class=\"centered\">Yes</td> <td class=\"centered\">NA</td> <td class=\"centered\">Yes, annually</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Inactivated polio vaccine</td> <td class=\"centered\">Yes</td> <td class=\"centered\">NA</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>MMR</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes<sup>&#182;</sup><sup>&#916;</sup></td> <td class=\"centered\">No</td> </tr> <tr> <td>Meningococcal conjugate vaccine</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes, if age appropriate or risk factors<sup>&#9674;</sup></td> </tr> <tr> <td>Pneumococcal conjugate vaccine (PCV13)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes<sup>&#167;</sup></td> <td class=\"centered\">NA</td> </tr> <tr> <td>PPSV23</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes<sup>&#165;</sup></td> <td class=\"centered\">Booster once 5 years after first dose of PPSV23 (max 2 lifetime PPSV23 doses)</td> </tr> <tr> <td>Tetanus, diphtheria (Td), acellular pertussis (Tdap)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">NA</td> <td class=\"centered\">Yes</td> <td class=\"centered\">After Tdap, Td booster every 10 years</td> </tr> <tr> <td>Varicella-zoster virus</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes<sup>&#135;</sup></td> <td class=\"centered\">Yes, if no evidence of immunity<sup>&#182;</sup><sup>&#916;</sup></td> <td class=\"centered\">NA</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table outlines screening procedures for pediatric patients with inflammatory bowel disease (IBD). Whenever possible, this screening should be completed before initiating therapy with anti-tumor necrosis factor (anti-TNF) therapies such as infliximab, or with newer biologic therapies as they become available.</div><div class=\"graphic_footnotes\">HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; anti-HBc: hepatitis B core antibody; anti-HBs: hepatitis B surface antibody; HPV: human papillomavirus; NA: not applicable; MMR: measles-mumps-rubella; PPSV23: pneumococcal polysaccharide vaccine.<br />* Should include review of vaccine record and any prior testing/serologies.<br />¶ If not receiving immunosuppressive therapy (please refer to text, vaccine section for dosing). Immunosuppressive therapy includes&nbsp;prednisone in the past 30 days, or any of the following in the past 3 months: 6-mercaptopurine, methotrexate, azathioprine, or any biologic agent, including anti-TNFα therapy.<br />Δ Dispense if live virus vaccine can be administered ≥4 weeks before starting immunosuppressive therapy.<br /><FONT class=lozenge>◊</FONT> Adolescents may require a booster dose of meningococcal conjugate vaccine, in accordance with the Advisory Committee on Immunization Practices (ACIP) vaccine schedule. Vaccine may also be needed if there are identified risk factors such as travel to a country where meningococcal disease is epidemic, or hyperendemic, or in patients with persistent complement deficiency, or functional or anatomic asplenia.<br />§ For children 6 to 18 years old, if no prior doses of PCV7 or PCV 13 then give 1 dose of PCV13, followed 8 weeks later by PPSV23.<br />¥ If both PCV13 and PPSV23 are indicated, PCV13 should be given first, followed by PPSV23 given ≥8 weeks afterward.<br />‡ Send serology if evidence of immunity unknown; evidence of immunity is defined as: health care provider diagnosis of varicella disease or herpes zoster, laboratory confirmation of disease, serologic evidence of past disease, or documentation of having received vaccine series.</div><div class=\"graphic_reference\">From: Ardura MI, Toussi SS, Siegel JD, et al. NASPGHAN clinical report: Surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-a inhibitors. J Pediatr Gastroenterol Nutr 2016; 63:130. DOI: <a href=\"http://journals.lww.com/jpgn/pages/articleviewer.aspx?year=2016&amp;issue=07000&amp;article=00027&amp;type=abstract\" target=\"_blank\">10.1097/MPG.0000000000001188</a>. Copyright &copy; 2016 ESPGHAN &amp; NASPGHAN. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108934 Version 1.0</div></div></div>"},"108936":{"type":"graphic_table","displayName":"Safe living practices to avoid infections in IBD","title":"Summary of recommendations for safe living in patients with IBD receiving anti-TNF alpha therapy and other immunosuppressive agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for safe living in patients with IBD receiving anti-TNF alpha therapy and other immunosuppressive agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Preventive practices</td> <td class=\"subtitle1\">Infectious agent</td> <td class=\"subtitle1\">Vaccines</td> </tr> <tr class=\"divider_bottom\"> <td>Food, water safety</td> <td>Drink boiled or filtered water, sealed bottled soda, water, sports drinks, carbonated drinks. Wash fresh produce before eating. Eat raw fruits only if you have peeled them yourself or know who has peeled. Raw poultry, meat, fish, and seafood should be handled separately from other foods. Cook poultry and&nbsp;meat according to recommendations. Avoid soft cheeses and&nbsp;smoked deli meats. Consume only pasteurized dairy products.</td> <td><em>Cryptosporidium</em> and other waterborne pathogens, Hepatitis A, <em>Salmonella</em>, <em>Toxoplasma</em>, <em>E coli 0157</em>, <em>Listeria monocytogenes</em>, Norovirus, <em>Brucella spp.</em></td> <td>HAV</td> </tr> <tr class=\"divider_bottom\"> <td>Environmental safety*</td> <td>Avoid construction sites and any other areas with large amount of dust in air. Avoid heavy exposure to soil. Avoid areas with heavy bird droppings.</td> <td><em>Aspergillus spp.</em>, NTM, <em>Cryptococcus</em>, <em>Histoplasma</em>, <em>Coccidioides</em>, <em>Blastomyces</em>, <em>Nocardia spp.</em></td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Animal safety</td> <td>Perform hand hygiene after contact with animals. Use soap and water if hands visibly soiled. Avoid&nbsp;cleaning [cat]&nbsp;litter box if possible, or wear gloves if must change litter box. Avoid reptiles as pets. Avoid contact with water in aquariums or use hand hygiene if contact cannot be avoided. </td> <td>Influenza strains transmitted from animals, <em>E coli 0157</em>, <em>Toxoplasma</em>, <em>Salmonella</em>, <em>Mycobacterium marinum</em></td> <td>Influenza vaccine</td> </tr> <tr class=\"divider_bottom\"> <td>Travel safety</td> <td>Follow food and water safety practices above. Consult CDC travel page for current preventive measures by geographic area (<a href=\"http://wwwnc.cdc.gov/travel\" target=\"_blank\">wwwnc.cdc.gov/travel</a>), with special attention to recommendations for those travelers who are immunocompromised; chemoprophylaxis and mosquito protection by area.</td> <td>Examples by geographic area: <em>N meningitidis</em> (the Hajj, sub-Saharan Africa), Japanese encephalitis virus, Yellow fever virus; <em>Salmonella typhi</em>, malaria, chikungunya, dengue</td> <td>HAV, HBV; specific vaccines per geographic area</td> </tr> <tr class=\"divider_bottom\"> <td>Person-to-person; respiratory tract; safe sex</td> <td>Avoid crowded places during influenza season. Avoid or maintain 3 to 6 feet distance from people who are coughing or sneezing.&nbsp;Screening for TB: (a) at initial IBD diagnosis (risk factor, PPD, TST, and IGRA); (b) annually while receiving anti-TNF&#945; (risk factors and immunodiagnostics, see text for details). Use latex condoms for sexual activity when not in a long-term monogamous relationship.</td> <td>Respiratory tract viruses, (eg, influenza, RSV); <em>Mycobacterium tuberculosis</em>; CMV, HSV, HIV, HPV, HBV, HCV, and other sexually transmitted agents</td> <td>Influenza vaccine patients, contacts; HBV, HPV</td> </tr> <tr> <td>Immunizations</td> <td>Immunize with killed vaccines per annual ACIP/AAP recommendations and IDSA recommendations for immunocompromised hosts. Avoid live virus vaccines during periods of immunosuppression.</td> <td>See vaccination section and annual immunization recommendations</td> <td>See vaccination section and annual immunization recommendations</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HAV: hepatitis A virus; NTM: nontuberculous mycobacteria; CDC: Centers for Disease Control and Prevention; HBV: hepatitis B virus; IBD: inflammatory bowel disease; TB: tuberculosis; PPD: purified protein derivative; TST: tuberculin skin test; IGRA: interferon γ release assay; anti-TNFα: anti-tumor necrosis factor alpha; RSV: respiratory syncytial virus; CMV: cytomegalovirus; HSV: herpes simplex virus; HIV: human immunodeficiency virus; HPV: human papillomavirus; HCV: hepatitis C virus; ACIP: Advisory Committee on Immunization Practices; AAP: American Academy of Pediatrics; IDSA: Infectious Diseases Society of America.<br />* Environmental safety is particularly important in areas endemic for histoplamosis, which include parts of the midwestern United States (eg, the Ohio and Mississippi river valleys), Mexico, Central and South America, Africa, and Asia.</div><div class=\"graphic_reference\">From: Ardura MI, Toussi SS, Siegel JD, et al. NASPGHAN clinical report: Surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-a inhibitors. J Pediatr Gastroenterol Nutr 2016; 63:130. DOI: <a href=\"http://journals.lww.com/jpgn/pages/articleviewer.aspx?year=2016&amp;issue=07000&amp;article=00027&amp;type=abstract\" target=\"_blank\">10.1097/MPG.0000000000001188</a>. Copyright &copy; 2016 ESPGHAN &amp; NASPGHAN. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108936 Version 1.0</div></div></div>"},"108941":{"type":"graphic_table","displayName":"Anesthetic goals for patients with aortic stenosis","title":"Key points for anesthetic and hemodynamic management for patients with aortic stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management for patients with aortic stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Sinus rhythm</td> <td>Avoid atrial fibrillation or other SVT</td> <td>5-lead ECG</td> <td>Manage new-onset atrial fibrillation or other SVT: <ul class=\"decimal_heading\"> <li>Control HR </li> <li>Cardioversion of atrial fibrillation for hemodynamic compromise </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Normal HR (60 to 80 bpm)</td> <td> <p>Avoid tachycardia</p> <p>Avoid severe bradycardia</p> Avoid junctional rhythm</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Prevent tachycardia by ensuring adequate depth of anesthesia and analgesia.</p> <p>Manage tachycardia related to hypotension with a vasoconstrictor (eg, phenylephrine, norepinephrine) and fluid administration.</p> Slow HR with beta blockers if necessary.</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain afterload</td> <td> <p>Avoid hypotension</p> Avoid sympathectomy (eg, spinal anesthesia)</td> <td>Intra-arterial blood pressure for major surgical procedures</td> <td>Administer a vasoconstrictor (eg, phenylephrine, norepinephrine) to manage hypotension.</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain preload</td> <td>Avoid hypovolemia</td> <td>Assess clinical response to fluid boluses</td> <td> <p>Maintain intravascular volume status.</p> Rapid resuscitation for hemorrhage.</td> </tr> <tr> <td>Maintain contractility</td> <td>Avoid doses of drugs that cause significant myocardial depression</td> <td>Hemodynamics</td> <td>If inotropic support needed, norepinephrine is preferred.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; SVT: supraventricular tachycardia; HR: heart rate; bpm: beats per minute.</div><div id=\"graphicVersion\">Graphic 108941 Version 4.0</div></div></div>"},"108942":{"type":"graphic_diagnosticimage","displayName":"Klippel-Trenaunay MRI","title":"Klippel-Trenaunay syndrome: Magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Klippel-Trenaunay syndrome: Magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:763px; height:441px;\" src=\"images/DERM/108942_Klippel-Trenaunay_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eight-year-old girl with Klippel-Trenaunay syndrome involving the right lower extremity.<br />(A) Coronal short T1 inversion recovery of bilateral thighs, demonstrating limb hypertrophy, enlarged lateral marginal vein (arrow), multifocal macrocystic lymphatic malformation (arrowheads), and diffuse intramuscular microcystic lymphatic versus venous malformation (asterisk). The lateral marginal vein drained to a persistent sciatic vein (not shown).<br />(B) Stitched coronal post-gadolinium T1 gradient image demonstrating patency of the enlarged lateral marginal vein (arrow) and expected lack of central enhancement in the macrocystic portion of the lymphatic malformation (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Andrew Phelps, MD.</div><div id=\"graphicVersion\">Graphic 108942 Version 1.0</div></div></div>"},"108944":{"type":"graphic_picture","displayName":"VP skin findings","title":"Blistering skin changes on the hand of an individual with variegate porphyria","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Blistering skin changes on the hand of an individual with variegate porphyria</div><div class=\"cntnt\"><img style=\"width:512px; height:362px;\" src=\"images/HEME/108944_Variegate_porphyria_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hand&nbsp;of a patient with variegate porphyria shows blisters, premature ageing, and changes in pigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Hift RJ, Peters TJ, Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady'. J Clin Pathol 2012; 65(3):200-5. Copyright &copy; 2012 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 108944 Version 1.0</div></div></div>"},"108945":{"type":"graphic_table","displayName":"Methods of hemoglobin analysis","title":"Methods of hemoglobin analysis for hemoglobinopathy testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods of hemoglobin analysis for hemoglobinopathy testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> </tbody> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom highlight_green_text\"> <td><strong>Protein-based methods</strong></td> <td> <ul> <li><strong>Extensive clinical experience</strong> </li> <li><strong>Widely available</strong> </li> </ul> </td> <td> <ul> <li><strong>Not possible to make a definitive diagnosis of alpha or beta thalassemia</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">High performance liquid chromatography (HPLC)</td> <td> <ul> <li>Fully automated </li> <li>High precision </li> <li>Rapid, high throughput (short run times) </li> <li>Only a very small sample (eg, fraction of a blood spot for newborn screening) is required </li> <li>Can identify and quantify many variant hemoglobins </li> <li>Can identify and quantify normal hemoglobins (including Hb F, Hb A2 and Hb Barts) </li> <li>Information from the pattern of variant peaks guides further testing </li> </ul> </td> <td> <ul> <li>Capital cost (equipment and reagents) </li> <li>Interpretation of results requires technical skill, experience </li> <li>Interference/interpretation of results affected by prematurity (in newborn), recent transfusion </li> <li>Decreased resolution with sample age due to Hb degradation </li> <li>Cannot distinguish Hb E, Hb Korle Bu, Hb Lepore from Hb A2 due to overlapping retention times </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Isoelectric focusing (IEF)</td> <td> <ul> <li>Excellent resolution of common Hb variants and Hb Barts </li> <li>Distinguishes Hb E from Hb O and Hb S from Hb D and Hb G </li> <li>Hb A and Hb F are clearly resolved </li> <li>Requires only small sample </li> </ul> </td> <td> <ul> <li>Cannot precisely quantify Hb variants </li> <li>Higher per-test cost than electrophoresis </li> <li>Methemoglobin and glycosylated Hb appear as separate bands with sample age </li> <li>Bands on gel are less sharp with automated compared with manual IEF </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Capillary electrophoresis</td> <td> <ul> <li>Fully automated </li> <li>High-throughput </li> <li>Identifies common Hb variants </li> <li>Separates Hb A2 from Hb E (unlike HPLC) </li> <li>Precise quantification of Hbs </li> <li>Information from zone pattern of variants guides further testing </li> <li>Complementary to HPLC </li> </ul> </td> <td> <ul> <li>Capital cost (equipment, reagents) </li> <li>Requires technical skill, expertise </li> <li>Poor separation of Hb S from Hb D </li> <li>Electrophoresis zones are shifted in the absence of Hb A </li> <li>Decreased resolution with sample age </li> <li>Minimal sample required (1 mL), but if sample is &#60;1 mL, dilution of other samples is required, adding labor </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Electrophoresis (cellulose acetate, citrate agar)</td> <td> <ul> <li>Low cost </li> <li>Separation of major Hbs (Hb A, Hb F, Hb S/D, Hb C/E/O-Arab) and several less common Hb variants </li> <li>Acid pH (citrate agar) resolves Hb S and Hb C </li> </ul> </td> <td> <ul> <li>Poor separation of Hbs other than Hbs A, F, S, C </li> <li>Cannot distinguish Hb E from Hb O, or Hb D from Hb G </li> <li>Labor intensive </li> </ul> </td> </tr> <tr class=\"divider_bottom highlight_green_text\"> <td><strong>DNA-based methods</strong></td> <td> <ul> <li><strong>Determines genotype</strong> </li> <li><strong>Diagnostic for thalassemias</strong> </li> </ul> </td> <td> <ul> <li><strong>Cost is higher than most protein-based techniques</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gap polymerase chain reaction (PCR)</td> <td> <ul> <li>Identification of common alpha thalassemia deletions </li> <li>Identification of beta thalassemia and HPFH deletions </li> <li>Identification of alpha globin gene duplications </li> <li>Can be multiplexed to test several deletions in single assay </li> </ul> </td> <td> <ul> <li>Testing is limited to selected/pre-defined deletions (cannot detect unknown deletions) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Traditional DNA sequencing (Sanger)</td> <td> <ul> <li>Identifies a spectrum of point mutations and small insertions and deletions (indels) that result in a hemoglobinopathy (thalassemia, Hb variants) </li> </ul> </td> <td> <ul> <li>Cannot identify large deletions or duplications </li> <li>Only one DNA sequence (up to 1 kb) can be obtained at a time </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Multiplex ligation-dependent probe amplification (MLPA)</td> <td> <ul> <li>Detects large deletions and duplications (alpha or beta genes) </li> </ul> </td> <td> <ul> <li>Capital cost, kits, reagents, software </li> <li>Requires technical skill, expertise </li> <li>Requires additional DNA sequencing to define deletion breakpoints (to characterize deletion) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Next-generation DNA sequencing (NGS)</td> <td> <ul> <li>Simultaneous identification of complete spectrum of deletions, duplications, point mutations in alpha and beta globin genes (single parallel assay) </li> <li>Requires very small sample (less than that for Sanger sequencing) </li> <li>Rapid </li> <li>High accuracy, reliability </li> </ul> </td> <td> <ul> <li>Capital cost, reagents (but less expensive than Sanger sequencing) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Allele-specific oligonucleotide testing (ASOT)</td> <td>&nbsp;</td> <td> <ul> <li>Testing is limited to selected/pre-defined mutations </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Restriction fragment length polymorphism (RFLP) testing</td> <td>&nbsp;</td> <td> <ul> <li>Testing is limited to selected/pre-defined mutations </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for further details on the screening and&nbsp;diagnostic approaches for specific hemoglobinopathies.</div><div class=\"graphic_footnotes\">Hb: hemoglobin; HPFH: hereditary persistence of fetal hemoglobin.</div><div id=\"graphicVersion\">Graphic 108945 Version 1.0</div></div></div>"},"108946":{"type":"graphic_algorithm","displayName":"Selecting a surgical procedure for rectal procidentia (prolapse)","title":"Selecting a surgical procedure for rectal procidentia (prolapse)","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Selecting a surgical procedure for rectal procidentia (prolapse)</div><div class=\"cntnt\"><img style=\"width:650px; height:300px;\" src=\"images/SURG/108946_Slctn_srg_prcdr_rctl_prcdnt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* A patient's candidacy for abdominal surgery is assessed clinically by his/her physical condition, age, frailty, and comorbid illnesses. Refer to UpToDate topic for additional information.<br />&#182; Whether or not a patient has preexisting constipation is determined clinically by assessing the patient's baseline bowel habit, including the frequency and ease of bowel movements, as well as any laxative use. Refer to UpToDate topic for additional information.</div><div id=\"graphicVersion\">Graphic 108946 Version 1.0</div></div></div>"},"108947":{"type":"graphic_table","displayName":"IR oral opioids for chronic non-cancer pain in adults","title":"Immediate-release oral opioids for chronic non-cancer pain in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immediate-release oral opioids for chronic non-cancer pain in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Immediate-release preparation</td> <td class=\"subtitle1\">Starting dose for opioid-na&#239;ve adult</td> <td class=\"subtitle1\">Half-life</td> </tr> <tr> <td>Hydromorphone (Dilaudid)</td> <td>1 to 2 mg orally every three to four hours</td> <td>Two to three hours</td> </tr> <tr> <td>Morphine</td> <td>2.5 to 15 mg orally every four hours*</td> <td>Two to three hours</td> </tr> <tr> <td>Oxycodone</td> <td>2.5 to 5 mg orally every four to six hours</td> <td>Two to three hours</td> </tr> <tr> <td>Oxymorphone</td> <td>2.5 to 5 mg orally every four to six hours</td> <td>Seven to nine hours</td> </tr> <tr> <td>Tapentadol</td> <td>50 mg orally every six hours</td> <td>Four hours</td> </tr> <tr> <td>Tramadol</td> <td>25 to 50 mg orally every six hours</td> <td>Six to nine hours (includes active metabolite)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The lowest strength immediate-release morphine oral tablet available in the United States is 15 mg. Oral liquids are available and may be useful for prescribing oral morphine doses less than 7.5 mg.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57:1331.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 108947 Version 4.0</div></div></div>"},"108954":{"type":"graphic_table","displayName":"ER opioid preps for chronic pain in opioid-tolerant adults","title":"Extended-release opioid preparations for chronic non-cancer pain in opioid-tolerant adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extended-release opioid preparations for chronic non-cancer pain in opioid-tolerant adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Opioid preparation<br /> (US brand name)</td> <td class=\"subtitle1\">Available preparations</td> <td class=\"subtitle1\">Usual dosing interval</td> </tr> <tr> <td>Buprenorphine transdermal patch (Butrans)</td> <td>5, 7.5, 10, 15, 20 mcg/hour</td> <td>Seven days</td> </tr> <tr> <td>Fentanyl transdermal patch (Duragesic)</td> <td>12, 25, 50, 75, 87.5, 100 mcg/hour</td> <td>Three days</td> </tr> <tr> <td>Hydrocodone ER 12 hour (Zohydro ER)</td> <td>10, 15, 20, 30, 40, 50 mg capsules</td> <td>12 hours</td> </tr> <tr> <td>Hydrocodone ER 24 hour (Hysingla ER)</td> <td>20, 30, 40, 60, 80, 100, 120 mg tablets</td> <td>24 hours</td> </tr> <tr> <td>Hydromorphone ER 24 hour (Exalgo)</td> <td>8, 12, 16, 32 mg tablets</td> <td>24 hours</td> </tr> <tr> <td>Methadone*</td> <td>5, 10 mg tablets</td> <td>8 to 12 hours</td> </tr> <tr> <td>Morphine sulfate ER 24 hour (Kadian)</td> <td>10, 20, 30, 45, 50, 60, 75, 80, 90, 120, 200 mg capsules</td> <td>24 hours</td> </tr> <tr> <td>Morphine sulfate ER (MS Contin)</td> <td>15, 30, 60, 100, 200 mg tablets</td> <td>8 to 12 hours</td> </tr> <tr> <td>Oxycodone ER 12 hour (OxyContin)</td> <td>10, 15, 20, 30, 40, 60, 80 mg tablets</td> <td>12 hours</td> </tr> <tr> <td>Oxymorphone ER 12 hour (Opana ER)</td> <td>5, 7.5, 10, 15, 20, 30, 40 mg tablets</td> <td>12 hours</td> </tr> <tr> <td>Tapentadol ER<sup>&#182;</sup> (Nucynta ER)</td> <td>50, 100, 150, 200, 250 mg tablets</td> <td>12 hours</td> </tr> <tr> <td>Tramadol ER 24 hour (Ultram ER)</td> <td>100, 150, 200, 300 mg tablets and capsules</td> <td>24 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>The total daily dose requirement for use of a long-acting formulation should be established first with the use of an appropriate immediate-release opioid analgesic.</li>&#xD;&#xA;    <li>Brand (trade) names and strengths listed in the table are for products available in the United States and some other countries.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">US: United States; ER: extended-release; MS: morphine sulphate.<br />* Due to challenges inherent in safe prescribing of methadone, it is not typically a first-line analgesic choice. Although methadone is not an ER preparation, it can be used as a long-acting opioid due to its prolonged half-life (0.5 to 7 days); guidelines for safe administration must be followed to reduce risk of unintentional overdose. Refer to UpToDate topic on&nbsp;cancer pain management with opioids, section on methadone.<br />¶ Patients should not consume alcoholic beverages or use prescription or nonprescription products that contain alcohol while taking tapentadol ER. The combination of alcohol with tapentadol ER may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol.</div><div class=\"graphic_reference\">Data from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 108954 Version 7.0</div></div></div>"},"108955":{"type":"graphic_table","displayName":"Approximate oral equianalgesic doses for commonly used opioids","title":"Approximate oral equianalgesic doses for commonly used opioids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approximate oral equianalgesic doses for commonly used opioids</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Approximate equivalent doses<br /> (oral immediate-release preparations)</td> <td class=\"subtitle1\">Approximate equianalgesic dose ratio<br /> (morphine:alternate opioid)</td> </tr> <tr> <td>Codeine*</td> <td>200 mg</td> <td>1:7</td> </tr> <tr> <td>Fentanyl</td> <td>No oral equivalent</td> <td>&nbsp;</td> </tr> <tr> <td>Hydrocodone</td> <td>30 mg</td> <td>1:1</td> </tr> <tr> <td>Hydromorphone</td> <td>7.5 mg</td> <td>4:1</td> </tr> <tr> <td>Morphine</td> <td>30 mg</td> <td>1:1 (reference standard)</td> </tr> <tr> <td>Oxycodone</td> <td>20 mg</td> <td>1.5:1</td> </tr> <tr> <td>Oxymorphone</td> <td>10 mg</td> <td>3:1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Equianalgesic conversions serve only as a general guide to estimate opioid dose equivalents. For a review of multiple factors that must be considered for safely individualizing conversion of opioid analgesia, refer to UpToDate topic on cancer pain management with opioids: optimizing analgesia.</div><div class=\"graphic_footnotes\">* Generally not recommended due to high variability in response.</div><div class=\"graphic_reference\">Data from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 108955 Version 4.0</div></div></div>"},"108959":{"type":"graphic_table","displayName":"Anesthetic goals for patients w/ aortic or mitral regurgitation","title":"Key points for anesthetic and hemodynamic management for patients with aortic regurgitation or mitral regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management for patients with aortic regurgitation or mitral regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Normal to fast heart rate (80 to 100 bpm)</td> <td>Avoid bradycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td>Management of bradycardia: <ul class=\"decimal_heading\"> <li>Ephedrine </li> <li>Glycopyrrolate if necessary </li> <li>Low-dose infusion of epinephrine if necessary </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Normal to low afterload</td> <td>Avoid hypertension</td> <td>Intra-arterial blood pressure</td> <td> <p>Prevent hypertension by providing adequate anesthetic depth and effective analgesia.</p> Treat hypotension with careful titration of ephedrine.</td> </tr> <tr class=\"divider_bottom\"> <td>Normal to low preload</td> <td>Avoid hypervolemia</td> <td>Assess clinical response to small fluid boluses</td> <td> <p>Restrictive fluid management.</p> Intravenous nitroglycerin infusion for volume overload.</td> </tr> <tr> <td>Maintain contractility</td> <td>Avoid doses of drugs that cause significant myocardial depression</td> <td>Hemodynamics</td> <td>If inotropic support is needed, milrinone, dobutamine, or low-dose epinephrine is preferred.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; bpm: beats per minute.</div><div id=\"graphicVersion\">Graphic 108959 Version 1.0</div></div></div>"},"108960":{"type":"graphic_table","displayName":"Anesthetic goals for patients with mitral stenosis","title":"Key points for anesthetic and hemodynamic management for patients with mitral stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management for patients with mitral stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Sinus rhythm</td> <td> <p>Avoid atrial fibrillation</p> Avoid tachyarrhythmias</td> <td>5-lead ECG</td> <td>Manage new-onset atrial fibrillation or other SVT: <ul class=\"decimal_heading\"> <li>Heart rate control </li> <li>Cardioversion, if appropriate, for hemodynamic compromise </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Slow to normal HR (50 to 70 bpm)</td> <td> <p>Avoid tachycardia</p> Avoid severe bradycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Prevent pain-induced tachycardia by ensuring adequate anesthetic depth and effective analgesia.</p> <p>Manage tachycardia related to hypotension with phenylephrine (or norepinephrine).</p> HR can be slowed with beta blockers if necessary.</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain afterload</td> <td> <p>Avoid hypotension</p> Avoid sympathectomy (eg, spinal anesthesia)</td> <td>Intra-arterial BP</td> <td>Administer a vasoconstrictor (eg, phenylephrine, norepinephrine) to manage hypotension.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Adequate preload</td> <td>Avoid hypervolemia</td> <td> <p>Clinical course and oxygenation</p> Development of flash pulmonary edema (may present as acute coughing and hypoxemia in the awake patient)</td> <td>Management of pulmonary edema: <ul class=\"decimal_heading\"> <li>Treat hypoxemia related to pulmonary edema immediately with 100% oxygen, PEEP, and, if necessary, intubation and controlled ventilation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Avoid hypovolemia</td> <td>Assess clinical response to fluid boluses</td> <td> <p>Maintain intravascular volume status.</p> Rapid resuscitation for hemorrhage.</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain RV contractility</td> <td>Avoid doses of drugs that cause significant myocardial depression</td> <td>Hemodynamics</td> <td>If inotropic support is needed, milrinone or dobutamine may be used if SVR and systemic BP are maintained; low-dose epinephrine may be necessary.</td> </tr> <tr> <td>Minimize PVR (optimize oxygenation and ventilation)</td> <td> <p>Avoid hypoxemia</p> Avoid hypercarbia</td> <td> <p>Pulse oximetry with visible waveform</p> Capnometry (end-tidal CO<sub>2</sub>)</td> <td>Minimize risk of hypoxemia and hypercarbia by: <ul class=\"decimal_heading\"> <li>Administering supplemental oxygen </li> <li>Ensuring well-controlled ventilation, if intubated </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; SVT: supraventricular tachyarrhythmia; bpm: beats per minute; HR: heart rate; BP: blood pressure; PEEP: positive end-expiratory pressure; IV: intravenous; MAC: monitored anesthesia care; RV: right ventricular; PVR: pulmonary vascular resistance; CO<SUB>2</SUB>: carbon dioxide.</div><div id=\"graphicVersion\">Graphic 108960 Version 2.0</div></div></div>"},"108961":{"type":"graphic_algorithm","displayName":"First-line treatment of metastatic esophagogastric CA","title":"Algorithmic approach to first-line treatment of metastatic esophagogastric cancer","html":"<div class=\"graphic\"><div style=\"width: 789px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to first-line treatment of metastatic esophagogastric cancer</div><div class=\"cntnt\"><img style=\"width:769px; height:353px;\" src=\"images/ONC/108961_First-line_trtmnt_metasta.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SCC: squamous cell cancer: HER2: human epidermal growth factor receptor 2; IHC: immunohistochemical staining; FU: fluorouracil.<br />* While there are no published guidelines for exclusion of patients for trastuzumab on the basis of excess cardiac risk, many clinicians caring for patients with breast cancer use the cardiac ineligibility criteria from the North American adjuvant trastuzumab trials, and it is reasonable to adopt this approach in esophagogastric cancer as well: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Angina pectoris requiring antianginal medication</LI>&#xD;&#xA;<LI>Arrhythmia requiring medication</LI>&#xD;&#xA;<LI>Severe conduction abnormality</LI>&#xD;&#xA;<LI>Clinically significant valvular heart disease</LI>&#xD;&#xA;<LI>Cardiomegaly on chest radiography</LI>&#xD;&#xA;<LI>Left ventricular hypertrophy on echocardiogram</LI>&#xD;&#xA;<LI>Poorly controlled hypertension</LI>&#xD;&#xA;<LI>Clinically significant pericardial effusion</LI>&#xD;&#xA;<LI>History of myocardial infarction, heart failure, or cardiomyopathy</LI>&#xD;&#xA;<LI>Left ventricular ejection fraction below the lower limit of normal</LI></UL>¶ Appropriate chemotherapy backbones for patients with HER2-positive adenocarcinomas who will be receiving a trastuzumab-containing regimen include oxaliplatin plus leucovorin and short-term infusional FU (FOLFOX), capecitabine plus oxaliplatin (CAPOX), cisplatin plus FU, or cisplatin plus capecitabine.<br />Δ Eg, FOLFOX, CAPOX, S-1 plus oxaliplatin, cisplatin/FU, or S-1 plus cisplatin.&nbsp;For patients who are willing to sacrifice a greater degree of treatment-related toxicity for a higher response rate and possibly prolonged progression-free survival, another option is the triplet combination of a fluoropyrimidine plus oxaliplatin&nbsp;and docetaxel. </div><div id=\"graphicVersion\">Graphic 108961 Version 2.0</div></div></div>"},"108962":{"type":"graphic_algorithm","displayName":"Second-line chemotherapy for metastatic esophagogastric CA","title":"Approach to later lines of therapy after progression on the first-line regimen for metastatic esophagogastric cancer","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Approach to later lines of therapy after progression on the first-line regimen for metastatic esophagogastric cancer</div><div class=\"cntnt\"><img style=\"width:594px; height:633px;\" src=\"images/ONC/108962_SLchemmtstcesphggstrcCA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>ECOG PS:</STRONG> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>0: Fully active; no performance restrictions.</LI>&#xD;&#xA;<LI>1: Strenuous physical activity restricted; fully ambulatory and able to carry out light work.</LI>&#xD;&#xA;<LI>2: Capable of self-care but unable to carry out any work activities; up and about &gt;50% of waking hours.</LI>&#xD;&#xA;<LI>3: Capable of only limited self-care; confined to bed or chair &gt;50% of waking hours.</LI>&#xD;&#xA;<LI>4: Completely disabled; cannot carry out any self-care; totally confined to bed or chair.</LI></UL></div><div class=\"graphic_footnotes\">PS: performance status; ECOG: Eastern Cooperative Oncology Group; SCC: squamous cell cancer; FOLFIRI: irinotecan plus leucovorin and short-term infusional fluorouracil; ECF: epirubicin plus cisplatin and fluorouracil; PD-L1: programmed cell death ligand 1.<br />* Outside of the United States, nivolumab is approved in Japan for unresectable, advanced, or recurrent gastric cancer that has progressed after conventional chemotherapy, and is not restricted to patients with PD-L1-overexpressing or deficient mismatch repair/microsatellite unstable tumors.<br />¶ Although the United States approval for pembrolizumab is for patients with PD-L1-overexpressing or mismatch repair deficient/microsatellite unstable tumors who have previously received two or more lines of chemotherapy, many clinicians administer the drug earlier for second-line therapy.</div><div id=\"graphicVersion\">Graphic 108962 Version 3.0</div></div></div>"},"108963":{"type":"graphic_table","displayName":"Subjective Global Nutritional Assessment for children","title":"Pediatric Subjective Global Nutritional Assessment (SGNA) form","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric Subjective Global Nutritional Assessment (SGNA) form</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td colspan=\"5\"><span style=\"font-size:1.2em;\"><strong>Pediatric SGNA rating form</strong></span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\">Consider severity and duration of changes, as well as recent progression when rating each item.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Nutrition-focused medical history</td> <td class=\"subtitle1\" colspan=\"3\">SGNA score</td> </tr> <tr> <td class=\"subtitle2\">Normal</td> <td class=\"subtitle2\">Moderate</td> <td class=\"subtitle2\">Severe</td> </tr> <tr> <td colspan=\"5\"><strong>Appropriateness of current height for age (stunting)</strong></td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\"> <li>Height percentile: _____ </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>&#8805;3<sup>rd</sup> centile</p> <p><span class=\"primarybox_left\">&nbsp;</span>Just below 3<sup>rd</sup> centile</p> <span class=\"primarybox_left\">&nbsp;</span>Far below 3<sup>rd</sup> centile</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Appropriate considering mid-parental height*? </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>Yes</p> <span class=\"primarybox_left\">&nbsp;</span>No</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\" start=\"3\"> <li>Serial growth<sup>&#182;</sup>: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>Following centiles</p> <p><span class=\"primarybox_left\">&nbsp;</span>Moving upwards on centiles</p> <span class=\"primarybox_left\">&nbsp;</span>Moving downwards on centiles (gradually or quickly)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"5\"><strong>Appropriateness of current weight for age (wasting)</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ideal body weight = _____ kg</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Percent ideal body weight:<br /> ___ ___ ___ %</td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>&#62;90%</p> <p><span class=\"primarybox_left\">&nbsp;</span>75-90%</p> <span class=\"primarybox_left\">&nbsp;</span>&#60;75%</td> </tr> <tr> <td colspan=\"5\"><strong>Unintentional changes in body weight</strong></td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\"> <li>Serial weight<sup>&#182;</sup>: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>Following centiles</p> <p><span class=\"primarybox_left\">&nbsp;</span>Crossed &#8805;1 centile upwards</p> <span class=\"primarybox_left\">&nbsp;</span>Crossed &#8805;1 centile downwards</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Weight loss: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>&#60;5% usual body weight</p> <p><span class=\"primarybox_left\">&nbsp;</span>5-10% usual body weight</p> <span class=\"primarybox_left\">&nbsp;</span>&#62;10% usual body weight</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\" start=\"3\"> <li>Change in past 2 weeks: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>No change</p> <p><span class=\"primarybox_left\">&nbsp;</span>Increased</p> <span class=\"primarybox_left\">&nbsp;</span>Decreased</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"5\"><strong>Adequacy of dietary intake</strong></td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\"> <li>Intake is: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>Adequate</p> <p><span class=\"primarybox_left\">&nbsp;</span>Inadequate - hypocaloric</p> <span class=\"primarybox_left\">&nbsp;</span>Inadequate - starvation (ie, taking little of anything)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Current intake versus usual: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>No change</p> <p><span class=\"primarybox_left\">&nbsp;</span>Increased</p> <span class=\"primarybox_left\">&nbsp;</span>Decreased</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\" start=\"3\"> <li>Duration of change: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>&#60;2 weeks</p> <span class=\"primarybox_left\">&nbsp;</span>&#8805;2 weeks</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"5\"><strong>Gastrointestinal symptoms</strong></td> </tr> <tr> <td colspan=\"2\"> <ol style=\"list-style-type: lower-alpha;\"> <li style=\"vertical-align: top; display: inline-block;\"> <p><span class=\"primarybox_left\">&nbsp;</span>No symptoms</p> <p><span class=\"primarybox_left\">&nbsp;</span>One or more symptoms; not daily</p> <span class=\"primarybox_left\">&nbsp;</span>Some or all symptoms; daily </li> </ol> </td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Duration of symptoms: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>&#60;2 weeks</p> <span class=\"primarybox_left\">&nbsp;</span>&#8805;2 weeks</td> </tr> <tr> <td colspan=\"5\"><strong>Functional capacity (nutritionally related)</strong></td> </tr> <tr> <td colspan=\"2\"> <ol style=\"list-style-type: lower-alpha;\"> <li style=\"vertical-align: top; display: inline-block;\"> <p><span class=\"primarybox_left\">&nbsp;</span>No impairment, energetic, able to perform age-appropriate activity</p> <p><span class=\"primarybox_left\">&nbsp;</span>Restricted in physically strenuous activity, but able to perform play and/or school activities in a light or sedentary nature; less energy; tired more often</p> <span class=\"primarybox_left\">&nbsp;</span>Little to no play activities, confined to bed or chair &#62;50% of waking time; no energy; sleeps often </li> </ol> </td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Function in past 2 weeks: </li> </ol> </td> <td> <p><span class=\"primarybox_left\">&nbsp;</span>No change</p> <p><span class=\"primarybox_left\">&nbsp;</span>Increased</p> <span class=\"primarybox_left\">&nbsp;</span>Decreased</td> </tr> <tr> <td colspan=\"5\"><strong>Metabolic stress of disease</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p><span class=\"primarybox_left\">&nbsp;</span>No stress</p> <p><span class=\"primarybox_left\">&nbsp;</span>Moderate stress<sup>&#916;</sup></p> <span class=\"primarybox_left\">&nbsp;</span>Severe stress<sup>&#9674;</sup> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Physical exam</td> <td class=\"subtitle1\" colspan=\"3\">SGNA score</td> </tr> <tr> <td class=\"subtitle2\">Normal</td> <td class=\"subtitle2\">Moderate</td> <td class=\"subtitle2\">Severe</td> </tr> <tr> <td colspan=\"5\"><strong>Loss of subcutaneous fat</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <p><span class=\"primarybox_left\">&nbsp;</span>No loss in most or all areas</p> <p><span class=\"primarybox_left\">&nbsp;</span>Loss in some but not all areas</p> <span class=\"primarybox_left\">&nbsp;</span>Severe loss in most or all areas</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"5\"><strong>Muscle wasting</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <p><span class=\"primarybox_left\">&nbsp;</span>No wasting in most or all areas</p> <p><span class=\"primarybox_left\">&nbsp;</span>Wasting in some but not all areas</p> <span class=\"primarybox_left\">&nbsp;</span>Severe wasting in most or all areas</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"5\"><strong>Edema (nutrition-related)</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p><span class=\"primarybox_left\">&nbsp;</span>No edema</p> <p><span class=\"primarybox_left\">&nbsp;</span>Moderate</p> <span class=\"primarybox_left\">&nbsp;</span>Severe</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle1\">Normal</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"2\"><strong>Overall SGNA ranking</strong></td> <td class=\"highlight_gray_text\">&nbsp;</td> <td class=\"highlight_gray_text\">&nbsp;</td> <td class=\"highlight_gray_text\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Guidelines for aggregating items into global score (overall SGNA ranking):</STRONG><br />In assigning an overall global score, consider all items in the context of each other. Give the most consideration to changes in weight gain and growth, intake, and physical signs of loss of fat or muscle mass. Use the other items to support or strengthen these ratings. Take recent changes in context with the patient's usual/chronic status. Was the patient starting off in a normal or nutritionally-compromised state? &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>Normal/well-nourished </STRONG>&#xD;&#xA;<UL>&#xD;&#xA;<LI>This patient is growing and gaining weight normally, has a grossly adequate intake without gastrointestinal symptoms, shows no or few physical signs of wasting, and exhibits normal functional capacity. Normal ratings in most or all categories, or significant, sustained improvement from a questionable or moderately malnourished state. It is possible to rate a patient as well-nourished in spite of some reductions in muscle mass, fat stores, weight, and intake. This is based on recent improvement in signs that are mild and inconsistent.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Moderately malnourished </STRONG>&#xD;&#xA;<UL>&#xD;&#xA;<LI>This patient has definite signs of a decrease in weight and/or growth, and intake, and may or may not have signs of diminished fat stores, muscle mass, and functional capacity. This patient is experiencing a downward trend, but started with normal nutritional status. Moderate ratings in most or all categories, with the potential to progress to a severely malnourished state.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Severely malnourished</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>This patient has progressive, malnutrition with a downward trend in most or all categories. There are significant physical signs of malnutrition-loss of fat stores, muscle wasting, weight loss &gt;10%-as well as decreased intake, excessive gastrointestinal losses and/or acute metabolic stress, and definite loss of functional capacity. Severe ratings in most or all categories with little or no sign of improvement.</LI></UL></LI></UL></div><div class=\"graphic_footnotes\">* Mid-parental height: Girls: Subtract 13 cm from father's height and average with the mother's height. Boys: Add 13 cm to the mother's height and average with the father's height. Thirteen cm is the average difference in height of women and men. For both girls and boys, 8.5 cm on either side of this calculated value (target height) represents the 3<SUP>rd</SUP> to 97<SUP>th</SUP> percentiles for anticipated adult height.<br />¶ 30% of healthy term infants cross one major percentile and 23% cross two major percentiles during the first 2 years of life, typically towards the 50<SUP>th</SUP> percentile rather than away from it. This is normal seeking of the growth channel.<br />Δ Conditions causing moderate metabolic stress include routine surgery (such as small resection of bowel); laparoscopic surgery; exploratory surgery; fracture; minor infection (bronchiolitis, gastroenteritis); pressure sores or decubitus ulcers.<br /><FONT class=lozenge>◊</FONT> Conditions associated with severe metabolic stress include major organ surgery (eg, stomach, liver, pancreas, lung, open chest, total cholecystectomy, or gastrointestinal pouch procedures); major bowel resection; trauma with multiple injuries, fractures or burns; multiorgan failure; severe pancreatitis, sepsis or inflammation; multiple deep pressure sores or ulcers; chronic illness with acute deterioration; current treatment for malignancy; acquired immune deficiency syndrome with a secondary infection; or hyperthyroidism.</div><div class=\"graphic_reference\">Reproduced from: Secker DJ, Jeejeebhoy KN. How to Perform Subjective Global Nutritional Assessment in Children. J Acad Nutr Diet 2012; 112:424. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 108963 Version 2.0</div></div></div>"},"108965":{"type":"graphic_diagnosticimage","displayName":"CT scan of Nutcracker syndrome","title":"CT scan of Nutcracker syndrome","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">CT scan of Nutcracker syndrome</div><div class=\"cntnt\"><img style=\"width:762px; height:304px;\" src=\"images/PEDS/108965_CT_scan_nutcracker_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal computed tomography scan in a 14-year-old girl with macroscopic hematuria and chronic pelvic pain shows findings consistent with but not specific for Nutcracker syndrome. These findings are highly suggestive of Nutcracker syndrome in the absence of other causes of hematuria.<br />(Panel A) Axial plane image demonstrates changes in left renal vein (delta) diameter with a ratio of 5:1 between the distended and narrowed portions.<br />(Panel B) Sagittal plane image demonstrates an acute aortomesenteric angle with a parallel course of the superior mesenteric artery (asterisk) to the aorta (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Laureline Berteloot.</div><div id=\"graphicVersion\">Graphic 108965 Version 1.0</div></div></div>"},"108966":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of Nutcracker syndrome","title":"Ultrasound of Nutcracker syndrome","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Ultrasound of Nutcracker syndrome</div><div class=\"cntnt\"><img style=\"width:480px; height:643px;\" src=\"images/PEDS/108966_Ultrasound_nutcracker_syndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound in an 11-year-old boy with Nutcracker syndrome and left varicocele who presented with intermittent macroscopic hematuria.<br />(Panel A) Transverse plane view of the left renal vein (delta) demonstrates significant narrowing between the superior mesenteric artery (asterisk) and the aorta (arrow).<br />(Panel B) Doppler study in sagittal plane view reveals increased velocity in the left renal vein towards its narrowed zone.</div><div class=\"graphic_reference\">Courtesy of Dr. Laureline Berteloot.</div><div id=\"graphicVersion\">Graphic 108966 Version 1.0</div></div></div>"},"108969":{"type":"graphic_picture","displayName":"Coxsackievirus A6 hand-foot-mouth disease adult","title":"Atypical hand, foot, and mouth disease caused by coxsackievirus A6 in adults","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Atypical hand, foot, and mouth disease caused by coxsackievirus A6 in adults</div><div class=\"cntnt\"><img style=\"width:493px; height:456px;\" src=\"images/DERM/108969_CVA6_hnd-ft-mth_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermatologic and mucosal manifestations of hand, foot, and mouth disease among military personnel, demonstrating: <br />(A) Extensive and confluent purpuric and hemorrhagic crusted papules and plaques on the foot and anterior shin.<br />(B) Erythematous papules and erosions on the palate.<br />(C) Grouped purpuric papules on the hand.<br />(D) Similar lesions with extensive involvement of the extensor aspects of the upper extremities — September 18, 2015.</div><div class=\"graphic_reference\">Reproduced from: Banta J, Lenz B, Pawlak M, et al. Notes from the Field: Outbreak of Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6 Among Basic Military Trainees - Texas, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:678.</div><div id=\"graphicVersion\">Graphic 108969 Version 1.0</div></div></div>"},"108973":{"type":"graphic_table","displayName":"The Deauville score for interpreting FDG-PET in lymphoma","title":"The Deauville score for interpreting FDG-PET in lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Deauville score for interpreting FDG-PET in lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">Findings</td> </tr> <tr> <td class=\"centered\">1</td> <td>No uptake</td> </tr> <tr> <td class=\"centered\">2</td> <td>Uptake &#8804; mediastinal blood pool</td> </tr> <tr> <td class=\"centered\">3</td> <td>Uptake &#62; mediastinal blood pool but &#8804; liver</td> </tr> <tr> <td class=\"centered\">4</td> <td>Uptake moderately more than liver uptake, at any site</td> </tr> <tr> <td class=\"centered\">5</td> <td>Uptake markedly higher than liver (ie, two to three times the maximum SUV in the liver) and/or new lesions</td> </tr> <tr> <td class=\"centered\">X</td> <td>New areas of uptake unlikely to be related to lymphoma</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Deauville score (also known as the 5-point scale) is a purely visual method of standardizing the interpretation of post-treatment positron emission tomography (PET) scans for primary nodal lymphoma allowing for the comparison of scans performed using different machines at different centers. The Deauville score uses a patient's fludeoxyglucose (FDG) uptake in the mediastinal blood pool and liver as an internal control. FDG uptake is always present in these two sites, with higher levels consistently seen in the liver. The Deauville score interprets FDG avidity of suspected disease (most intense uptake in a site of initial disease) in relation to FDG uptake in these two locations.<br />NOTE: If mediastinal blood pool activity is equal to or greater than activity in the liver, then the uptake within the lesion should be compared with that in the liver (uptake lesion &lt; liver score 2; lesion = liver score 3).</div><div class=\"graphic_footnotes\">SUV: standardized uptake value.</div><div class=\"graphic_reference\">European Journal of Nuclear Medicine and Molecular Imaging, Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma, Vol. 37, 2010, p. 1824, Barrington SF, Qian W, Somer EJ, et al, ©&nbsp;Springer-Verlag 2010, with permission of Springer.</div><div id=\"graphicVersion\">Graphic 108973 Version 4.0</div></div></div>"},"108977":{"type":"graphic_picture","displayName":"Iododerma","title":"Iododerma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Iododerma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/108977_Iododerma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustular eruption with secondary impetiginization in a patient exposed to iodides.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 108977 Version 1.0</div></div></div>"},"108978":{"type":"graphic_picture","displayName":"Urticating spider hairs","title":"Urticating spider hairs","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Urticating spider hairs</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/EM/108978_Urticatingspiderhairs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tarantulas&nbsp;have urticating hairs as shown above. When threatened, they dislodge these small (above 1 mm long) barbed hairs at the posterior of the abdomens and launch them at their attacker.</div><div class=\"graphic_reference\">Copyright &copy; Joseph Warfel.</div><div id=\"graphicVersion\">Graphic 108978 Version 2.0</div></div></div>"},"108981":{"type":"graphic_table","displayName":"Components of the preoperative airway physical examination","title":"Components of the preoperative airway physical examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of the preoperative airway physical examination</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Airway examination component</td> <td class=\"subtitle1\">Nonreassuring findings</td> </tr> <tr> <td>Length of upper incisors</td> <td>Relatively long</td> </tr> <tr> <td>Relationship of maxillary and mandibular incisors during normal jaw closure</td> <td>Prominent \"overbite\" (maxillary incisors anterior to mandibular incisors)</td> </tr> <tr> <td>Relationship of maxillary and mandibular incisors during voluntary protrusion of mandible</td> <td>Patient cannot bring mandibular incisors anterior to (in front of) maxillary incisors</td> </tr> <tr> <td>Interincisor distance</td> <td>Less than 3 cm</td> </tr> <tr> <td>Visibility of uvula</td> <td>Not visible when tongue is protruded with patient in sitting position (eg, Mallampati class &#62;2)</td> </tr> <tr> <td>Shape of palate</td> <td>Highly arched or very narrow</td> </tr> <tr> <td>Compliance of mandibular space</td> <td>Stiff, indurated, occupied by mass, or non-resilient</td> </tr> <tr> <td>Thyromental distance</td> <td>Less than three ordinary finger-breadths</td> </tr> <tr> <td>Length of neck</td> <td>Short</td> </tr> <tr> <td>Thickness of neck</td> <td>Thick</td> </tr> <tr> <td>Range of motion of head and neck</td> <td>Patient cannot touch tip of chin to chest or cannot extend neck</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table displays some findings of the airway physical examination that may suggest the presence of a difficult intubation. The decision to examine some or all of the airway components shown on this table is dependent on the clinical context and judgment of the practitioner. The table is not intended as a mandatory or exhaustive list of the components of an airway examination. The order of presentation in this table follows the \"line of sight\" that occurs during conventional oral laryngoscopy.</div><div class=\"graphic_reference\">From: Apfelbaum JL, Hagberg CA, Caplan RA, et al. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology 2013; 118:251. DOI: <a href=\"http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918684\" target=\"_blank\">10.1097/ALN.0b013e31827773b2</a>. Copyright &copy; 2013 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 108981 Version 3.0</div></div></div>"},"108983":{"type":"graphic_table","displayName":"High- and low-risk factors in syncope patients","title":"High- and low-risk factors in syncope patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High- and low-risk factors in syncope patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Low-risk factors</td> <td class=\"subtitle1\">High-risk factors</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Characteristics of the patients</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Young age (&#60;40 years)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Characteristics of syncope</td> </tr> <tr> <td class=\"indent1\">Only while in standing position</td> <td>During exertion</td> </tr> <tr> <td class=\"indent1\">Standing from supine/sitting position</td> <td>In supine position</td> </tr> <tr> <td class=\"indent1\">Nausea/vomiting before syncope</td> <td>New onset of chest discomfort</td> </tr> <tr> <td class=\"indent1\">Feeling of warmth before syncope</td> <td>Palpitations before syncope</td> </tr> <tr> <td class=\"indent1\">Triggered by painful/emotionally distressing stimulus</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Triggered by cough/defecation/micturition</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Factors present in the history of the patient</td> </tr> <tr> <td class=\"indent1\">Prolonged history (years) of syncope with the same characteristics of the current episode</td> <td>Family history of sudden death</td> </tr> <tr> <td>&nbsp;</td> <td>Congestive heart failure</td> </tr> <tr> <td>&nbsp;</td> <td>Aortic stenosis</td> </tr> <tr> <td>&nbsp;</td> <td>Left ventricular outflow tract disease</td> </tr> <tr> <td>&nbsp;</td> <td>Dilated cardiomyopathy</td> </tr> <tr> <td>&nbsp;</td> <td>Hypertrophic cardiomyopathy</td> </tr> <tr> <td>&nbsp;</td> <td>Arrhythmogenic right ventricular cardiomyopathy</td> </tr> <tr> <td>&nbsp;</td> <td>Left ventricular ejection fraction &#60;35%</td> </tr> <tr> <td>&nbsp;</td> <td>Previously documented arrhythmia (ventricular)</td> </tr> <tr> <td>&nbsp;</td> <td>Coronary artery disease</td> </tr> <tr> <td>&nbsp;</td> <td>Congenital heart disease</td> </tr> <tr> <td>&nbsp;</td> <td>Previous myocardial infarction</td> </tr> <tr> <td>&nbsp;</td> <td>Pulmonary hypertension</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Previous ICD implantation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Symptoms, signs, or variables associated with the syncopal episode</td> </tr> <tr> <td>&nbsp;</td> <td>Anemia (Hb &#60;9 g/dL)</td> </tr> <tr> <td>&nbsp;</td> <td>Lowest systolic blood pressure in the ED &#60;90 mmHg</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Sinus bradycardia (&#60;40 bpm)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">ECG features*</td> </tr> <tr> <td>&nbsp;</td> <td>New (or previously unknown) left bundle branch block</td> </tr> <tr> <td>&nbsp;</td> <td>Bifascicular block + first degree AV block</td> </tr> <tr> <td>&nbsp;</td> <td>Brugada ECG pattern</td> </tr> <tr> <td>&nbsp;</td> <td>ECG changes consistent with acute ischemia</td> </tr> <tr> <td>&nbsp;</td> <td>Non-sinus rhythm (new)</td> </tr> <tr> <td>&nbsp;</td> <td>Bifascicular block</td> </tr> <tr> <td>&nbsp;</td> <td>Prolonged QTc (&#62;450 ms)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">According to characteristics of the patient and the syncopal episode, the subject can be defined as low, high or indeterminate risk. Low risk: patients with one or more low-risk characteristics and without any high-risk characteristics. High risk: patients with at least one high-risk characteristic. Intermediate or indeterminate risk: patients without any high- or low-risk characteristics, or patients with only low-risk factors and some co-morbidities such as chronic renal failure, respiratory failure, hepatic failure, neoplasm, cerebrovascular disease or previous history of heart disease. Note that finding any of these abnormalities does not always lead to a definite diagnosis.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter defibrillator; AV: atrioventricular.<br />* Note that not all the ECG patterns are covered by the table and some other ECG patterns could be considered in stratifying the patients risk such as short QT syndrome, early repolarization, ECG findings indicating hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and incidental finding of Q wave.</div><div class=\"graphic_reference\">Reproduced from: Costantino G, Sun BC, Barbic F, et al. Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department. Eur Heart J 2016; 37(19):1493-8, by permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright © 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org</A>.</div><div id=\"graphicVersion\">Graphic 108983 Version 5.0</div></div></div>"},"108984":{"type":"graphic_table","displayName":"Electrolyte and acid-base changes associated with purging","title":"Electrolyte and acid-base changes associated with purging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electrolyte and acid-base changes associated with purging</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Method of purging</td> <td class=\"subtitle1\" colspan=\"5\">Serum levels</td> <td class=\"subtitle1\" colspan=\"3\">Urine levels</td> </tr> <tr> <td class=\"subtitle2\">Sodium</td> <td class=\"subtitle2\">Potassium</td> <td class=\"subtitle2\">Chloride</td> <td class=\"subtitle2\">Bicarbonate</td> <td class=\"subtitle2\">pH</td> <td class=\"subtitle2\">Sodium</td> <td class=\"subtitle2\">Potassium</td> <td class=\"subtitle2\">Chloride</td> </tr> <tr> <td>Vomiting</td> <td class=\"centered\">Increased, decreased, or normal</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Increased</td> <td class=\"centered\">Increased</td> <td class=\"centered\">Decreased or normal</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Decreased</td> </tr> <tr> <td>Laxatives</td> <td class=\"centered\">Increased, decreased, or normal</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Increased or decreased</td> <td class=\"centered\">Increased or decreased</td> <td class=\"centered\">Increased or decreased</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Decreased</td> </tr> <tr> <td>Diuretics</td> <td class=\"centered\">Increased, decreased, or normal</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Increased</td> <td class=\"centered\">Increased</td> <td class=\"centered\">Increased</td> <td class=\"centered\">Increased</td> <td class=\"centered\">Increased</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Mehler PS, Walsh K. Electrolyte and acid-base abnormalities associated with purging behaviors. Int J Eat Disord 2016; 49:311. DOI: <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/eat.22503/abstract\" target=\"_blank\">10.1002/eat.22503</a>. Copyright &copy; 2016 Wiley Periodicals, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 108984 Version 1.0</div></div></div>"},"108985":{"type":"graphic_algorithm","displayName":"DAS extubation guidelines: Basic algorithm","title":"DAS extubation guidelines: Basic algorithm","html":"<div class=\"graphic\"><div style=\"width: 940px\" class=\"figure\"><div class=\"ttl\">DAS extubation guidelines: Basic algorithm</div><div class=\"cntnt\"><img style=\"width:920px; height:610px;\" src=\"images/ANEST/108985_DAS_extubation_Basic.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OSA: obstructive sleep apnea; HDU: high dependency unit; ICU: intensive care unit; O<sub>2</sub>: oxygen.</div><div class=\"graphic_reference\">Reproduced from Popat M, Mitchell V, Dravid R, Patel A, Swampillai C, Higgs A. Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia 2012; 67: 318-340, with permission from the Association of Anaesthetists of Great Britain &amp; Ireland/Blackwell Publishing Ltd.</div><div id=\"graphicVersion\">Graphic 108985 Version 1.0</div></div></div>"},"108986":{"type":"graphic_algorithm","displayName":"DAS extubation guidelines: \"Low-risk\" algorithm","title":"DAS extubation guidelines: \"Low-risk\" algorithm","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">DAS extubation guidelines: \"Low-risk\" algorithm</div><div class=\"cntnt\"><img style=\"width:784px; height:616px;\" src=\"images/ANEST/108986_DAS_extubation_Low_risk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The technique described for awake extubation is a suggested approach. Practice may vary in experienced hands.</div><div class=\"graphic_footnotes\">O<SUB>2</SUB>: oxygen.</div><div class=\"graphic_reference\">Reproduced from Popat M, Mitchell V, Dravid R, Patel A, Swampillai C, Higgs A. Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia 2012; 67: 318-340, with permission from the Association of Anaesthetists of Great Britain &amp; Ireland/Blackwell Publishing Ltd.</div><div id=\"graphicVersion\">Graphic 108986 Version 1.0</div></div></div>"},"108987":{"type":"graphic_algorithm","displayName":"DAS extubation guidelines: \"At-risk\" algorithm","title":"DAS extubation guidelines: \"At-risk\" algorithm","html":"<div class=\"graphic\"><div style=\"width: 964px\" class=\"figure\"><div class=\"ttl\">DAS extubation guidelines: \"At-risk\" algorithm</div><div class=\"cntnt\"><img style=\"width:944px; height:600px;\" src=\"images/ANEST/108987_DAS_extubation_At_risk.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HDU: high dependency unit; ICU: intensive care unit; O<sub>2</sub>: oxygen.<br />* Advanced techniques: Require training and experience.</div><div class=\"graphic_reference\">Reproduced from Popat M, Mitchell V, Dravid R, Patel A, Swampillai C, Higgs A. Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia 2012; 67: 318-340, with permission from the Association of Anaesthetists of Great Britain &amp; Ireland/Blackwell Publishing Ltd.</div><div id=\"graphicVersion\">Graphic 108987 Version 1.0</div></div></div>"},"108988":{"type":"graphic_algorithm","displayName":"Algorithm for diagnosis of suspected Brugada syndrome","title":"Algorithm for evaluation of a patient with suspected Brugada syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of a patient with suspected Brugada syndrome</div><div class=\"cntnt\"><img style=\"width:410px; height:372px;\" src=\"images/CARD/108988_Algo_suspectd_Brugada_syndr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 108988 Version 1.0</div></div></div>"}};